"Trade_Name
",Chemical,Manufacturer,Top_15_Brand_Corporation,Biologic_(by_Product),Biosimilar,NAS,Oncology,Rare_Disease_(FDA),Rare_Disease_(EMA),Rare_Disease_(FDA_or_EMA),HC-HTA_Aligned_Review,Health_Canada_Submission_Date,NOC_Date,Health_Canada_Review_Time,HTA_Agency,CADTH_Submission_Date,CADTH_Timing_of__Submission,CADTH_Submission_Type_-_Agency_Specific,CADTH_Indication,CADTH_Review_Status,CADTH_Final_Recommendation/Withdrawn_Date,CADTH_Recommended_-_Agency_Specific,CADTH_Decision_Type_-_Standardized,INESSS_Submission_Date,INESSS_Timing_of__Submission,INESSS_Submission_Type_-_Agency_Specific,INESSS_Indication,INESSS_Review_Status,INESSS_Final_Recommendation/Withdrawn_Date,INESSS_Recommended_-_Agency_Specific,INESSS_Decision_Type_-_Standardized,pCPA_Negotiation,pCPA_First_Date,pCPA_Final_Date,pCPA_Type,pCPA_Negotiation_Outcome,BC_Status,AB_Status,SK_Status,MB_Status,ON_Status,NB_Status,NS_Status,PEI_Status,NL_Status,QC_Status,Listing_BC_Date,Listing_AB_Date,Listing_SK_Date,Listing_MB_Date,Listing_ON_Date,Listing_NB_Date,Listing_NS_Date,Listing_PEI_Date,Listing_NL_Date,Listing_QC_Date,First_Prov_Listing_(excl_QC),First_Prov_Listing_(inc_QC),Rank_BC_Listing_Date,Rank_AB_Listing_Date,Rank_SK_Listing_Date,Rank_MB_Listing_Date,Rank_ON_Listing_Date,Rank_NB_Listing_Date,Rank_NS_Listing_Date,Rank_PEI_Listing_Date,Rank_NL_Listing_Date,Rank_QC_Listing_Date,Rank_1,Rank_2,Rank_3,Rank_4,Rank_5,Rank_6,Rank_7,Rank_8,Rank_9,Rank_10,Total_population_coverage_(incl_QC),Date_>_50%_Cumulative_Ranking,Date_>_80%_Cumulative_Ranking,NOC_to_CADTH_Submission,NOC_to_INESSS_Submission,CADTH_Duration,INESSS_Duration,CADTH_to_pCPA_Initiation,INESSS_to_pCPA_Initiation,pCPA_LOI_to_LOE,pCPA_to_Listing_BC_Date,pCPA_to_Listing_AB_Date,pCPA_to_Listing_SK_Date,pCPA_to_Listing_MB_Date,pCPA_to_Listing_ON_Date,pCPA_to_Listing_NB_Date,pCPA_to_Listing_NS_Date,pCPA_to_Listing_PEI_Date,pCPA_to_Listing_NL_Date,pCPA_to_Listing_QC_Date,pCPA_to_Listing_Nat_Avg_(excl_QC),pCPA_Completion_to_1st_Listing_(excl_QC),pCPA_to_Listing_Nat_Avg_(incl_QC),pCPA_Completion_to_1st_Listing_(incl_QC),pCPA_Completion_to_80%_Listing,NOC_to_Listing_BC_Date,NOC_to_Listing_AB_Date,NOC_to_Listing_SK_Date,NOC_to_Listing_MB_Date,NOC_to_Listing_ON_Date,NOC_to_Listing_NB_Date,NOC_to_Listing_NS_Date,NOC_to_Listing_PEI_Date,NOC_to_Listing_NL_Date,NOC_to_Listing_QC_Date,NOC_to_Listing_Nat_Avg_(excl_QC),NOC_to_Listing_Nat_Avg_(inc_QC),"NOC_to_1st_Provincial_Listing
(unique_at_product/indication_level)_exc_QC","CADTH_Submission_to_1st_Provincial_Listing
exc_QC",CADTH_Recommendation_to_1st_Provincial_Listing_exc_QC,HTA_Rec_to_BC_Listing_Date,HTA_Rec_to_AB_Listing_Date,HTA_Rec_to_SK_Listing_Date,HTA_Rec_to_MB_Listing_Date,HTA_Rec_to_ON_Listing_Date,HTA_Rec_to_NB_Listing_Date,HTA_Rec_to_NS_Listing_Date,HTA_Rec_to_PEI_Listing_Date,HTA_Rec_to_NL_Listing_Date,HTA_Rec_to_QC_Listing_Date,Nat`l_Avg_(excl_QC),NOC_to_CADTH_Rec,NOC_to_INESSS_Rec,CADTH_Rec_to_pCPA_Decision,INESSS_Rec_to_pCPA_Decision,NOC_to_80%_Listing,First_Provincial_Listing_to_80%_Listing_(incl_QC),First_Provincial_Listing_to_80%_Listing_(excl_QC),First_Provincial_Listing_to_50%_Listing_(incl_QC),50%_Listing_to_80%_Listing,HC_Sub_to_CADTH_Rec
Abecma,idecabtagene vicleucel,Celgene,Y,N,N,Y,Y,Y,Y,Y,N,01-Oct-20,26-May-21,237,CADTH & INESSS,16-Dec-20,pre-NOC,Initial,"For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody",Completed,12-Nov-21,Do not fund,Negative,19-Feb-21,pre-NOC,New Drug,"For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody",Completed,01-Sep-21,Avis de refus ,Negative,None,,,Under consideration for negotiation,n/a,,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-161,-96,331,194,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,170,98,,,,,,,,407
Abilify (MDD),aripiprazole,Bristol-Myers Squibb ,Y,N,N,N,N,N,N,N,N,,29-May-13,,CADTH,01-Oct-13,post-NOC,Initial,"Depression, Major Depressive Disorder (MDD)",Completed,22-Oct-14,Do not list ,Negative,,,,,,,,,none,02-Dec-14,,Do Not Negotiate,n/a,NR,FB/RB,NR,FB,NR,FB,FB,NR,NR,NR,,01-Jan-12,,24-May-12,,18-Jun-20,01-Aug-21,,,,01-Jan-12,01-Jan-12,,1,,2,,3,4,,,,4.50%,10.00%,10.90%,12.20%,,,,,,,12.20%,,,125,,386,,41,,,,,,,,,,,,,,,,,,,-514,,-370,,2577,2986,,,,1170,1170,-514,-639,-1025,,-1025,,-881,,2066,2475,,,,659,511,,,,,,,,,41934
Abilify Maintena,aripiprazole,Otsuka Pharmaceutical & Lundbeck,N,N,N,N,N,N,N,N,N,,10-Feb-14,,CADTH & INESSS,06-Jan-14,pre-NOC,Initial,Schizophrenia,Completed,19-Dec-14,List with criteria/condition,Conditional,22-Mar-14,post-NOC,New Drug,Schizophrenia,Completed,01-Oct-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,29-Jan-15,14-Jun-15,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,FB,FB,FB,SA,SA,FB,11-Aug-15,01-Sep-15,01-Jul-15,22-Oct-15,29-Jul-15,14-Oct-15,01-Sep-15,25-Apr-16,01-Aug-15,01-Oct-14,01-Jul-15,01-Oct-14,5,6,2,9,3,8,7,10,4,1,28.60%,34.30%,66.50%,67.20%,87.50%,91.90%,93.20%,94.10%,99.60%,100.00%,100.00%,29-Jul-15,11-Aug-15,-35,40,347,193,41,120,136,58,79,17,130,45,122,79,316,48,-256,99,17,64,-256,58,547,568,506,619,534,611,568,805,537,233,588,553,506,541,194,235,256,194,307,222,299,256,493,225,0,276,312,233,177,256,547,314,41,301,13,41992
Abraxane,nab paclitaxel,Celgene ,N,N,N,N,Y,Y,N,Y,N,,16-Jul-14,,CADTH & INESSS,14-Feb-14,pre-NOC,New indication,GI: Metastatic Pancreatic Cancer,Completed,23-Sep-14,Cond'l on Cost,Conditional,04-Aug-14,post-NOC,New Indication,Metastatic Pancreatic Cancer,Completed,02-Feb-15,Ajout d’une indication reconnue à la Liste Établissements – Médicament d’exception – Avis de refus – À moins que le rapport entre le coût et l’efficacité soit modifié pour atteindre un niveau acceptable,Conditional,1st,29-Oct-14,02-Mar-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Nov-14,30-Mar-15,01-May-15,20-Apr-15,17-Apr-15,15-Jul-15,01-Apr-15,01-Aug-18,01-Sep-15,20-Nov-15,01-Nov-14,01-Nov-14,1,2,6,5,4,7,3,10,8,9,20.30%,24.70%,26.00%,58.30%,63.80%,69.50%,70.40%,71.10%,99.60%,100.00%,100.00%,17-Apr-15,20-Nov-15,-152,19,221,182,36,-96,124,-121,28,60,49,46,135,30,1248,183,263,184,-121,192,-121,263,108,257,289,278,275,364,259,1477,412,492,413,421,108,260,39,39,188,220,209,206,295,190,1408,343,291,344,69,201,160,28,492,384,384,167,217,41905
Actemra ,tocilizumab,Hoffmann-La Roche Ltd.,Y,Y,N,N,N,N,N,N,N,01-May-17,27-Oct-17,179,CADTH & INESSS,25-Sep-17,pre-NOC,Initial,Giant cell arteritis (GCA),Completed,27-Mar-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New Indication,Arteritis,Completed,06-Jun-18,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,26-Jul-18,06-Dec-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,NR,SA,SA,EM,12-Mar-19,01-Mar-19,01-May-19,31-May-19,17-Apr-19,22-Oct-20,,28-Feb-22,15-Jun-20,02-Oct-19,01-Mar-19,01-Mar-19,2,1,4,5,3,8,,9,7,6,4.50%,24.70%,56.90%,62.70%,68.20%,96.80%,97.40%,98.30%,98.70%,,98.70%,17-Apr-19,02-Oct-19,-32,,183,,121,50,133,96,85,146,176,132,686,,1180,557,300,382,85,373,85,300,501,490,551,581,537,1091,,1585,962,705,787,778,490,522,339,350,339,400,430,386,940,,1434,811,483,636,151,222,254,183,705,215,215,47,168,330
Actemra (JIA),tocilizumab,Hoffmann-La Roche Ltd.,Y,Y,N,N,N,Y,N,Y,N,,19-Jan-12,,CADTH & INESSS,30-Jan-12,post-NOC,Initial,"Arthritis, juvenile idiopathic ",Completed,19-Jul-12,List with clinical criteria and/or conditions,Conditional,,,New Indication,JIA,Completed,01-Oct-12,Ajout d'une indication reconnue par l'INESSS - Médicament d'exception,Conditional,none,,,,,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,11-Apr-13,01-Nov-12,01-Jan-13,17-Jul-13,,14-Feb-13,01-Feb-13,01-Oct-13,01-Jul-16,01-Oct-12,01-Nov-12,01-Oct-12,6,2,3,7,,5,4,8,9,1,28.60%,33.00%,38.80%,40.10%,41.00%,61.20%,66.70%,67.10%,67.80%,,67.80%,11-Apr-13,,11,,171,,,,,,,,,,,,,,,,,,,,448,287,348,545,,392,379,621,1625,256,581,545,287,276,105,266,105,166,363,,210,197,439,1443,0,399,182,256,,,,,,192,,41109
Actemra (pJIA),tocilizumab,Hoffmann-La Roche Ltd.,Y,Y,N,N,N,Y,N,Y,N,,17-Oct-13,,CADTH & INESSS,29-Jul-13,pre-NOC,Initial,Polyarticular juvenile idiopathic arthritis,Completed,19-Mar-14,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Indication,pJIA,Completed,02-Feb-15,Ajout d'une indication reconnue - Médicament d'exception,Conditional,none,31-May-14,,Negotiation by Province,n/a,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,09-Dec-14,01-May-15,01-Nov-14,19-Jan-15,09-Apr-14,12-Apr-16,01-Jun-16,25-Apr-16,01-Jul-16,02-Feb-15,09-Apr-14,09-Apr-14,3,6,2,4,1,7,9,8,10,5,32.20%,38.00%,58.20%,63.70%,92.30%,96.80%,97.70%,98.00%,99.30%,100.00%,100.00%,09-Dec-14,02-Feb-15,-80,291,233,182,73,-247,,,,,,,,,,,,,,,,,418,561,380,459,174,908,958,921,988,473,641,624,174,254,21,265,408,227,306,21,755,805,768,835,0,488,153,473,,,473,299,299,244,55,41717
Actemra SC (RA),tocilizumab,Hoffmann-La Roche Ltd.,Y,Y,N,N,N,N,N,N,N,,06-May-14,,CADTH & INESSS,03-Mar-14,pre-NOC,Initial,"Arthritis, Rheumatoid",Completed,19-Feb-15,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Form,"Arthritis, Rheumatoid",Completed,02-Feb-15,Avis de refus,Negative,1st,01-May-15,16-Dec-15,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,19-Feb-16,01-Mar-16,01-May-16,18-Apr-16,,12-Apr-16,01-Jun-16,25-Apr-16,01-Jul-16,15-Jun-16,19-Feb-16,19-Feb-16,1,2,6,4,,3,7,5,9,8,20.30%,24.70%,25.60%,31.10%,31.50%,37.20%,38.50%,67.10%,67.80%,,67.80%,15-Jun-16,,-64,90,353,182,71,88,229,65,76,137,124,,118,168,131,198,182,127,65,133,65,,654,665,726,713,,707,757,720,787,771,716,722,654,718,365,365,376,437,424,,418,468,431,498,499,427,289,272,300,317,,,,117,,42054
Actikerall,fluorouracil and Salicylic Acid,Cipher Pharmaceuticals ,N,N,N,N,N,N,N,N,N,,28-Aug-15,,CADTH,31-Aug-16,post-NOC,Initial,Hyperkeratotic actinic keratosis,Completed,22-Mar-17,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,23-Feb-18,22-Aug-18,Negotiation,Completed with Agreements,NR,FB,FB,FB,FB,FB,FB,FB,SA,NR,,01-Dec-18,01-Jan-19,24-Jan-19,31-Oct-18,08-Nov-18,01-Apr-19,24-Dec-18,20-Dec-18,,31-Oct-18,31-Oct-18,,3,6,7,1,2,8,5,4,,32.20%,33.10%,37.60%,38.30%,38.60%,44.30%,49.90%,51.20%,,,51.20%,01-Apr-19,,369,,203,,338,,180,,101,132,155,70,78,222,124,120,,125,70,125,70,,,1191,1222,1245,1160,1168,1312,1214,1210,,1215,1215,1160,791,588,,619,650,673,588,596,740,642,638,,643,572,,518,,,,,152,,42816
Adcetris,brentuximab vedotin,Seattle Genetics,N,Y,N,Y,Y,Y,Y,Y,N,,01-Feb-13,,CADTH & INESSS,14-Mar-13,post-NOC,New drug,Hodgkin Lymphoma (HL):For HL patients after failure of ASCT or after failure of at least two prior therapies in patients who are not ASCT candidates,Completed,29-Aug-13,Cond'l on Cost,Conditional,01-Oct-13,post-NOC,New Drug,Hodgkin Lymphoma (HL):For HL patients after failure of ASCT or after failure of at least two prior therapies in patients who are not ASCT candidates,Completed,02-Jun-14,Ajout d’une indication reconnue à la Liste Établissements – Médicament d’exception – Avec l’instauration d’un suivi clinique,Conditional,1st,,31-Jan-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jun-14,01-May-14,04-Feb-14,01-Mar-14,19-Feb-14,01-Oct-14,01-Jan-15,,25-Jun-18,02-Jun-14,04-Feb-14,04-Feb-14,5,4,1,3,2,7,8,,9,6,5.70%,38.00%,43.50%,47.90%,68.20%,96.80%,97.70%,99.00%,99.60%,,99.60%,01-Jun-14,02-Jun-14,41,242,168,244,,,,121,90,4,29,19,243,335,,1606,122,306,4,285,4,122,485,454,368,393,383,607,699,,1970,486,670,649,368,327,159,276,245,159,184,174,398,490,,1761,0,461,209,486,155,-122,486,118,118,117,1,41515
Adcetris,brentuximab vedotin,Seattle Genetics,N,Y,N,Y,Y,Y,Y,Y,N,,01-Feb-13,,CADTH & INESSS,15-Mar-13,post-NOC,New drug,Systemic Anaplastic Large Cell Lymphoma (sALC),Completed,05-Dec-13,Cond'l on Cost,Conditional,02-Aug-13,post-NOC,New Drug,Systemic Anaplastic Large Cell Lymphoma (sALC),Completed,03-Feb-14,Ajout à la Liste Établissements - Médicament d'exception - Conditionnel à ce que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable et à l'instauration d'un suivi,Conditional,1st,04-Sep-13,31-Jan-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jun-14,01-May-14,04-Feb-14,01-Mar-14,19-Feb-14,01-Oct-15,01-Jan-15,,25-Jun-18,03-Feb-14,04-Feb-14,03-Feb-14,6,5,2,4,3,8,7,,9,1,28.60%,34.30%,66.50%,72.10%,76.50%,96.80%,98.10%,99.00%,99.60%,,99.60%,19-Feb-14,01-Jun-14,42,182,265,185,-92,-152,149,121,90,4,29,19,608,335,,1606,3,352,4,313,3,121,485,454,368,393,383,972,699,,1970,367,716,677,368,326,61,178,147,61,86,76,665,392,,1663,0,409,307,367,57,-3,485,118,117,16,102,41613
Adcetris,brentuximab vedotin,Seattle Genetics,N,Y,N,N,Y,Y,Y,Y,N,,20-Jul-17,,CADTH,05-Apr-16,pre-NOC,New indication,Hodgkin Lymphoma (post-ASCT consolidation): For post-ASCT consolidation treatment of patients with Hodgkin Lymphoma (HL) at high risk of relapse or progression,Withdrawn,07-Jul-16,n/a,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-471,,93,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-378,,,,,,,,,42558
Adcetris,brentuximab vedotin,Seattle Genetics,N,Y,N,N,Y,Y,Y,Y,N,,20-Jul-17,,CADTH,10-Aug-17,post-NOC,Resubmission,Hodgkin’s Lymphoma at high risk of relapse or progression post-ASCT,Completed,21-Feb-18,Cond'l on Cost,Conditional,,,,,,,,,1st,22-Jun-18,13-Mar-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,EM,01-Feb-19,10-Apr-20,01-May-19,01-Apr-19,17-Dec-19,25-Jul-19,01-Jul-19,,29-Jul-19,11-Apr-19,01-Feb-19,01-Feb-19,1,9,4,2,8,6,5,,7,3,20.30%,25.80%,54.40%,60.10%,61.40%,62.30%,63.00%,95.20%,99.60%,,99.60%,11-Apr-19,17-Dec-19,21,,195,,121,,264,-40,394,49,19,279,134,110,,138,29,135,-40,124,-40,279,561,995,650,620,880,735,711,,739,630,736,725,561,540,345,345,779,434,404,664,519,495,,523,,520,216,,385,,880,319,319,69,250,43152
Adcetris,brentuximab vedotin,Seattle Genetics,N,Y,N,N,Y,Y,Y,Y,N,01-May-19,22-Nov-19,205,CADTH & INESSS,08-Oct-19,pre-NOC,New indication,"Peripheral T-Cell Lymphoma (PTCL): For the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).",Completed,04-Jun-20,Fund,Positive,25-Oct-19,pre-NOC,New Indication,"Peripheral T-Cell Lymphoma (PTCL): For the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).",Completed,10-Jun-20,Inscription - Avec conditions,Conditional,1st,03-Jul-20,21-Sep-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,01-Dec-20,28-Feb-21,01-Jan-21,25-Aug-22,31-Jan-22,,,,,11-Nov-20,01-Dec-20,11-Nov-20,2,4,3,6,5,,,,,1,28.60%,48.80%,54.60%,59.00%,91.20%,96.80%,,,,,96.80%,01-Jan-21,31-Jan-22,-45,-28,240,229,29,23,80,71,160,102,703,497,,,,,51,307,71,264,51,497,375,464,406,1007,801,,,,,355,611,568,375,420,180,180,269,211,812,606,,,,,154,416,195,201,109,103,801,446,426,51,395,400
Adcetris,brentuximab vedotin,Seattle Genetics,N,Y,N,N,Y,Y,Y,Y,N,01-Apr-18,21-Dec-18,264,CADTH & INESSS,30-Mar-20,post-NOC,New indication,Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-Expressing Mycosis Fungoides,Completed,03-Dec-20,Cond'l on Cost,Conditional,08-May-20,post-NOC,New Indication,Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-Expressing Mycosis Fungoides,Completed,14-Oct-20,Inscription - Avec conditions,Conditional,1st,05-Feb-21,28-Apr-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,01-Aug-21,01-Jul-21,01-Aug-21,07-Mar-22,31-Jan-22,,,,,18-Aug-21,01-Jul-21,01-Jul-21,2,1,3,6,5,,,,,4,4.50%,24.70%,30.40%,59.00%,91.20%,96.80%,,,,,96.80%,18-Aug-21,31-Jan-22,465,504,248,159,64,114,82,95,64,95,313,278,,,,,112,169,64,160,64,278,954,923,954,1172,1137,,,,,971,1028,1019,923,458,210,241,210,241,459,424,,,,,308,315,713,663,146,196,1137,214,214,48,166,977
Adcetris,brentuximab vedotin,Seattle Genetics,N,Y,N,N,Y,Y,Y,Y,N,01-Jul-18,02-May-19,305,CADTH & INESSS,02-Apr-20,post-NOC,New indication,"Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)",Completed,03-Dec-20,Cond'l on Cost,Conditional,22-May-20,post-NOC,New Indication,"Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)",Completed,05-Nov-20,Inscription - Avec conditions,Conditional,1st,05-Feb-21,28-Apr-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,01-Aug-21,31-Jul-21,01-Aug-21,25-Aug-22,30-Nov-21,,,,,18-Aug-21,31-Jul-21,31-Jul-21,2,1,3,6,5,,,,,4,4.50%,24.70%,30.40%,59.00%,91.20%,96.80%,,,,,96.80%,18-Aug-21,30-Nov-21,336,386,245,167,64,92,82,95,94,95,484,216,,,,,112,197,94,183,94,216,822,821,822,1211,943,,,,,839,924,910,821,485,240,241,240,241,630,362,,,,,286,343,581,553,146,174,943,122,122,18,104,886
Adcetris (Resubmission),brentuximab vedotin,Seattle Genetics,N,Y,N,Y,Y,Y,Y,Y,N,,01-Feb-13,,CADTH,27-Aug-18,post-NOC,Resubmission,Hodgkin Lymphoma: For the treatment of patients with HL after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates,Completed,07-Mar-19,Do Not Fund,Negative,,,,,,,,,None,17-May-19,,Do Not Negotiate,n/a,Funded,Not funded,Not funded,Under provincial consideration,Funded,Not funded,Under provincial consideration,Not funded,Not funded,NR,01-Jun-14,,,,30-Nov-21,,,,,,01-Jun-14,01-Jun-14,1,,,,2,,,,,,20.30%,52.50%,,,,,,,,,52.50%,30-Nov-21,,2033,,192,,71,,,,,,,,,,,,,,,,,,485,,,,3224,,,,,,1855,1855,485,-1548,-1740,-1740,,,,999,,,,,,-371,2225,,,,,,,2739,,43531
Adempas (PAH WHO I),riociguat,Bayer ,Y,N,N,N,N,Y,Y,Y,N,,06-Mar-14,,CADTH & INESSS,25-Jun-15,post-NOC,Initial,Pulmonary arterial hypertension (WHO group 1),Completed,17-Dec-15,List with clinical criteria and/or conditions,Conditional,04-Aug-14,post-NOC,New Indication,Pulmonary arterial hypertension (WHO group 1),Completed,02-Feb-15,Avis de refus - Valeur thérapeutique,Negative,1st,31-Oct-16,31-Jan-17,Negotiation,No agreement reached,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,476,151,175,182,319,637,92,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,651,333,411,729,,,,,,42355
Adempas (PH),riociguat,Bayer ,Y,N,N,Y,N,Y,Y,Y,N,,19-Sep-13,,CADTH & INESSS,30-Sep-13,post-NOC,Initial,"Pulmonary hypertension, chronic thromboembolic (CTEPH)",Completed,17-Jul-14,List with criteria/condition,Conditional,,,New Drug,"Pulmonary hypertension, chronic thromboembolic (CTEPH)",Completed,24-Apr-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,31-Aug-14,23-Jan-15,Negotiation,Completed with Agreements,NR,NR,EDS,EDS,EAP,SA,EDS,SA,SA,EM,,,01-Jul-15,20-Apr-15,11-Feb-15,23-Jul-15,29-Jun-15,01-Aug-18,01-Jun-15,24-Apr-14,11-Feb-15,24-Apr-14,,,6,3,2,7,5,8,4,1,28.60%,60.80%,66.30%,67.00%,68.30%,74.00%,74.90%,75.30%,,,75.30%,11-Feb-15,,11,,290,,45,129,145,,,159,87,19,181,157,1286,129,-274,288,19,218,-274,,,,650,578,510,672,648,1777,620,217,779,709,510,499,209,,,349,277,209,371,347,1476,319,0,478,301,217,190,274,,,,293,,41837
Adlyxine,lixisenatide,Sanofi-Aventis ,Y,N,N,Y,N,N,N,N,N,01-Jun-16,25-May-17,358,CADTH & INESSS,29-May-17,post-NOC,Initial,"Diabetes mellitus, Type 2",Completed,23-Nov-17,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,Diabetes,Completed,01-Feb-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,27-Apr-18,21-Nov-19,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,FB,SA,EDS,SA,SA,NR,,01-Jul-20,01-Jan-21,05-Aug-21,20-Dec-19,21-May-20,19-Apr-22,28-Mar-22,03-May-22,,20-Dec-19,20-Dec-19,,3,4,5,1,2,7,6,8,,32.20%,33.10%,37.60%,43.30%,48.80%,49.20%,50.50%,51.20%,,,51.20%,19-Apr-22,,4,,178,,155,85,573,,223,407,623,29,182,880,858,894,,512,29,512,29,,,1133,1317,1533,939,1092,1790,1768,1804,,1422,1422,939,935,757,,951,1135,1351,757,910,1608,1586,1622,,1240,182,252,728,658,,,,851,,540
Admelog (Cancelled),insulin lispro,sanofi-aventis Canada Inc.,Y,Y,Y,N,N,N,N,N,N,01-Jan-17,16-Nov-17,319,CADTH & INESSS,N/A,na,n/a,"Diabetes mellitus, Type 1 & 2",Cancelled,,Cancelled or withdrawn,n/a,,,New Drug,Diabetes,Completed,14-May-20,Inscription,Positive,1st,29-Jan-20,30-Sep-20,Negotiation,Completed with Agreements,FB,FB,FB,FB,FB,FB,,FB,FB,FB,30-Nov-21,01-Aug-21,01-Jan-21,01-Apr-21,18-Dec-20,26-Nov-20,,27-Sep-21,03-May-22,03-Mar-21,26-Nov-20,26-Nov-20,8,6,3,5,2,1,,7,9,4,0.90%,33.10%,38.80%,67.40%,73.00%,77.40%,77.80%,98.00%,98.70%,,98.70%,03-Mar-21,30-Nov-21,,,,,,-106,245,426,305,93,183,79,57,,362,580,154,261,57,249,57,426,1475,1354,1142,1232,1128,1106,,1411,1629,1203,1310,1298,1106,,,,,,,,,,,,293,,,910,,139,1475,369,369,97,272,-42736
Adtralza,tralokinumab,LEO Pharma Inc.,N,Y,N,Y,N,N,N,N,Y,01-Dec-20,13-Oct-21,316,CADTH & INESSS,27-Apr-21,pre-NOC,Initial,atopic dermatitis,Completed,07-Mar-22,Do not reimburse,Negative,20-Aug-21,pre-NOC,New Drug,Moderate to severe atopic dermatitis,Completed,04-Feb-22,Refus d'inscription,Negative,none,03-May-22,,Do Not Negotiate,n/a,NR,,NR,,,NR,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-169,-54,314,168,57,88,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,145,114,,,,,,,,461
Aduhelm,aducanumab,"Biogen Canada, Inc.",N,Y,N,Y,N,N,N,N,N,01-Jun-21,,,CADTH & INESSS,26-Nov-21,na,Initial,Alzheimer's disease,Withdrawn,09-Jun-22,Cancelled or withdrawn,n/a,25-Mar-22,,New Drug,Alzheimer's disease,withdrawn,n/a,n/a,n/a,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,195,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,373
Aermony RespiClick,fluticasone propionate ,Teva Canada Innovation,N,N,N,N,N,N,N,N,N,01-Oct-16,22-Aug-17,325,CADTH & INESSS,04-Oct-17,post-NOC,Initial,Asthma,Completed,19-Dec-18,Reimburse with clinical criteria and/or conditions,Conditional,11-Jan-20,post-NOC,New drug,Asthma,Completed,14-May-20,Inscription - Avec conditions,Conditional,1st,12-Apr-19,31-Jul-19,Negotiation,No agreement reached,FB,FB,FB,FB,FB,FB,FB,FB,FB,FB,12-Aug-21,01-Apr-21,01-May-21,05-Aug-21,29-Mar-21,22-Apr-21,22-Feb-22,22-Nov-21,07-Jul-21,03-Mar-21,29-Mar-21,03-Mar-21,8,3,5,7,2,4,10,9,6,1,28.60%,60.80%,65.30%,66.20%,71.90%,72.60%,78.10%,98.30%,98.70%,100.00%,100.00%,29-Mar-21,12-Aug-21,43,872,441,124,114,-398,110,743,610,640,736,607,631,937,845,707,581,717,607,704,581,743,1451,1318,1348,1444,1315,1339,1645,1553,1415,1289,1425,1412,1315,1272,831,967,834,864,960,831,855,1161,1069,931,293,941,484,996,224,-288,1451,162,136,26,136,809
Afinitor,everolimus,Novartis,Y,N,N,N,Y,Y,N,Y,N,,02-Feb-12,,CADTH & INESSS,27-Feb-12,post-NOC,New indication,GI: Pancreatic neuroendocrine tumours ,Completed,30-Aug-12,Cond'l on Cost,Conditional,,,New Indication,GI: Pancreatic neuroendocrine tumours ,Completed,15-Nov-12,Avis de refus (2.5mg and 5mg); Ajout d'une indication reconnue - Méd. d'exc. - Conditionnel à une entente de partage de risque financier (10mg),Conditional,1st,26-Aug-13,11-Oct-13,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jun-11,25-Mar-13,01-Feb-13,17-Jul-14,08-Nov-13,19-Dec-13,01-Oct-14,,06-Mar-14,15-Nov-12,01-Jun-11,01-Jun-11,1,4,3,8,5,6,9,,7,2,20.30%,48.80%,54.60%,59.00%,91.20%,92.10%,92.80%,98.30%,99.60%,,99.60%,01-Feb-13,08-Nov-13,25,,185,,361,284,46,-863,-200,-252,279,28,69,355,,146,-330,-55,-863,-85,-863,28,-246,417,365,896,645,686,972,,763,287,562,532,-246,-271,-456,-456,207,155,686,435,476,762,,553,0,352,210,287,407,330,645,891,891,611,280,41151
Afinitor,everolimus,Novartis,Y,N,N,N,Y,N,N,N,N,,10-Jan-13,,CADTH & INESSS,05-Sep-12,pre-NOC,New indication,Advanced Breast Cancer,Completed,25-Mar-13,Cond'l on Cost,Conditional,02-Aug-13,post-NOC,New Indication,Advanced Breast Cancer,Completed,03-Feb-14,"Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable (10 mg) Avis de refus (2,5 mg, 5 mg)",Conditional,1st,,31-Jan-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Dec-13,19-Dec-13,16-Dec-13,17-Jul-14,08-Nov-13,19-Dec-13,01-Oct-14,,06-Mar-14,03-Feb-14,08-Nov-13,08-Nov-13,2,4,3,8,1,5,9,,7,6,32.20%,52.50%,58.20%,62.70%,63.60%,92.10%,92.80%,98.30%,99.60%,,99.60%,01-Dec-13,03-Feb-14,-127,204,201,185,,,,-61,-43,-46,167,-84,-43,243,,34,3,21,-84,19,-84,3,325,343,340,553,302,343,629,,420,389,407,405,302,429,228,251,269,266,479,228,269,555,,346,0,333,74,389,312,-3,389,87,87,23,64,41358
Afinitor,everolimus,Novartis,Y,N,N,N,Y,Y,N,Y,N,,17-May-16,,CADTH & INESSS,30-May-16,post-NOC,New indication,"Endocrine, neuroendocrine tumours of GI or lung origin",Completed,01-Dec-16,Cond'l on Cost,Conditional,12-Aug-16,post-NOC,New Indication,Neuroendocrine tumours of Gastrointestinal or Lung origin,Completed,01-Feb-17,Avis de refus d’ajout d’une indication reconnue aux listes des médicaments – Médicament d’exception – À moins que certaines conditions soient respectées,Conditional,1st,31-Mar-17,01-Sep-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,,Funded,EM,01-Feb-18,04-Sep-18,01-Oct-17,28-Jan-18,20-Nov-17,20-Mar-18,30-May-21,,29-Jul-19,15-Dec-17,01-Oct-17,01-Oct-17,5,7,1,4,2,6,9,,8,3,5.70%,38.00%,66.50%,72.10%,92.30%,93.20%,97.70%,98.30%,99.60%,,99.60%,15-Dec-17,01-Feb-18,13,87,185,173,120,58,154,153,368,30,149,80,200,1367,,696,105,380,30,350,30,153,625,840,502,621,552,672,1839,,1168,577,852,822,502,489,304,427,642,304,423,354,474,1641,,970,317,654,198,260,274,212,625,123,123,75,48,42705
Afinitor (TSC),everolimus ,Novartis ,Y,N,N,N,N,Y,N,Y,N,,25-Jan-13,,CADTH,08-Mar-13,post-NOC,Initial,Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) ,Completed,25-Sep-13,Do not list ,Negative,,,,,,,,,none,01-Nov-13,,Do Not Negotiate,n/a,NR,NR,NR,NR,EAP,NR,NR,NR,NR,NR,,,,,08-Nov-13,,,,,,08-Nov-13,08-Nov-13,,,,,1,,,,,,32.20%,,,,,,,,,,32.20%,,,42,,201,,37,,,,,,,,,,,,,,,,,,,,,,287,,,,,,287,287,287,245,44,,,,,44,,,,,,44,243,,,,,,,,,41542
Aimovig,erenumab,Novartis,Y,Y,N,Y,N,N,N,N,N,01-Oct-17,01-Aug-18,304,CADTH & INESSS,02-May-19,post-NOC,Initial,Migraine,Completed,22-Jul-20,Reimburse with clinical criteria and/or conditions,Conditional,07-Jun-19,post-NOC,New Drug,Migraine,Completed,11-Dec-19,Refus d'inscription,Negative,1st,25-Jan-21,13-Dec-21,Negotiation,No agreement reached,NR,,NR,,,NR,,,NR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,274,310,447,187,187,411,322,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,721,497,509,733,,,,,,1025
Ajovy,fremanezumab,Teva Canada Innovation,N,Y,N,Y,N,N,N,N,N,01-Jun-19,09-Apr-20,313,CADTH & INESSS,03-Jun-20,post-NOC,Initial,migraine,Completed,24-Mar-21,Reimburse with clinical criteria and/or conditions,Conditional,18-Sep-20,post-NOC,New Drug,Migraine,Completed,31-Mar-21,Refus d'inscription,Negative,1st,16-Jul-21,03-Dec-21,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,FB,SA,EM,29-Mar-22,01-Feb-22,01-Feb-22,01-Jun-22,09-Jun-22,24-Mar-22,21-Mar-22,28-Dec-22,05-Apr-22,02-Feb-22,01-Feb-22,01-Feb-22,6,1,2,8,9,5,4,10,7,3,4.50%,10.20%,38.80%,40.10%,41.00%,61.20%,61.90%,67.40%,99.60%,100.00%,100.00%,29-Mar-22,09-Jun-22,55,162,294,194,114,107,140,116,60,60,180,188,111,108,390,123,61,148,60,140,60,188,719,663,663,783,791,714,711,993,726,664,751,743,663,608,314,370,314,314,434,442,365,362,644,377,308,402,349,356,254,247,791,128,128,56,72,662
Akynzeo,netupitant / palonosetron,Purdue Pharma,N,N,N,Y,N,N,N,N,N,01-Dec-16,28-Sep-17,301,CADTH & INESSS,08-Dec-17,post-NOC,Initial,Nausea and vomiting (chemotherapy induced) prevention,Completed,20-Jun-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,Nausea and vomiting (chemotherapy induced) prevention,Completed,09-May-18,Avis de refus d’inscription aux listes des médicaments (chimiothérapie hautement émétisante) Avis de refus d’inscription aux listes des médicaments ? Valeur thérapeutique (chimiothérapie modérément émétisante),Negative,1st,19-Sep-18,24-Apr-19,Negotiation,Completed with Agreements,SA,UR,NR,EDS,LU,SA,EDS,SA,SA,EM,26-Nov-19,,,16-Jul-20,28-Jun-19,07-Nov-19,01-Sep-19,23-Sep-19,18-Jul-19,04-Jul-19,28-Jun-19,28-Jun-19,7,,,8,1,6,4,5,3,2,32.20%,60.80%,61.50%,62.80%,63.10%,64.00%,84.30%,89.80%,,,89.80%,04-Jul-19,26-Nov-19,71,,194,,91,133,217,216,,,449,65,197,130,152,85,71,185,65,171,65,216,789,,,1022,638,770,703,725,658,644,758,744,638,567,373,524,,,757,373,505,438,460,393,421,493,265,223,308,350,789,151,151,6,145,566
Albrioza,sodium phenylbutyrate and ursodoxicoltaurine,Amylyx Canada,N,N,N,Y,N,N,Y,Y,Y,01-Aug-21,10-Jun-22,313,CADTH & INESSS,24-Nov-21,pre-NOC,Initial,Amyotrophic lateral sclerosis (ALS),Completed,21-Jul-22,Reimburse with clinical criteria and/or conditions,Conditional,04-Mar-22,pre-NOC,New Drug,Treatment of amyotrophic lateral sclerosis,Completed,27-Jul-22,Refus d'inscription,Negative,1st,09-Aug-22,,Active,n/a,UR,,,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-198,-98,239,145,19,13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,41,47,,,,,,,,354
Alecensaro,alectinib,Hoffman-La Roche ,Y,N,N,Y,Y,Y,N,Y,N,01-Feb-16,29-Sep-16,241,CADTH & INESSS,03-Oct-16,post-NOC,New drug,Non-Small Cell Lung Cancer (with CNS metastases) ,Completed,04-May-17,Do not fund,Negative,24-Nov-16,post-NOC,New Drug,Non-Small Cell Lung Cancer (with CNS metastases),Completed,01-Jun-17,Avis de refus d'inscription aux listes des médicaments,Negative,None,31-Jul-17,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,4,56,213,189,88,60,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,217,245,,,,,,,,458
Alecensaro,alectinib,Hoffman-La Roche ,Y,N,N,N,Y,Y,N,Y,N,01-Feb-16,29-Sep-16,241,CADTH & INESSS,18-Aug-17,post-NOC,New indication,Locally advanced or metastatic non-small cell lung cancer (second line),Completed,29-Mar-18,Cond'l on Cost,Conditional,24-Nov-16,post-NOC,New Drug,Locally advanced or metastatic non-small cell lung cancer (second line),Completed,01-Jun-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,07-Sep-18,11-Dec-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-May-19,01-Mar-19,11-Feb-19,31-May-19,17-Apr-19,16-May-19,03-Oct-19,,27-Sep-19,01-Feb-19,11-Feb-19,01-Feb-19,5,3,2,7,4,6,9,,8,1,28.60%,34.30%,38.80%,71.00%,91.20%,92.10%,97.70%,98.30%,99.60%,,99.60%,17-Apr-19,01-May-19,323,56,223,189,162,463,95,141,80,62,171,127,156,296,,290,52,165,62,153,52,141,944,883,865,974,930,959,1099,,1093,855,968,956,865,542,319,398,337,319,428,384,413,553,,547,610,422,546,245,257,558,944,89,79,75,14,787
Alecensaro,alectinib,Hoffman-La Roche ,Y,N,N,N,Y,Y,N,Y,N,01-Dec-17,11-Jun-18,192,CADTH & INESSS,15-Jan-18,pre-NOC,New indication,Non-Small Cell Lung Cancer (first line),Completed,25-Jul-18,Cond'l on Cost,Conditional,,,New Indication,Locally advanced or metastatic ALK+ NSCLC (first line),Completed,05-Sep-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,07-Sep-18,11-Dec-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-May-19,01-Mar-19,11-Feb-19,31-May-19,17-Apr-19,16-May-19,03-Oct-19,06-Dec-21,27-Sep-19,01-Feb-19,11-Feb-19,01-Feb-19,5,3,2,7,4,6,9,10,8,1,28.60%,34.30%,38.80%,71.00%,91.20%,92.10%,97.70%,98.30%,99.60%,100.00%,100.00%,17-Apr-19,01-May-19,-147,,191,,44,2,95,141,80,62,171,127,156,296,1091,290,52,268,62,247,52,141,324,263,245,354,310,339,479,1274,473,235,451,430,245,392,201,280,219,201,310,266,295,435,1230,429,149,407,44,86,139,97,324,89,79,75,14,236
Alimta,pemetrexed,Eli Lilly,N,N,N,N,Y,N,N,N,N,,09-May-13,,CADTH & INESSS,31-May-13,post-NOC,New indication,Advanced Non-Squamous Non Small Cell Lung Cancer,Completed,19-Nov-13,Cond'l on Cost,Conditional,07-Aug-13,post-NOC,New Indication,Advanced Non-Squamous Non Small Cell Lung Cancer - maintenance after pemetrexed or cisplatin,Completed,03-Feb-14,Avis de refus - à moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable,Conditional,1st,09-Dec-13,28-Feb-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-May-14,01-May-14,03-Mar-14,01-Jun-14,01-Apr-14,01-Sep-14,01-Apr-14,23-Nov-15,01-Apr-14,01-Oct-14,03-Mar-14,03-Mar-14,5,6,1,7,2,8,3,10,4,9,5.70%,38.00%,39.30%,39.90%,60.20%,64.60%,70.20%,71.10%,99.60%,100.00%,100.00%,01-May-14,01-Oct-14,22,90,172,180,20,-56,81,62,62,3,93,32,185,32,633,32,215,126,3,135,3,215,357,357,298,388,327,480,327,928,327,510,421,430,298,276,104,163,163,104,194,133,286,133,734,133,240,227,194,270,101,25,510,212,212,59,153,41597
Aloxi (capsule),palonosetron hydrocholoride ,Eisai Ltd. ,N,N,N,Y,N,N,N,N,N,,14-Mar-12,,CADTH & INESSS,05-Oct-12,post-NOC,Initial,Nausea and vomiting (chemotherapy induced) prevention ,Completed,24-Apr-13,Do not list ,Negative,,,New Drug,Nausea and vomiting (chemotherapy induced) prevention ,Completed,01-Oct-13,Avis de refus,Negative,none,21-Aug-13,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,205,,201,,119,-41,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,406,566,,,,,,,,41388
Aloxi (capsule) (Resub) (Withdrawn),palonosetron,Eisai Ltd. ,N,N,N,Y,N,N,N,N,N,,14-Mar-12,,CADTH,06-Feb-15,post-NOC,Resubmission,Nausea and vomiting (chemotherapy induced) prevention ,Withdrawn,30-Jul-15,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,1059,,174,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1233,,,,,,,,,42215
Aloxi (injection),palonosetron hydrocholoride ,Eisai Ltd. ,N,N,N,Y,N,N,N,N,N,,14-Mar-12,,CADTH & INESSS,05-Oct-12,post-NOC,Initial,Nausea and vomiting (chemotherapy induced) prevention ,Completed,15-May-13,Do not list at the submitted price ,Negative,,,New Drug,Nausea and vomiting (chemotherapy induced) prevention ,Completed,01-Feb-13,Avis de refus - Valeur thérapeutique,Negative,none,21-Aug-13,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,205,,222,,98,201,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,427,324,,,,,,,,41409
Alsitek,masitinib mesylate,AB Science SA,N,N,N,Y,N,Y,Y,Y,Y,01-May-22,,,CADTH,28-Oct-22,na,Initial,Amyotrophic lateral sclerosis (ALS),Suspended,,Suspended,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44682
Alunbrig,brigatinib,Takeda ,Y,N,N,Y,Y,Y,N,Y,N,01-Nov-17,26-Jul-18,267,CADTH & INESSS,05-Dec-18,post-NOC,New drug,For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on or who were intolerant to an ALK inhibitor (crizotinib),Completed,01-Aug-19,Do Not Fund,Negative,03-Dec-18,post-NOC,New Drug,Non-Small Cell Lung Cancer (NSCLC),Completed,10-Jul-19,Refus d'inscription,Negative,None,05-Sep-19,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,132,130,239,219,35,57,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,371,349,,,,,,,,638
Alunbrig,brigatinib,Takeda ,Y,N,N,N,Y,Y,N,Y,N,01-May-20,03-Mar-21,306,CADTH & INESSS,30-Sep-20,pre-NOC,New indication,For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor,Completed,21-Apr-21,Cond'l on Cost,Conditional,02-Oct-20,pre-NOC,New Indication,Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer,Completed,07-May-21,Inscription - Avec conditions,Conditional,1st,29-Oct-21,16-Dec-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jun-22,28-Feb-22,01-Mar-22,01-Jun-22,28-Feb-22,29-Apr-22,11-Jul-22,26-Sep-22,31-Oct-22,02-Feb-22,28-Feb-22,02-Feb-22,6,2,4,7,3,5,8,9,10,1,28.60%,33.00%,65.30%,71.00%,71.90%,92.10%,97.70%,99.00%,99.30%,100.00%,100.00%,28-Feb-22,01-Jun-22,-154,-152,203,217,191,175,48,167,74,75,167,74,134,207,284,319,48,167,74,155,48,167,455,362,363,455,362,422,495,572,607,336,455,443,362,516,313,406,313,314,406,313,373,446,523,558,271,406,49,65,239,223,455,119,93,26,93,355
Anoro Ellipta,umeclidinium / vilanterol,GlaxoSmithKline,Y,N,N,Y,N,N,N,N,N,,23-Dec-13,,CADTH & INESSS,26-Feb-14,post-NOC,Initial,COPD (Chronic Obstructive Pulmonary Disease),Completed,15-Jan-15,List with criteria/condition,Conditional,,,New Drug,COPD,Completed,01-Feb-16,Avis d'inscription aux listes de médicaments - Médicament d'exception,Conditional,1st,04-Feb-15,01-May-15,Negotiation,Completed with Agreements,SA,SA,EDS,FB,LU,SA,EDS,SA,SA,EM,11-Aug-15,01-Jun-15,01-Jul-15,22-Jul-15,29-Jun-15,29-Jun-15,01-Sep-15,21-Sep-15,01-Oct-15,24-Mar-16,01-Jun-15,01-Jun-15,6,1,4,5,2,3,7,8,9,10,4.50%,36.70%,37.60%,43.30%,48.80%,69.10%,70.40%,70.70%,71.40%,100.00%,100.00%,11-Aug-15,24-Mar-16,65,,323,,20,-362,86,102,31,61,82,59,59,123,143,153,328,90,31,114,31,328,596,525,555,576,553,553,617,637,647,822,584,608,525,460,137,208,137,167,188,165,165,229,249,259,52,196,388,770,106,-276,822,297,297,71,226,42019
Aptiom,eslicarbazepine acetate ,Sunovion Pharmaceuticals ,N,N,N,Y,N,N,N,N,N,,08-Jul-14,,CADTH & INESSS,15-Aug-14,post-NOC,Initial,"Epilepsy, partial-onset seizures ",Completed,16-Apr-15,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Drug,"Epilepsy, partial-onset seizures ",Completed,02-Feb-15,Avis de refus,Negative,1st,15-Jun-15,08-Sep-15,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,10-Nov-15,01-Nov-15,01-Jan-16,18-Jan-16,26-Nov-15,01-Mar-16,01-Mar-16,25-Apr-16,01-Dec-15,15-Mar-17,01-Nov-15,01-Nov-15,2,1,5,6,3,7,8,9,4,10,4.50%,24.70%,56.90%,57.60%,63.30%,68.90%,69.80%,71.10%,71.40%,100.00%,100.00%,26-Nov-15,15-Mar-17,38,27,244,182,60,133,85,63,54,115,132,79,175,175,230,84,554,123,54,166,54,554,490,481,542,559,506,602,602,657,511,981,550,593,481,443,199,208,199,260,277,224,320,320,375,229,772,268,282,209,145,218,981,500,500,25,475,42110
Arbesda Respiclick,fluticasone propionate / salmeterol xinafoate,Teva Canada Innovation,N,N,N,N,N,N,N,N,N,01-Nov-16,06-Apr-18,521,CADTH,04-Oct-17,pre-NOC,Initial,Asthma,Completed,19-Dec-18,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,12-Apr-19,31-Jul-19,Negotiation,No agreement reached,NR,UR,NR,UR,UR,UR,UR,UR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-184,,441,,114,,110,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,257,,224,,,,,,,778
Arnuity Ellipta,fluticasone furoate,GlaxoSmithKline,Y,N,N,N,N,N,N,N,N,,21-Sep-15,,CADTH & INESSS,26-Jun-15,pre-NOC,Initial,Asthma,Completed,17-Dec-15,List with criteria/condition,Conditional,22-Mar-16,post-NOC,New Drug,Asthma,Completed,16-Dec-16,Avis d'inscription aux listes des médicaments,Positive,1st,13-Apr-16,08-Aug-16,Negotiation,Completed with Agreements,FB,FB,FB,FB,FB,FB,FB,FB,FB,FB,12-Oct-16,01-Feb-17,01-Oct-16,20-Oct-16,29-Sep-16,29-Sep-16,01-Dec-16,24-Apr-17,01-Apr-17,16-Dec-16,29-Sep-16,29-Sep-16,4,8,3,5,1,2,6,10,9,7,32.20%,33.10%,38.80%,59.10%,64.60%,65.90%,94.50%,99.00%,99.60%,100.00%,100.00%,12-Oct-16,16-Dec-16,-87,183,174,269,118,-247,117,65,177,54,73,52,52,115,259,236,130,120,52,121,52,130,387,499,376,395,374,374,437,581,558,452,442,443,374,461,287,300,412,289,308,287,287,350,494,471,0,355,87,452,235,-130,452,78,78,13,65,42355
Arzerra,ofatumumab,GlaxoSmithKline,Y,Y,N,N,Y,Y,Y,Y,N,,02-Oct-14,,CADTH & INESSS,14-Apr-14,pre-NOC,New drug,Chronic Lymphocytic Leukemia (CLL),Completed,29-Jan-15,Do Not Fund,Negative,22-Mar-15,post-NOC,New Drug,Chronic Lymphocytic Leukemia (CLL),Completed,01-Oct-15,Avis de refus - Valeur thérapeutique,Negative,None,27-Feb-15,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-171,171,290,193,29,-216,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,119,364,,,,,,,,42033
Atectura Breezhaler,indacaterol /mometasone furoate,Novartis Pharmaceuticals Canada Inc.,Y,N,N,N,N,N,N,N,N,01-Jul-19,06-May-20,310,CADTH & INESSS,19-May-20,post-NOC,Initial,"Asthma maintenance (adults, children 12 or older)",Completed,24-Nov-20,Reimburse with clinical criteria and/or conditions,Conditional,26-Jun-20,post-NOC,New Drug,Asthma,Completed,02-Dec-20,Inscription - Avec conditions,Conditional,1st,23-Jun-21,30-Sep-21,Negotiation,Completed with Agreements,SA,SA,EDS,FB,LU,SA,EDS,SA,SA,EM,14-Jun-22,01-Nov-21,01-Mar-22,24-Feb-22,28-Feb-22,16-Dec-21,30-Nov-21,28-Mar-22,11-May-22,15-Dec-21,01-Nov-21,01-Nov-21,10,1,7,5,6,4,2,8,9,3,4.50%,5.80%,34.30%,35.20%,40.80%,73.00%,78.70%,79.10%,79.70%,100.00%,100.00%,28-Feb-22,14-Jun-22,13,51,189,159,211,203,99,257,32,152,147,151,77,61,179,223,76,142,32,136,32,257,769,544,664,659,663,589,573,691,735,588,654,648,544,531,342,567,342,462,457,461,387,371,489,533,378,452,202,210,310,302,769,225,225,119,106,512
Atriance,nelarabine,Novartis,Y,N,N,N,Y,Y,Y,Y,N,,31-Jul-15,,CADTH,n/a,na,Request for Advice,Acute Lymphoblastic Leukemia,File-Closed Not Submitted,,n/a,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0
Atriance,nelarabine,N/A,N/A,N,N,N,Y,Y,Y,Y,N,,,,CADTH,06-Mar-23,na,Non-sponsored Submission,"Adition to front-line multi-agent therapy of pediatric, adolescent, and young adult (AYA) patients (aged 1–30 years at diagnosis) with intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL).",Active,,TBD,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0
Aubagio,teriflunomide,Sanofi Genzyme,Y,N,N,Y,N,N,N,N,N,,14-Nov-13,,CADTH & INESSS,28-Aug-13,pre-NOC,Initial,"Multiple Sclerosis, relapsing",Completed,18-Jun-14,Do not list at the submitted price,Negative,24-Nov-13,post-NOC,New Drug,"Multiple Sclerosis, relapsing",Completed,02-Jun-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,31-Jul-14,26-Sep-14,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,09-Dec-14,01-Dec-14,01-Nov-14,19-Jan-15,20-Nov-14,06-Mar-15,29-Dec-14,25-May-15,01-Mar-15,02-Jun-14,01-Nov-14,02-Jun-14,5,4,2,7,3,9,6,10,8,1,28.60%,34.30%,66.50%,71.00%,91.20%,92.60%,98.10%,98.80%,99.60%,100.00%,100.00%,20-Nov-14,09-Dec-14,-78,10,294,190,43,59,57,74,66,36,115,55,161,94,241,156,-116,111,36,88,-116,74,390,382,352,431,371,477,410,557,472,200,427,404,352,430,136,174,166,136,215,155,261,194,341,256,0,211,216,200,100,116,390,190,38,171,19,41808
Avastin,bevacizumab,Hoffman-La Roche ,Y,Y,N,N,Y,N,N,N,N,,,,CADTH,27-Oct-14,na,New indication,Cervical Cancer,Completed,23-Mar-15,Cond'l on Cost,Conditional,,,,,,,,,1st,30-Apr-15,04-Nov-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,,01-Apr-14,18-Dec-15,28-Dec-15,16-Nov-15,11-Jan-16,15-Dec-16,01-Feb-16,01-Aug-18,05-Nov-15,,01-Apr-14,01-Apr-14,1,4,5,3,6,8,7,9,2,,20.30%,20.90%,26.50%,30.90%,36.60%,68.90%,70.20%,71.10%,71.40%,,71.40%,11-Jan-16,,,,147,,38,,188,-582,44,54,12,68,407,89,1001,1,,122,-582,122,-582,,,,,,,,,,,,,,,-209,-356,-356,270,280,238,294,633,315,1227,227,,348,,,226,,,,,650,,42086
Avastin,bevacizumab,Hoffman-La Roche ,Y,Y,N,N,Y,Y,N,Y,N,,15-May-15,,CADTH & INESSS,28-Nov-14,pre-NOC,New indication,Ovarian Cancer,Completed,04-Jun-15,Cond'l on Cost,Conditional,,,New Indication,"In combination with paclitaxel and carboplatin for the front-line treatment of epithelial ovarian, fallopian tube or primary peritoneal cancer patients with high risk of relapse (stage III sub-optimally debulked, or stage III unresectable, or stage IV patients",Completed,01-Jun-16,Avis de refus d’ajout d’une indication reconnue à la Liste Établissements – Médicament d’exception - À moins que certaines conditions soient respectées,Conditional,1st,30-Jun-15,04-Nov-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Oct-17,18-Dec-15,28-Dec-15,16-Nov-15,30-Mar-16,15-Dec-16,01-Feb-16,,05-Nov-15,15-Nov-17,05-Nov-15,05-Nov-15,8,3,4,2,6,7,5,,1,9,0.70%,6.20%,10.70%,16.40%,17.70%,49.90%,50.80%,71.10%,99.60%,,99.60%,15-Dec-16,15-Nov-17,-168,,188,,26,-337,127,697,44,54,12,147,407,89,,1,742,181,1,244,1,742,870,217,227,185,320,580,262,,174,915,354,417,174,342,154,850,197,207,165,300,560,242,,154,532,334,20,383,153,-210,915,741,741,406,335,42159
Avastin,bevacizumab,Hoffman-La Roche ,Y,Y,N,N,Y,Y,N,Y,N,,28-Sep-15,,CADTH & INESSS,29-Oct-15,post-NOC,New indication,Genitourinany Platinum-Resistant Ovarian Cancer,Completed,05-May-16,Cond'l on Cost,Conditional,24-Nov-15,post-NOC,New Indication,Platinum-Resistant Ovarian Cancer,Completed,19-Aug-16,Avis de refus d’ajout d’une indication reconnue à la Liste Établissements – Médicament d’exception - À moins que certaines conditions soient respectées,Conditional,1st,15-Jul-16,21-Aug-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Oct-17,08-May-18,01-Sep-17,01-Sep-17,05-Oct-17,09-Jan-18,01-Feb-18,,11-Aug-17,15-Nov-17,11-Aug-17,11-Aug-17,4,9,2,3,5,7,8,,1,6,0.70%,6.40%,11.90%,32.20%,64.40%,93.00%,93.90%,95.20%,99.60%,,99.60%,05-Oct-17,15-Nov-17,31,57,189,269,71,-35,402,41,260,11,11,45,141,164,,-10,86,83,-10,83,-10,86,734,953,704,704,738,834,857,,683,779,776,776,683,652,463,514,733,484,484,518,614,637,,463,453,556,220,326,473,367,779,96,96,55,41,42495
Avastin,bevacizumab,Hoffman-La Roche ,Y,Y,N,N,Y,Y,N,Y,N,,,,CADTH,16-Dec-16,na,New indication,Malignant Pleural Mesothelioma,Withdrawn,11-Apr-17,n/a,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,116,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,42836
Baqsimi,glucagon,Eli Lilly ,N,N,N,N,N,N,N,N,Y,01-Nov-18,25-Sep-19,328,CADTH & INESSS,24-Jul-19,pre-NOC,Initial,Severe hypoglycemic reactions,Completed,22-Jan-20,Reimburse with clinical criteria and/or conditions,Conditional,19-Jul-19,pre-NOC,New Drug,Hypoglycemia,Completed,05-Feb-20,Inscription - Avec conditions,Conditional,1st,14-Dec-20,22-Nov-21,Negotiation,Completed with Agreements,FB,RB,FB,RB,LU,SA,EDS,SA,SA,EM,05-Apr-22,01-Feb-22,01-Mar-22,01-Jun-22,31-Jan-21,17-Feb-22,27-Jun-22,01-Jun-22,01-Feb-22,02-Feb-22,31-Jan-21,31-Jan-21,7,2,6,8,1,5,10,9,3,4,32.20%,36.70%,37.40%,65.90%,66.80%,72.60%,92.80%,98.30%,98.70%,100.00%,100.00%,02-Feb-22,05-Apr-22,-63,-68,182,201,327,313,343,134,71,99,191,-295,87,217,191,71,72,85,-295,84,-295,134,923,860,888,980,494,876,1006,980,860,861,874,873,494,557,375,804,741,769,861,375,757,887,861,741,728,755,119,133,670,656,923,429,429,367,62,447
Basaglar,insulin glargine,Eli Lilly ,N,Y,Y,N,N,N,N,N,N,,01-Sep-15,,CADTH & INESSS,05-Oct-15,post-NOC,Initial,"Diabetes mellitus, Type 1 & 2",Completed,14-Apr-16,List with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New Drug,"Diabetes mellitus, Type 1 & 2",Completed,01-Jun-16,Avis d'inscription aux listes des médicaments-Médicament d'exception,Conditional,1st,15-Jun-16,07-Jul-17,Negotiation,Completed with Agreements,SA,FB,FB,FB,FB,FB,FB,FB,FB,EM,21-Aug-18,01-Oct-17,01-Jan-18,19-Oct-17,28-Mar-19,24-Oct-17,01-Sep-17,25-Sep-17,01-Oct-17,18-Aug-17,01-Sep-17,18-Aug-17,9,4,8,6,10,7,2,3,5,1,28.60%,29.90%,30.20%,34.70%,35.40%,40.90%,41.80%,47.50%,67.80%,100.00%,100.00%,21-Aug-18,28-Mar-19,34,84,192,190,62,14,387,410,86,178,104,629,109,56,80,86,42,193,56,178,42,629,1085,761,853,779,1304,784,731,755,761,717,868,853,731,697,505,859,535,627,553,1078,558,505,529,535,443,642,226,274,449,401,1304,587,573,368,219,42474
Bavencio,avelumab,EMD Serono - Pfizer Alliance,Y,Y,N,Y,Y,Y,Y,Y,N,01-Apr-17,18-Dec-17,261,CADTH & INESSS,10-Oct-17,pre-NOC,New drug,Metastatic Merkel Cell Carcinoma,Completed,21-Mar-18,Cond'l on Cost,Conditional,,,New Drug,Metastatic Merkel Cell Carcinoma,Completed,06-Jun-18,Avis de refus d'inscription à la Liste Établissements - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,16-Jul-18,17-Jan-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-May-19,07-Oct-19,01-May-19,14-Feb-19,18-Apr-19,24-Jun-19,03-Oct-19,,26-Aug-19,07-Mar-19,14-Feb-19,14-Feb-19,4,9,5,1,3,6,8,,7,2,5.50%,34.10%,66.30%,86.60%,92.30%,93.20%,93.90%,95.20%,99.60%,,99.60%,18-Apr-19,01-May-19,-69,,162,,117,40,185,104,263,104,28,91,158,259,,221,49,154,28,142,28,104,499,658,499,423,486,553,654,,616,444,549,537,423,492,330,406,565,406,330,393,460,561,,523,274,456,93,170,302,225,499,76,76,63,13,354
Bavencio,avelumab,EMD Serono - Pfizer Alliance,Y,Y,N,N,Y,N,N,N,N,01-Jun-20,10-Dec-20,192,CADTH & INESSS,18-Sep-20,pre-NOC,New indication,First-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy.,Completed,23-Mar-21,Cond'l on Cost,Conditional,02-Oct-20,pre-NOC,New Indication,First-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy.,Completed,03-Mar-21,Inscription - Avec conditions,Conditional,1st,22-Jul-21,15-Dec-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,01-Jun-22,28-Feb-22,01-Jun-22,15-Dec-22,30-Apr-21,,,,,02-Feb-22,30-Apr-21,30-Apr-21,4,3,5,6,1,,,,,2,32.20%,60.80%,65.30%,85.50%,91.20%,96.80%,,,,,96.80%,02-Feb-22,01-Jun-22,-83,-69,186,152,121,141,146,168,75,168,365,-229,,,,,49,109,-229,99,-229,168,538,445,538,735,141,,,,,419,479,469,141,224,38,435,342,435,632,38,,,,,336,376,103,83,267,287,538,397,397,278,119,295
Beleodaq,belinostat,Servier,N,N,N,Y,Y,Y,Y,Y,N,,,,CADTH,29-Jun-18,na,New drug,Peripheral T-Cell Lymphoma (PTCL),Withdrawn,24-Oct-18,n/a,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,117,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,43397
Benlysta,belimumab,GlaxoSmithKline Inc.,Y,Y,N,N,N,N,N,N,N,01-Oct-20,13-Jul-21,285,CADTH,07-Jul-22,post-NOC,Initial,Lupus nephritis,Completed,19-Jan-23,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,359,,196,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,555,,,,,,,,,840
Beovu,brolucizumab,Novartis ,Y,Y,N,Y,N,N,N,N,Y,01-May-19,12-Mar-20,316,CADTH & INESSS,26-Sep-19,pre-NOC,Initial,"Macular degeneration, age-related",Completed,21-May-20,Reimburse with clinical criteria and/or conditions,Conditional,03-Jan-20,pre-NOC,New Drug,the neovascular (wet) form of age-related macular degeneration,Completed,08-Jul-20,Refus d’inscription,Negative,1st,27-Apr-21,31-Aug-21,Negotiation,Completed with Agreements,,RB,EDS,,LU,SA,,SA,,NR,,01-Feb-22,01-Mar-22,,17-Dec-21,16-Dec-21,,28-Dec-22,,,16-Dec-21,16-Dec-21,,3,4,,2,1,,5,,,0.90%,33.10%,37.60%,43.30%,43.70%,,,,,,43.70%,,,-168,-69,238,187,341,293,126,,154,182,,108,107,,484,,,207,107,207,107,,,691,719,,645,644,,1021,,,744,744,644,812,574,,621,649,,575,574,,951,,,674,70,118,467,419,,,,,,386
Beovu,brolucizumab,Novartis Pharmaceuticals Canada Inc.,Y,Y,N,N,N,N,N,N,Y,01-Feb-22,30-Nov-22,302,CADTH & INESSS,30-Jun-22,pre-NOC,Initial,Diabetic macular edema,Completed,18-Jan-23,Reimburse with clinical criteria and/or conditions,Conditional,20-Jan-23,post-NOC,New Indication,Diabetic macular edema,under review,TBD,TBD,TBD,1st,06-Mar-23,,Active,n/a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-153,51,202,,47,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,49,,,,,,,,,351
Besponsa,Inotuzumab Ozogamicin,Pfizer,Y,Y,N,Y,Y,Y,Y,Y,N,01-May-17,15-Mar-18,318,CADTH & INESSS,13-Nov-17,pre-NOC,New drug,Acute Lymphoblastic Leukemia (ALL),Completed,06-Jul-18,Cond'l on Cost,Conditional,14-Nov-17,pre-NOC,New Drug,Acute Lymphoblastic Leukemia (ALL),Completed,06-Jun-18,Avis de refus d'inscription à la Liste Établissements - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,07-Sep-18,06-Feb-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,EM,01-Jun-19,31-Oct-22,03-Sep-19,26-Jun-19,18-Jul-19,01-Nov-19,01-Feb-20,,,07-Mar-19,01-Jun-19,07-Mar-19,2,8,5,3,4,6,7,,,1,28.60%,48.80%,54.40%,86.60%,92.30%,93.20%,94.50%,99.00%,,,99.00%,26-Jun-19,18-Jul-19,-122,-121,235,204,63,93,152,115,1363,209,140,162,268,360,,,29,374,115,331,29,162,443,1691,537,468,490,596,688,,,357,702,659,443,565,330,330,1578,424,355,377,483,575,,,274,589,113,83,215,245,490,133,47,111,22,431
Bijuva,estradiol and progesterone,Knight Therapeutics Inc.,N,N,N,N,N,N,N,N,N,01-Nov-19,17-Sep-20,321,CADTH,30-Jun-21,post-NOC,Initial,Vasomotor symptoms associated with menopause,Completed,10-Feb-22,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,13-Jul-22,,Active,n/a,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,286,,225,,153,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,511,,,,,,,,,832
Biktarvy,bictegravir/emtricitabine/tenofovir/alafenamide,Gilead Sciences ,Y,N,N,Y,N,N,N,N,N,01-Sep-17,10-Jul-18,312,CADTH & INESSS,30-Apr-18,pre-NOC,Initial,HIV-1 infection,Completed,25-Oct-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,HIV,Completed,12-Dec-18,Inscription – Avec conditions,Conditional,1st,27-Feb-19,14-Jun-19,Negotiation,Completed with Agreements,HIV,HIV,EDS,EDS,FB,SA,HIV,HIV,SA,FB,,22-Aug-19,01-Aug-19,02-Mar-20,31-Jul-19,24-Oct-19,06-Feb-20,28-Oct-19,24-Oct-19,15-Aug-19,31-Jul-19,31-Jul-19,,4,2,9,1,5,8,7,6,3,32.20%,38.00%,66.50%,71.00%,71.90%,72.60%,72.90%,74.20%,79.70%,,79.70%,15-Aug-19,,-71,,178,,125,77,107,,69,48,262,47,132,237,136,132,62,133,47,125,47,,,408,387,601,386,471,576,475,471,401,472,464,386,457,279,,301,280,494,279,364,469,368,364,246,365,107,155,232,184,,,,15,,419
Bimzelx,bimekizumab,UCB Canada Inc.,N,Y,N,Y,N,N,N,N,Y,01-Apr-21,14-Feb-22,319,CADTH & INESSS,17-Aug-21,pre-NOC,Initial,"Psoriasis, moderate to severe plaque",Completed,30-Mar-22,Reimburse with clinical criteria and/or conditions,Conditional,31-Dec-21,pre-NOC,New Drug,"Psoriasis, moderate to severe plaque",Completed,01-Jun-22,Inscription - Avec conditions,Conditional,1st,13-Sep-22,09-Dec-22,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,,,,,EM,31-Jan-23,01-Feb-23,01-Feb-23,01-Apr-23,31-Mar-23,,,,,01-Mar-23,31-Jan-23,31-Jan-23,1,2,3,6,5,,,,,4,20.30%,24.70%,30.40%,59.00%,91.20%,96.80%,,,,,96.80%,01-Mar-23,31-Mar-23,-181,-45,225,152,167,104,87,53,54,54,113,112,,,,,82,77,53,78,53,112,351,352,352,411,410,,,,,380,375,376,351,532,307,307,308,308,367,366,,,,,273,331,44,107,254,191,410,59,59,29,30,363
Blincyto,blinatumomab,Amgen ,Y,Y,N,Y,Y,Y,Y,Y,N,01-Apr-15,22-Dec-15,265,CADTH & INESSS,24-Aug-15,pre-NOC,New drug,Acute Lymphoblastic Leukemia ,Completed,18-Apr-16,Do Not Fund,Negative,22-Mar-16,post-NOC,New Drug,Acute Lymphoblastic Leukemia ,Completed,18-Aug-17,Avis de refus d'inscription à la Liste Établissements - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,27-Apr-16,09-Jan-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,EM,01-Nov-17,31-Oct-22,02-Aug-17,15-Feb-17,24-Apr-17,24-Aug-17,01-Feb-18,,,07-Mar-19,15-Feb-17,15-Feb-17,5,8,3,1,2,4,6,,,7,5.50%,37.80%,43.50%,44.40%,64.60%,65.90%,94.50%,99.00%,,,99.00%,01-Nov-17,07-Mar-19,-120,91,238,514,9,-478,257,296,2121,205,37,105,227,388,,,787,483,37,521,37,787,680,2505,589,421,489,611,772,,,1171,867,905,421,541,303,562,2387,471,303,371,493,654,,,566,749,118,605,266,-221,1171,750,750,259,491,383
Blincyto,blinatumomab,Amgen ,Y,Y,N,N,Y,Y,Y,Y,N,01-Sep-16,28-Apr-17,239,CADTH & INESSS,24-Feb-17,pre-NOC,New indication,Pediatric Acute Lymphoblastic Leukemia (ALL),Completed,23-Aug-17,Cond'l on Cost,Conditional,22-Mar-16,pre-NOC,New Drug,Pediatric Acute Lymphoblastic Leukemia (ALL),Completed,01-Feb-18,Avis d'inscription à la Liste Établissements - Médicament d'exception,Positive,1st,29-Dec-17,15-Jan-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,EM,01-May-19,31-Oct-22,01-May-19,01-Jun-19,12-Jun-19,01-Nov-19,01-Dec-19,,,07-Mar-19,01-May-19,07-Mar-19,2,8,3,4,5,6,7,,,1,28.60%,48.80%,54.60%,60.10%,92.30%,93.20%,94.50%,99.00%,,,99.00%,01-May-19,12-Jun-19,-63,-402,180,681,128,-34,382,106,1385,106,137,148,290,320,,,51,356,106,318,51,148,733,2012,733,764,775,917,947,,,678,983,945,733,796,616,616,1895,616,647,658,800,830,,,399,866,117,279,510,348,775,97,42,55,42,356
Blincyto,blinatumomab,Amgen ,Y,Y,N,N,Y,Y,Y,Y,N,01-Dec-17,19-Dec-19,748,CADTH,29-Jun-18,pre-NOC,New indication,Minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (ALL),Withdrawn,16-Oct-18,n/a,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-538,,109,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-429,,,,,,,,,319
Blincyto,blinatumomab,Amgen ,Y,Y,N,N,Y,Y,Y,Y,N,01-May-17,05-Mar-18,308,CADTH & INESSS,31-Aug-18,post-NOC,New indication,Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL),Completed,04-Apr-19,Cond'l on Cost,Conditional,27-Jul-18,post-NOC,New Indication,Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL),Completed,13-Mar-19,Inscription - Avec conditions,Conditional,1st,04-Jul-19,25-Sep-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,EM,01-May-20,31-Oct-22,03-Sep-20,01-Nov-19,25-Feb-20,01-Nov-19,01-Dec-19,,,16-Dec-20,01-Nov-19,01-Nov-19,5,8,6,1,4,2,3,,,7,5.50%,6.40%,7.70%,40.00%,60.20%,65.90%,94.50%,99.00%,,,99.00%,01-May-20,16-Dec-20,179,144,216,229,91,113,83,219,1132,344,37,153,37,67,,,448,284,37,305,37,448,788,1701,913,606,722,606,636,,,1017,853,874,606,427,211,393,1306,518,211,327,211,241,,,644,458,395,373,174,196,1017,411,411,182,229,703
Blincyto,blinatumomab,Amgen ,Y,Y,N,N,Y,Y,Y,Y,N,01-Dec-17,19-Dec-19,748,CADTH & INESSS,20-Jan-20,post-NOC,Resubmission,Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL),Completed,29-Oct-20,Cond'l on Cost,Conditional,03-Feb-20,post-NOC,New Indication,Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL),Completed,05-Aug-20,Inscription - Avec conditions,Conditional,1st,17-Dec-20,21-May-21,Negotiation,Completed with Agreements,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,01-Nov-22,,,,30-Aug-21,,,,,07-Jul-21,30-Aug-21,07-Jul-21,3,,,,2,,,,,1,28.60%,60.80%,81.10%,,,,,,,,81.10%,30-Aug-21,01-Nov-22,32,46,283,184,49,134,155,529,,,,101,,,,,47,315,101,226,47,529,1048,,,,620,,,,,566,834,745,620,588,305,733,,,,305,,,,,336,519,315,230,204,289,1048,482,428,54,428,1063
Blincyto (resubmission),blinatumomab,Amgen ,Y,Y,N,Y,Y,Y,Y,Y,N,,22-Dec-15,,CADTH & INESSS,24-Feb-17,post-NOC,Resubmission,"For the treatment of all adult patients with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL), including those who have had one prior line of therapy (i.e., adult patients who are refractory or patients who are in first or later relapse)",Completed,31-Aug-17,Cond'l on Cost,Conditional,22-Mar-16,post-NOC,New Drug,"For the treatment of all adult patients with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL), including those who have had one prior line of therapy (i.e., adult patients who are refractory or patients who are in first or later relapse)",Completed,18-Aug-17,Notice of Refusal to be Registered in Establishments - Exceptional Drug - With Conditions,Conditional,1st,29-Dec-17,15-Jan-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,Under provincial consideration,EM,01-May-19,31-Oct-22,01-May-19,01-Jun-19,12-Jun-19,01-Nov-19,,,,07-Mar-19,01-May-19,07-Mar-19,2,7,3,4,5,6,,,,1,28.60%,48.80%,54.60%,60.10%,92.30%,93.20%,97.70%,,,,97.70%,01-May-19,12-Jun-19,430,91,188,514,120,133,382,106,1385,106,137,148,290,,,,51,362,106,318,51,148,1226,2505,1226,1257,1268,1410,,,,1171,1482,1438,1226,796,608,608,1887,608,639,650,792,,,,566,864,618,605,502,515,1268,97,42,55,42,42978
Bosulif,bosutinib,Pfizer,Y,N,N,Y,Y,Y,Y,Y,N,,07-Mar-14,,CADTH & INESSS,30-May-14,post-NOC,New drug,Chronic Myeloid Leukemia,Completed,21-Apr-15,Cond'l on Cost,Conditional,22-Mar-14,post-NOC,New Drug,Chronic Myeloid Leukemia,Completed,01-Oct-14,Avis de refus - Valeur thérapeutique,Negative,1st,31-May-15,09-Nov-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,NR,01-Dec-16,03-Feb-16,28-Dec-15,18-Apr-16,26-Feb-16,12-Apr-16,02-May-16,18-Aug-20,01-Feb-16,,28-Dec-15,28-Dec-15,8,3,1,6,4,5,7,9,2,,5.70%,6.40%,10.80%,43.10%,44.00%,49.50%,50.80%,71.10%,71.40%,,71.40%,02-May-16,,84,15,326,193,40,242,162,388,86,49,161,109,155,175,1744,84,,328,49,328,49,,1000,698,661,773,721,767,787,2356,696,,940,940,661,577,251,590,288,251,363,311,357,377,1946,286,,530,410,208,202,404,,,,126,,42115
Bosulif (RFA),bosutinib,Pfizer,Y,N,N,Y,Y,Y,Y,Y,N,,07-Mar-14,,CADTH & INESSS,08-Apr-19,post-NOC,Request for Advice,Chronic Myeloid Leukemia,Completed,01-Aug-19,Fund,Positive,22-Mar-14,post-NOC,New Drug,Chronic Myeloid Leukemia,Completed,01-Oct-14,Notice of Refusal - Therapeutic Value,Negative,1st,27-Aug-19,19-Feb-20,Negotiation,Completed with Agreements,Under provincial consideration,Funded,Under provincial consideration,Funded,Funded,Funded,Funded,Funded,Funded,NR,,30-Jul-20,,16-Jul-20,31-Mar-21,20-Aug-20,31-Mar-21,,01-Jun-21,,16-Jul-20,16-Jul-20,,2,,1,4,3,5,,6,,5.50%,10.00%,10.90%,43.10%,44.40%,45.10%,,,,,45.10%,,,1858,15,115,193,26,1791,176,,162,,148,406,183,406,,468,,296,148,296,148,,,2337,,2323,2581,2358,2581,,2643,,2471,2471,2323,465,350,,364,,350,608,385,608,,670,,498,1973,208,202,1967,,,,,,43678
Botox (UI)(OAB),onabotulinumtoxinA,Allergan ,N,Y,N,N,N,N,N,N,N,,10-Oct-13,,CADTH,25-Nov-13,post-NOC,Initial,Urinary incontinence,Completed,12-Nov-14,List with criteria/condition,Conditional,,,,,,,,,none,31-Jan-15,,Negotiation by Province,n/a,SA,FB,EDS,EDS,LU,SA,EDS,NR,NR,,26-Feb-19,01-Jul-93,01-Aug-18,19-Jul-18,28-May-15,18-Jul-18,10-Sep-20,,,,01-Jul-93,01-Jul-93,6,1,5,4,2,3,7,,,,4.50%,36.70%,37.60%,43.10%,48.80%,69.10%,70.40%,,,,70.40%,26-Feb-19,,46,,352,,80,,,,,,,,,,,,,,,,,,1965,-7406,1756,1743,595,1742,2527,,,,417,417,-7406,-7452,-7804,1567,-7804,1358,1345,197,1344,2129,,,,19,398,,,,,,,9371,,41955
Braftovi,encorafenib,Pfizer,Y,N,N,N,Y,N,N,N,Y,01-May-20,31-Mar-21,334,CADTH & INESSS,16-Dec-20,pre-NOC,Initial,"In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, after prior therapy.",Completed,26-Jul-21,Cond'l on Cost,Conditional,22-Jan-21,pre-NOC,New Drug,"Metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, after prior therapy",Completed,30-Jun-21,Inscription - Avec conditions,Conditional,1st,03-Nov-21,06-Jul-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,EM,01-Dec-22,30-Sep-22,01-Dec-22,24-Jan-23,31-Dec-22,21-Nov-22,01-Jan-23,,25-Jan-23,17-Aug-22,30-Sep-22,17-Aug-22,4,2,5,8,6,3,7,,9,1,28.60%,33.00%,33.90%,54.20%,59.90%,92.10%,93.40%,99.00%,99.60%,,99.60%,01-Dec-22,31-Dec-22,-105,-68,222,159,100,126,245,148,86,148,202,178,138,179,,203,42,160,86,147,42,178,610,548,610,664,640,600,641,,665,504,622,609,548,653,431,493,431,493,547,523,483,524,,548,413,505,117,91,345,371,640,136,92,106,30,451
Braftovi and Mektovi,encorafenib,Pfizer,Y,N,N,Y,Y,Y,N,Y,Y,01-Jun-20,02-Mar-21,274,CADTH & INESSS,16-Dec-20,pre-NOC,Initial,"Braftovi (encorafenib): In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Mektovi (binimetinib): In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation",Completed,26-Jul-21,Cond'l on Cost,Conditional,22-Jan-21,pre-NOC,New Drug,Unresectable or metastatic melanoma with a BRAF V600 mutation. ,Completed,30-Jun-21,Inscription - Avec conditions,Conditional,1st,03-Nov-21,06-Jul-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,EM,01-Dec-22,30-Sep-22,01-Dec-22,24-Jan-23,31-Jan-23,21-Nov-22,01-Jan-23,,25-Jan-23,17-Aug-22,30-Sep-22,17-Aug-22,4,2,5,7,9,3,6,,8,1,28.60%,33.00%,33.90%,54.20%,59.90%,61.20%,66.70%,67.40%,99.60%,,99.60%,01-Dec-22,31-Jan-23,-76,-39,222,159,100,126,245,148,86,148,202,209,138,179,,203,42,164,86,151,42,209,639,577,639,693,700,629,670,,694,533,655,642,577,653,431,493,431,493,547,554,483,524,,548,413,509,146,120,345,371,700,167,123,106,61,420
Brenzys (SEB),etanercept,Merck,Y,Y,Y,N,N,N,N,N,N,,31-Aug-16,,CADTH & INESSS,20-Apr-16,pre-NOC,Initial,"Rheumatoid arthritis, Ankylosing spondylitis ",Completed,25-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,pre-NOC,New Drug,Ankylosing spondylitis + Rheumatoid arthritis,Completed,21-Apr-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,14-Nov-16,19-Jun-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,18-Jul-17,01-Sep-17,01-Oct-17,19-Oct-17,31-Jul-17,24-Oct-17,01-Oct-17,25-Sep-17,01-Mar-18,18-Aug-17,18-Jul-17,18-Jul-17,1,4,6,8,2,9,7,5,10,3,20.30%,52.50%,81.10%,85.50%,85.90%,91.60%,92.90%,98.40%,99.30%,100.00%,100.00%,31-Jul-17,18-Aug-17,-133,-19,188,252,20,-158,217,29,74,104,122,42,127,104,98,255,60,106,29,102,29,60,321,366,396,414,334,419,396,390,547,352,398,394,321,454,266,266,311,341,359,279,364,341,335,492,119,343,55,233,237,59,352,31,31,13,18,42668
Breo Ellipta (Asthma Withdrawn),fluticasone furoate/vilanterol,GlaxoSmithKline,Y,N,N,N,N,N,N,N,N,,05-Aug-15,,CADTH,02-May-18,post-NOC,Initial,Asthma,Withdrawn,14-Aug-18,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,1001,,104,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1105,,,,,,,,,43326
Breo Ellipta (Asthma),fluticasone furoate and vilanterol (as trifenatate),GlaxoSmithKline,Y,N,N,N,N,N,N,N,N,,05-Aug-15,,CADTH & INESSS,10-Aug-15,post-NOC,Initial,Asthma,Completed,18-Feb-16,List with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Indication,Asthma,Completed,16-Dec-16,Avis d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception,Conditional,1st,13-Apr-16,11-Jul-16,Negotiation,Completed with Agreements,SA,SA,EDS,FB,LU,SA,EDS,SA,SA,EM,13-Sep-16,01-Feb-17,01-Oct-16,20-Oct-16,30-Aug-16,24-Aug-16,01-Sep-16,24-Oct-16,01-Nov-16,16-Dec-16,24-Aug-16,24-Aug-16,4,10,5,6,2,1,3,7,8,9,0.90%,33.10%,34.40%,54.70%,60.40%,65.90%,66.30%,67.00%,95.50%,100.00%,100.00%,13-Sep-16,16-Dec-16,5,230,192,269,55,-247,89,64,205,82,101,50,44,52,105,113,158,91,44,97,44,158,405,546,423,442,391,385,393,446,454,499,432,438,385,380,188,208,349,226,245,194,188,196,249,257,0,235,197,499,144,-158,499,114,114,20,94,42418
Breo Ellipta (COPD Withdrawn),fluticasone furoate/vilanterol,GlaxoSmithKline,Y,N,N,Y,N,N,N,N,N,,03-Jul-13,,CADTH,28-Jun-17,post-NOC,Initial,COPD,Withdrawn,09-Nov-17,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,1456,,134,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1590,,,,,,,,,43048
Breo Ellipta (COPD),fluticasone furoate / vilanterol,GlaxoSmithKline,Y,N,N,Y,N,N,N,N,N,,03-Jul-13,,CADTH & INESSS,29-Oct-13,post-NOC,Initial,Chronic Obstructive Pulmonary Disease (COPD),Completed,18-Aug-14,List with criteria/condition,Conditional,,,New Drug,COPD,Completed,01-Feb-16,Avis d'inscription aux listes de médicaments - Médicament d'exception,Conditional,1st,06-Oct-14,03-Feb-15,Negotiation,Completed with Agreements,SA,SA,EDS,FB,LU,SA,EDS,SA,SA,EM,15-May-15,01-Jun-15,01-Apr-15,20-Apr-15,31-Mar-15,06-Mar-15,01-Apr-15,25-May-15,01-Jul-15,24-Mar-16,06-Mar-15,06-Mar-15,6,8,3,5,2,1,4,7,9,10,0.90%,33.10%,38.80%,40.20%,45.70%,65.90%,66.30%,70.70%,71.40%,100.00%,100.00%,15-May-15,24-Mar-16,118,,293,,49,-483,120,101,118,57,76,56,31,57,111,148,415,84,31,117,31,415,681,698,637,656,636,611,637,691,728,995,664,697,611,493,200,270,287,226,245,225,200,226,280,317,52,253,411,943,169,-363,995,384,384,70,314,41869
Breyanzi,lisocabtagene maraleucel,Bristol-Myers Squibb ,Y,N,N,Y,Y,Y,Y,Y,N,01-Feb-21,06-May-22,459,CADTH & INESSS,09-Aug-21,pre-NOC,Initial,"For the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) after at least 2 prior therapies.",Completed,29-Jun-22,Cond'l on Cost,Conditional,31-Dec-21,pre-NOC,New Drug,"For the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) after at least 2 prior therapies.",Completed,29-Jun-22,Inscription - Avec conditions,Conditional,1st,20-Jan-23,,Active,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-270,-126,324,180,205,205,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,54,54,,,,,,,,513
Breztri Aerosphere,budesonide/ glycopyrronium /formoterol fumarate,AstraZeneca Canada Inc.,Y,N,N,N,N,N,N,N,N,01-Sep-20,15-Jul-21,317,CADTH & INESSS,28-Jan-21,pre-NOC,Initial,chronic obstructive pulmonary disease (COPD),Completed,14-Sep-21,Reimburse with clinical criteria and/or conditions,Conditional,18-Jun-21,pre-NOC,New Drug,COPD,Completed,30-Nov-21,Inscription - Avec conditions,Conditional,1st,28-Feb-22,15-Jun-22,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,02-Nov-22,01-Nov-22,01-Nov-22,20-Sep-22,31-Oct-22,19-Dec-22,01-Nov-22,27-Mar-23,07-Dec-22,17-Aug-22,20-Sep-22,17-Aug-22,7,4,5,2,3,9,6,10,8,1,28.60%,34.10%,66.30%,70.80%,76.50%,77.80%,98.10%,98.80%,99.60%,100.00%,100.00%,31-Oct-22,02-Nov-22,-168,-27,229,165,167,90,107,140,139,139,97,138,187,139,285,175,63,160,97,150,63,140,475,474,474,432,473,522,474,620,510,398,495,485,432,600,371,414,413,413,371,412,461,413,559,449,260,434,61,138,274,197,475,77,43,75,2,378
Brilinta (atherothrombotic events ),ticagrelor,AstraZeneca ,Y,N,N,N,N,N,N,N,N,,30-May-16,,CADTH & INESSS,18-Feb-16,pre-NOC,Initial,Prevention of atherothrombotic events with history of myocardial infarction,Completed,25-Aug-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Indication,Prevention of atherothrombotic events with history of myocardial infarction,Completed,01-Feb-17,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,04-Aug-17,30-Nov-17,Negotiation,No agreement reached,NR,NR,EDS,NR,NR,NR,NR,NR,NR,NR,,,01-Aug-19,,,,,,,,01-Aug-19,01-Aug-19,,,1,,,,,,,,5.70%,,,,,,,,,,5.70%,,,-102,74,189,173,344,184,118,,,609,,,,,,,,609,609,609,609,,,,1158,,,,,,,,1158,1158,1158,1260,1071,,,1071,,,,,,,,1071,87,247,462,302,,,,,,42607
Brineura,cerliponase alfa,BioMarin Pharmaceutical ,N,Y,N,Y,N,Y,Y,Y,N,01-Jun-18,19-Dec-18,201,CADTH & INESSS,31-Jul-18,pre-NOC,Initial,Neuronal Ceroid Lipofuscinosis Type 2,Completed,23-May-19,Reimburse with clinical criteria and/or conditions,Conditional,01-Aug-18,pre-NOC,New Drug,Neuronal Ceroid Lipofuscinosis Type 2,Completed,13-Feb-19,Inscription - Avec conditions,Conditional,1st,29-Mar-19,22-Jan-20,Negotiation,Completed with Agreements,EDRD,UR,UR,EDS,EAP,SA,EDF,UR,SA,UR,01-Feb-20,,,22-Oct-20,11-Nov-19,13-May-21,06-Feb-20,,05-Mar-20,,11-Nov-19,11-Nov-19,2,,,5,1,6,3,,4,,32.20%,52.50%,53.80%,54.50%,60.00%,60.90%,,,,,60.90%,01-Feb-20,,-141,-140,296,196,-55,44,299,10,,,274,-72,477,15,,43,,125,-72,125,-72,,409,,,673,327,876,414,,442,,524,524,327,468,172,254,,,518,172,721,259,,287,,369,155,56,244,343,,,,82,,356
Brivlera,brivaracetam,UCB ,N,N,N,Y,N,N,N,N,N,01-May-15,09-Mar-16,313,CADTH & INESSS,19-Apr-16,post-NOC,Initial,"Epilepsy, partial-onset seizures",Completed,25-Jan-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Nov-16,post-NOC,New Drug,"Epilepsy, partial-onset seizures",Completed,01-Jun-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,29-May-17,22-Oct-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,03-Sep-21,01-Dec-18,01-Jan-19,31-May-19,21-Dec-18,07-Feb-19,01-Apr-19,28-Jan-19,06-Dec-18,13-Dec-18,01-Dec-18,01-Dec-18,10,1,5,9,4,7,8,6,2,3,4.50%,5.10%,33.70%,65.90%,71.70%,72.00%,72.90%,74.20%,79.70%,100.00%,100.00%,21-Dec-18,03-Sep-21,41,260,281,189,124,-3,511,1047,40,71,221,60,108,161,98,45,52,206,40,190,40,1047,2004,997,1028,1178,1017,1065,1118,1055,1002,1009,1163,1147,997,956,675,1682,675,706,856,695,743,796,733,680,560,841,322,449,635,508,2004,1007,1007,20,987,635
Brukinsa,zanubrutinib,BeiGene,N,N,N,Y,Y,Y,N,Y,N,01-Sep-20,01-Mar-21,181,CADTH & INESSS,21-May-21,post-NOC,Initial,For the treatment of patients with Waldenström’s macroglobulinemia (WM),Completed,21-Dec-21,Cond'l on Cost,Conditional,20-Aug-21,post-NOC,New Drug,For the treatment of patients with Waldenström’s macroglobulinemia (WM),Completed,04-Feb-22,Inscription - Avec conditions,Conditional,1st,05-Oct-22,22-Dec-22,Negotiation,Completed with Agreements,Funded,Funded,Under provincial consideration,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,01-Apr-23,31-Jan-23,,01-Apr-23,09-Mar-23,,,,,01-Feb-23,31-Jan-23,31-Jan-23,4,1,,5,3,,,,,2,4.50%,33.00%,65.30%,85.50%,91.10%,,,,,,91.10%,09-Mar-23,01-Apr-23,81,172,214,168,288,243,78,100,40,,100,77,,,,,41,79,40,72,40,100,761,701,,761,738,,,,,702,740,733,701,620,406,466,406,,466,443,,,,,362,445,295,340,366,321,761,60,60,37,23,476
Brukinsa,zanubrutinib,BeiGene ,N,N,N,N,Y,Y,N,Y,N,01-Sep-20,22-Jul-21,324,CADTH & INESSS,30-Sep-21,post-NOC,Initial,For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.,Completed,27-Jul-22,Do not Fund,Negative,25-Mar-22,post-NOC,New Indication,For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.,Completed,31-Aug-22,Refus d’inscription,Negative,None,07-Sep-22,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,70,246,300,159,42,7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,370,405,,,,,,,,694
Brukinsa,zanubrutinib,BeiGene ,N,N,N,N,Y,Y,N,Y,N,01-Jul-22,,,CADTH,20-Jan-23,na,Initial,For the treatment of adult patients with chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL).,Active,,TBD,n/a,17-Mar-23,,New Indication,For the treatment of adult patients with chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL).,Under review,TBD,TBD,TBD,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44743
Bystolic,nebivolol,Forest Laboratories ,N,N,N,Y,N,N,N,N,N,,21-Dec-12,,CADTH & INESSS,04-Feb-13,post-NOC,Initial,"Hypertension, essential ",Completed,18-Jul-13,Do not list at the submitted price ,Negative,,,New Drug,"Hypertension, essential ",Completed,01-Oct-13,Avis de refus,Negative,none,22-Aug-13,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,45,,164,,35,-40,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,209,284,,,,,,,,41473
"Cabenuva, Vocabria",cabotegravir-rilpivirine cabotegravir sodium,ViiV Healthcare ,N,N,N,Y,N,N,N,N,Y,01-May-19,18-Mar-20,322,CADTH & INESSS,19-Aug-19,pre-NOC,Initial,HIV-1 infection,Completed,22-Jul-20,Reimburse with clinical criteria and/or conditions,Conditional,27-Sep-19,pre-NOC,New Drug,HIV Infection,Completed,14-May-20,Inscription - Avec conditions,Conditional,1st,22-Oct-20,07-Sep-21,Negotiation,Completed with Agreements,,,EDS,EDS,FB,SA,NR,HIV,SA,FB,,,01-Dec-21,24-Feb-22,30-Nov-21,16-Dec-21,,23-May-22,20-Jul-22,15-Dec-21,30-Nov-21,30-Nov-21,,,2,5,1,4,,6,7,3,32.20%,38.00%,66.50%,67.40%,73.00%,73.30%,74.00%,,,,74.00%,15-Dec-21,,-212,-173,338,230,92,161,320,,,85,170,84,100,,258,316,99,169,84,159,84,,,,623,708,622,638,,796,854,637,707,697,622,834,496,,,497,582,496,512,,670,728,580,581,126,57,412,481,,,,15,,448
Cablivi,caplacizumab,Sanofi Genzyme,Y,Y,N,Y,N,Y,Y,Y,N,01-Aug-19,28-Feb-20,211,CADTH & INESSS,13-Sep-19,pre-NOC,Initial,Acquired thrombotic thrombocytopenia purpura (aTTP),Completed,26-Aug-20,Do not reimburse,Negative,06-Sep-19,pre-NOC,New Drug,Acquired thrombocytopenic purpura,Completed,08-Apr-20,Refus d'inscription,Negative,none,23-Oct-20,,Do Not Negotiate,n/a,,,NR,,,NR,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-168,-175,348,215,58,198,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,180,40,,,,,,,,391
Cablivi,caplacizumab,Sanofi-aventis Canada Inc.,Y,Y,N,Y,N,Y,Y,Y,N,01-Aug-19,28-Feb-20,211,CADTH,07-Jun-22,post-NOC,Resubmission,Acquired thrombotic thrombocytopenic purpura (aTTP),Active,,Active,n/a,,,,,,,,,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,830,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-43678
Cabometyx,cabozantinib,Ipsen ,N,N,N,Y,Y,N,N,N,N,01-Jul-17,14-Sep-18,440,CADTH,06-Oct-17,pre-NOC,New drug,Advanced Renal Cell Carcinoma (RCC),Withdrawn,25-Jan-18,n/a,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-343,,111,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-232,,,,,,,,,208
Cabometyx,cabozantinib,Ipsen ,N,N,N,Y,Y,N,N,N,N,01-Jul-17,14-Sep-18,440,CADTH & INESSS,17-Sep-18,post-NOC,Resubmission,Renal Cell Carcinoma,Completed,20-Feb-19,Cond'l on Cost,Conditional,,,New Drug,Renal Cell Carcinoma,Completed,08-Nov-18,Inscription – Avec conditions,Conditional,1st,07-Jun-19,05-Nov-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jan-20,10-Apr-20,01-Mar-20,02-Apr-20,06-May-20,16-Jul-20,01-Jun-20,06-Dec-21,30-Sep-21,18-Dec-19,01-Jan-20,18-Dec-19,2,5,3,4,6,8,7,10,9,1,28.60%,48.80%,54.60%,60.10%,64.50%,96.80%,98.10%,99.00%,99.60%,100.00%,100.00%,01-Mar-20,06-May-20,3,,156,,107,211,151,57,157,117,149,183,254,209,762,695,43,287,57,263,43,183,474,574,534,566,600,671,626,1179,1112,460,704,680,474,471,315,315,415,375,407,441,512,467,1020,953,405,545,159,55,258,362,600,140,126,74,66,599
Cabometyx,cabozantinib,Ipsen ,N,N,N,N,Y,Y,N,Y,Y,01-Jan-19,08-Nov-19,311,CADTH & INESSS,16-Oct-19,pre-NOC,New indication,Hepatocelluar Carcinoma:For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy,Completed,22-Apr-20,Cond'l on Cost,Conditional,08-Nov-19,pre-NOC,New Indication,Hepatocellular Carcinoma,Completed,10-Jun-20,Inscription - Avec conditions,Conditional,1st,24-Nov-20,24-Aug-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jan-22,30-Nov-21,01-Nov-21,25-Nov-21,31-Mar-22,16-Dec-21,30-Nov-21,23-Jan-23,30-Sep-21,29-Sep-21,30-Sep-21,29-Sep-21,8,5,3,4,9,7,6,10,2,1,28.60%,29.30%,35.00%,40.50%,45.00%,46.30%,47.20%,67.40%,99.60%,100.00%,100.00%,01-Jan-22,31-Mar-22,-23,0,189,215,216,167,273,130,98,69,93,219,114,98,517,37,36,153,37,141,36,219,785,753,724,748,874,769,753,1172,692,691,808,796,692,715,526,619,587,558,582,708,603,587,1006,526,476,642,166,215,489,440,874,183,182,94,89,477
Cabometyx,cabozantinib,Ipsen Biopharmaceuticals Canada,N,N,N,N,Y,Y,N,Y,Y,01-Nov-21,29-Apr-22,179,CADTH & INESSS,27-Apr-22,pre-NOC,Initial,Treatment of adult and adolescent patients 12 years of age and older with differentiated thyroid carcinoma (DTC) that has progressed following prior therapy and who are radioactive iodine-refractory or ineligible,Completed,02-Nov-22,Cond'l on Cost,Conditional,28-Oct-22,post-NOC,New Indication,Treatment of adult and adolescent patients 12 years of age and older with differentiated thyroid carcinoma (DTC) that has progressed following prior therapy and who are radioactive iodine-refractory or ineligible,Under review,TBD,TBD,TBD,None,,,Under consideration for negotiation,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-2,182,189,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,187,,,,,,,,,366
Cabometyx,cabozantinib,Ipsen Biopharmaceuticals Canada Inc.,N,N,N,N,Y,N,N,N,N,01-Dec-20,12-Oct-21,315,CADTH,17-Feb-23,post-NOC,Initial,"Cabometyx in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC.",Active,,TBD,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,493,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44166
Calquence,acalabrutinib,AstraZeneca,Y,N,N,Y,Y,Y,Y,Y,Y,01-Oct-19,28-Nov-19,58,CADTH & INESSS,07-Apr-20,post-NOC,New drug,Chronic Lymphocytic Leukemia (CLL) (previously untreated),Completed,08-Jan-21,Cond'l on Cost,Conditional,08-May-20,post-NOC,New Drug,Chronic Lymphocytic Leukemia (CLL) (previously untreated),Completed,14-Oct-20,Inscription - Avec conditions,Conditional,1st,27-May-21,05-Oct-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Feb-22,31-Jan-22,01-Feb-22,24-Feb-22,31-Dec-21,29-Apr-22,10-Jun-22,12-Dec-22,31-Oct-22,15-Dec-21,31-Dec-21,15-Dec-21,4,3,5,6,2,7,8,10,9,1,28.60%,60.80%,65.30%,85.50%,91.20%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,31-Dec-21,01-Feb-22,131,162,276,159,139,225,131,119,118,119,142,87,206,248,433,391,71,207,87,193,71,119,796,795,796,819,764,883,925,1110,1068,748,884,870,764,633,357,389,388,389,412,357,476,518,703,661,427,477,407,321,270,356,796,48,32,16,32,465
Calquence,acalabrutinib,AstraZeneca,Y,N,N,Y,Y,Y,Y,Y,Y,01-Oct-19,28-Nov-19,58,CADTH & INESSS,07-Apr-20,post-NOC,New drug,Chronic Lymphocytic Leukemia (CLL),Completed,17-Nov-20,Cond'l on Cost,Conditional,08-May-20,post-NOC,New Drug,Chronic Lymphocytic Leukemia (CLL),Completed,14-Oct-20,Inscription - Avec conditions,Conditional,1st,27-May-21,05-Oct-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Feb-22,31-Jan-22,01-Feb-22,24-Feb-22,31-Dec-21,29-Apr-22,10-Jun-22,12-Dec-22,31-Oct-22,15-Dec-21,31-Dec-21,15-Dec-21,4,3,5,6,2,7,8,10,9,1,28.60%,60.80%,65.30%,85.50%,91.20%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,31-Dec-21,01-Feb-22,131,162,224,159,191,225,131,119,118,119,142,87,206,248,433,391,71,207,87,193,71,119,796,795,796,819,764,883,925,1110,1068,748,884,870,764,633,409,441,440,441,464,409,528,570,755,713,427,529,355,321,322,356,796,48,32,16,32,413
Camzyos,mavacamten,Bristol Myers Squibb,Y,N,N,Y,N,N,N,N,Y,01-Jan-22,08-Nov-22,311,CADTH,22-Sep-22,pre-NOC,Initial,Obstructive hypertrophic cardiomyopathy,Active,,Active,n/a,,,,,,,,,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-47,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44562
Caprelsa,vandetanib,Sanofi,Y,N,N,Y,Y,Y,N,Y,N,,12-Jan-12,,CADTH,15-Aug-16,post-NOC,New drug,Medullary thyroid cancer,Completed,30-Mar-17,Cond'l on Cost,Conditional,,,,,,,,,1st,02-Jun-17,16-Aug-17,Negotiation,No Agreement Reached,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,1677,,227,,64,,75,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1904,,139,,,,,,,42824
Caprelsa,vandetanib,Sanofi,Y,N,N,Y,Y,Y,N,Y,N,,12-Jan-12,,CADTH,15-Aug-16,post-NOC,New drug,"Endocrine, medullary thyroid cancer",Completed,30-Mar-17,Cond'l on Cost,Conditional,,,,,,,,,2nd,28-Dec-17,01-Jun-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,,01-Dec-18,04-Sep-18,15-Nov-18,18-Oct-18,13-Sep-18,17-Dec-18,01-Dec-19,23-Jan-23,06-Dec-21,,04-Sep-18,04-Sep-18,5,1,4,3,2,6,7,9,8,,4.50%,36.70%,42.20%,47.90%,68.20%,69.10%,70.40%,71.10%,71.40%,,71.40%,01-Dec-18,,1677,,227,,273,,155,183,95,167,139,104,199,548,1697,1284,,491,95,491,95,,2515,2427,2499,2471,2436,2531,2880,4029,3616,,2823,2823,2427,750,523,611,523,595,567,532,627,976,2125,1712,,919,1904,,428,,,,,88,,42824
Carvykti,ciltacabtagene autoleucel,Janssen Inc.,Y,N,N,Y,Y,Y,Y,Y,N,01-Apr-22,09-Feb-23,314,CADTH,23-Sep-22,pre-NOC,Initial,"For the treatment of patients with relapsed or refractory multiple myeloma (RRMM), who previously received at least three prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody.",Active,,TBD,n/a,,,New Indication,"For the treatment of patients with relapsed or refractory multiple myeloma (RRMM), who previously received at least three prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody.",Pending,TBD,TBD,TBD,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-139,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44652
Cerdelga,eliglustat,Sanofi Genzyme,Y,N,N,Y,N,Y,Y,Y,N,01-May-15,21-Apr-17,721,CADTH & INESSS,20-Jan-17,pre-NOC,Initial,Gaucher disease,Completed,26-Jul-17,Reimburse with clinical criteria and/or conditions,Conditional,19-Aug-17,post-NOC,New Drug,Gaucher disease ,Completed,01-Feb-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,16-Nov-17,31-May-18,Negotiation,No agreement reached,UR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-91,120,187,166,113,-77,196,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,96,286,309,119,,,,,,817
Cibinqo,abrocitinb,Pfizer Canada ULC,Y,N,N,Y,N,N,N,N,Y,01-Dec-20,29-Jun-22,575,CADTH & INESSS,26-Apr-21,pre-NOC,Initial,"Atopic dermatitis, moderate to severe",Completed,19-Aug-22,Reimburse with clinical criteria and/or conditions,Conditional,06-Aug-21,pre-NOC,New Drug,Atopic dermatitis 12+,under review,TBD,TBD,TBD,1st,14-Feb-23,,Active,n/a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-429,-327,480,,179,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,51,,,,,,,,,626
Cimzia (AS),certolizumab pegol ,UCB ,N,Y,N,N,N,N,N,N,N,,15-Jan-14,,CADTH & INESSS,23-Jun-14,post-NOC,Initial,Ankylosing spondylitis,Completed,17-Apr-15,List with criteria/condition,Conditional,,,New Indication,Ankylosing spondylitis,Completed,01-Oct-14,Ajout d’une indication reconnue – Médicament d’exception – Avis de refus – Valeur thérapeutique,Conditional,1st,05-Oct-15,06-Jan-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,19-Feb-16,01-Mar-16,01-May-16,18-Apr-16,26-Apr-16,12-Apr-16,01-Feb-16,22-Feb-16,01-Mar-16,02-Feb-15,01-Feb-16,02-Feb-15,3,5,10,8,9,7,2,4,6,1,28.60%,29.90%,50.10%,50.50%,55.00%,55.60%,56.50%,62.00%,94.30%,100.00%,100.00%,19-Feb-16,26-Apr-16,159,,298,,171,369,93,44,55,116,103,111,97,26,47,55,-338,73,26,32,-338,111,765,776,837,824,832,818,747,768,776,383,794,753,747,588,290,308,319,380,367,375,361,290,311,319,124,337,457,259,264,462,832,449,85,382,67,42111
Cimzia (PsA),certolizumab pegol ,UCB ,N,Y,N,N,N,N,N,N,N,,02-Jan-14,,CADTH & INESSS,02-Sep-14,post-NOC,Initial,"Arthritis, psoriatic ",Completed,17-Apr-15,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Indication,"Arthritis, psoriatic ",Completed,02-Feb-15,Ajout d'une indication reconnue - Médicament d'exception,Conditional,1st,30-Jun-15,31-Jan-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,19-Feb-16,01-Mar-16,01-May-16,18-Apr-16,26-Apr-16,12-Apr-16,01-Feb-16,22-Feb-16,01-Mar-16,02-Feb-15,01-Feb-16,02-Feb-15,3,5,10,8,9,7,2,4,6,1,28.60%,29.90%,50.10%,50.50%,55.00%,55.60%,56.50%,62.00%,94.30%,100.00%,100.00%,19-Feb-16,26-Apr-16,243,214,227,182,74,148,215,19,30,91,78,86,72,1,22,30,-363,48,1,7,-363,86,778,789,850,837,845,831,760,781,789,396,807,766,760,517,290,308,319,380,367,375,361,290,311,319,0,337,470,396,289,363,845,449,85,382,67,42111
Cimzia (PsO),certolizumab pegol,UCB ,N,Y,N,N,N,N,N,N,N,01-Oct-17,16-Aug-18,319,CADTH & INESSS,13-May-19,post-NOC,Initial,"Psoriasis, moderate to severe plaque",Completed,20-Nov-19,Reimburse with clinical criteria and/or conditions,Conditional,14-Jun-19,post-NOC,New Indication,Psoriasis,Completed,08-Jan-20,Refus d'inscription,Negative,1st,28-Jan-20,07-May-21,Negotiation,No agreement reached,,,NR,,,NR,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,270,302,191,208,69,20,465,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,461,510,534,485,,,,,,780
Cinqair,reslizumab,Teva Canada Innovation,N,Y,N,Y,N,N,N,N,N,01-Sep-15,20-Jul-16,323,CADTH & INESSS,04-Aug-16,post-NOC,Initial,"Asthma, eosinophilic",Completed,22-Mar-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Nov-16,post-NOC,New Drug,Supportive treatment of severe eosinophilic asthma,Completed,01-Jun-17,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,24-Jul-17,15-Nov-18,Negotiation,No agreement reached,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,15,127,230,189,124,53,479,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,245,316,603,532,,,,,,568
Cinqair (Advice),reslizumab,Teva Canada Innovation,N,Y,N,Y,N,N,N,N,N,01-Sep-15,20-Jul-16,323,CADTH,24-Oct-18,post-NOC,Request for Advice,"Asthma, eosinophilic",Completed,27-Mar-19,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,none,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,826,,154,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,980,,,,,,,,,1303
Constella,linaclotide,Actavis ,N,N,N,Y,N,N,N,N,N,,02-Dec-13,,CADTH & INESSS,17-Dec-14,post-NOC,Initial,Irritable bowel syndrome with constipation,Completed,23-Sep-15,Do not list ,Negative,22-Mar-15,post-NOC,New Drug,Irritable bowel syndrome with constipation,Completed,01-Oct-15,Avis de refus d'inscription aux listes de médicaments,Negative,none,02-Nov-15,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,380,475,280,193,40,32,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,660,668,,,,,,,,42270
Contrave,naltrexone hydrochloride and bupropion hydrochloride,Bausch Health (Valeant) ,N,N,N,N,N,N,N,N,N,01-Apr-17,13-Feb-18,318,CADTH,01-May-19,post-NOC,Initial,Chronic weight management in adults,Completed,27-May-20,Do not reimburse,Negative,,,,,,,,,none,13-Oct-20,,Do Not Negotiate,n/a,NR,,NR,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,442,,392,,139,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,834,,,,,,,,,1152
Cortiment,budesonide,Ferring Pharmaceuticals,N,N,N,N,N,N,N,N,N,,20-Jun-16,,CADTH & INESSS,24-May-16,pre-NOC,Initial,Ulcerative Colitis,Completed,22-Mar-17,Do not reimburse,Negative,04-Aug-16,post-NOC,New Drug,Ulcerative Colitis,Completed,01-Feb-17,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,none,07-Apr-17,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-27,45,302,181,16,65,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,275,226,,,,,,,,42816
Corzyna,ranolazine,KYE Pharmaceuticals Inc.,N,N,N,Y,N,N,N,N,Y,01-Jul-20,31-Dec-20,183,CADTH & INESSS,17-Aug-20,pre-NOC,Initial,"Stable angina pectoris, adults",Completed,27-May-21,Do not reimburse,Negative,18-Sep-20,pre-NOC,New Drug,Stable angina,Completed,31-Mar-21,Inscription - Avec conditions,Conditional,1st,24-Oct-22,23-Jan-23,Negotiation,No agreement reached,,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-136,-104,283,194,515,572,91,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,147,90,606,663,,,,,,330
Cosentyx (AS),secukinumab,Novartis ,Y,Y,N,N,N,N,N,N,N,,20-Apr-16,,CADTH & INESSS,19-Feb-16,pre-NOC,Initial,Ankylosing spondylitis,Completed,23-Aug-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Indication,Ankylosing spondylitis,Completed,01-Feb-17,Avis de refus d’ajout d’une indication reconnue aux listes des médicaments –Médicament d’exception – Valeur thérapeutique,Negative,1st,13-Apr-17,19-Dec-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,NR,24-Apr-18,01-Jun-18,01-Apr-18,19-Apr-18,01-Apr-18,08-May-18,01-May-19,26-Mar-18,01-Mar-18,,01-Mar-18,01-Mar-18,6,8,3,5,4,7,9,2,1,,0.70%,1.00%,6.70%,39.00%,44.50%,64.80%,65.70%,70.10%,71.40%,,71.40%,24-Apr-18,,-61,114,186,173,233,71,250,126,164,103,121,103,140,498,97,72,,158,72,158,72,,734,772,711,729,711,748,1106,705,680,,766,766,680,741,555,609,647,586,604,586,623,981,580,555,,641,125,287,483,321,,,,54,,42605
Cosentyx (PsA),secukinumab,Novartis ,Y,Y,N,N,N,N,N,N,N,,20-Apr-16,,CADTH & INESSS,19-Feb-16,pre-NOC,Initial,"Arthritis, psoriatic",Completed,23-Aug-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Indication,Psoriatic arthritis,Completed,01-Feb-17,Avis de refus d’ajout d’une indication reconnue aux listes des médicaments –Médicament d’exception – Valeur thérapeutique,Negative,1st,13-Apr-17,19-Dec-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,24-Apr-18,01-Jun-18,01-Apr-18,19-Apr-18,01-Apr-18,08-May-18,01-May-19,26-Mar-18,01-Mar-18,27-Sep-18,01-Mar-18,01-Mar-18,6,8,3,5,4,7,10,2,1,9,0.70%,1.00%,6.70%,39.00%,44.50%,64.80%,65.70%,70.10%,98.70%,100.00%,100.00%,24-Apr-18,27-Sep-18,-61,114,186,173,233,71,250,126,164,103,121,103,140,498,97,72,282,158,72,171,72,282,734,772,711,729,711,748,1106,705,680,890,766,779,680,741,555,609,647,586,604,586,623,981,580,555,603,641,125,287,483,321,890,210,210,54,156,42605
Cosentyx (PsO),secukinumab,Novartis ,Y,Y,N,Y,N,N,N,N,N,,27-Feb-15,,CADTH & INESSS,08-Dec-14,pre-NOC,Initial,"Psoriasis, moderate to severe plaque",Completed,28-Oct-15,List with criteria/condition,Conditional,22-Mar-15,post-NOC,New Drug,"Psoriasis, moderate to severe plaque",Completed,01-Oct-15,Avis d'inscription aux listes de médicaments - Médicament d'exception,Conditional,1st,15-Dec-15,08-Jun-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,28-Jul-16,01-Aug-16,01-Apr-16,20-Oct-16,30-Aug-16,07-Jul-16,01-Dec-16,24-Oct-16,01-Nov-16,01-Oct-15,01-Apr-16,01-Oct-15,4,5,2,7,6,3,10,8,9,1,28.60%,34.30%,35.20%,55.40%,59.90%,92.10%,97.70%,98.00%,98.70%,100.00%,100.00%,28-Jul-16,30-Aug-16,-81,23,324,193,48,75,176,50,54,-68,134,83,29,176,138,146,-251,82,-68,49,-251,83,517,521,399,601,550,496,643,605,613,216,549,516,399,480,156,274,278,156,358,307,253,400,362,370,0,306,243,216,224,251,550,334,151,301,33,42305
Cotellic,cobimetinib,Hoffman-La Roche ,Y,N,N,Y,Y,Y,N,Y,N,01-Apr-15,22-Feb-16,327,CADTH & INESSS,11-Dec-15,pre-NOC,New drug,Metastatic Melanoma,Completed,30-Jun-16,Cond'l on Cost,Conditional,22-Mar-16,post-NOC,New Drug,Metastatic Melanoma,Completed,03-Oct-16,Avis de refus d’inscription aux listes des médicaments – Médicament d’exception - À moins que certaines conditions soient respectées,Conditional,1st,12-Aug-16,11-May-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Sep-17,28-Nov-17,01-Sep-17,19-Oct-17,17-Nov-17,22-Sep-17,01-May-20,01-Aug-18,01-Jun-17,19-Jul-17,01-Jun-17,01-Jun-17,3,8,4,6,7,5,10,9,1,2,0.70%,29.30%,49.50%,55.20%,56.10%,61.60%,93.90%,98.30%,98.70%,100.00%,100.00%,01-Sep-17,17-Nov-17,-73,29,202,195,43,-52,272,113,201,113,161,190,134,1086,447,21,69,274,21,254,21,190,557,645,557,605,634,578,1530,891,465,513,718,698,465,538,336,428,516,428,476,505,449,1401,762,336,289,589,129,224,315,220,634,169,169,92,77,456
Cresemba,isavuconazole,AVIR Pharma ,N,N,N,Y,N,Y,Y,Y,Y,01-Feb-18,19-Dec-18,321,CADTH & INESSS,02-Nov-18,pre-NOC,Initial,Treatment of invasive aspergillosis and mucormycosis,Completed,15-May-19,Reimburse with clinical criteria and/or conditions,Conditional,04-Sep-18,pre-NOC,New Drug,Aspergillous and mucormycosis ,Completed,13-Mar-19,Inscription – Avec conditions,Conditional,1st,15-Jul-19,25-Nov-19,Negotiation,Completed with Agreements,SA,RB/SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,23-Feb-21,01-Feb-20,01-Mar-20,02-Mar-20,04-Mar-20,19-Mar-20,14-Dec-20,23-Jan-23,12-Nov-20,05-Feb-20,01-Feb-20,01-Feb-20,9,1,3,4,5,6,8,10,7,2,4.50%,33.00%,38.80%,44.30%,76.50%,77.40%,78.10%,79.40%,99.60%,100.00%,100.00%,04-Mar-20,23-Feb-21,-47,-106,194,190,61,124,133,456,68,97,98,100,115,385,1155,353,72,314,68,290,68,456,797,409,438,439,441,456,726,1496,694,413,655,631,409,456,262,650,262,291,292,294,309,579,1349,547,329,508,147,84,194,257,797,388,388,32,356,468
Crysvita,burosumab,Kyowa Kirin Limited,N,Y,N,Y,N,Y,Y,Y,N,01-Jun-18,05-Dec-18,187,CADTH & INESSS,23-Jul-19,post-NOC,Initial,Treatment of X-Linked Hypophosphatemia,Completed,27-May-20,Reimburse with clinical criteria and/or conditions,Conditional,16-Aug-19,post-NOC,New Drug,Hypophosphatemia,Completed,04-Mar-20,Refus d'inscription,Negative,1st,09-Oct-20,10-Sep-21,Negotiation,Completed with Agreements,EDRD,SA,EDS,EDS,EAP,SA,EDS,SA,SA,NR,29-Oct-21,01-Feb-22,01-Dec-21,24-Feb-22,21-Dec-21,24-Mar-22,27-Jun-22,25-Jul-22,21-Nov-22,,29-Oct-21,29-Oct-21,1,4,2,5,3,6,7,8,9,,20.30%,26.00%,58.20%,62.70%,68.20%,69.10%,70.40%,70.70%,71.40%,,71.40%,21-Dec-21,,230,254,309,201,135,219,336,49,144,82,167,102,195,290,318,437,,198,49,198,49,,1059,1154,1092,1177,1112,1205,1300,1328,1447,,1208,1208,1059,829,520,520,615,553,638,573,666,761,789,908,,669,539,455,471,555,,,,53,,726
Cuvposa,glycopyrrolate,MEDEXUS Pharmaceuticals,N,N,N,N,N,Y,N,Y,N,01-Jan-17,30-Oct-17,302,CADTH & INESSS,31-May-19,post-NOC,Initial,"Chronic severe drooling, neurologic (pediatric)",Completed,24-Jun-20,Do not reimburse,Negative,10-May-19,post-NOC,New Drug,Sialorrhea,Completed,06-Nov-19,Inscription - Avec conditions,Conditional,1st,24-Oct-22,16-Jan-23,Negotiation,Completed with Agreements,NR,,,,,NR,,,SA,EM,,,,,,,,,02-Dec-22,01-Feb-23,02-Dec-22,02-Dec-22,,,,,,,,,1,2,0.70%,29.30%,,,,,,,,,29.30%,,,578,557,390,180,852,1083,84,,,,,,,,,-45,16,-45,-45,-15,-45,,,,,,,,,,1859,1920,1859,1890,1859,1281,891,,,,,,,,,891,1183,891,968,737,936,1167,,,,,,1270
Cyramza,ramucirumab,Eli Lilly,N,Y,N,N,Y,N,N,N,N,,,,CADTH,n/a,na,New indication,Non-Small Cell Lung Cancer,File-Closed Not Submitted,,n/a,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0
Cyramza,ramucirumab,Eli Lilly,N,Y,N,Y,Y,Y,Y,Y,N,,16-Jul-15,,CADTH & INESSS,15-Apr-15,pre-NOC,New drug,Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma,Completed,15-Oct-15,Cond'l on Cost,Conditional,04-Aug-15,post-NOC,New Drug,Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma,Completed,01-Feb-16,En monothérapie : Avis de refus d’inscription à la Liste Établissements – Médicament d’exception -Valeur thérapeutique En association avec le paclitaxel : Avis de refus d’inscription à la Liste Établissements – Médicament d’exception - À moins que certaines conditions soient respectées,Conditional,1st,12-Nov-15,27-Oct-16,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-May-17,03-Apr-17,21-Dec-16,12-Dec-16,28-Feb-17,24-Aug-17,30-May-17,,03-Aug-17,16-Dec-16,12-Dec-16,12-Dec-16,6,5,3,1,4,9,7,,8,2,5.50%,34.10%,39.80%,72.10%,76.50%,96.80%,98.10%,98.80%,99.60%,,99.60%,28-Feb-17,01-May-17,-92,19,183,181,28,-81,350,186,158,55,46,124,301,215,,280,50,171,46,157,46,186,655,627,524,515,593,770,684,,749,519,640,626,515,607,424,564,536,433,424,502,679,593,,658,319,549,91,200,378,269,655,140,140,78,62,42292
Cystadrops,cysteamine,Recordati Rare Diseases Canada Inc.,N,N,N,N,N,N,N,N,N,01-Feb-18,11-Feb-19,375,CADTH & INESSS,10-Dec-18,pre-NOC,Initial,Corneal cystine crystal deposits,Completed,18-Jun-19,Reimburse with clinical criteria and/or conditions,Conditional,12-Jul-19,post-NOC,New Drug,Cystine corneal deposits,Completed,08-Apr-20,Refus d'inscription,Negative,1st,26-Jun-19,22-Aug-19,Negotiation,Completed with Agreements,SA,SA,UR,EDS,UR,SA,EDS,UR,SA,EM,28-Feb-22,01-Dec-19,,02-Mar-20,,26-Feb-20,01-Jan-21,,15-Apr-21,08-Jul-20,01-Dec-19,01-Dec-19,7,1,,3,,2,5,,6,4,4.50%,5.30%,10.90%,39.50%,40.80%,41.40%,61.70%,,,,61.70%,28-Feb-22,,-63,151,190,271,8,-287,57,921,101,,193,,188,498,,602,321,417,101,403,101,,1113,293,,385,,380,690,,794,513,609,595,293,356,166,986,166,,258,,253,563,,667,91,482,127,422,65,-230,,,,820,,502
Daklinza (Drug Plan Submission),daclatasvir,Bristol-Myers Squibb ,Y,N,N,Y,N,N,N,N,N,,13-Aug-15,,CADTH & INESSS,06-Jan-16,post-NOC,Request for Advice,"Hepatitis C, chronic",Completed,19-May-16,Reimburse with clinical criteria and/or conditions,Conditional,04-Aug-15,pre-NOC,New Drug,Hepatitis C,Completed,01-Feb-16,Avis d'inscription aux listes des médicaments-Médicament d'exception,Conditional,2nd,22-Jul-16,17-Feb-17,Negotiation,Completed with Agreements,DL,SA,EDS,EDS,DL,SA,EDS,NR,SA,EM,21-Mar-17,01-Apr-17,01-Apr-17,20-Apr-17,28-Feb-17,29-Mar-17,01-May-17,,01-Sep-17,15-Mar-17,28-Feb-17,28-Feb-17,3,5,6,7,1,4,8,,9,2,32.20%,60.80%,81.10%,82.00%,86.40%,92.10%,97.70%,99.00%,99.60%,,99.60%,15-Mar-17,21-Mar-17,146,-9,134,181,64,172,210,32,43,43,62,11,40,73,,196,26,63,11,58,11,32,586,597,597,616,565,594,627,,750,580,617,612,565,419,285,306,317,317,336,285,314,347,,470,408,337,280,172,274,382,586,21,21,15,6,42509
Daklinza,daclatasvir,Bristol-Myers Squibb ,Y,N,N,Y,N,N,N,N,N,,13-Aug-15,,CADTH & INESSS,13-Feb-15,pre-NOC,Initial,"Hepatitis C, chronic",Completed,21-Sep-15,List with clinical criteria and/or conditions,Conditional,04-Aug-15,pre-NOC,New Drug,Hepatitis C,Completed,01-Feb-16,Avis d'inscription aux listes des médicaments-Médicament d'exception,Conditional,1st,,17-Mar-16,Negotiation,No agreement reached,DL,SA,EDS,EDS,DL,SA,EDS,NR,SA,EM,21-Mar-17,01-Apr-17,01-Apr-17,20-Apr-17,28-Feb-17,29-Mar-17,01-May-17,,01-Sep-17,15-Mar-17,28-Feb-17,28-Feb-17,3,5,6,7,1,4,8,,9,2,32.20%,60.80%,81.10%,82.00%,86.40%,92.10%,97.70%,99.00%,99.60%,,99.60%,15-Mar-17,21-Mar-17,-181,-9,220,181,,,,369,380,380,399,348,377,410,,533,363,400,348,395,348,369,586,597,597,616,565,594,627,,750,580,617,612,565,746,526,547,558,558,577,526,555,588,,711,408,578,39,172,178,45,586,21,21,15,6,42268
Darzalex,daratumumab,Janssen ,Y,Y,N,Y,Y,Y,Y,Y,N,01-Nov-15,29-Jun-16,241,CADTH & INESSS,21-Apr-16,pre-NOC,New drug,For the treatment of patients with multiple myeloma who 1) have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD); OR 2) have failed or are intolerant to a PI and who have failed or are intolerant to an IMiD,Completed,01-Dec-16,Do not fund,Negative,12-Aug-16,post-NOC,New Drug,For the treatment of patients with multiple myeloma who 1) have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD); OR 2) have failed or are intolerant to a PI and who have failed or are intolerant to an IMiD,Completed,01-Feb-17,Avis de refus d'inscription à la Liste Établissements - Valeur thérapeutique,Negative,None,23-Dec-16,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-69,44,224,173,22,-40,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,155,217,,,,,,,,396
Darzalex,daratumumab,Janssen ,Y,Y,N,N,Y,Y,Y,Y,N,01-Oct-16,13-Apr-17,194,CADTH & INESSS,03-Mar-17,pre-NOC,New indication,"Multiple Myeloma (second-line or beyond):In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy",Completed,05-Oct-17,Cond'l on Cost,Conditional,,,New Indication,"Multiple Myeloma (second-line or beyond):In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy",Completed,01-Feb-18,n/a,n/a,1st,09-Mar-18,14-Nov-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Feb-19,29-Jan-19,15-Jul-19,08-Jan-19,15-Mar-19,26-Apr-19,01-May-19,01-Jul-22,16-Aug-19,13-Dec-18,08-Jan-19,13-Dec-18,4,3,8,2,5,6,7,10,9,1,28.60%,34.10%,38.60%,58.80%,91.10%,91.90%,93.30%,99.00%,99.60%,100.00%,100.00%,01-Feb-19,15-Mar-19,-41,,216,,155,36,250,79,76,243,55,121,163,168,1325,275,29,278,55,253,29,121,659,656,823,635,701,743,748,1905,855,609,858,833,635,676,460,484,481,648,460,526,568,573,1730,680,315,683,175,294,405,286,701,92,66,50,42,369
Darzalex,daratumumab,Janssen ,Y,Y,N,N,Y,Y,Y,Y,N,01-Jan-18,27-Nov-18,330,CADTH & INESSS,04-Jan-19,post-NOC,New indication,Multiple Myeloma (newly diagnosed),Completed,29-Aug-19,Cond'l on Cost,Conditional,01-Feb-19,post-NOC,New Indication,"In combination with bortezomib, melphalan and prednisone, for the treatment of patients with newly diagnosed multiple myeloma who are not suitable for autologous stem cell transplant",Completed,07-Aug-19,Refus d'inscription,Negative,1st,29-Nov-19,25-Feb-22,Negotiation,Completed with Agreements,Funded,Funded,Under provincial consideration,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,NR,01-Jun-22,30-Sep-22,,26-May-22,30-Sep-22,,,01-Jul-22,,,26-May-22,26-May-22,2,4,,1,5,,,3,,,5.50%,25.80%,26.10%,30.60%,62.80%,,,,,,62.80%,30-Sep-22,,38,66,237,187,92,114,819,96,217,,90,217,,,126,,,149,90,149,90,,1282,1403,,1276,1403,,,1312,,,1335,1335,1276,1238,1001,1007,1128,,1001,1128,,,1037,,,1060,275,253,911,933,,,,127,,605
Darzalex,daratumumab,Janssen ,Y,Y,N,N,Y,Y,Y,Y,Y,01-May-19,25-Oct-19,177,CADTH & INESSS,17-Jul-19,pre-NOC,New indication,In combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant,Completed,05-Mar-20,Cond'l on Cost,Conditional,09-Aug-19,pre-NOC,New Indication,In combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant,Completed,04-Mar-20,Refus d'inscription,Negative,1st,26-Feb-21,25-Feb-22,Negotiation,Completed with Agreements,Funded,Funded,,,Funded,Funded,Under provincial consideration,Funded,Under provincial consideration,EM,01-Jun-22,30-Sep-22,,,31-Aug-21,,,,,13-Apr-22,31-Aug-21,31-Aug-21,3,4,,,1,,,,,2,32.20%,60.80%,81.10%,85.50%,,,,,,,85.50%,13-Apr-22,01-Jun-22,-100,-77,232,208,358,359,364,96,217,,,-178,,,,,47,45,-178,46,-178,96,950,1071,,,676,,,,,901,899,900,676,776,544,818,939,,,544,,,,,770,767,132,131,722,723,950,274,274,225,49,309
Darzalex SC,daratumumab,Janssen ,Y,Y,N,N,Y,Y,Y,Y,N,01-Nov-20,12-Apr-21,162,CADTH & INESSS,15-Jul-21,post-NOC,Initial,"Darzalex SC in combination with bortezomib, cyclophosphamide, and dexamethasone, for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis",Completed,28-Jan-22,Cond'l on Cost,Conditional,06-Aug-21,post-NOC,New Indication,"Darzalex SC in combination with bortezomib, cyclophosphamide, and dexamethasone, for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis",Completed,02-Mar-22,Inscription - Avec conditions,Conditional,1st,04-Mar-22,11-Mar-22,Negotiation,Completed with Agreements,Funded,Funded,Under provincial consideration,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,01-Sep-22,30-Sep-22,,19-Oct-22,31-Aug-22,,,01-Jul-22,,13-Apr-22,01-Jul-22,13-Apr-22,4,5,,6,3,,,2,,1,28.60%,28.90%,61.20%,81.40%,85.90%,91.40%,,,,,91.40%,31-Aug-22,01-Sep-22,94,116,197,208,35,2,7,174,203,,222,173,,,112,,33,177,112,153,33,174,507,536,,555,506,,,445,,366,510,486,445,351,154,216,245,,264,215,,,154,,42,219,291,324,42,9,507,141,62,140,1,453
Daurismo,glasdegib,Pfizer,Y,N,N,Y,Y,Y,Y,Y,N,01-Jul-19,28-Apr-20,302,CADTH & INESSS,06-May-20,post-NOC,New drug,Acute Myeloid Leukemia (AML),Completed,08-Jan-21,Do Not Fund,Negative,29-May-20,post-NOC,New Drug,Acute Myeloid Leukemia (AML),Completed,02-Dec-20,Refus d'inscription,Negative,None,23-Feb-21,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,8,31,247,187,46,83,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,255,218,,,,,,,,557
Dayvigo,lemborexant,Eisai Limited,N,N,N,Y,N,N,N,N,N,01-Jan-20,04-Nov-20,308,CADTH & INESSS,28-Feb-22,post-NOC,Initial,Insomnia,Completed,10-Jan-23,Do not reimburse,Negative,28-Oct-22,post-NOC,New Drug,Insomnia,Completed,29-Mar-23,Refus d'inscription,Negative,none,,,,,UR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,481,723,316,152,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,797,875,,,,,,,,1105
Delstrigo,doravirine lamuvidine tenofovir disoproxil fumarate,Merck,Y,N,N,N,N,N,N,N,N,01-Jan-18,09-Nov-18,312,CADTH & INESSS,16-Nov-18,post-NOC,Initial,HIV-1,Completed,14-May-19,Reimburse with clinical criteria and/or conditions,Conditional,16-Nov-18,post-NOC,New Drug,HIV,Completed,08-May-19,Inscription,Positive,1st,14-Jun-19,15-Oct-19,Negotiation,Completed with Agreements,HIV,UR,UR,EDS,FB,SA,HIV,HIV,SA,FB,,,,02-Mar-20,31-Oct-19,21-May-20,01-Mar-21,31-May-21,11-Sep-20,14-Nov-19,31-Oct-19,31-Oct-19,,,,3,1,4,6,7,5,2,32.20%,60.80%,66.30%,67.20%,67.90%,69.20%,69.60%,,,,69.60%,14-Nov-19,,7,7,179,173,31,37,123,,,,139,16,219,503,594,332,30,301,16,262,16,,,,,479,356,559,843,934,672,370,641,602,356,349,170,,,,293,170,373,657,748,486,190,455,186,180,154,160,,,,14,,498
Descovy,emtricitabine /tenofovir alafenamide,Gilead Sciences ,Y,N,N,N,N,N,N,N,N,,29-Apr-16,,CADTH & INESSS,29-Jan-16,pre-NOC,Initial,HIV-1 infection,Completed,24-Aug-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Drug,HIV-1 infection,Completed,01-Jun-17,Avis d'inscription aux listes des médicaments,Positive,1st,04-Aug-17,08-Jun-18,Negotiation,No agreement reached,NR,NR,NR,NR,NR,NR,NR,NR,NR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-91,105,208,293,345,64,308,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,117,398,653,372,,,,,,42606
Diacomit,stiripentol,Biocodex,N,N,N,Y,N,Y,N,Y,N,,21-Dec-12,,CADTH & INESSS,30-Oct-13,post-NOC,Initial,"severe myoclonic epilepsy in infancy (as per PCPA), Dravet syndrome (as per CADTH)",Completed,16-Oct-14,List with criteria/condition,Conditional,,,New Drug,Dravet syndrome,Completed,02-Jun-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,30-Nov-14,11-May-15,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,07-Jul-15,01-Oct-15,01-Jul-15,22-Jul-15,22-Jun-15,24-Nov-15,01-May-16,01-Aug-18,01-Oct-15,02-Jun-14,22-Jun-15,02-Jun-14,4,6,3,5,2,8,9,10,7,1,28.60%,60.80%,66.50%,86.80%,92.30%,96.80%,97.40%,98.30%,99.60%,100.00%,100.00%,22-Jun-15,07-Jul-15,313,,351,,45,181,162,57,143,51,72,42,197,356,1178,143,-343,249,42,190,-343,57,928,1014,922,943,913,1068,1227,2049,1014,528,1120,1061,913,600,249,264,350,258,279,249,404,563,1385,350,0,456,664,528,207,343,928,400,15,385,15,41928
Dificid,fidaxomicin,"Optimer Pharmaceuticals Canada, Inc. ",N,N,N,Y,N,N,N,N,N,,07-Jun-12,,CADTH & INESSS,10-Jul-12,post-NOC,Initial,Clostridium difficile infection ,Completed,19-Dec-12,Do not list at the submitted price ,Negative,,,New Drug,Clostridium difficile infection ,Completed,01-Feb-13,Avis de refus,Negative,1st,,13-Nov-13,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,25-Feb-14,01-Mar-16,01-Jan-15,17-Jul-14,16-Dec-13,11-Sep-14,01-May-17,23-Nov-15,01-Oct-15,02-Jun-14,16-Dec-13,16-Dec-13,2,9,6,4,1,5,10,8,7,3,32.20%,52.50%,81.10%,86.60%,87.50%,93.20%,93.90%,94.20%,98.70%,100.00%,100.00%,25-Feb-14,02-Jun-14,33,,162,,,,,104,839,414,246,33,302,1265,740,687,201,514,33,483,33,201,628,1363,938,770,557,826,1789,1264,1211,725,1038,1007,557,524,362,433,1168,743,575,362,631,1594,1069,1016,486,843,195,239,329,285,725,168,168,71,97,41262
Dojolvi,triheptanoin,Ultragenyx Canada Inc,N,N,N,Y,N,Y,Y,Y,N,01-Aug-20,15-Feb-21,198,CADTH & INESSS,31-Mar-21,post-NOC,Initial,Indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD). ?,Completed,21-Jan-22,Reimburse with clinical criteria and/or conditions,Conditional,06-Aug-21,post-NOC,New Drug,Indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD). ?,Completed,29-Dec-21,Refus d'inscription,Negative,1st,22-Apr-22,14-Mar-23,Negotiation,Completed with Agreements,,,,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,44,172,296,145,91,114,326,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,340,317,417,440,,,,,,538
Doptelet,avatrombopag,Sobi Canada,N,Y,N,Y,N,N,N,N,N,01-Jun-21,,,CADTH & INESSS,03-Feb-22,na,Initial,Chronic immune thrombocytopenia (ITP),Suspended,,Suspended,n/a,,,New Drug,Thrombocytopenia,withdrawn,n/a,n/a,n/a,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44348
Dovato,dolutegravir/lamivudine,ViiV Healthcare,N,N,N,N,N,N,N,N,Y,01-Oct-18,22-Aug-19,325,CADTH & INESSS,21-Feb-19,pre-NOC,Initial,HIV-1 infection,Completed,30-Sep-19,Reimburse with clinical criteria and/or conditions,Conditional,01-Mar-19,pre-NOC,New drug,HIV Infection,Completed,16-Oct-19,Inscription - Avec conditions,Conditional,1st,04-Oct-19,21-Nov-19,Negotiation,Completed with Agreements,HIV,UR,EDS,EDS,FB,SA,HIV,FB,SA,EM,,,01-Mar-20,02-Mar-20,31-Jan-20,19-Mar-20,14-Dec-20,28-Dec-20,16-Dec-20,18-Dec-19,31-Jan-20,18-Dec-19,,,3,4,2,5,6,8,7,1,28.60%,60.80%,66.50%,72.10%,73.00%,74.30%,74.90%,75.30%,,,75.30%,31-Jan-20,,-182,-174,221,229,4,-12,48,,,101,102,71,119,389,403,391,27,225,71,200,27,,,,192,193,162,210,480,494,482,118,316,291,162,344,123,,,153,154,123,171,441,455,443,63,277,39,55,52,36,,,,44,,364
Duaklir Genuair,aclidinium bromide/formoterol fumarate dihydrate,AstraZeneca ,Y,N,N,N,N,N,N,N,N,,02-Apr-15,,CADTH & INESSS,01-Apr-15,pre-NOC,Initial,Chronic Obstructive Pulmonary Disease (COPD),Completed,18-Sep-15,List with clinical criteria and/or conditions,Conditional,04-Aug-15,post-NOC,New Indication,Chronic Obstructive Pulmonary Disease (COPD),Completed,01-Feb-16,Avis de refus d'inscription aux listes de médicaments - Valeur thérapeutique,Negative,1st,23-Oct-15,15-Dec-15,Negotiation,Completed with Agreements,SA,SA,EDS,FB,LU,SA,EDS,SA,SA,NR,05-Apr-16,01-Feb-16,01-May-16,18-Apr-16,25-Feb-16,21-Dec-15,01-Mar-16,28-Mar-16,01-May-16,,21-Dec-15,21-Dec-15,6,2,8,7,3,1,4,5,9,,0.90%,5.30%,37.60%,38.90%,39.20%,59.50%,65.00%,70.70%,71.40%,,71.40%,05-Apr-16,,-1,124,170,181,35,-101,53,112,48,138,125,72,6,77,104,138,,91,6,91,6,,369,305,395,382,329,263,334,361,395,,348,348,263,264,94,200,136,226,213,160,94,165,192,226,,179,169,305,88,-48,,,,106,,42265
Duobrii,halobetasol propionate and tazarotene,Bausch Health (Valeant) ,N,N,N,Y,N,N,N,N,Y,01-May-18,10-Jun-20,771,CADTH,04-Feb-19,pre-NOC,Initial,"Psoriasis, moderate to severe plaque",Withdrawn,19-Feb-19,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-492,,15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-477,,,,,,,,,294
Duobrii,Halobetasol propionate and tazarotene,Bausch Health (Valeant) ,N,N,N,N,N,N,N,N,Y,01-May-18,10-Jun-20,771,CADTH & INESSS,24-Jan-20,pre-NOC,Initial,"Psoriasis, moderate to severe plaque",Completed,28-Oct-20,Reimburse with clinical criteria and/or conditions,Conditional,13-Mar-20,pre-NOC,New drug,Plaque psoriasis,Completed,09-Sep-20,Refus d’inscription,Negative,1st,17-Sep-21,30-Nov-21,Negotiation,Completed with Agreements,NR,SA,FB,FB,FB,FB,EDS,SA,SA,NR,,01-Feb-22,01-Mar-22,24-Feb-22,31-Jan-21,17-Feb-22,16-May-22,28-Dec-22,07-Jul-22,,31-Jan-21,31-Jan-21,,2,5,4,1,3,6,8,7,,32.20%,36.70%,37.60%,43.10%,48.80%,50.10%,50.80%,51.20%,,,51.20%,16-May-22,,-138,-89,278,180,324,373,74,,63,91,86,-303,79,167,393,219,,99,-303,99,-303,,,601,629,624,235,617,705,931,757,,637,637,235,373,95,,461,489,484,95,477,565,791,617,,497,140,91,398,447,,,,470,,911
Dupixent,dupilumab,Sanofi Genzyme,Y,Y,N,Y,N,N,N,N,N,01-Feb-17,30-Nov-17,302,CADTH & INESSS,27-Oct-17,pre-NOC,Initial,atopic dermatitis,Completed,27-Jun-18,Do not reimburse,Negative,,,New Drug,Atopic dermatitis,Completed,09-May-18,Avis de refus d'inscription aux listes des médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,22-Nov-18,17-Sep-19,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,,,,,,EM,,01-Jul-22,01-Jun-21,05-Aug-21,,,,,,02-Oct-19,01-Jun-21,02-Oct-19,,4,2,3,,,,,,1,28.60%,34.30%,39.80%,44.30%,,,,,,,44.30%,,,-34,,243,,148,197,299,,1018,623,688,,,,,,15,776,623,586,15,,,1674,1279,1344,,,,,,671,1432,1242,1279,1313,1070,,1465,1070,1135,,,,,,511,1223,209,160,447,496,,,,,,511
Dupixent,dupilumab,"Sanofi Genzyme, a division of sanofi-aventis Canada Inc.",Y,Y,N,N,N,N,N,N,N,01-Jan-20,12-Nov-20,316,CADTH & INESSS,26-Nov-20,post-NOC,Initial,Add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma,Completed,08-Jun-21,Reimburse with clinical criteria and/or conditions,Conditional,01-Jan-21,post-NOC,New Indication,Severe eosinophilic asthma,Completed,02-Jun-21,Inscription - Avec conditions,Conditional,1st,01-Nov-21,28-Jun-22,Negotiation,No Agreement reached,NR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,14,50,194,152,146,152,239,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,208,202,385,391,,,,,,524
Dupixent,dupilumab,Sanofi-aventis Canada Inc.,Y,Y,N,N,N,N,N,N,N,01-May-21,25-Mar-22,328,CADTH,28-Jun-22,post-NOC,Initial,Asthma,Completed,20-Jan-23,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,10-Mar-23,10-Mar-23,Negotiation,Completed with Agreements,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,95,,206,,49,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,301,,49,,,,,,,629
Dupixent,dupilumab,"Sanofi Genzyme, a division of sanofi-aventis Canada Inc.",Y,Y,N,N,N,N,N,N,N,01-Nov-18,25-Sep-19,328,CADTH,15-Jul-22,post-NOC,Request for Advice,atopic dermatitis,Completed,18-Jan-23,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,1024,,187,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1211,,,,,,,,,1539
Dupixent (12+),dupilumab,Sanofi Genzyme,Y,Y,N,N,N,N,N,N,N,01-Nov-18,25-Sep-19,328,CADTH & INESSS,22-Oct-19,post-NOC,Initial,atopic dermatitis,Completed,22-Apr-20,Reimburse with clinical criteria and/or conditions,Conditional,22-Nov-19,post-NOC,New Indication,"Atopic dermatitis, adolescents",Completed,08-Jul-20,Inscription - Avec conditions,Conditional,1st,28-Jul-20,25-Feb-21,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,,01-Jul-22,01-Jun-21,05-Aug-21,06-May-21,13-May-21,30-Nov-21,22-Nov-21,17-Jan-22,27-May-21,06-May-21,06-May-21,,9,4,5,1,2,7,6,8,3,32.20%,33.10%,61.70%,67.40%,73.00%,73.30%,74.60%,75.30%,79.70%,,79.70%,27-May-21,,27,58,183,229,97,20,212,,491,96,161,70,77,278,270,326,91,221,70,207,70,,,1010,615,680,589,596,797,789,845,610,740,726,589,562,379,,800,405,470,379,386,587,579,635,323,530,210,287,309,232,,,,21,,538
Dymista,azelastine HCl and fluticasone propionate,Meda Pharmaceuticals Ltd.,N,N,N,Y,N,N,N,N,N,,23-Oct-14,,CADTH,09-Dec-14,post-NOC,Initial,Seasonal allergic rhinitis,Completed,17-Jun-15,Do not list ,Negative,,,,,,,,,none,24-Jul-15,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,47,,190,,37,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,237,,,,,,,,,42172
Dysport Therapeutic,abobotulinumtoxinA,Ipsen Biopharmaceuticals ,N,Y,N,N,N,N,N,N,N,,03-Jan-17,,CADTH & INESSS,24-Apr-17,post-NOC,Initial,Upper limb spasticity,Completed,24-Oct-17,Reimburse with clinical criteria and/or conditions,Conditional,,,New Indication,Treatment of upper limb spasticity,Completed,01-Feb-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,04-May-18,17-Jul-18,Negotiation,Completed with Agreements,SA,FB,EDS,EDS,LU,SA,EDS,UR,UR,EM,26-Feb-19,01-Dec-18,01-Oct-18,18-Oct-18,27-Sep-18,23-Aug-18,01-Aug-19,,,11-Apr-19,23-Aug-18,23-Aug-18,6,5,3,4,2,1,8,,,7,0.90%,33.10%,38.80%,44.40%,48.80%,69.10%,97.70%,99.00%,,,99.00%,26-Feb-19,11-Apr-19,111,,183,,192,92,74,224,137,76,93,72,37,380,,,268,146,37,161,37,268,784,697,636,653,632,597,940,,,828,706,721,597,486,303,490,403,342,359,338,303,646,,,434,412,294,394,266,166,828,231,231,187,44,43032
Dysport Therapeutic (cervical),abobotulinumtoxinA,Ipsen Biopharmaceuticals ,N,Y,N,N,N,N,N,N,N,,15-Jun-16,,CADTH & INESSS,31-Jan-17,post-NOC,Initial,Cervical dystonia,Completed,26-Jul-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,Treatment of Cervical Dystonia,Completed,18-Oct-17,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,04-May-18,17-Jul-18,Negotiation,Completed with Agreements,SA,FB,EDS,EDS,LU,SA,EDS,UR,UR,EM,26-Feb-19,01-Dec-18,01-Oct-18,18-Oct-18,27-Sep-18,23-Aug-18,01-Aug-19,,,11-Apr-19,23-Aug-18,23-Aug-18,6,5,3,4,2,1,8,,,7,0.90%,33.10%,38.80%,44.40%,48.80%,69.10%,97.70%,99.00%,,,99.00%,26-Feb-19,11-Apr-19,230,282,176,208,282,198,74,224,137,76,93,72,37,380,,,268,146,37,161,37,268,986,899,838,855,834,799,1142,,,1030,908,923,799,569,393,580,493,432,449,428,393,736,,,540,502,406,490,356,272,1030,231,231,187,44,42942
Dysport Therapeutic (lower),abobotulinumtoxinA,Ipsen Biopharmaceuticals ,N,Y,N,N,N,N,N,N,N,,15-Jun-16,,CADTH & INESSS,07-Feb-18,post-NOC,Initial,lower limb spasticity,Completed,23-Aug-18,Reimburse with clinical criteria and/or conditions,Conditional,24-Sep-18,post-NOC,New Indication,Treatment of lower limb spasticity in infacts age 2 or older,Completed,13-Feb-19,Inscription – Avec conditions,Conditional,1st,30-Aug-18,30-Aug-18,Negotiation,Completed with Agreements,SA,FB,EDS,EDS,LU,SA,EDS,UR,UR,EM,26-Feb-19,01-Dec-18,01-Oct-18,24-Jan-19,27-Sep-18,17-Dec-18,01-Aug-19,,,11-Apr-19,27-Sep-18,27-Sep-18,6,3,2,5,1,4,8,,,7,32.20%,38.00%,42.40%,43.30%,48.80%,69.10%,97.70%,99.00%,,,99.00%,26-Feb-19,11-Apr-19,602,831,197,142,7,-167,0,180,93,32,147,28,109,336,,,224,132,28,144,28,224,986,899,838,953,834,915,1142,,,1030,938,950,834,232,35,187,100,39,154,35,116,343,,,57,139,799,973,7,-167,1030,196,196,152,44,43335
Edarbi,azilsartan medoxomil ,Takeda Canada Inc.,Y,N,N,Y,N,N,N,N,N,,08-Mar-12,,CADTH & INESSS,08-Mar-13,post-NOC,Initial,"Hypertension, essential ",Completed,17-Oct-13,Do not list at the submitted price,Negative,,,New Drug,"Hypertension, essential ",Completed,03-Jun-13,Avis de refus,Negative,none,12-Nov-13,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,365,,223,,26,162,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,588,452,,,,,,,,41564
Edarbyclor,azilsartan medoxomil + chlorthalidone ,Takeda Canada Inc. ,Y,N,N,N,N,N,N,N,N,,03-Dec-12,,CADTH & INESSS,08-Mar-13,post-NOC,Initial,"Hypertension, essential ",Completed,17-Oct-13,Do not list ,Negative,,,New Drug,"Hypertension, essential ",Completed,01-Oct-13,Avis de refus,Negative,none,12-Nov-13,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,95,,223,,26,42,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,318,302,,,,,,,,41564
Egrifta,tesamorelin,Theratechnologies Inc.,N,N,N,Y,N,N,N,N,N,,29-Apr-14,,CADTH & INESSS,02-Mar-16,post-NOC,Initial,"Lipodystrophy, HIV-infected patients",Completed,24-Aug-16,Do not reimburse,Negative,22-Mar-16,post-NOC,New Drug,"Lipodystrophy, HIV-infected patients",Completed,01-Jun-16,Avis de refus d’inscription aux listes des médicaments – Valeur thérapeutique,Negative,none,14-Oct-16,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,673,693,175,71,51,135,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,848,764,,,,,,,,42606
Elelyso,taliglucerase alfa ,Pfizer ,Y,Y,N,Y,N,Y,Y,Y,N,,29-May-14,,CADTH & INESSS,15-Aug-14,post-NOC,Initial,Gaucher disease ,Completed,28-Oct-15,Do not list ,Negative,24-Nov-14,post-NOC,Resubmission,Gaucher disease ,Completed,15-Jul-15,Avis de refus d’inscription – À moins que certaines conditions soient respectées,Conditional,none,31-Jan-16,,Do Not Negotiate,n/a,UR,NR,NR,NR,NR,NR,NR,NR,NR,EM,,,,,,,,,,15-Jul-15,,15-Jul-15,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,78,179,439,233,95,200,,,,,,,,,,,,,,,,,,,,,,,,,,412,,412,,,,,,,,,,,,,0,,517,412,,,,,,,,42305
Elelyso (2nd pCPA),taliglucerase alfa,Pfizer ,Y,Y,N,Y,N,Y,Y,Y,N,,29-May-14,,CADTH & INESSS,15-Aug-14,post-NOC,Initial,Gaucher disease ,Completed,28-Oct-15,Do not list,Negative,24-Nov-14,post-NOC,Resubmission,Gaucher disease ,Completed,15-Jul-15,Avis de refus d’inscription – À moins que certaines conditions soient respectées,Conditional,1st,17-Nov-17,17-May-18,Negotiation,Completed with Agreements,UR,SA,UR,EDS,UR,SA,EDS,UR,UR,,,01-Sep-19,,18-Oct-18,,27-Mar-19,31-Jul-20,,,,18-Oct-18,18-Oct-18,,3,,1,,2,4,,,,5.50%,6.40%,10.90%,12.20%,,,,,,,12.20%,,,78,179,439,233,751,856,181,,472,,154,,314,806,,,,437,154,437,154,,,1921,,1603,,1763,2255,,,,1886,1886,1603,1525,1086,,1404,,1086,,1246,1738,,,,1369,517,412,932,1037,,,,,,42305
Eliquis (AF),apixaban,Bristol-Myers Squibb & Pfizer ,Y,N,N,N,N,N,N,N,N,,05-Dec-12,,CADTH & INESSS,25-Sep-12,pre-NOC,Initial,"Thromboembolic events prevention, (atrial fibrillation) ",Completed,20-Mar-13,List with clinical criteria and/or conditions,Conditional,04-Aug-13,post-NOC,New Indication,Prevention of stroke and systemic embolism in patients with atrial fibrillation,Completed,01-Oct-13,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,,10-Oct-13,Negotiation,Completed with Agreements,FB,FB,EDS,EDS,LU,FB,EDS,SA,SA,EM,19-Sep-13,01-Mar-14,01-Nov-13,17-Oct-13,29-Aug-13,21-Nov-14,01-Dec-13,17-Feb-14,01-Mar-15,01-Oct-13,29-Aug-13,29-Aug-13,2,8,5,4,1,9,6,7,10,3,32.20%,52.50%,81.10%,86.60%,92.30%,93.60%,94.00%,98.40%,99.30%,100.00%,100.00%,19-Sep-13,01-Oct-13,-71,242,176,58,,,,-21,142,22,7,-42,407,52,130,507,-9,134,-42,120,-42,-9,288,451,331,316,267,716,361,439,816,300,443,429,267,338,162,183,346,226,211,162,611,256,334,711,0,338,105,300,204,9,300,33,33,21,12,41353
Eliquis (Treat VTE&recurrence),apixaban ,Bristol-Myers Squibb & Pfizer ,Y,N,N,N,N,N,N,N,N,,01-Nov-14,,CADTH & INESSS,18-Sep-14,pre-NOC,Initial,venous thromboembolic events and prevent recurrent deep-vein thrombosis and pulmonary embolism,Completed,07-May-15,List with clinical criteria and/or conditions,Conditional,24-Nov-14,post-NOC,Resubmission,Treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and preventing recurrence,Completed,01-Jun-15,Ajout d'une indication reconnue - Médicament d'exception,Conditional,1st,11-Jun-15,09-Jul-15,Negotiation,Completed with Agreements,FB,FB,EDS,EDS,LU,FB,EDS,SA,SA,EM,05-Apr-16,01-Nov-15,01-Oct-15,22-Oct-15,30-Sep-15,14-Oct-15,01-Dec-16,25-Apr-16,01-Sep-15,01-Jun-15,01-Sep-15,01-Jun-15,8,7,4,6,3,5,10,9,2,1,28.60%,29.30%,61.50%,67.20%,68.10%,73.60%,78.10%,98.30%,98.70%,100.00%,100.00%,30-Sep-15,05-Apr-16,-44,23,231,189,35,10,28,271,115,84,105,83,97,511,291,54,-38,179,54,157,-38,271,521,365,334,355,333,347,761,541,304,212,429,407,304,348,117,334,178,147,168,146,160,574,354,117,0,242,187,212,63,38,521,309,217,121,188,42131
Emgality,galcanezumab,Eli Lilly Canada Inc. (Lilly),Y,Y,N,Y,N,N,N,N,N,01-Oct-18,30-Jul-19,302,CADTH & INESSS,03-Jun-21,post-NOC,Initial,Prevention of migraine,Completed,15-Dec-21,Reimburse with clinical criteria and/or conditions,Conditional,24-Sep-21,post-NOC,New Drug,Prevention of migraine,Completed,30-Mar-22,Inscription - Avec conditions,Conditional,1st,29-Mar-22,22-Nov-22,Negotiation,Completed with Agreements,,SA,EDS,EDS,EAP,,,,SA,EM,,01-Feb-23,01-Feb-23,01-Apr-23,01-Dec-22,,,,07-Mar-23,01-Feb-23,01-Dec-22,01-Dec-22,,2,3,6,1,,,,5,4,32.20%,36.70%,42.40%,71.00%,71.70%,77.20%,,,,,77.20%,01-Feb-23,,674,787,195,187,104,-1,238,,71,71,130,9,,,,105,71,77,9,76,9,,,1282,1282,1341,1220,,,,1316,1282,1288,1287,1220,546,351,,413,413,472,351,,,,447,308,419,869,974,342,237,,,,62,,1171
Empaveli,pegcetacoplan,SOBI Canada,N,N,N,Y,N,Y,Y,Y,N,01-Jun-22,08-Dec-22,190,CADTH,26-Aug-22,pre-NOC,Initial,Paroxysmal nocturnal hemoglobinuria,Active,,Active,n/a,,,,,,,,,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-104,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44713
Enerzair Breezhaler,indacaterol glycopyrronium mometasone furoate,Novartis Pharmaceuticals Canada Inc.,Y,N,N,N,N,N,N,N,N,01-Sep-19,02-Jul-20,305,CADTH & INESSS,19-May-20,pre-NOC,Initial,"Asthma maintenance, adults",Completed,24-Nov-20,Reimburse with clinical criteria and/or conditions,Conditional,26-Jun-20,pre-NOC,New Drug,Asthma,Completed,02-Dec-20,Inscription - Avec conditions,Conditional,1st,23-Jun-21,30-Sep-21,Negotiation,Completed with Agreements,SA,SA,,EDS,LU,SA,EDS,SA,SA,EM,14-Jun-22,01-Nov-21,,24-Feb-22,28-Feb-22,20-Jan-22,30-Nov-21,28-Mar-22,11-May-22,15-Dec-21,01-Nov-21,01-Nov-21,9,1,,5,6,4,2,7,8,3,4.50%,5.80%,34.30%,35.20%,40.80%,73.00%,73.40%,74.00%,94.30%,,94.30%,28-Feb-22,14-Jun-22,-44,-6,189,159,211,203,99,257,32,,147,151,112,61,179,223,76,145,32,138,32,257,712,487,,602,606,567,516,634,678,531,600,593,487,531,342,567,342,,457,461,422,371,489,533,378,455,145,153,310,302,712,225,225,119,106,450
Enhertu,trastuzumab deruxtecan,AstraZeneca,Y,Y,Y,Y,Y,N,N,N,Y,01-Jan-22,15-Jun-22,165,CADTH & INESSS,23-Mar-22,pre-NOC,Initial,Anticipated indication as filed with Health Canada: for the treatment of adult patients with unresectable or metastatic HER2 (human epidermal growth factor receptor 2)-positive breast cancer who have received a prior treatment with an anti-HER2-based regimen in the metastatic setting or developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy,Completed,28-Sep-22,Cond'l on Cost,Conditional,29-Apr-22,pre-NOC,New Drug,Treatment of adult patients with unresectable or metastatic HER2 (human epidermal growth factor receptor 2)-positive breast cancer who have received a prior treatment with an anti-HER2-based regimen in the metastatic setting or developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.,Completed,01-Feb-23,Inscription - Avec conditions,Conditional,1st,21-Dec-22,,Active,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-84,-47,189,278,84,-42,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,105,231,,,,,,,,270
Enhertu,trastuzumab deruxtecan,AstraZeneca,Y,Y,Y,N,Y,N,N,N,Y,01-Jul-22,06-Jan-23,189,CADTH,13-Dec-22,pre-NOC,Initial,As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Patients with HR+ breast cancer should additionally have received or be ineligible for endocrine therapy.,Active,,TBD,n/a,08-Jul-22,pre-NOC,New Indication,As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Patients with HR+ breast cancer should additionally have received or be ineligible for endocrine therapy.,Under review,TBD,TBD,TBD,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-24,-182,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44743
Enspryng,satralizumab,Hoffmann-La Roche Ltd.,Y,Y,N,Y,N,Y,Y,Y,N,01-Dec-19,01-Jun-20,183,CADTH & INESSS,22-Oct-20,post-NOC,Initial,Neuromyelitis optica spectrum disorder,Completed,21-Apr-21,Reimburse with clinical criteria and/or conditions,Conditional,13-Nov-20,post-NOC,New Drug,NOSD,Completed,07-May-21,Inscription - Avec conditions,Conditional,1st,30-Jun-21,28-Jun-22,Negotiation,Completed with Agreements,,,EDS,EDS,EAP,SA,EDS,,,EM,,,01-Nov-22,24-Jan-23,03-Feb-23,24-Oct-22,01-Feb-23,,,17-Aug-22,24-Oct-22,17-Aug-22,,,3,4,6,2,5,,,1,28.60%,29.50%,35.20%,40.70%,42.00%,74.30%,,,,,74.30%,03-Feb-23,,143,165,181,175,70,54,363,,,126,210,220,118,218,,,50,178,118,157,50,,,,883,967,977,875,975,,,807,935,914,875,732,551,,,559,643,653,551,651,,,467,611,324,340,433,417,,,,170,,507
Entresto,sacubitril/valsartan,Novartis ,Y,N,N,Y,N,N,N,N,N,,02-Oct-15,,CADTH & INESSS,18-Sep-15,pre-NOC,Initial,"Heart failure, NYHA class II or III",Completed,18-Mar-16,List with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New Drug,"Heart failure, NYHA class II or III",Completed,01-Jun-16,Avis d'inscription aux listes des médicaments-Médicament d'exception-Avec conditions,Conditional,1st,30-Jun-16,06-Mar-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,06-Mar-18,01-Sep-17,01-Apr-17,19-Jul-17,27-Apr-17,22-Sep-17,01-Apr-19,01-Aug-19,01-Jun-18,15-Mar-17,01-Apr-17,15-Mar-17,7,5,2,4,3,6,9,10,8,1,28.60%,34.30%,66.50%,72.10%,76.50%,77.40%,97.70%,98.30%,99.60%,100.00%,100.00%,27-Apr-17,06-Mar-18,-14,53,182,190,104,29,249,365,179,26,135,52,200,756,878,452,9,338,26,305,9,365,886,700,547,656,573,721,1277,1399,973,530,859,826,547,561,379,718,532,379,488,405,553,1109,1231,805,287,691,168,243,353,278,886,356,339,43,313,42447
Entresto,sacubitril/valsartan,Novartis Pharma Inc.,Y,N,N,Y,N,N,N,N,N,,02-Oct-15,,CADTH & INESSS,22-May-20,post-NOC,Initial,"Heart failure, NYHA class II or III (without prior exposure to ACE or ARB)",Completed,24-Mar-21,Reimburse with clinical criteria and/or conditions,Conditional,03-Jul-20,post-NOC,New Indication,Cardiac insuficiency,Completed,02-Dec-20,Modification d’une indication reconnue – Avec conditions,Conditional,1st,17-Aug-22,17-Aug-22,Negotiation,Completed with Agreements,,,,,,,,,,EM,,,,,,,,,,28-Sep-22,,28-Sep-22,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,1694,1736,306,152,511,623,0,,,,,,,,,,42,,,42,42,,,,,,,,,,,2553,,2553,,,,,,,,,,,,,665,,2000,1888,511,623,,,,,,44279
Entuzity KwikPen,human insulin,Eli Lilly Canada Inc.,Y,Y,N,N,N,N,N,N,N,01-Sep-16,27-Jul-17,329,CADTH & INESSS,27-Jan-21,post-NOC,Initial,To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day,Completed,23-Aug-21,Reimburse with clinical criteria and/or conditions,Conditional,13-Nov-18,post-NOC,New Drug,Diabetes,Completed,10-Apr-19,Inscription,Positive,1st,18-Nov-21,07-Feb-22,Negotiation,Completed with Agreements,FB,SA,FB,FB,FB,FB,EDS,SA,SA,FB,31-May-22,01-Apr-22,01-Apr-22,01-Jun-22,29-Apr-22,29-Apr-22,27-Jun-22,20-Feb-23,07-Jul-22,02-Mar-22,01-Apr-22,02-Mar-22,6,2,3,7,4,5,8,10,9,1,28.60%,33.00%,38.80%,71.00%,71.90%,92.10%,97.70%,99.00%,99.60%,100.00%,100.00%,29-Apr-22,31-May-22,1280,474,208,148,87,953,81,113,53,53,114,81,81,140,378,150,23,129,53,119,23,113,1769,1709,1709,1770,1737,1737,1796,2034,1806,1679,1785,1775,1709,429,221,281,221,221,282,249,249,308,546,318,1057,297,1488,622,168,1034,1769,90,60,58,32,1817
Entyvio,vedolizumab,Takeda Canada Inc.,Y,Y,N,N,N,N,N,N,N,,19-Nov-20,,CADTH & INESSS,23-Jul-20,pre-NOC,Initial,Crohn's Disease,Completed,21-Jan-21,Reimburse with clinical criteria and/or conditions,Conditional,24-Jan-21,post-NOC,New Drug,Crohn's Disease,Completed,02-Jun-21,Inscription - Avec conditions,Conditional,1st,15-Apr-21,13-Aug-21,Negotiation,Completed with Agreements,SA,SA,,EDS,EAP,SA,EDS,SA,SA,EM,12-Apr-22,01-Mar-22,,25-Nov-21,11-Jan-22,14-Oct-21,29-Apr-22,22-Nov-21,21-Feb-22,15-Dec-21,14-Oct-21,14-Oct-21,8,7,,3,5,1,9,2,6,4,0.90%,1.20%,6.80%,35.40%,67.60%,68.30%,72.70%,93.00%,94.30%,,94.30%,11-Jan-22,12-Apr-22,-119,66,182,129,84,-48,120,242,200,,104,151,62,259,101,192,124,164,62,159,62,242,509,467,,371,418,329,526,368,459,391,431,426,329,448,266,446,404,,308,355,266,463,305,396,196,368,63,195,204,72,509,180,180,89,91,44217
Entyvio (CD),vedolizumab,Takeda Canada Inc.,Y,Y,N,N,N,N,N,N,N,,22-Mar-16,,CADTH & INESSS,27-Apr-16,post-NOC,Initial,Crohn’s disease,Completed,31-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,,,New Indication,Crohn's Disease,Completed,03-Oct-16,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,08-Nov-16,03-Mar-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,02-May-17,01-Jul-17,01-Apr-17,19-Jul-17,18-Apr-17,29-May-17,01-May-17,07-Aug-17,11-May-17,21-Apr-17,01-Apr-17,01-Apr-17,5,8,1,9,2,7,4,10,6,3,5.70%,38.00%,66.50%,67.80%,88.10%,88.80%,89.70%,94.10%,99.60%,100.00%,100.00%,21-Apr-17,02-May-17,36,,187,,8,36,115,60,120,29,138,46,87,59,157,69,49,85,29,81,29,60,406,466,375,484,392,433,405,503,415,395,431,427,375,339,152,183,243,152,261,169,210,182,280,192,200,208,223,195,123,151,406,31,31,20,11,42674
Entyvio (UC),vedolizumab,Takeda Canada Inc.,Y,Y,N,Y,N,N,N,N,N,,29-Jan-15,,CADTH & INESSS,20-Feb-15,post-NOC,Initial,Ulcerative Colitis,Completed,28-Oct-15,List with clinical criteria and/or conditions,Conditional,22-Mar-15,post-NOC,New Drug,Ulcerative Colitis,Completed,01-Oct-15,Avis d'inscription aux listes des médicaments-Médicament d'exception,Conditional,1st,26-May-16,03-Mar-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,02-May-17,01-Jul-17,01-Apr-17,19-Jul-17,18-Apr-17,29-May-17,01-May-17,01-Aug-18,11-May-17,21-Apr-17,01-Apr-17,01-Apr-17,5,8,1,9,2,7,4,10,6,3,5.70%,38.00%,66.50%,67.80%,88.10%,88.80%,89.70%,94.10%,99.60%,100.00%,100.00%,21-Apr-17,02-May-17,22,52,250,193,211,238,281,60,120,29,138,46,87,59,516,69,49,125,29,117,29,60,824,884,793,902,810,851,823,1280,833,813,889,881,793,771,521,552,612,521,630,538,579,551,1008,561,568,617,272,245,492,519,824,31,31,20,11,42305
Entyvio (UC),vedolizumab,Takeda Canada Inc.,Y,Y,N,Y,N,N,N,N,N,,29-Jan-15,,CADTH & INESSS,21-Nov-19,post-NOC,Initial,Ulcerative Colitis,Completed,19-May-20,Reimburse with clinical criteria and/or conditions,Conditional,22-May-20,post-NOC,New Indication,Ulcerative Colitis,Completed,09-Sep-20,Inscription - Avec conditions,Conditional,1st,19-Oct-20,13-Aug-21,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,12-Apr-22,01-Mar-22,01-Dec-21,25-Nov-21,11-Jan-22,14-Oct-21,29-Apr-22,22-Nov-21,21-Feb-22,15-Dec-21,14-Oct-21,14-Oct-21,9,8,4,3,6,1,10,2,7,5,0.90%,1.20%,6.80%,12.50%,41.10%,73.30%,74.00%,78.40%,98.70%,100.00%,100.00%,11-Jan-22,12-Apr-22,1757,1940,180,110,153,40,298,242,200,110,104,151,62,259,101,192,124,158,62,155,62,242,2630,2588,2498,2492,2539,2450,2647,2489,2580,2512,2546,2543,2450,693,513,693,651,561,555,602,513,710,552,643,462,609,1937,2050,451,338,2630,180,180,89,91,43970
Epclusa,sofosbuvir/ velpatasvir,Gilead Sciences ,Y,N,N,Y,N,N,N,N,N,01-Jan-16,11-Jul-16,192,CADTH & INESSS,22-Apr-16,pre-NOC,Initial,"Hepatitis C, chronic",Completed,26-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Drug,chronic hepatitis C (CHC),Completed,01-Feb-17,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,26-Oct-16,17-Feb-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,21-Mar-17,01-Apr-17,01-Apr-17,20-Apr-17,28-Feb-17,04-Apr-17,01-May-17,01-May-17,01-Aug-17,15-Mar-17,28-Feb-17,28-Feb-17,3,4,5,7,1,6,8,9,10,2,32.20%,60.80%,81.10%,85.50%,91.20%,92.10%,97.70%,99.00%,99.30%,100.00%,100.00%,15-Mar-17,21-Mar-17,-80,32,187,173,0,-98,114,32,43,43,62,11,46,73,73,165,26,61,11,57,11,32,253,264,264,283,232,267,294,294,386,247,282,278,232,312,125,146,157,157,176,125,160,187,187,279,42,175,107,205,114,16,253,21,21,15,6,299
Erbitux,cetuximab,Bristol-Myers Squibb,Y,Y,N,N,Y,N,N,N,N,,20-Dec-12,,CADTH & INESSS,10-Jun-13,post-NOC,New indication,Metastatic Colorectal Cancer,Completed,10-Jan-14,Do Not Fund,Negative,24-Nov-12,pre-NOC,New Drug,"For the treatment of EGFR-expressing K-RAS wild Type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (Irinotecan, 5-fluorouracil, leucovorin) for first line treatment",Completed,03-Feb-14,Ajout d'une indication reconnue - Médicament d'exception - Avis de refus,Negative,None,21-Jan-14,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,172,-26,214,436,11,-13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,386,410,,,,,,,,41649
Erelzi,etanercept,Sandoz Canada Inc.,Y,Y,Y,N,N,N,N,N,N,01-Jun-16,06-Apr-17,309,CADTH & INESSS,02-Feb-17,pre-NOC,Initial,"Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis",Completed,25-Jul-17,Reimburse with clinical criteria and/or conditions,Conditional,11-Aug-17,post-NOC,New Drug,"Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis",Completed,01-Feb-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,21-Apr-17,17-Oct-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,14-Nov-17,01-Mar-18,01-Apr-18,19-Apr-18,21-Dec-17,22-Jan-18,01-Aug-18,24-Nov-17,01-Apr-18,01-Feb-18,14-Nov-17,14-Nov-17,1,6,7,9,3,4,10,2,8,5,20.30%,20.60%,52.80%,53.70%,82.30%,86.80%,92.50%,93.20%,98.70%,100.00%,100.00%,21-Dec-17,01-Feb-18,-63,127,173,174,-95,-286,179,28,135,166,184,65,97,288,38,166,107,130,28,127,28,107,222,329,360,378,259,291,482,232,360,301,324,321,222,285,112,112,219,250,268,149,181,372,122,250,0,214,110,301,84,-107,301,79,79,37,42,419
Erivedge,vismodegib,Hoffman-La Roche ,Y,N,N,Y,Y,N,N,N,N,,12-Jul-13,,CADTH & INESSS,14-Jun-13,pre-NOC,New drug,Advanced Basal Cell Carcinoma,Completed,10-Jan-14,Cond'l on Cost,Conditional,24-Nov-15,post-NOC,New Drug,Carcinome basocellulaire,Completed,19-Aug-16,Avis de refus d'inscription aux listes des médicaments,Negative,1st,21-Jan-14,01-Apr-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Oct-14,20-Jun-14,18-Jul-14,01-Jul-14,16-Apr-14,25-Jun-14,29-Dec-14,18-Aug-20,01-Oct-14,24-May-18,16-Apr-14,16-Apr-14,6,2,5,4,1,3,8,10,7,9,32.20%,36.70%,37.60%,43.10%,48.80%,69.10%,69.80%,71.10%,99.60%,100.00%,100.00%,01-Oct-14,24-May-18,-28,865,210,269,11,-941,70,183,80,108,91,15,85,272,2331,183,1514,372,15,486,15,1514,446,343,371,354,278,348,535,2594,446,1777,635,749,278,306,96,264,161,189,172,96,166,353,2412,264,643,453,182,1134,81,-871,1777,1499,1499,168,1331,41649
Erleada,apalutamide,Janssen ,Y,N,N,Y,Y,N,N,N,N,01-Jan-18,03-Jul-18,183,CADTH & INESSS,16-Apr-18,pre-NOC,New drug,Castrate Resistant Prostate Cancer,Completed,01-Nov-18,Cond'l on Cost,Conditional,,,New Drug,Castrate Resistant Prostate Cancer,Completed,17-Oct-18,Inscription – Avec conditions,Conditional,1st,14-Mar-19,09-Jul-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-May-20,10-Apr-20,01-Jan-20,02-Mar-20,14-Jan-20,16-Jul-20,01-Jul-20,20-Feb-23,31-Mar-22,15-Aug-19,01-Jan-20,15-Aug-19,6,5,2,4,3,8,7,10,9,1,28.60%,34.30%,66.50%,72.10%,76.50%,96.80%,98.10%,99.00%,99.60%,100.00%,100.00%,14-Jan-20,01-May-20,-78,,199,,133,148,117,297,276,176,237,189,373,358,1322,996,37,469,176,426,37,297,668,647,547,608,560,744,729,1693,1367,408,840,797,547,625,426,547,526,426,487,439,623,608,1572,1246,302,719,121,106,250,265,668,260,121,152,108,304
Erleada,apalutamide,Janssen,Y,N,N,N,Y,N,N,N,N,01-Jun-19,12-Dec-19,194,CADTH & INESSS,15-Oct-19,pre-NOC,New indication,Metastatic Castration-Sensitive Prostate Cancer,Completed,22-Apr-20,Cond'l on Cost,Conditional,25-Oct-19,pre-NOC,New Indication,Metastatic Castration-Sensitive Prostate Cancer,Completed,10-Jun-20,Inscription - Avec conditions,Conditional,1st,09-Oct-20,17-Aug-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,Funded,EM,01-Dec-21,30-Nov-21,01-Nov-21,23-Nov-21,31-Dec-21,20-Jan-22,,20-Feb-23,31-Mar-22,29-Sep-21,01-Nov-21,29-Sep-21,5,4,2,3,6,7,,9,8,1,28.60%,34.30%,39.80%,44.30%,64.50%,96.80%,97.70%,98.30%,98.70%,,98.70%,01-Dec-21,31-Dec-21,-58,-48,190,229,170,121,312,106,105,76,98,136,156,,552,226,43,182,76,166,43,136,720,719,690,712,750,770,,1166,840,657,796,780,690,748,558,588,587,558,580,618,638,,1034,708,476,664,132,181,482,433,750,93,60,63,30,326
Esbriet,pirfenidone ,InterMune,N,N,N,Y,N,Y,Y,Y,N,,01-Oct-12,,CADTH & INESSS,05-Oct-12,post-NOC,Initial,"Pulmonary fibrosis (idiopathic, mild to moderate) ",Completed,18-Apr-13,Do not list ,Negative,,,New Drug,"Pulmonary fibrosis (idiopathic, mild to moderate) ",Completed,03-Jun-13,Avis de refus - Valeur thérapeutique,Negative,none,31-Jan-14,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,4,,195,,288,242,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,199,245,,,,,,,,41382
Esbriet (2nd pCPA),pirfenidone ,InterMune,N,N,N,Y,N,Y,Y,Y,N,,01-Oct-12,,CADTH & INESSS,05-Oct-12,post-NOC,Initial,"Pulmonary fibrosis (idiopathic, mild to moderate) ",Completed,18-Apr-13,Do not list ,Negative,,,New Drug,"Pulmonary fibrosis (idiopathic, mild to moderate) ",Completed,03-Jun-13,Avis de refus - Valeur thérapeutique,Negative,1st,,15-Aug-14,Negotiation,Completed with Agreements,NR,NR,EDS,EDS,EAP,SA,EDS,SA,SA,NR,,,01-Nov-14,19-Jan-15,19-Aug-14,03-Oct-14,31-Oct-14,27-Apr-15,14-Oct-14,,19-Aug-14,19-Aug-14,,,5,6,1,2,4,7,3,,32.20%,33.10%,33.80%,35.10%,40.80%,46.30%,46.70%,,,,46.70%,,,4,,195,,,,,,,78,157,4,49,77,255,60,,97,4,97,4,,,,761,840,687,732,760,938,743,,780,780,687,683,488,,,562,641,488,533,561,739,544,,581,199,245,484,438,,,,,,41382
Esbriet (Resub),pirfenidone,Hoffmann-La Roche Ltd.,Y,N,N,Y,N,Y,Y,Y,N,,01-Oct-12,,CADTH & INESSS,29-Aug-14,post-NOC,Resubmission,"Pulmonary fibrosis (idiopathic, mild to moderate) ",Completed,15-Apr-15,List with criteria/condition,Conditional,,,New Drug,"Pulmonary fibrosis (idiopathic, mild to moderate) ",Completed,02-Feb-15,Avis de refus - Valeur thérapeutique,Negative,2nd,30-Apr-15,11-Sep-16,Negotiation,Completed with Agreements,SA,SA,,,,,,,,EM,06-Feb-18,01-Nov-16,,,,,,,,18-Apr-18,01-Nov-16,01-Nov-16,2,1,,,,,,,,3,4.50%,24.70%,53.30%,,,,,,,,53.30%,18-Apr-18,,697,,229,,15,87,500,513,51,,,,,,,,584,282,51,383,51,,1954,1492,,,,,,,,2025,1723,1824,1492,795,566,1028,566,,,,,,,,1171,797,926,854,515,587,,,,533,,42109
Eucrisa,crisaborole,Pfizer ,Y,N,N,Y,N,N,N,N,N,01-Aug-17,07-Jun-18,310,CADTH & INESSS,25-May-18,pre-NOC,Initial,Atopic dermatitis,Completed,27-Mar-19,Do not reimburse,Negative,25-May-18,pre-NOC,New Drug,Atopic Dermatitis,Completed,12-Dec-18,Refus d’inscription,Negative,none,16-Apr-19,,Do Not Negotiate,n/a,NR,UR,NR,UR,UR,UR,UR,UR,UR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-13,-13,306,201,20,125,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,293,188,,,,,,,,603
Evenity,romosozumab,Amgen Canada Inc.,Y,Y,N,Y,N,N,N,N,N,01-Oct-16,17-Jun-19,989,CADTH & INESSS,01-Feb-21,post-NOC,Initial,"The treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture.",Completed,11-Nov-21,Reimburse with clinical criteria and/or conditions,Conditional,01-Jan-21,post-NOC,Resubmission,"Osteoporosis, postmenopausal women",Completed,02-Jun-21,Inscription - Avec conditions,Conditional,1st,31-Mar-22,,Active,n/a,UR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,595,564,283,152,140,302,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,878,716,,,,,,,,1867
Evrysdi,risdiplam,Hoffmann-La Roche Ltd.,Y,N,N,Y,N,Y,Y,Y,N,01-Oct-20,14-Apr-21,195,CADTH & INESSS,19-Nov-20,pre-NOC,Initial,Spinal muscular atrophy (SMA),Completed,26-Aug-21,Reimburse with clinical criteria and/or conditions,Conditional,19-Feb-21,pre-NOC,New Drug,Spinal amyotrophy,Completed,28-Jul-21,Inscription - Avec conditions,Conditional,1st,27-Aug-21,19-Jan-22,Negotiation,Completed with Agreements,EDRD,SA,EDS,EDS,EAP,SA,EDS,SA,,EM,10-Feb-22,01-Mar-22,01-Mar-22,01-Jun-22,28-Mar-22,24-May-22,01-Oct-22,27-Mar-23,,02-Feb-22,10-Feb-22,02-Feb-22,2,3,4,7,5,6,8,9,,1,28.60%,48.80%,53.30%,59.00%,91.20%,92.10%,97.70%,99.00%,99.30%,,99.30%,01-Mar-22,28-Mar-22,-146,-54,280,159,1,30,145,22,41,41,133,68,125,255,432,,14,140,22,126,14,68,302,321,321,413,348,405,535,712,,294,420,406,302,448,168,168,187,187,279,214,271,401,578,,189,286,134,105,146,175,348,54,46,27,27,329
Eylea (Macular Edema BRVO),aflibercept,Bayer ,Y,Y,N,N,N,N,N,N,N,,10-Dec-15,,CADTH & INESSS,14-Dec-15,post-NOC,Initial,Macular edema secondary to branch retinal vein occlusion,Completed,27-Jul-16,Reimburse with clinical criteria and/or conditions,Conditional,24-Nov-14,pre-NOC,New Indication,Macular edema secondary to branch retinal vein occlusion,Completed,01-Feb-17,Avis d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,22-Feb-17,13-Mar-17,Negotiation,Completed with Agreements,BCRDT,RB,EDS,NR,LU,SA,NR,SA,SA,EM,,01-Aug-17,01-Jul-17,,28-Mar-17,24-Oct-17,,01-Aug-18,15-May-17,01-Jun-17,28-Mar-17,28-Mar-17,,5,4,,1,6,,7,2,3,32.20%,32.90%,61.50%,67.20%,71.70%,72.60%,72.90%,,,,72.90%,01-Jun-17,,4,-381,226,800,210,21,19,,141,110,,15,225,,506,63,80,177,15,163,15,,,600,569,,474,684,,965,522,539,636,622,474,470,244,,370,339,,244,454,,735,292,120,406,230,419,229,40,,,,65,,42578
Eylea (Macular Edema CRVO),aflibercept,Bayer ,Y,Y,N,N,N,N,N,N,N,,16-Oct-14,,CADTH & INESSS,17-Oct-14,post-NOC,Initial,Macular edema secondary to central retinal vein occlusion ,Completed,07-May-15,List with clinical criteria and/or conditions,Conditional,24-Nov-14,post-NOC,New Indication,Macular edema secondary to central retinal vein occlusion ,Completed,01-Jun-15,Ajout d'une indication reconnue - Médicament d'exception,Conditional,1st,,30-Jun-15,Negotiation,Completed with Agreements,BCRDT,RB,EDS,NR,LU,SA,NR,SA,SA,EM,,01-Aug-17,01-Jul-15,,29-Jul-15,29-Jun-15,,01-Aug-18,01-Jul-15,01-Jun-15,29-Jun-15,01-Jun-15,,6,3,,5,2,,7,4,1,28.60%,29.50%,35.20%,35.90%,68.10%,72.60%,72.90%,,,,72.90%,29-Jul-15,,1,39,202,189,,,,,763,1,,29,-1,,1128,1,-29,320,-1,270,-29,,,1020,258,,286,256,,1385,258,228,577,527,256,255,53,,817,55,,83,53,,1182,55,0,374,203,228,54,29,,,,58,,42131
Eylea (MDA) ,aflibercept,Bayer ,Y,Y,N,Y,N,N,N,N,N,,08-Nov-13,,CADTH & INESSS,18-Nov-13,post-NOC,Initial,"Macular degeneration, age-related",Completed,20-Oct-14,List with criteria/condition,Conditional,,,New Drug,nAMD,Completed,24-Apr-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,none,31-Jan-15,,Negotiation by Province,n/a,,,,NR,,,,,,EM,,,,,,,,,,24-Apr-14,,24-Apr-14,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,10,,336,,103,282,,,,,,,,,,,,,,,,,,,,,,,,,,167,,167,,,,,,,,,,,,,0,,346,167,,,,,,,,41932
Eylea (MDA) pCPA 2nd,aflibercept,Bayer ,Y,Y,N,Y,N,N,N,N,N,,08-Nov-13,,CADTH & INESSS,18-Nov-13,post-NOC,Initial,"Macular degeneration, age-related",Completed,20-Oct-14,List with criteria/condition,Conditional,,,New Drug,nAMD,Completed,24-Apr-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,,27-Mar-15,Negotiation,Completed with Agreements,BCRDT,RB,EDS,NR,LU,SA,NR,SA,SA,,,01-Aug-17,01-Jul-15,,29-Jul-15,29-Jun-15,,25-May-15,01-Jul-15,,25-May-15,25-May-15,,6,3,,5,2,,1,4,,0.40%,1.20%,7.00%,7.60%,39.90%,44.30%,,,,,44.30%,,,10,,336,,,,,,858,96,,124,94,,59,96,,221,59,221,59,,,1362,600,,628,598,,563,600,,725,725,563,553,217,,1016,254,,282,252,,217,254,,379,346,167,158,337,,,,,,41932
Eylea (MED),aflibercept ,Bayer ,Y,Y,N,N,N,N,N,N,N,,28-Nov-14,,CADTH & INESSS,16-Sep-14,pre-NOC,Initial,"Macular edema, diabetic ",Completed,07-May-15,List with clinical criteria and/or conditions,Conditional,24-Nov-14,pre-NOC,New Indication,"Macular edema, diabetic ",Completed,01-Jun-15,Ajout d'une indication reconnue - Médicament d'exception,Conditional,1st,,30-Jun-15,Negotiation,Completed with Agreements,BCRDT,RB,EDS,NR,LU,SA,NR,SA,SA,EM,,01-Aug-17,01-Jul-15,,29-Jul-15,29-Jun-15,,01-Aug-18,01-Jul-15,01-Jun-15,29-Jun-15,01-Jun-15,,6,3,,5,2,,7,4,1,28.60%,29.50%,35.20%,35.90%,68.10%,72.60%,72.90%,,,,72.90%,29-Jul-15,,-73,-4,233,189,,,,,763,1,,29,-1,,1128,1,-29,320,-1,270,-29,,,977,215,,243,213,,1342,215,185,534,484,213,286,53,,817,55,,83,53,,1182,55,0,374,160,185,54,29,,,,58,,42131
Fampyra,fampridine,Biogen,N,N,N,Y,N,N,N,N,N,,10-Feb-12,,CADTH & INESSS,16-Apr-12,post-NOC,Initial,"Multiple Sclerosis, improve walking disability ",Completed,28-Nov-12,Do not list ,Negative,,,New Drug,"Multiple Sclerosis, improve walking disability ",Completed,01-Oct-12,Avis de refus - Valeur thérapeutique,Negative,none,31-Jan-14,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,66,,226,,429,487,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,292,234,,,,,,,,41241
Fampyra (Resub) (withdrawn),fampridine ,Biogen,N,N,N,Y,N,N,N,N,N,,10-Feb-12,,CADTH,06-Nov-14,post-NOC,Resubmission,"Multiple Sclerosis, improve walking disability ",Withdrawn,01-Jun-15,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,1000,,207,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1207,,,,,,,,,42156
Fasenra,benralizumab,AstraZeneca ,Y,Y,N,Y,N,N,N,N,N,01-Apr-17,22-Feb-18,327,CADTH & INESSS,23-Feb-18,post-NOC,Initial,"Asthma, severe eosinophilic",Completed,21-Aug-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New drug,"Asthma, severe eosinophilic",Completed,05-Sep-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,30-Nov-18,03-May-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,01-Apr-20,01-Aug-19,01-Aug-19,02-Mar-20,13-Jun-19,04-Jul-19,01-Sep-19,15-Mar-21,19-Jul-19,04-Jul-19,13-Jun-19,13-Jun-19,9,5,6,8,1,2,7,10,4,3,32.20%,33.10%,61.70%,62.40%,66.80%,72.60%,73.90%,79.40%,99.60%,100.00%,100.00%,04-Jul-19,01-Apr-20,1,,179,,101,86,154,334,90,90,304,41,62,121,682,77,62,200,41,186,41,334,769,525,525,739,476,497,556,1117,512,497,635,621,476,475,296,589,345,345,559,296,317,376,937,332,302,455,180,195,255,240,769,293,293,21,272,507
Fasenra (Advice),benralizumab,AstraZeneca ,Y,Y,N,Y,N,N,N,N,N,01-Apr-17,22-Feb-18,327,CADTH & INESSS,24-Oct-18,post-NOC,Request for Advice,"Asthma, severe eosinophilic",Completed,27-Mar-19,Reimburse with clinical criteria and/or conditions,Conditional,,,New drug,"Asthma, severe eosinophilic",Completed,13-Mar-19,Modification d’une indication reconnue – Avec conditions,Conditional,none,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,244,,154,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,398,384,,,,,,,,725
Faslodex,fulvestrant,AstraZeneca,Y,N,N,Y,Y,N,N,N,N,01-Jan-17,08-Nov-17,311,CADTH & INESSS,17-Jul-17,pre-NOC,New drug,"For hormonal treatment of non-visceral locally advanced or metastatic HER2- breast cancer in postmenopausal women, regardless of age, who have not been previously treated with endocrine therapy",Completed,01-Feb-18,Cond'l on Cost,Conditional,,,New Drug,Locally Advanced or Metastatic Breast Cancer,Completed,09-May-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,03-Aug-18,29-Jan-19,Negotiation,No Agreement Reached,Not funded,Funded,Funded,Not funded,Funded,Not funded,Not funded,Not funded,Funded,NR,,30-Sep-20,,,30-Nov-20,,,,22-Oct-19,,22-Oct-19,22-Oct-19,,2,,,3,,,,1,,0.70%,5.10%,37.40%,,,,,,,,37.40%,,,-114,,199,,183,86,179,,610,,,671,,,,266,,516,266,516,266,,,1057,,,1118,,,,713,,963,963,713,827,628,,972,,,1033,,,,628,,878,85,182,362,265,,,,,,396
Fentora,fentanyl buccal ,Teva Canada Innovation,N,N,N,N,N,N,N,N,N,,21-Nov-13,,CADTH,12-Jul-16,post-NOC,Initial,"Pain (breakthrough), cancer (adults)",Completed,21-Feb-17,Do not reimburse,Negative,,,,,,,,,none,31-Mar-17,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,964,,224,,38,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1188,,,,,,,,,42787
Ferriprox,deferiprone,ApoPharma ,N,N,N,Y,N,N,N,N,N,,13-Feb-15,,CADTH,24-Sep-15,post-NOC,Initial,Transfusional iron overload,Completed,18-Mar-16,List with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,13-May-16,07-Sep-16,Negotiation,Completed with Agreements,SA,SA,EDS,NR,EAP,SA,EDS,NR,SA,NR,25-Oct-16,01-Jul-17,01-Jan-17,,17-Oct-16,21-Dec-16,01-Dec-16,,25-May-17,,17-Oct-16,17-Oct-16,2,7,5,,1,4,3,,6,,32.20%,52.50%,53.80%,54.70%,60.40%,61.10%,65.50%,,,,65.50%,25-Oct-16,,223,,176,,56,,117,48,297,116,,40,105,85,,260,,136,40,136,40,,620,869,688,,612,677,657,,832,,708,708,612,389,213,221,470,289,,213,278,258,,433,,309,399,,173,,,,,8,,42447
Ferriprox,deferiprone,Chiesi Canada Corp.,N,N,N,N,N,N,N,N,N,01-Dec-20,13-Oct-21,316,CADTH,08-Jun-22,post-NOC,Initial,Transfusional iron overload,Completed,19-Jan-23,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,238,,225,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,463,,,,,,,,,779
Fibristal,ulipristal acetate,Actavis ,N,N,N,Y,N,N,N,N,N,,24-Jun-13,,CADTH & INESSS,17-Apr-13,pre-NOC,Initial,Uterine fibroids (signs and symptoms) ,Completed,15-Nov-13,List with criteria/condition,Conditional,02-Aug-13,post-NOC,New Drug,Uterine fibroids (signs and symptoms) ,Completed,03-Feb-14,Ajout aux listes de médicaments,Positive,1st,28-Feb-14,18-Sep-15,Negotiation,Completed with Agreements,DL,RB,DL,EDS,DL,SA,DL,DL,DL,FB,02-Oct-18,01-Jan-16,01-May-16,18-Jan-16,28-Jan-16,12-Apr-16,01-May-17,27-Jun-16,01-Aug-16,03-Feb-14,01-Jan-16,03-Feb-14,10,2,6,3,4,5,9,7,8,1,28.60%,33.00%,38.60%,70.80%,71.70%,77.40%,77.80%,78.40%,79.70%,100.00%,100.00%,28-Jan-16,02-Oct-18,-68,39,212,185,105,25,567,1110,105,226,122,132,207,591,283,318,-592,344,105,250,-592,1110,1926,921,1042,938,948,1023,1407,1099,1134,224,1160,1066,921,989,777,1782,777,898,794,804,879,1263,955,990,0,1016,144,224,672,592,1926,1702,1005,724,978,41593
Fibristal (Advice) (Ineligible for surgery),ulipristal acetate,Allergan ,N,N,N,N,N,N,N,N,N,,17-Dec-15,,CADTH,28-Mar-19,post-NOC,Request for Advice,Uterine fibroids (signs and symptoms),Completed,24-Jul-19,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,none,,,,,NR,RB,DL,EDS,DL,SA,DL,,,,,01-Sep-19,01-Nov-19,02-Mar-20,31-Oct-19,26-Feb-20,06-Jul-20,,,,01-Sep-19,01-Sep-19,,1,3,5,2,4,6,,,,4.50%,36.70%,42.40%,43.30%,48.80%,50.10%,,,,,50.10%,06-Jul-20,,1197,,118,,,,,,,,,,,,,,,,,,,,,1354,1415,1537,1414,1532,1663,,,,1486,1486,1354,157,39,,39,100,222,99,217,348,,,,171,1315,,,,,,,309,,43670
Fibristal (Advice) (Intermittent),ulipristal acetate,Allergan ,N,N,N,N,N,N,N,N,N,,17-Dec-15,,CADTH,21-Jun-17,post-NOC,Request for Advice,Uterine fibroids (signs and symptoms),Completed,22-Nov-17,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,28-Sep-18,06-Aug-19,Negotiation,Completed with Agreements,NR,RB,DL,EDS,DL,SA,DL,,,,,01-Sep-19,01-Nov-19,02-Mar-20,31-Oct-19,26-Feb-20,06-Jul-20,,,,01-Sep-19,01-Sep-19,,1,3,5,2,4,6,,,,4.50%,36.70%,42.40%,43.30%,48.80%,50.10%,,,,,50.10%,06-Jul-20,,552,,154,,310,,312,,26,87,209,86,204,335,,,,158,26,158,26,,,1354,1415,1537,1414,1532,1663,,,,1486,1486,1354,802,648,,648,709,831,708,826,957,,,,780,706,,622,,,,,309,,43061
Firazyr,icatibant,Shire ,Y,N,N,Y,N,Y,Y,Y,N,,04-Jun-14,,CADTH & INESSS,04-Mar-14,pre-NOC,Initial,"Angioedema, hereditary",Completed,19-Dec-14,List with clinical criteria and/or conditions,Conditional,24-Nov-14,post-NOC,New Drug,"Angioedema, hereditary",Completed,01-Jun-15,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,28-Feb-15,28-Aug-15,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,06-Feb-18,01-Jan-16,01-Aug-16,18-Jan-16,05-Nov-15,01-Mar-16,02-May-16,27-Jun-16,01-Oct-18,01-Jun-15,05-Nov-15,01-Jun-15,9,3,8,4,2,5,6,7,10,1,28.60%,60.80%,65.30%,70.80%,71.70%,73.00%,73.40%,79.10%,99.30%,100.00%,100.00%,05-Nov-15,06-Feb-18,-92,173,290,189,71,-93,181,893,126,339,143,69,186,248,304,1130,-88,382,69,335,-88,893,1343,576,789,593,519,636,698,754,1580,362,832,785,519,611,321,1145,378,591,395,321,438,500,556,1382,0,634,198,362,252,88,1343,981,824,157,824,41992
Firdapse,amifampridine,KYE Pharmaceuticals Inc.,N,N,N,Y,N,Y,N,Y,N,01-Feb-20,31-Jul-20,181,CADTH & INESSS,15-Nov-21,post-NOC,Initial,"Lambert-Eaton Myasthenic Syndrome, adults",Completed,16-Jun-22,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-22,post-NOC,New Drug,Lambert Eaton myasthenia syndrome,Completed,01-Feb-23,Inscription – Avec conditions,Conditional,none,,,,,UR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,472,742,213,173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,685,915,,,,,,,,866
Folotyn,pralatrexate,Servier,N,N,N,Y,Y,Y,Y,Y,Y,01-Nov-17,26-Oct-18,359,CADTH & INESSS,01-Jun-18,pre-NOC,New drug,Peripheral T-Cell Lymphoma (PTCL): for the treatment of patients with relapsed or refractory PTCL,Completed,04-Apr-19,Cond'l on Cost,Conditional,,,New Drug,Peripheral T-Cell Lymphoma (PTCL): for the treatment of patients with relapsed or refractory PTCL,Completed,13-Feb-19,Refus d’inscription,Negative,1st,06-Jun-19,10-Jan-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,Funded,Under provincial consideration,NR,01-Apr-20,15-Sep-20,01-Jun-20,22-Jul-20,17-Jul-20,,01-Jul-20,,,,01-Apr-20,01-Apr-20,1,6,2,5,4,,3,,,,20.30%,26.00%,27.30%,59.50%,65.00%,69.50%,,,,,69.50%,17-Jul-20,,-147,,307,,63,113,218,82,249,143,194,189,,173,,,,172,82,172,82,,523,690,584,635,630,,614,,,,613,613,523,670,363,363,530,424,475,470,,454,,,,453,160,110,281,331,,,,107,,519
Forxiga,dapagliflozin,AstraZeneca,Y,N,N,N,N,N,N,N,Y,01-Jul-19,02-Apr-20,276,CADTH & INESSS,31-Mar-20,pre-NOC,Initial,Heart failure with reduced ejection fraction,Completed,23-Dec-20,Reimburse with clinical criteria and/or conditions,Conditional,08-May-20,post-NOC,New Indication,Chronic cardiac insufficiency,Completed,14-Oct-20,Inscription - Avec conditions,Conditional,1st,17-Jun-21,18-Nov-21,Negotiation,Completed with Agreements,FB,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,11-Jan-22,01-Mar-22,01-Feb-22,24-Feb-22,17-Dec-21,17-Feb-22,27-Jun-22,12-Dec-22,21-Apr-22,15-Dec-21,17-Dec-21,15-Dec-21,3,7,4,6,2,5,9,10,8,1,28.60%,60.80%,81.10%,86.80%,87.70%,93.20%,97.70%,98.30%,99.60%,100.00%,100.00%,17-Dec-21,11-Jan-22,-2,36,267,159,176,246,154,54,103,75,98,29,91,221,389,154,27,135,29,124,27,54,649,698,670,693,624,686,816,984,749,622,730,719,624,626,359,384,433,405,428,359,421,551,719,484,427,465,265,195,330,400,649,27,25,2,25,541
Forxiga,dapagliflozin,AstraZeneca Canada Inc.,Y,N,N,N,N,N,N,N,N,01-Feb-21,10-Aug-21,190,CADTH,17-Jun-22,post-NOC,Non-sponsored Submission,Chronic kidney disease,Active,,Active,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,311,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44228
"Forxiga (w/ Met OR SU OR insulin+/-Met)
with insulin)",dapagliflozin,AstraZeneca ,Y,N,N,Y,N,N,N,N,N,,12-Dec-14,,CADTH & INESSS,30-Apr-15,post-NOC,Initial,"Diabetes mellitus, Type 2 (with metformin OR sulfonylurea, not both)",Completed,20-Nov-15,List with clinical criteria and/or conditions,Conditional,22-Mar-15,post-NOC,New Drug,Diabetes mellitus (Type 2),Completed,01-Oct-15,Avis d'inscription aux listes de médicaments - Médicament d'exception,Conditional,1st,27-May-16,03-Oct-16,Negotiation,Completed with Agreements,NR,SA,NR,EDS,FB,SA,EDS,NR,NR,EM,,01-Apr-17,,25-Jan-17,30-Nov-16,30-Nov-16,01-Aug-17,,,01-Oct-15,30-Nov-16,01-Oct-15,,5,,4,2,3,6,,,1,28.60%,60.80%,61.70%,67.20%,71.70%,73.00%,,,,,73.00%,30-Nov-16,,139,100,204,193,189,239,129,,180,,114,58,58,302,,,-368,142,58,57,-368,,,841,,775,719,719,963,,,293,803,718,719,580,376,,498,,432,376,376,620,,,0,460,343,293,318,368,,,,426,,42328
"Forxiga (w/Metformin AND SU)
and a sulfonylurea",dapagliflozin,AstraZeneca ,Y,N,N,N,N,N,N,N,N,,02-Dec-15,,CADTH & INESSS,04-Sep-15,pre-NOC,Initial,"Diabetes mellitus, type 2 (in combination with metformin AND sulfonylurea)",Completed,27-Apr-16,Do not list,Negative,,,New Indication,Diabetes mellitus (Type 2),Completed,01-Jun-16,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments-Médicament d'exception,Negative,1st,27-May-16,03-Oct-16,Negotiation,Completed with Agreements,NR,NR,EDS,NR,FB,NR,NR,SA,SA,NR,,,01-Jan-17,,30-Nov-16,,,24-Apr-17,01-Feb-17,,30-Nov-16,30-Nov-16,,,2,,1,,,4,3,,32.20%,38.00%,38.60%,39.00%,,,,,,,39.00%,,,-89,,236,,30,-5,129,,,90,,58,,,203,121,,118,58,118,58,,,,396,,364,,,509,427,,424,424,364,453,217,,,249,,217,,,362,280,,277,147,182,159,124,,,,,,42487
Fulphila,pegfilgrastim,BGP PHARMA ULC,N,Y,Y,N,N,N,N,N,Y,01-Jan-17,24-Dec-18,722,CADTH & INESSS,14-Nov-18,pre-NOC,Initial,Febrile neutropenia in non-myeloid malignancies,Completed,22-Feb-19,Not Applicable: Biosimilar,n/a,06-Nov-18,pre-NOC,New Drug,Neutropenia,Completed,13-Mar-19,Inscription – Avec conditions,Conditional,1st,28-Feb-19,23-Sep-19,Negotiation,Completed with Agreements,NR,SA,UR,UR,FB,SA,EDS,SA,SA,EM,,01-Mar-20,,,29-May-20,18-Jun-20,22-Apr-20,25-Oct-21,25-Feb-21,29-Apr-20,01-Mar-20,01-Mar-20,,1,,,4,5,2,7,6,3,4.50%,5.80%,34.30%,66.60%,67.50%,68.10%,68.50%,,,,68.50%,29-May-20,,-40,-48,100,127,6,-13,207,,160,,,249,269,212,763,521,219,362,160,342,160,,,433,,,522,542,485,1036,794,492,635,615,433,473,373,,373,,,462,482,425,976,734,413,575,60,79,213,194,,,,89,,782
Fycompa (seizures),perampanel ,Eisai Ltd. ,N,N,N,Y,N,N,N,N,N,,04-Apr-13,,CADTH & INESSS,08-Mar-13,pre-NOC,Initial,"Epilepsy, partial onset seizures ",Completed,17-Oct-13,List with criteria/condition,Conditional,02-Aug-13,post-NOC,New Drug,"Epilepsy, partial onset seizures ",Completed,03-Feb-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,none,31-Jan-14,,Negotiation by Province,n/a,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,15-Aug-14,01-May-14,01-Jul-14,17-Jul-14,27-Feb-14,11-Sep-14,23-May-14,25-Apr-16,20-May-14,03-Feb-14,27-Feb-14,03-Feb-14,8,3,6,7,2,9,5,10,4,1,28.60%,60.80%,65.30%,65.90%,67.30%,73.00%,78.50%,98.80%,99.60%,100.00%,100.00%,27-Feb-14,15-Aug-14,-27,120,223,185,106,-3,,,,,,,,,,,,,,,,,498,392,453,469,329,525,414,1117,411,305,512,491,329,356,133,302,196,257,273,133,329,218,921,215,0,316,196,305,,,498,193,169,24,169,41564
"Fycompa (seizures, primary)",perampanel,Eisai Ltd. ,N,N,N,N,N,N,N,N,N,,01-Dec-15,,CADTH & INESSS,24-Nov-15,pre-NOC,Initial,"Epilepsy, primary generalized tonic-clonic seizures",Completed,18-May-16,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Indication,"Epilepsy, primary generalized tonic-clonic seizures",Completed,03-Oct-16,Avis d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception,Conditional,1st,15-Aug-16,02-Jul-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,UR,EM,24-Sep-20,01-Aug-19,01-Nov-19,02-Mar-20,30-Sep-19,19-Dec-19,01-Mar-21,22-Nov-21,,15-Aug-19,01-Aug-19,01-Aug-19,7,1,4,6,3,5,8,9,,2,4.50%,33.00%,65.30%,71.00%,71.90%,77.40%,97.70%,99.00%,99.30%,,99.30%,30-Sep-19,24-Sep-20,-7,112,176,195,89,-49,1051,450,30,122,244,90,170,608,874,,44,324,30,292,30,450,1759,1339,1431,1553,1399,1479,1917,2183,,1353,1633,1601,1339,1346,1170,1590,1170,1262,1384,1230,1310,1748,2014,,1046,1464,169,307,1140,1002,1759,420,420,60,360,42508
Galafold,migalastat,Amicus Therapeutics,N,N,N,Y,N,Y,Y,Y,N,01-Nov-16,05-Sep-17,308,CADTH & INESSS,09-Jun-17,pre-NOC,Initial,Fabry Disease,Completed,24-Jan-18,Reimburse with clinical criteria and/or conditions,Conditional,01-Jun-18,post-NOC,New Drug,Fabry Disease,Completed,16-Nov-18,Inscription – Avec conditions,Conditional,1st,28-Mar-18,28-Aug-18,Negotiation,Completed with Agreements,UR,SA,UR,UR,EAP,SA,EDS,UR,SA,EM,,01-Oct-19,,,13-May-19,16-May-19,01-Aug-19,,19-Aug-21,07-Mar-19,13-May-19,07-Mar-19,,5,,,2,3,4,,6,1,28.60%,60.80%,61.70%,63.00%,67.50%,68.10%,,,,,68.10%,13-May-19,,-88,269,229,168,63,-233,153,,399,,,258,261,338,,1087,191,469,258,422,191,,,756,,,615,618,695,,1444,548,826,779,615,703,474,,615,,,474,477,554,,1303,111,685,141,437,216,-80,,,,67,,449
Galexos (pre_NOC),simeprevir,Janssen ,Y,N,N,Y,N,N,N,N,N,,18-Nov-13,,CADTH & INESSS,22-Aug-13,pre-NOC,Initial,"Hepatitis C, chronic",Completed,18-Jun-14,List with criteria/condition,Conditional,24-Nov-13,post-NOC,New Drug,"Hepatitis C, chronic",Completed,02-Jun-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,31-Jul-14,20-Aug-14,Negotiation,Completed with Agreements,DL,DL,DL,DL,DL,DL,DL,NR,DL,DL,28-Oct-14,01-Jan-15,01-Nov-14,19-Jan-15,09-Sep-14,12-Dec-14,29-Dec-14,,01-Jun-15,02-Jun-14,09-Sep-14,02-Jun-14,3,7,4,8,2,5,6,,9,1,28.60%,60.80%,81.10%,86.80%,87.70%,89.00%,93.40%,99.00%,99.60%,,99.60%,09-Sep-14,28-Oct-14,-88,6,300,190,43,59,20,69,134,73,152,20,114,131,,285,-79,122,20,100,-79,69,344,409,348,427,295,389,406,,560,196,397,375,295,383,83,132,197,136,215,83,177,194,,348,0,185,212,196,63,79,344,148,49,99,49,41808
Gavreto,pralsetinib,Hoffmann-La Roche,Y,N,N,Y,Y,Y,N,Y,N,01-Nov-20,30-Jun-21,241,CADTH & INESSS,09-Mar-22,post-NOC,Initial,Gavreto is indicated for the treatment of adult patients with rearranged during transfection (RET) fusion-positive locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC).,Completed,29-Sep-22,Cond'l on Cost,Conditional,28-Oct-22,post-NOC,New Drug,Gavreto is indicated for the treatment of adult patients with rearranged during transfection (RET) fusion-positive locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC).,Under review,TBD,TBD,TBD,None,,,Under consideration for negotiation,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,252,485,204,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,456,,,,,,,,,697
Gazyva,obinutuzumab,Hoffman-La Roche ,Y,Y,N,Y,Y,Y,Y,Y,N,,25-Nov-14,,CADTH & INESSS,11-Aug-14,pre-NOC,New drug,Chronic Lymphocytic Leukemia (CLL),Completed,27-Jan-15,Fund,Positive,24-Nov-14,pre-NOC,New Drug,Chronic Lymphocytic Leukemia (CLL),Completed,01-Jun-15,Ajout à la Liste Établissements - Médicament d'exception,Positive,1st,10-Feb-15,15-May-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-May-16,06-Aug-15,22-Jun-15,22-Jun-15,17-Jul-15,02-May-16,15-Oct-15,01-Aug-18,03-Jul-18,01-Jun-15,22-Jun-15,01-Jun-15,7,5,2,3,4,8,6,10,9,1,28.60%,34.30%,39.80%,72.10%,76.50%,77.80%,98.10%,99.00%,99.60%,100.00%,100.00%,17-Jul-15,01-May-16,-106,-1,169,189,14,-111,94,352,83,38,38,63,353,153,1174,1145,17,378,38,342,17,352,523,254,209,209,234,524,324,1345,1316,188,549,513,209,315,146,460,191,146,146,171,461,261,1282,1253,0,486,63,188,108,-17,523,335,314,46,289,42031
Gazyva,obinutuzumab,Hoffman-La Roche ,Y,Y,N,N,Y,Y,Y,Y,N,,29-Dec-16,,CADTH & INESSS,04-Nov-16,pre-NOC,New indication,Lymphoma and Myeloma (follicular lymphoma) ,Completed,02-Jun-17,Cond'l on Cost,Conditional,24-Mar-17,post-NOC,New Indication,Relapsed/Refractory Follicular Lymphyoma,Completed,18-Oct-17,Avis d'ajout d'une indication reconnue à la Liste Établissements - Médicament d'exception,Positive,1st,10-Oct-17,08-Jan-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jul-18,04-Sep-18,15-Aug-18,01-Jun-18,17-Oct-18,19-Oct-18,15-Oct-18,,03-Jul-18,24-May-18,01-Jun-18,24-May-18,3,6,5,2,8,9,7,,4,1,28.60%,34.10%,54.40%,55.00%,60.80%,65.20%,66.50%,98.80%,99.60%,,99.60%,01-Jul-18,17-Oct-18,-55,85,210,208,130,-8,90,174,239,219,144,282,284,280,,176,136,225,144,215,136,282,549,614,594,519,657,659,655,,551,511,600,590,519,574,364,394,459,439,364,502,504,500,,396,218,445,155,293,220,82,657,146,138,38,108,42888
Gazyva,obinutuzumab,Hoffman-La Roche ,Y,Y,N,N,Y,Y,Y,Y,N,01-Sep-17,05-Jul-18,307,CADTH & INESSS,15-Mar-18,pre-NOC,New indication,Follicular lymphoma (previously untreated),Completed,01-Nov-18,Do Not Fund,Negative,,,New Indication,Follicular lymphoma (previously untreated),Completed,17-Oct-18,Refus d’inscription,Negative,None,07-Dec-18,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-112,,231,,36,51,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,119,104,,,,,,,,426
"Genotropin (GHD, adult)",somatropin ,Pfizer ,Y,Y,N,N,N,Y,N,Y,N,,07-Feb-13,,CADTH & INESSS,27-May-13,post-NOC,Initial,"Growth hormone deficiency, adult",Completed,20-Dec-13,List with criteria/condition,Conditional,02-Aug-13,post-NOC,New Drug,"GHD, adut",Completed,03-Feb-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,none,31-Jan-14,,Negotiation by Province,n/a,NR,SA,NR,NR,EAP,NR,NR,NR,NR,EM,,01-May-14,,,06-Jul-14,,,,,03-Feb-14,01-May-14,03-Feb-14,,2,,,3,,,,,1,28.60%,33.00%,65.30%,,,,,,,,65.30%,06-Jul-14,,109,176,207,185,42,-3,,,,,,,,,,,,,,,,,,448,,,514,,,,,361,481,441,448,339,132,,132,,,198,,,,,0,165,316,361,,,,,,153,,41628
"Genotropin (GHD, pediatric )",somatropin ,Pfizer ,Y,Y,N,N,N,Y,N,Y,N,,07-Feb-13,,CADTH & INESSS,27-May-13,post-NOC,Initial,"Growth hormone deficiency, pediatric",Completed,20-Dec-13,List with criteria/condition,Conditional,02-Aug-13,post-NOC,New Drug,"GHD, pediatric",Completed,03-Feb-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,none,31-Jan-14,,Negotiation by Province,n/a,SA,NR,EDS,EDS,EAP,SA,NR,GH Program,NR,EM,05-Aug-14,,01-Apr-14,16-Oct-14,06-Jul-14,12-Dec-14,,25-May-15,,03-Feb-14,01-Apr-14,03-Feb-14,4,,2,5,3,6,,7,,1,28.60%,34.30%,66.50%,86.80%,92.30%,93.20%,93.60%,,,,93.60%,06-Jul-14,05-Aug-14,109,176,207,185,42,-3,,,,,,,,,,,,,,,,,544,,418,616,514,673,,837,,361,600,566,418,309,102,228,,102,300,198,357,,521,,0,284,316,361,,,544,183,126,153,30,41628
Genotropin (TS),somatropin ,Pfizer ,Y,Y,N,N,N,N,N,N,N,,07-Feb-13,,CADTH & INESSS,27-May-13,post-NOC,Initial,Turner Syndrome ,Completed,20-Dec-13,List with criteria/condition,Conditional,02-Aug-13,post-NOC,New Drug,Turner Syndrome,Completed,03-Feb-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,none,31-Jan-14,,Negotiation by Province,n/a,NR,NR,NR,EDS,EAP,SA,EDS,GH Program,NR,NR,,,,16-Oct-14,06-Jul-14,12-Dec-14,23-Jul-14,25-May-15,,,06-Jul-14,06-Jul-14,,,,3,1,4,2,5,,,32.20%,33.50%,39.10%,40.00%,40.30%,,,,,,40.30%,,,109,176,207,185,42,-3,,,,,,,,,,,,,,,,,,,,616,514,673,531,837,,,634,634,514,405,198,,,,300,198,357,215,521,,,318,316,361,,,,,,,,41628
Genvoya,elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide,Gilead Sciences ,Y,N,N,Y,N,N,N,N,N,,27-Nov-15,,CADTH & INESSS,24-Sep-15,pre-NOC,Initial,HIV-1 infection,Completed,18-Mar-16,List,Positive,22-Mar-16,post-NOC,New Drug,HIV-1 infection,Completed,16-Dec-16,Avis de refus d'inscription aux listes des médicaments,Negative,1st,15-Aug-16,13-Mar-17,Negotiation,Completed with Agreements,HIV,HIV,EDS,EDS,FB,SA,HIV,FB,SA,FB,12-Jul-17,04-May-17,01-Jul-17,19-Jul-17,27-Apr-17,15-Aug-17,01-Feb-18,28-Jan-19,01-Aug-17,21-Apr-17,27-Apr-17,21-Apr-17,5,3,4,6,2,8,9,10,7,1,28.60%,60.80%,65.30%,71.00%,91.20%,96.80%,97.40%,98.30%,99.60%,100.00%,100.00%,27-Apr-17,12-Jul-17,-64,116,176,269,150,-123,210,121,52,110,128,45,155,325,686,141,39,196,45,180,39,121,593,524,582,600,517,627,797,1158,613,511,668,652,517,581,405,481,412,470,488,405,515,685,1046,501,126,556,112,385,360,87,593,82,76,6,76,42447
Giotrif,afatinib,Boehringer Ingelheim,N,N,N,Y,Y,Y,N,Y,N,,01-Nov-13,,CADTH & INESSS,07-Jun-13,pre-NOC,New drug,Advanced Non Small Cell Lung Cancer,Completed,02-May-14,Cond'l on Cost,Conditional,,,New Drug,Advanced Non Small Cell Lung Cancer,Completed,02-Feb-15,Avis de refus,Negative,1st,09-May-14,03-Jul-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Oct-14,30-Sep-14,15-Sep-14,16-Oct-14,19-Aug-14,11-Sep-14,29-Dec-14,24-Oct-16,01-Jun-15,04-May-16,19-Aug-14,19-Aug-14,5,4,3,6,1,2,7,10,8,9,32.20%,33.10%,38.80%,43.30%,63.60%,69.10%,70.40%,71.10%,99.60%,100.00%,100.00%,01-Oct-14,04-May-16,-147,,329,,7,-269,55,90,89,74,105,47,70,179,844,333,671,203,47,250,47,671,334,333,318,349,291,314,423,1088,577,915,447,494,291,438,109,152,151,136,167,109,132,241,906,395,457,265,182,458,62,-214,915,624,624,43,581,41761
Giotrif,afatinib,Boehringer Ingelheim,N,N,N,Y,Y,Y,N,Y,N,,01-Nov-13,,CADTH,07-Jun-13,pre-NOC,New drug,Advanced Non Small Cell Lung Cancer,Completed,02-May-14,Cond'l on Cost,Conditional,,,,,,,,,2nd,07-Jul-17,23-Nov-17,Negotiation,Completed with Agreements,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-147,,329,,1162,,139,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,182,,1301,,,,,,,41761
Givlaari,givosiran,Alnylam Netherlands B.V.,N,N,N,Y,N,Y,Y,Y,N,01-Apr-20,09-Oct-20,191,CADTH & INESSS,23-Feb-21,post-NOC,Initial,Treatment of acute hepatic porphyria (AHP) in adults,Completed,08-Sep-21,Reimburse with clinical criteria and/or conditions,Conditional,18-Jun-21,post-NOC,New Drug,Treatment of acute hepatic porphyria (AHP) in adults,Completed,30-Nov-21,Inscription - Avec conditions,Conditional,1st,25-Mar-22,,Active,n/a,,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,137,252,197,165,198,115,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,334,417,,,,,,,,525
Glatect,glatiramer acetate,Pendopharm,N,N,N,N,N,N,N,N,N,,17-Jan-17,,CADTH & INESSS,20-Jan-17,post-NOC,Initial,"Multiple Sclerosis, relapsing - remitting",Completed,25-Jul-17,Reimburse with clinical criteria and/or conditions,Conditional,11-Oct-17,post-NOC,New Drug,Multiple sclerosis,Completed,11-Apr-18,Avis d’inscription aux listes des médicaments – Médicament d’exception,Conditional,1st,08-Sep-17,01-Mar-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,FB,EDS,SA,SA,EM,27-Nov-18,01-Jul-18,01-Jul-18,19-Apr-18,27-Sep-18,11-Jun-18,01-Feb-20,26-Jul-21,21-Aug-18,05-Jul-18,19-Apr-18,19-Apr-18,8,3,4,1,7,2,9,10,6,5,5.50%,6.40%,10.90%,16.60%,45.20%,45.80%,78.10%,98.30%,99.60%,100.00%,100.00%,27-Sep-18,27-Nov-18,3,267,186,182,45,-215,174,271,122,122,49,210,102,702,1243,173,126,333,49,312,49,271,679,530,530,457,618,510,1110,1651,581,534,741,720,457,454,268,490,341,341,268,429,321,921,1462,392,85,552,189,449,219,-41,679,222,222,161,61,42941
Grastek,phleum pratense,Merck,Y,Y,N,N,N,N,N,N,N,,12-Dec-13,,CADTH,30-Sep-13,pre-NOC,Initial,Allergy (grass),Completed,24-Sep-14,Do not list ,Negative,,,,,,,,,none,30-Oct-14,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,EM,,,,,,,,,,01-Oct-14,,01-Oct-14,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,-73,,359,,36,,,,,,,,,,,,,,,,,,,,,,,,,,,293,,293,,,,,,,,,,,,,,,286,,,,,,,,,41906
Grastofil (SEB),filgrastim,Apotex ,N,Y,Y,N,N,N,N,N,N,,07-Dec-15,,CADTH & INESSS,11-Sep-15,pre-NOC,Initial,Prevention or treatment of neutropenia in various indications,Completed,18-Mar-16,List with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Drug,Prevention or treatment of neutropenia in various indications,Completed,16-Dec-16,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,15-Jun-16,12-Dec-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,FB,SA,NR,SA,SA,EM,31-Jan-17,01-Apr-17,01-Jul-17,19-Jul-17,22-Dec-16,29-May-17,,07-Aug-17,01-Nov-17,27-Sep-18,22-Dec-16,22-Dec-16,2,3,5,6,1,4,,7,8,9,32.20%,52.50%,56.90%,57.80%,63.60%,69.10%,69.40%,70.10%,98.70%,,98.70%,31-Jan-17,27-Sep-18,-87,106,189,269,89,-184,180,50,110,201,219,10,168,,238,324,654,165,10,219,10,654,421,481,572,590,381,539,,609,695,1025,536,590,381,468,279,319,379,470,488,279,437,,507,593,650,434,102,375,269,-4,1025,644,644,40,604,42447
Harvoni,ledipasvir / sofosbuvir,Gilead Sciences ,Y,N,N,Y,N,N,N,N,N,,15-Oct-14,,CADTH & INESSS,15-Sep-14,pre-NOC,Initial,"Hepatitis C, chronic ",Completed,18-Mar-15,List with criteria/condition,Conditional,24-Nov-14,post-NOC,New Drug,"Hepatitis C, chronic",Completed,15-Jul-15,Avis d'inscription sur les listes de médicaments - Médicament d'exception - Avec conditions,Conditional,1st,31-Dec-14,05-Feb-15,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,NR,SA,EM,24-Mar-15,01-Apr-15,01-Apr-15,20-Apr-15,24-Mar-15,23-Mar-15,01-Apr-15,,01-Jun-15,15-Jul-15,23-Mar-15,23-Mar-15,2,4,5,7,3,1,6,,8,9,0.90%,21.10%,53.40%,57.80%,63.60%,64.90%,70.40%,71.10%,99.60%,,99.60%,24-Mar-15,15-Jul-15,-30,40,184,233,-77,-196,36,47,55,55,74,47,46,55,,116,160,62,46,73,46,160,160,168,168,187,160,159,168,,229,273,175,186,159,189,5,6,14,14,33,6,5,14,,75,0,21,154,273,-41,-160,273,114,114,1,113,42081
Harvoni (Drug Plan Submission),"ledipasvir, sofosbuvir",Gilead Sciences ,Y,N,N,Y,N,N,N,N,N,,15-Oct-14,,CADTH & INESSS,06-Jan-16,post-NOC,Request for Advice,"Hepatitis C, chronic",Completed,18-May-16,Reimburse with clinical criteria and/or conditions,Conditional,24-Nov-14,post-NOC,Drug Plan Submission,"Hepatitis C, chronic",Completed,01-Feb-17,Avis de modification d’une indication reconnue aux listes des médicaments – Médicament d’exception,Conditional,2nd,,17-Feb-17,Negotiation,Completed with Agreements,,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,448,40,133,800,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,581,840,275,16,,,,,,42508
Hemangiol,propranolol oral solution,Pierre Fabre Dermo-Cosmétique,N,N,N,N,N,Y,N,Y,N,,23-Sep-16,,CADTH & INESSS,25-Aug-16,pre-NOC,Initial,Infantile hemangioma,Completed,21-Feb-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,Proliferating infantile haemangioma requiring systemic therapy,Completed,18-Oct-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,04-Aug-17,16-Jul-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,29-Jan-19,01-Dec-18,01-Jan-19,18-Oct-18,29-Oct-18,30-Nov-18,10-Sep-20,27-Mar-23,27-Aug-19,27-Sep-18,18-Oct-18,27-Sep-18,7,5,6,2,3,4,9,10,8,1,28.60%,34.10%,66.30%,67.20%,71.70%,77.40%,97.70%,98.30%,99.60%,100.00%,100.00%,29-Oct-18,29-Jan-19,-29,182,180,208,164,-75,346,197,138,169,94,105,137,787,1715,407,73,417,94,382,73,197,858,799,830,755,766,798,1448,2376,1068,734,1078,1043,755,784,604,707,648,679,604,615,647,1297,2225,917,344,927,151,390,510,271,858,124,103,32,92,42787
Hemangiol (Withdrawn),propranolol ,Pierre Fabre Dermo-Cosmétique ,N,N,N,N,N,Y,N,Y,N,,23-Sep-16,,CADTH,23-Dec-14,pre-NOC,Initial,Infantile hemangioma,Withdrawn,30-Jan-15,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-640,,38,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-602,,,,,,,,,42034
Hemlibra,emicizumab,Hoffmann-La Roche Ltd.,Y,Y,N,Y,N,Y,N,Y,N,01-Feb-18,02-Aug-18,182,CADTH,30-Jun-20,post-NOC,Initial,"Bleeding prevention, hemophilia A",Completed,21-Dec-20,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,698,,174,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,872,,,,,,,,,1054
Holkira Pak,ombitasvir / paritaprevir / ritonavir and dasabuvir,AbbVie ,Y,N,N,Y,N,N,N,N,N,,22-Dec-14,,CADTH & INESSS,03-Dec-14,pre-NOC,Initial,"Hepatitis C, chronic",Completed,18-Jun-15,List with clinical criteria and/or conditions,Conditional,24-Dec-14,post-NOC,New Drug,"Hepatitis C, chronic",Completed,15-Jul-15,Avis d'inscription sur les listes de médicaments - Médicament d'exception - Avec conditions,Conditional,1st,27-Apr-15,16-Jun-15,Negotiation,Completed with Agreements,DL,DL,DL,DL,DL,DL,DL,DL,DL,DL,28-Jul-15,01-Sep-15,01-Aug-15,22-Jul-15,29-Jun-15,14-Oct-15,01-Sep-15,,01-Aug-15,15-Jul-15,29-Jun-15,29-Jun-15,4,7,5,3,1,9,8,,6,2,32.20%,60.80%,66.30%,86.60%,92.30%,93.00%,97.40%,98.80%,99.60%,,99.60%,15-Jul-15,28-Jul-15,-19,2,197,203,-52,-79,50,42,77,46,36,13,120,77,,46,29,57,13,54,13,42,218,253,222,212,189,296,253,,222,205,233,230,189,208,11,40,75,44,34,11,118,75,,44,0,55,178,205,-2,-29,218,29,29,16,13,42173
Holkira Pak (Drug Plan Submission),ombitasvir/paritaprevir/ritonavir and dasabuvir,AbbVie ,Y,N,N,Y,N,N,N,N,N,,22-Dec-14,,CADTH & INESSS,06-Jan-16,post-NOC,Request for Advice,"Hepatitis C, chronic",Completed,19-May-16,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,"Hepatitis C, chronic",Completed,24-Mar-16,Avis d'inscription sur les listes de médicaments - Médicament d'exception - Avec conditions,Conditional,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,380,,134,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,514,458,,,,,,,,42509
Humira (HS),adalimumab,AbbVie ,Y,Y,N,N,N,Y,N,Y,N,,31-Dec-15,,CADTH & INESSS,03-Nov-15,pre-NOC,Initial,Hidradenitis suppurativa,Completed,19-May-16,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Indication,Hidradenitis suppurativa,Completed,03-Oct-16,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception - Valeur thérapeutique,Negative,none,22-Dec-16,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-58,82,198,195,217,80,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,140,277,,,,,,,,42509
Humira (HS) (2nd pCPA),adalimumab,AbbVie ,Y,Y,N,N,N,Y,N,Y,N,,31-Dec-15,,CADTH & INESSS,03-Nov-15,pre-NOC,Initial,Hidradenitis suppurativa,Completed,19-May-16,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Indication,Hidradenitis suppurativa,Completed,03-Oct-16,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception - Valeur thérapeutique,Negative,1st,24-Jul-17,23-Oct-17,Negotiation,Completed with Agreements,SA,DL,EDS,EDS,EAP,SA,EDS,NR,SA,NR,06-Mar-18,01-Apr-18,01-Jan-18,25-Jan-18,,12-Feb-18,01-Oct-18,,26-Aug-19,,01-Jan-18,01-Jan-18,4,5,1,2,,3,6,,7,,5.70%,11.20%,12.10%,32.40%,36.90%,38.20%,38.80%,,,,38.80%,,,-58,82,198,195,431,294,91,134,160,70,94,,112,343,,672,,226,70,226,70,,796,822,732,756,,774,1005,,1334,,888,888,732,790,592,656,682,592,616,,634,865,,1194,,748,140,277,522,385,,,,,,42509
Humira (JIA),adalimumab,AbbVie ,Y,Y,N,N,N,N,N,N,N,,28-Nov-12,,CADTH & INESSS,04-Feb-13,post-NOC,Initial,"Arthritis, Juvenile Idiopathic ",Completed,18-Jul-13,List with clinical criteria and/or conditions,Conditional,,,New Indication,pJIA,Completed,01-Oct-13,Ajout d'une indication reconnue - Médicament d'exception - Avis de refus,Conditional,none,31-Jan-14,,Negotiation by Province,n/a,SA,DL,EDS,EDS,EAP,SA,EDS,SA,SA,NR,25-Feb-14,01-Oct-14,01-Apr-14,23-Jan-14,18-Feb-14,29-Jun-15,20-May-14,25-Apr-16,01-Dec-15,,23-Jan-14,23-Jan-14,3,6,4,1,2,7,5,9,8,,5.50%,37.80%,58.00%,63.70%,65.00%,69.50%,70.40%,71.10%,71.40%,,71.40%,25-Feb-14,,68,,164,,197,122,,,,,,,,,,,,,,,,,454,672,489,421,447,943,538,1244,1098,,701,701,421,353,189,222,440,257,189,215,711,306,1012,866,,469,232,307,,,,,,33,,41473
Humira (UC),adalimumab,AbbVie ,Y,Y,N,N,N,N,N,N,N,,21-Nov-13,,CADTH & INESSS,25-Sep-15,post-NOC,Initial,Ulcerative Colitis,Completed,15-Apr-16,Do not list at the submitted price,Negative,,,New Indication,Ulcerative Colitis,Completed,03-Oct-16,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception - Valeur thérapeutique,Negative,1st,31-May-16,23-May-17,Negotiation,Completed with Agreements,SA,DL,EDS,EDS,EAP,SA,EDS,SA,SA,EM,20-Jul-17,01-Oct-17,01-Jul-17,19-Oct-17,01-Aug-17,15-Aug-17,01-Oct-18,01-Aug-18,01-Aug-17,01-Mar-18,01-Jul-17,01-Jul-17,2,6,1,7,3,5,10,9,4,8,5.70%,26.00%,58.20%,58.90%,59.80%,64.20%,69.80%,98.30%,98.70%,100.00%,100.00%,01-Aug-17,01-Mar-18,673,,203,,46,-125,357,58,131,39,149,70,84,496,435,70,282,170,39,181,39,282,1337,1410,1318,1428,1349,1363,1775,1714,1349,1561,1449,1460,1318,645,442,461,534,442,552,473,487,899,838,473,514,573,876,1047,403,232,1561,243,243,31,212,42475
Humira (UC) (Withdrawn),adalimumab,AbbVie ,Y,Y,N,N,N,N,N,N,N,,21-Nov-13,,CADTH & INESSS,23-Dec-13,post-NOC,Initial,Ulcerative colitis,Withdrawn,08-Jan-15,Cancelled or withdrawn,n/a,,,New Indication,Ulcerative Colitis,Completed,02-Jun-14,Ajout d'une indication reconnue - Médicament d'exception - Avis de refus - Valeur thérapeutique,Conditional,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,32,,381,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,413,193,,,,,,,,42012
HyQvia,immune globulin human and recombinant human hyaluronidase (TBC),Takeda Canada Inc.,Y,Y,N,Y,N,N,N,N,N,01-Feb-21,14-Jan-22,347,CADTH,24-Jun-21,pre-NOC,Initial,Humoral immunodeficiency,Completed,15-Jun-22,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-204,,356,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,152,,,,,,,,,499
Ibrance,palbociclib,Pfizer,Y,N,N,Y,Y,N,N,N,N,,16-Mar-16,,CADTH & INESSS,11-Nov-15,pre-NOC,New drug,Advanced Breast Cancer,Withdrawn,25-Jul-16,n/a,n/a,22-Mar-16,post-NOC,New Drug,Advanced Breast Cancer,Completed,15-Mar-17,Avis de refus d'inscription aux listes des médicaments,Negative,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-126,6,257,358,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,131,364,,,,,,,,42576
Ibrance (with Faslodex),palbociclib (with fulvestrant),Pfizer,Y,N,N,N,Y,N,N,N,N,01-Jul-16,19-May-17,322,CADTH & INESSS,28-Sep-18,post-NOC,New indication,Advanced or Metastatic Breast Cancer,Completed,03-May-19,Cond'l on Cost,Conditional,15-Oct-18,post-NOC,New Indication,Advanced or Metastatic Breast Cancer,Completed,05-Nov-20,Inscription - Avec conditions,Conditional,1st,14-Aug-19,08-Apr-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Mar-21,15-Sep-20,01-Aug-20,22-Oct-20,28-Feb-21,17-Sep-20,01-Nov-20,14-Feb-22,28-Feb-22,11-Nov-20,01-Aug-20,01-Aug-20,8,2,1,4,7,3,5,9,10,6,5.70%,10.20%,11.10%,16.60%,17.90%,46.50%,78.70%,99.00%,99.30%,100.00%,100.00%,28-Feb-21,01-Mar-21,497,514,217,752,103,-449,238,327,160,115,197,326,162,207,677,691,217,318,115,308,115,327,1382,1215,1170,1252,1381,1217,1262,1732,1746,1272,1373,1363,1170,673,456,668,501,456,538,667,503,548,1018,1032,6,659,714,1266,341,-211,1382,212,212,211,1,1036
Ibrance resubmission,palbociclib,Pfizer,Y,N,N,Y,Y,N,N,N,N,,16-Mar-16,,CADTH & INESSS,10-Jun-16,post-NOC,Resubmission,"Breast, advanced breast cancer",Completed,21-Nov-16,Cond'l on Cost,Conditional,22-Mar-16,post-NOC,New Drug,Advanced Breast Cancer,Completed,15-Mar-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,15-May-17,21-Dec-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Apr-18,08-May-18,23-Feb-18,19-Apr-18,20-Feb-18,12-Feb-18,31-Jul-18,01-Oct-19,04-May-18,01-Feb-18,12-Feb-18,01-Feb-18,5,8,4,6,3,2,9,10,7,1,28.60%,29.50%,61.70%,67.40%,87.70%,93.20%,93.90%,98.30%,99.60%,100.00%,100.00%,20-Feb-18,01-Apr-18,86,6,164,358,175,61,220,101,138,64,119,61,53,222,649,134,42,171,53,158,42,101,746,783,709,764,706,698,867,1294,779,687,816,803,698,612,448,496,533,459,514,456,448,617,1044,529,323,566,250,364,395,281,746,59,48,19,40,42695
Iclusig,ponatinib,Ariad,N,N,N,Y,Y,Y,Y,Y,N,,02-Apr-15,,CADTH & INESSS,13-Mar-15,pre-NOC,New drug,Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia,Completed,01-Oct-15,Cond'l on Cost,Conditional,04-Aug-15,post-NOC,New Drug,Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia,Completed,19-Aug-16,Avis de refus d'inscription aux listes des médicaments-Médicament d'exception- À moins que certaines conditions soient respectées,Conditional,1st,28-Oct-15,04-Jul-16,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,UR,01-Dec-16,18-Oct-16,08-Aug-16,25-Jan-17,03-Aug-16,29-Sep-16,01-Dec-16,,01-Jul-18,,03-Aug-16,03-Aug-16,5,4,2,7,1,3,6,,8,,32.20%,38.00%,38.80%,43.30%,63.60%,64.90%,70.40%,71.10%,,,71.10%,01-Dec-16,,-20,124,202,381,27,-296,250,150,106,35,205,30,87,150,,727,,186,30,186,30,,609,565,494,664,489,546,609,,1186,,645,645,489,509,307,427,383,312,482,307,364,427,,1004,,463,182,505,277,-46,,,,120,,42278
Idhifa,enasidenib,Celgene,N,N,N,Y,Y,Y,N,Y,N,01-Jul-18,06-Feb-19,220,CADTH & INESSS,05-Apr-19,post-NOC,New drug,Acute Myeloid Leukemia (AML),Completed,31-Oct-19,Do not Fund,Negative,10-May-19,post-NOC,New Drug,Acute Myeloid Leukemia (AML),Completed,11-Dec-19,Refus d'inscription,Negative,None,,,Under consideration for negotiation,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,58,93,209,215,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,267,308,,,,,,,,487
Ikervis (Withdrawn),cyclosporine,Santen,N,N,N,N/A,N,Y,Y,Y,N,,,,CADTH,15-May-17,na,Initial,"keratitis, severe",Withdrawn,11-Jul-17,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,57,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,42927
Ilaris (SJIA),canakinumab,Novartis ,Y,Y,N,N,N,N,N,N,N,,12-Dec-13,,CADTH,23-Dec-15,post-NOC,Initial,Systemic juvenile idiopathic arthritis,Completed,17-Jun-16,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,27-Apr-18,19-Nov-18,Negotiation,Completed with Agreements,NR,NR,UR,NR,EAP,SA,EDS,NR,NR,NR,,,,,19-Apr-18,06-Jun-19,01-May-19,,,,19-Apr-18,19-Apr-18,,,,,1,3,2,,,,32.20%,33.50%,34.40%,,,,,,,,34.40%,,,741,,177,,679,,206,,,,,-214,199,163,,,,49,-214,49,-214,,,,,,1589,2002,1966,,,,1852,1852,1589,848,671,,,,,671,1084,1048,,,,934,918,,885,,,,,,,42538
Ilumya,tildrakizumab,Sun Pharma,N,Y,N,Y,N,N,N,N,Y,01-Feb-19,19-May-21,838,CADTH & INESSS,15-Jul-19,pre-NOC,Initial,Treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,Completed,21-Jun-21,Reimburse with clinical criteria and/or conditions,Conditional,09-Aug-19,pre-NOC,New drug,moderate to severe plaque psoriasis,withdrawn,,,,1st,17-Sep-21,20-Dec-21,Negotiation,Completed with Agreements,,SA,EDS,EDS,LU,SA,EDS,SA,SA,,,01-Dec-21,01-Apr-22,24-Feb-22,28-Feb-22,24-Mar-22,13-Jul-22,20-Feb-23,25-Jul-22,,01-Dec-21,01-Dec-21,,1,5,2,3,4,6,8,7,,4.50%,10.00%,42.20%,43.10%,48.80%,50.10%,50.80%,51.20%,,,51.20%,13-Jul-22,,-674,-649,707,,88,,94,,-19,102,66,70,94,205,427,217,,145,-19,145,-19,,,196,317,281,285,309,420,642,432,,360,360,196,870,163,,163,284,248,252,276,387,609,399,,327,33,,182,,,,,224,,871
Iluvien,fluocinolone acetonide intravitreal implant,Knight Therapeutics ,N,N,N,N,N,N,N,N,N,01-Feb-17,23-Nov-18,660,CADTH & INESSS,03-Apr-19,post-NOC,Initial,Diabetic macular edema,Completed,26-Sep-19,Do not reimburse,Negative,24-May-19,post-NOC,New Drug,Diabetic macular edemia,Completed,11-Dec-19,Inscription - Avec conditions,Conditional,none,01-Nov-19,,Do Not Negotiate,n/a,,,NR,,,NR,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,131,182,176,201,36,-40,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,307,383,,,,,,,,967
Iluvien (Withdrawn),fluocinolone acetonide,Knight Therapeutics ,N,N,N,N,N,N,N,N,N,01-Feb-17,23-Nov-18,660,CADTH,21-Dec-17,pre-NOC,Initial,Diabetic macular edema (DME),Withdrawn,23-Mar-18,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-337,,92,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-245,,,,,,,,,415
Imbruvica,ibrutinib,Janssen ,Y,N,N,Y,Y,Y,Y,Y,N,,17-Nov-14,,CADTH & INESSS,15-Aug-14,pre-NOC,New drug,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Completed,05-Mar-15,Cond'l on Cost,Conditional,24-Nov-14,post-NOC,New Drug,Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma,Completed,15-Jul-15,Avis d'inscription sur les listes de médicaments - Médicament d'exception - Avec conditions,Conditional,1st,06-Mar-15,02-Jun-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Dec-15,06-Aug-15,01-Oct-15,18-Jan-16,14-Jul-15,28-Apr-22,02-Nov-15,01-Aug-18,01-Dec-15,01-Oct-15,14-Jul-15,14-Jul-15,6,2,3,8,1,10,5,9,7,4,32.20%,36.70%,42.40%,71.00%,72.30%,92.60%,93.20%,98.80%,99.10%,100.00%,100.00%,01-Oct-15,01-Dec-15,-94,7,202,233,1,-131,88,182,65,121,230,42,2522,153,1156,182,121,517,42,477,42,182,379,262,318,427,239,2719,350,1353,379,318,714,674,239,333,131,271,154,210,319,131,2611,242,1245,271,78,606,108,240,89,-43,379,140,140,79,61,42068
Imbruvica,ibrutinib,Janssen ,Y,N,N,N,Y,Y,Y,Y,N,,28-Jul-15,,CADTH & INESSS,29-Jan-16,post-NOC,New indication,Mantle Cell Lymphoma,Completed,19-Jul-16,Cond'l on Cost,Conditional,12-Aug-16,post-NOC,New Indication,Relapsed/refractory mantle cell lymphoma,Completed,01-Feb-17,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments - Médicament exception,Conditional,1st,12-Aug-16,27-Jun-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Mar-18,08-May-18,01-Oct-17,19-Oct-17,01-Oct-17,11-Jun-18,15-Oct-18,,01-May-18,18-Aug-17,01-Oct-17,18-Aug-17,5,7,2,4,3,8,9,,6,1,28.60%,34.30%,66.50%,72.10%,92.30%,93.00%,97.40%,98.30%,99.60%,,99.60%,01-Oct-17,01-Mar-18,185,381,172,173,24,-173,319,247,315,96,114,96,349,475,,308,52,250,96,228,52,247,947,1015,796,814,796,1049,1175,,1008,752,950,928,796,611,439,590,658,439,457,439,692,818,,651,198,593,357,554,343,146,947,195,151,44,151,42570
Imbruvica,ibrutinib,Janssen ,Y,N,N,N,Y,Y,N,Y,N,,31-Mar-16,,CADTH & INESSS,22-Apr-16,post-NOC,New indication,Waldenstrom's macroglobulinemia,Completed,03-Nov-16,Do Not Fund,Negative,12-Aug-16,post-NOC,New Indication,Waldenstrom's Macroglobulinemia,Completed,01-Feb-17,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments - Médicament exception,Negative,None,23-Dec-16,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,22,134,195,173,50,-40,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,217,307,,,,,,,,42677
Imbruvica,ibrutinib,Janssen ,Y,N,N,N,Y,Y,Y,Y,N,,19-Jul-16,,CADTH & INESSS,20-Apr-16,pre-NOC,New indication,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (previously untreated),Completed,03-Nov-16,Cond'l on Cost,Conditional,12-Aug-16,post-NOC,New Indication,Previously untreated CLL/SLL,Completed,01-Feb-17,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments - Médicament exception,Negative,1st,20-Dec-16,27-Jun-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Oct-16,08-May-18,01-Oct-17,19-Oct-17,28-Dec-17,11-Jun-18,15-Oct-18,,01-May-18,18-Aug-17,01-Oct-16,01-Oct-16,1,7,3,4,5,8,9,,6,2,20.30%,48.80%,54.60%,60.10%,92.30%,93.00%,97.40%,98.30%,99.60%,,99.60%,01-Oct-17,28-Dec-17,-90,24,197,173,47,-43,189,-269,315,96,114,184,349,475,,308,52,197,-269,180,-269,184,74,658,439,457,527,692,818,,651,395,540,523,74,164,-33,-33,551,332,350,420,585,711,,544,198,433,107,197,236,146,527,453,453,365,88,42677
Imfinzi,durvalumab,AstraZeneca,Y,Y,N,Y,Y,N,N,N,N,01-Sep-17,04-May-18,245,CADTH & INESSS,21-Sep-18,post-NOC,New drug,Non-Small Cell Lung Cancer,Completed,03-May-19,Cond'l on Cost,Conditional,20-Jul-18,post-NOC,New Drug,Non-Small Cell Lung Cancer,Completed,13-Mar-19,Inscription – Avec conditions,Conditional,1st,08-Jul-19,26-Aug-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Feb-20,10-Apr-20,01-Jan-20,16-Dec-19,22-Jan-20,20-Mar-20,01-Feb-20,,01-Jun-20,02-Oct-19,16-Dec-19,02-Oct-19,5,8,3,2,4,7,6,,9,1,28.60%,34.10%,39.80%,72.10%,92.30%,93.60%,94.50%,99.00%,99.60%,,99.60%,22-Jan-20,01-Feb-20,140,77,224,236,66,117,49,159,228,128,112,149,207,159,,280,37,178,112,162,37,159,638,707,607,591,628,686,638,,759,516,657,641,591,451,227,274,343,243,227,264,322,274,,395,203,293,364,313,115,166,638,122,47,112,10,609
Imfinzi,durvalumab,AstraZeneca,Y,Y,N,N,Y,Y,N,Y,N,01-Nov-19,01-Oct-20,335,CADTH & INESSS,01-Dec-20,post-NOC,Initial,In combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC),Completed,27-Jul-21,Cond'l on Cost,Conditional,22-Jan-21,post-NOC,New Indication,In combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC),Completed,30-Jun-21,Refus d'inscription,Negative,1st,21-Oct-21,18-May-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,01-Oct-22,30-Jun-22,01-Aug-22,11-Jul-22,30-Jul-22,,,,,06-Jul-22,30-Jun-22,30-Jun-22,6,1,5,3,4,,,,,2,4.50%,33.00%,38.60%,70.80%,76.50%,96.80%,,,,,96.80%,30-Jul-22,01-Oct-22,61,113,238,159,86,113,209,136,43,75,54,73,,,,,49,76,43,72,43,136,730,637,669,648,667,,,,,643,670,666,637,576,338,431,338,370,349,368,,,,,371,371,299,272,295,322,730,93,93,30,63,634
Imfinzi,durvalumab,AstraZeneca Canada,Y,Y,N,N,Y,Y,N,Y,N,01-Apr-22,28-Sep-22,180,CADTH & INESSS,14-Jul-22,pre-NOC,Initial,In combination with chemotherapy for the treatment of patients with locally advanced or metastatic biliary tract cancer.,Completed,03-Feb-23,Cond'l on Cost,Conditional,16-Dec-22,post-NOC,New Indication,In combination with chemotherapy for the treatment of patients with locally advanced or metastatic biliary tract cancer.,Under review,TBD,TBD,TBD,None,,,Under consideration for negotiation,n/a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-76,79,204,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,128,,,,,,,,,308
Imvexxy,estradiol,Knight Therapeutics ,N,N,N,N,N,N,N,N,N,01-Oct-19,17-Aug-20,321,CADTH & INESSS,23-Jun-21,post-NOC,Initial,Dyspareunia,Completed,20-Jan-22,Reimburse with clinical criteria and/or conditions,Conditional,24-Jan-22,post-NOC,New Drug,Dyspareunia,Completed,04-May-22,Inscription - Avec conditions,Conditional,1st,13-Jul-22,20-Jan-23,Negotiation,Completed with Agreements,UR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,310,525,211,100,174,70,191,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,521,625,365,261,,,,,,842
Increlex,mecasermin,"Ipsen Biopharmaceuticals Canada, Inc.",N,Y,N,Y,N,Y,Y,Y,N,01-Feb-20,17-Dec-20,320,CADTH & INESSS,14-Jun-21,post-NOC,Initial,Severe primary insulin-like growth factor-1 deficiency,Completed,21-Jan-22,Reimburse with clinical criteria and/or conditions,Conditional,05-Nov-21,post-NOC,New Drug,Severe primary insulin-like growth factor-1 deficiency,Completed,30-Mar-22,Refus d'inscription,Negative,1st,13-Jun-22,06-Feb-23,Negotiation,Completed with Agreements,UR,,,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,179,323,221,145,143,75,238,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,400,468,381,313,,,,,,720
Incruse Ellipta,umeclidinium,GlaxoSmithKline,Y,N,N,N,N,N,N,N,N,,16-Apr-14,,CADTH & INESSS,04-Mar-15,post-NOC,Initial,Chronic Obstructive Pulmonary Disease (COPD),Completed,18-Sep-15,List with criteria/condition,Conditional,22-Mar-16,post-NOC,New Indication,Chronic Obstructive Pulmonary Disease (COPD),Completed,03-Oct-16,Avis d'inscription aux listes des médicaments,Positive,1st,23-Oct-15,15-Dec-15,Negotiation,Completed with Agreements,FB,FB,EDS,FB,FB,SA,EDS,SA,SA,FB,15-Mar-16,01-Feb-16,01-May-16,18-Apr-16,25-Feb-16,28-Mar-16,01-Mar-16,28-Mar-16,01-Feb-16,03-Oct-16,01-Feb-16,01-Feb-16,5,1,9,8,3,6,4,7,2,10,4.50%,5.10%,37.40%,38.70%,58.90%,59.80%,60.20%,65.70%,71.40%,100.00%,100.00%,15-Mar-16,03-Oct-16,322,706,198,195,35,-346,53,91,48,138,125,72,104,77,104,48,293,90,48,110,48,293,699,656,746,733,680,712,685,712,656,901,698,718,656,334,136,179,136,226,213,160,192,165,192,136,0,178,520,901,88,-293,901,245,245,43,202,42265
Inflectra (SEB; Crohn's & UC)),infliximab,"Hospira HealthCare Corporation, a Pfizer Company",Y,Y,Y,N,N,N,N,N,N,,10-Jun-16,,CADTH & INESSS,12-Apr-16,pre-NOC,Initial,"ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn’s disease and Ulcerative Colitis",Completed,25-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Indication,Crohn's Disease,Completed,01-Feb-17,Avis d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception,Conditional,1st,,31-Oct-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,01-Nov-16,01-Dec-16,01-Jan-17,25-Jan-17,30-Nov-16,30-Nov-16,01-Dec-16,01-Aug-18,05-Dec-16,01-Feb-17,01-Nov-16,01-Nov-16,1,4,7,8,2,3,5,10,6,9,20.30%,52.50%,53.40%,57.80%,59.10%,59.80%,65.50%,71.10%,99.60%,100.00%,100.00%,30-Nov-16,01-Feb-17,-59,63,196,173,,,,1,31,62,86,30,30,31,639,35,93,105,1,104,1,93,144,174,205,229,173,173,174,782,178,236,248,247,144,203,7,7,37,68,92,36,36,37,645,41,0,111,137,236,6,-93,236,92,92,29,63,42668
Inflectra (SEB; RD),infliximab ,"Hospira HealthCare Corporation, a Pfizer Company",Y,Y,Y,N,N,N,N,N,N,,15-Jan-14,,CADTH & INESSS,17-Jun-14,post-NOC,Initial,"Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis ",Completed,19-Dec-14,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Drug,"Rheumatoid arthritis , ankylosing spondylitis , psoriatic arthritis and chronic plaque psoriasis",Completed,02-Feb-15,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,14-Jan-15,19-Nov-15,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,19-Feb-16,01-Apr-16,01-May-16,18-Apr-16,25-Feb-16,01-Jun-16,01-Jun-16,27-Jun-16,01-May-16,02-Feb-15,19-Feb-16,02-Feb-15,2,4,6,5,3,8,9,10,7,1,28.60%,48.80%,81.10%,85.50%,91.10%,96.80%,97.40%,98.30%,99.60%,100.00%,100.00%,25-Feb-16,25-Feb-16,153,201,185,182,26,-19,309,92,134,164,151,98,195,195,221,164,-290,157,92,112,-290,98,765,807,837,824,771,868,868,894,837,383,830,785,765,612,427,427,469,499,486,433,530,530,556,499,0,492,338,383,335,290,771,388,6,388,0,41992
Inlyta,axitinib,Pfizer,Y,N,N,Y,Y,N,Y,Y,N,,12-Jul-12,,CADTH & INESSS,16-Aug-12,post-NOC,New drug,"For the treatment of patients with metastatic renal cell carcinoma (RCC) of clear histology after failure of prior systemic therapy with either a cytokine or the VEGFR-TKI, sunitinib",Completed,07-Mar-13,Fund,Positive,02-Aug-12,post-NOC,New Drug,Metastatic Renal Cell Carcinoma,Completed,01-Feb-13,Avis de refus à défaut d'un dévelop. preuve et d'une entente de partage de risque financier,Conditional,1st,06-May-13,22-Nov-13,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Mar-14,05-Mar-14,16-Dec-13,16-Apr-14,17-Dec-13,30-Apr-14,01-Oct-14,01-Aug-18,01-Apr-14,01-Feb-13,16-Dec-13,01-Feb-13,4,5,2,7,3,8,9,10,6,1,28.60%,34.30%,66.50%,86.80%,91.20%,91.90%,97.40%,98.30%,99.60%,100.00%,100.00%,17-Dec-13,01-Mar-14,35,21,203,183,60,94,200,99,103,24,145,25,159,313,1713,130,-294,301,24,242,-294,99,597,601,522,643,523,657,811,2211,628,204,799,740,522,487,284,359,363,284,405,285,419,573,1973,390,0,561,238,204,260,294,597,393,75,319,74,41340
Inlyta,axitinib,Pfizer,Y,N,N,Y,Y,N,Y,Y,N,,12-Jul-12,,CADTH,18-Apr-17,post-NOC,Request for Advice,"For the treatment of patients with metastatic renal cell carcinoma (RCC) of clear histology after failure of prior systemic therapy with either a cytokine or the VEGFR-TKI, sunitinib",Completed,29-Jun-17,Fund,Positive,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,1741,,72,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1813,,,,,,,,,42915
Inqovi,decitabine-cedazuridine,Taiho Pharma ,N,N,N,Y,Y,Y,Y,Y,N,01-Jan-20,07-Jul-20,188,CADTH & INESSS,09-Oct-20,post-NOC,New drug,Myelodysplastic Syndromes (MDS),Completed,22-Sep-21,Cond'l on Cost,Conditional,15-Jan-21,post-NOC,New Drug,Myelodysplastic Syndromes (MDS),Completed,28-Jul-21,Refus d'inscription,Negative,1st,16-Feb-22,22-Apr-22,Negotiation,No Agreement Reached,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,NR,01-Nov-22,30-Sep-22,01-Dec-22,24-Jan-23,31-Jan-23,21-Nov-22,01-Jan-23,,,,30-Sep-22,30-Sep-22,2,1,4,6,7,3,5,,,,4.50%,24.70%,25.60%,31.30%,32.60%,38.20%,70.40%,,,,70.40%,31-Jan-23,,94,192,348,194,147,203,65,193,161,223,277,284,213,254,,,,229,161,229,161,,847,815,877,931,938,867,908,,,,883,883,815,721,373,405,373,435,489,496,425,466,,,,441,442,386,212,268,,,,123,,630
Inqovi,decitabine-cedazuridine,Taiho Pharma ,N,N,N,Y,Y,Y,Y,Y,N,01-Jan-20,07-Jul-20,188,CADTH & INESSS,09-Oct-20,post-NOC,New drug,Myelodysplastic Syndromes (MDS),Completed,22-Sep-21,Cond'l on Cost,Conditional,15-Jan-21,post-NOC,New Drug,Myelodysplastic Syndromes (MDS),Completed,28-Jul-21,Refus d'inscription,Negative,2nd,25-Aug-22,25-Aug-22,Negotiation,Completed with Agreements,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,94,192,348,194,337,393,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,442,386,337,393,,,,,,630
Inrebic,fedratinib,Celgene,N,N,N,Y,Y,Y,Y,Y,N,01-Oct-19,27-Jul-20,300,CADTH & INESSS,05-Nov-20,post-NOC,Initial,"For the treatment of splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib",Completed,21-Jun-21,Cond'l on Cost,Conditional,27-Apr-21,post-NOC,New Drug,"For the treatment of splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib",Completed,07-Dec-21,Inscription - Avec conditions,Conditional,1st,21-Dec-21,13-May-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,EM,01-Sep-22,30-Sep-22,01-Aug-22,20-Sep-22,30-Sep-22,26-Sep-22,01-Nov-22,,08-Feb-23,26-May-22,01-Aug-22,26-May-22,3,6,2,4,7,5,8,,9,1,28.60%,34.30%,54.60%,60.10%,61.00%,65.40%,97.70%,99.00%,99.60%,,99.60%,01-Sep-22,30-Sep-22,101,274,228,224,183,14,143,111,140,80,130,140,136,172,,271,13,148,80,133,13,140,766,795,735,785,795,791,827,,926,668,803,788,735,634,406,437,466,406,456,466,462,498,,597,170,474,329,498,326,157,795,127,60,98,29,629
Inspiolto Respimat,tiotropium / olodaterol,Boehringer Ingelheim ,N,N,N,N,N,N,N,N,N,,28-May-15,,CADTH & INESSS,04-Jun-15,post-NOC,Initial,Chronic Obstructive Pulmonary Disease (COPD),Completed,17-Dec-15,List with criteria/condition,Conditional,04-Aug-15,post-NOC,New Drug,Chronic Obstructive Pulmonary Disease (COPD),Completed,01-Feb-16,Avis d'inscription aux listes de médicaments - Médicament d'exception,Conditional,1st,22-Feb-16,02-Mar-16,Negotiation,Completed with Agreements,SA,SA,EDS,FB,LU,SA,EDS,SA,SA,EM,05-Apr-16,01-May-16,01-May-16,21-Jul-16,30-Mar-16,25-Apr-16,02-May-16,25-Apr-16,01-Jul-16,30-Mar-16,30-Mar-16,30-Mar-16,3,6,7,10,1,4,8,5,9,2,32.20%,60.80%,81.10%,82.00%,82.30%,86.80%,92.50%,93.80%,94.50%,100.00%,100.00%,30-Mar-16,05-Apr-16,7,68,196,181,67,21,9,34,60,60,141,28,54,61,54,121,28,68,28,64,28,34,313,339,339,420,307,333,340,333,400,307,347,343,307,300,104,110,136,136,217,104,130,137,130,197,58,144,203,249,76,30,313,6,6,0,6,42355
Inspra (HF),eplerenone,Pfizer ,Y,N,N,N,N,N,N,N,N,,30-Aug-12,,CADTH & INESSS,12-Jul-13,post-NOC,Initial,"Heart failure, NYHA class II",Completed,24-Apr-14,Do not list at the submitted price,Negative,,,New Indication,"Heart failure, NYHA class II",Completed,03-Jun-13,Ajout d'une indication reconnue - Médicament d'exception,Conditional,1st,09-May-14,31-Mar-15,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,LU,SA,EDS,NR,SA,EM,,01-Sep-15,01-Jul-15,22-Jul-15,28-May-15,14-Oct-15,01-Sep-15,,01-Aug-15,03-Jun-13,28-May-15,03-Jun-13,,6,3,4,2,8,7,,5,1,28.60%,60.80%,66.50%,72.10%,72.70%,77.20%,78.50%,79.40%,,,79.40%,28-May-15,,316,,286,,15,340,326,,154,92,113,58,197,154,,123,-666,127,58,28,-666,,,1097,1035,1056,1001,1140,1097,,1066,277,1070,971,1001,685,399,,495,433,454,399,538,495,,464,0,468,602,277,341,666,,,,724,,41753
Intrarosa,prasterone,Lupin Pharma Canada Ltd.,N,N,N,Y,N,N,N,N,N,01-Dec-16,01-Nov-19,1065,CADTH & INESSS,01-Oct-21,post-NOC,Initial,Postmenopausal vulvovaginal atrophy,Completed,14-Apr-22,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-22,post-NOC,New Drug,Post-menupausal vulvovagina atrophy,Completed,28-Dec-22,Inscription – Avec conditions,Conditional,1st,15-Dec-22,,Active,n/a,,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,700,1015,195,138,245,-13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,895,1153,,,,,,,,1960
Intuniv XR,guanfacine hydrochloride,Shire ,Y,N,N,Y,N,N,N,N,N,,05-Jul-13,,CADTH & INESSS,27-Aug-13,post-NOC,Initial,Attention deficit hyperactivity disorder (ADHD),Completed,24-Sep-14,Do not list ,Negative,,,New Drug,Attention deficit hyperactivity disorder (ADHD),Completed,03-Feb-14,Avis de refus - Valeur thérapeutique (monothérapie) Ajout aux listes de médicaments - Médicament d'exception (traitement d'appoint),Conditional,none,18-Nov-14,,Do Not Negotiate,n/a,NR,NR,NR,NR,LU,NR,NR,NR,NR,EM,,,,,31-Jan-20,,,,,03-Feb-14,31-Jan-20,03-Feb-14,,,,,2,,,,,1,28.60%,60.80%,,,,,,,,,60.80%,31-Jan-20,,53,,393,,55,288,,,,,,,,,,,,,,,,,,,,,2401,,,,,213,2401,1307,2401,2348,1955,,,,,1955,,,,,0,1955,446,213,,,,,,2188,,41906
Invokamet,canagliflozin and metformin hydrochloride,Janssen ,Y,N,N,N,N,N,N,N,N,,01-Jun-16,,CADTH & INESSS,03-Mar-16,pre-NOC,Initial,"Diabetes mellitus, type 2",Completed,25-Aug-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Drug,"Diabetes mellitus, type 2",Completed,15-Mar-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,05-May-17,20-Oct-17,Negotiation,No agreement reached,NR,NR,NR,NR,NR,NR,NR,NR,NR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-90,72,175,215,253,51,168,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,85,287,421,219,,,,,,42607
Invokana,canagliflozin,Janssen ,Y,N,N,Y,N,N,N,N,N,,23-May-14,,CADTH & INESSS,24-Feb-14,pre-NOC,Initial,Diabetes mellitus (Type 2),Completed,15-Jan-15,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Drug,Diabetes mellitus (Type 2),Completed,02-Feb-15,Ajout aux listes de médicaments - Médicament d'exception,Positive,1st,28-Feb-15,02-Jul-15,Negotiation,Completed with Agreements,UR,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,,01-Oct-15,01-Oct-15,22-Oct-15,29-Jul-15,14-Oct-15,01-Sep-15,21-Sep-15,01-Aug-15,02-Feb-15,29-Jul-15,02-Feb-15,,6,7,9,2,8,4,5,3,1,28.60%,60.80%,61.50%,62.80%,63.10%,67.60%,73.30%,74.20%,79.70%,,79.70%,29-Jul-15,,-88,73,325,182,44,26,124,,91,91,112,27,104,61,81,30,-150,75,27,50,-150,,,496,496,517,432,509,466,486,435,255,480,455,432,520,195,,259,259,280,195,272,229,249,198,0,243,237,255,168,150,,,,177,,42019
Invokana (Withdrawn),canagliflozin ,Janssen ,Y,N,N,Y,N,N,N,N,N,,23-May-14,,CADTH,05-Jun-13,pre-NOC,Initial,"Diabetes mellitus, type 2 ",Withdrawn,07-Jun-13,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-352,,2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-350,,,,,,,,,41432
Istodax,romidepsin,Celgene ,N,Y,N,Y,Y,Y,Y,Y,N,,16-Oct-13,,CADTH & INESSS,01-Dec-14,post-NOC,New drug,Peripheral T-Cell Lymphoma,Completed,19-May-15,Cond'l on Cost,Conditional,,,New Drug,Peripheral T-Cell lymphoma ,Completed,24-Mar-16,Avis de refus d’inscription – À moins que certaines conditions soient respectées,Conditional,1st,02-Jun-15,16-Sep-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,EM,01-Feb-17,18-Dec-15,01-Oct-15,01-Jan-16,11-Jan-16,21-Jul-16,01-Feb-16,01-Feb-19,,24-Mar-16,01-Oct-15,01-Oct-15,8,2,1,3,4,7,5,9,,6,5.70%,10.20%,15.70%,47.90%,49.20%,77.80%,78.70%,99.00%,99.30%,,99.30%,24-Mar-16,01-Feb-17,411,,169,,14,-296,106,504,93,15,107,117,309,138,1234,,190,315,15,301,15,504,1204,793,715,807,817,1009,838,1934,,890,1015,1001,715,304,135,624,213,135,227,237,429,258,1354,,0,435,580,890,120,-190,1204,489,489,175,314,42143
Izba,travoprost ophthalmic solution,Novartis ,Y,N,N,N,N,N,N,N,N,,23-Sep-16,,CADTH & INESSS,01-Mar-17,post-NOC,Initial,open-angle glaucoma,Completed,25-Oct-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,Reduction of intraocular pressure in patients with open angle glaucoma or ocular hypertension,Completed,18-Oct-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,12-Apr-18,06-Dec-18,Negotiation,Completed with Agreements,NR,FB,FB,FB,LU,NR,FB,SA,FB,NR,,01-Mar-19,01-May-19,02-Mar-20,30-Apr-19,,03-Jun-20,27-Jun-22,20-Apr-21,,01-Mar-19,01-Mar-19,,1,3,4,2,,5,7,6,,4.50%,36.70%,42.40%,47.90%,49.20%,49.90%,50.30%,,,,50.30%,27-Jun-22,,159,182,238,208,169,176,238,,85,146,452,145,,545,1299,866,,505,85,505,85,,,889,950,1256,949,,1349,2103,1670,,1309,1309,889,730,492,,492,553,859,552,,952,1706,1273,,912,397,390,407,414,,,,1214,,43033
Jakavi,ruxolitinib,Novartis Pharmaceuticals Canada Inc,Y,N,N,N,N,N,N,N,Y,01-Mar-21,19-May-22,444,CADTH & INESSS,10-Aug-21,pre-NOC,Initial,Graft versus host disease,Completed,15-Sep-22,Reimburse with clinical criteria and/or conditions,Conditional,04-Mar-22,pre-NOC,New Indication,Graft versus host disease,Completed,07-Oct-22,Inscription - Avec conditions,Conditional,1st,06-Feb-23,,Active,n/a,UR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-282,-76,401,217,144,122,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,119,141,,,,,,,,563
Jakavi,ruxolitinib,Novartis Pharmaceuticals Canada Inc,Y,N,N,N,N,N,N,N,Y,01-Mar-21,19-May-22,444,CADTH & INESSS,10-Aug-21,pre-NOC,Initial,Graft versus host disease,Completed,15-Jul-22,Reimburse with clinical criteria and/or conditions,Conditional,04-Mar-22,pre-NOC,New Indication,Graft versus host disease,Completed,29-Jun-22,Inscription - Avec conditions,Conditional,1st,06-Feb-23,,Active,n/a,UR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-282,-76,339,117,206,222,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,57,41,,,,,,,,501
Jakavi,ruxolitinib,Novartis,Y,N,N,Y,Y,Y,Y,Y,N,,19-Jun-12,,CADTH & INESSS,25-Jun-12,post-NOC,New drug,Myelofibrosis,Completed,14-Jan-13,Cond'l on Cost,Conditional,,,New Drug,Myelofibrosis,Completed,01-Feb-13,Avis de refus à défaut d'une entente de partage de risque financier,Conditional,1st,01-Feb-13,03-Sep-13,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Nov-13,31-Oct-13,25-Nov-13,16-Apr-14,20-Sep-13,19-Dec-13,01-Oct-14,01-Sep-20,15-Jan-14,15-Mar-13,20-Sep-13,15-Mar-13,4,3,5,8,2,6,9,10,7,1,28.60%,60.80%,65.30%,85.50%,91.20%,92.10%,92.80%,98.30%,99.60%,100.00%,100.00%,20-Sep-13,01-Nov-13,6,,203,,18,0,214,59,58,83,225,17,107,393,2555,134,-172,403,17,346,-172,59,500,499,524,666,458,548,834,2996,575,269,844,787,458,452,249,291,290,315,457,249,339,625,2787,366,42,635,209,227,232,214,500,231,42,189,42,41288
Jakavi,ruxolitinib,Novartis,Y,N,N,N,Y,Y,Y,Y,N,,24-Nov-15,,CADTH & INESSS,27-Aug-15,pre-NOC,New indication,Polycythemia vera,Completed,03-Mar-16,Cond'l on Cost,Conditional,24-Nov-15,pre-NOC,New Indication,Polycythemia vera,Completed,19-Aug-16,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments-Médicament d'exception-À moins que certaines conditions soient respectées,Conditional,1st,30-Jun-16,08-Aug-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Apr-18,08-May-18,23-Feb-18,19-Oct-17,20-Nov-17,08-May-18,03-Sep-19,,01-Aug-19,15-Nov-17,19-Oct-17,19-Oct-17,5,6,4,1,3,7,9,,8,2,5.50%,34.10%,66.30%,72.10%,92.30%,96.80%,97.70%,98.30%,99.60%,,99.60%,20-Nov-17,01-Apr-18,-89,0,189,269,119,-50,404,236,273,199,72,104,273,756,,723,99,330,72,304,72,236,859,896,822,695,727,896,1379,,1346,722,953,927,695,784,595,759,796,722,595,627,796,1279,,1246,453,853,100,269,523,354,859,164,164,32,132,42432
Jardiance,empagliflozin,Boehringer Ingelheim ,N,N,N,Y,N,N,N,N,N,,23-Jul-15,,CADTH & INESSS,23-Apr-15,pre-NOC,Initial,Diabetes mellitus (Type 2),Completed,15-Oct-15,List with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New Drug,Diabetes mellitus (Type 2),Completed,01-Jun-16,Avis d'inscription aux listes des médicaments-Médicament d'exception-Avec conditions,Conditional,1st,03-Mar-16,13-Apr-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,27-May-19,01-Jun-16,01-May-16,21-Jul-16,31-May-16,07-Jul-16,01-Jul-16,24-Oct-16,02-May-16,03-Oct-16,01-May-16,01-May-16,10,4,1,7,3,6,5,9,2,8,5.70%,6.40%,38.60%,43.10%,44.40%,45.30%,50.80%,79.40%,79.70%,100.00%,100.00%,21-Jul-16,27-May-19,-91,124,175,190,140,-90,41,1139,49,18,99,48,85,79,194,19,173,192,18,190,18,1139,1404,314,283,364,313,350,344,459,284,438,457,455,283,374,199,1320,230,199,280,229,266,260,375,200,124,373,84,314,181,-49,1404,1121,1121,81,1040,42292
Jardiance,empagliflozin,Boehringer Ingelheim (Canada) Ltd.,N,N,N,N,N,N,N,N,N,01-Jan-21,29-Oct-21,301,CADTH & INESSS,06-Apr-22,post-NOC,Initial,Heart failure,Completed,14-Oct-22,Reimburse with clinical criteria and/or conditions,Conditional,25-Nov-22,post-NOC,New Indication,Heart failure,under review,TBD,TBD,TBD,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,159,392,191,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,350,,,,,,,,,651
Jardiance,empagliflozin,Boehringer Ingelheim ,N,N,N,N,N,N,N,N,N,,27-Jul-16,,CADTH & INESSS,27-Apr-16,pre-NOC,Initial,"Diabetes mellitus, type 2 with high cardiovascular risk",Completed,26-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,,,New Indication,Diabetes mellitus,Completed,03-Oct-16,Avis d'inscription aux listes des médicaments-Médicament d'exception-Avec conditions,Conditional,1st,19-Aug-16,11-Sep-18,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,,01-Jan-19,01-Jan-19,31-May-19,31-Oct-18,27-Feb-19,01-Jan-19,01-Aug-19,22-Oct-19,27-Sep-18,31-Oct-18,27-Sep-18,,3,4,7,2,6,5,8,9,1,28.60%,60.80%,65.30%,71.00%,72.30%,73.20%,78.70%,79.10%,79.70%,,79.70%,31-Oct-18,,-91,,182,,-68,-45,753,,112,112,262,50,169,112,324,406,16,193,50,174,16,,,888,888,1038,826,945,888,1100,1182,792,969,950,826,917,735,,797,797,947,735,854,797,1009,1091,724,878,91,68,685,708,,,,34,,42669
Jemperli,dostarlimab,GlaxoSmithKline ,N,Y,N,Y,Y,N,N,N,N,01-Apr-21,23-Dec-21,266,CADTH & INESSS,07-Oct-21,pre-NOC,Initial,Dostarlimab is indicated for monotherapy for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer (EC) that has progressed on or following prior treatment with a platinum containing regimen.,Completed,24-Aug-22,Do not Fund,Negative,22-Apr-22,post-NOC,New Drug,Dostarlimab is indicated for monotherapy for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer (EC) that has progressed on or following prior treatment with a platinum containing regimen.,Completed,02-Nov-22,Refus d’inscription,Negative,None,19-Oct-22,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-77,120,321,194,56,-14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,244,314,,,,,,,,510
Jentadueto,linagliptin-metformin ,Boehringer Ingelheim ,N,N,N,N,N,N,N,N,N,,07-Mar-13,,CADTH & INESSS,08-Mar-13,post-NOC,Initial,Diabetes mellitus (Type 2) ,Completed,17-Oct-13,List with criteria/condition,Conditional,04-Aug-13,post-NOC,New Drug,Type 2 diabetes mellitus,Completed,01-Oct-13,Ajout aux listes de médicaments - Médicament d'exception,Conditional,none,31-Jan-14,,Negotiation by Province,n/a,SA,SA,EDS,EDS,FB,NR,NR,SA,SA,EM,05-Aug-14,01-Dec-14,01-Apr-14,16-Oct-14,27-Mar-14,,,27-Jul-15,07-Mar-14,01-Oct-13,07-Mar-14,01-Oct-13,5,7,4,6,3,,,8,2,1,28.60%,29.30%,61.50%,67.20%,87.50%,93.00%,97.40%,97.80%,,,97.80%,27-Mar-14,05-Aug-14,1,150,223,58,106,122,,,,,,,,,,,,,,,,,516,634,390,588,385,,,872,365,208,536,495,365,364,141,292,410,166,364,161,,,648,141,0,312,224,208,,,516,308,151,177,131,41564
Jentadueto (2nd pCPA),linagliptin and linagliptin-metformin ,Boehringer Ingelheim ,N,N,N,N,N,N,N,N,N,,07-Mar-13,,CADTH & INESSS,08-Mar-13,post-NOC,Initial,Type 2 diabetes mellitus,Completed,17-Oct-13,List with criteria/condition,Conditional,04-Aug-13,post-NOC,New Drug,Type 2 diabetes mellitus,Completed,01-Oct-13,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,04-Sep-15,12-Apr-16,Negotiation,Completed with Agreements,,,,,,SA,EDS,,,,,,,,,28-Oct-16,02-May-16,,,,02-May-16,02-May-16,,,,,,2,1,,,,1.30%,2.20%,,,,,,,,,2.20%,,,1,150,223,58,687,703,221,,,,,,199,20,,,,110,20,110,20,,,,,,,1331,1152,,,,1242,1242,1152,1151,928,,,,,,1107,928,,,,1018,224,208,908,924,,,,,,41564
Jetrea,ocriplasmin,Alcon ,N,Y,N,Y,N,N,N,N,N,,13-Aug-13,,CADTH & INESSS,06-Jun-13,pre-NOC,Initial,Vitreomacular adhesion,Completed,20-Dec-13,List with criteria/condition,Conditional,,,New Drug,Vitreomacular adhesion,Completed,02-Jun-14,Avis de refus - Valeur thérapeutique,Negative,1st,04-Mar-14,10-Oct-14,Negotiation,Completed with Agreements,SA,RB,EDS,EDS,DL,SA,EDS,SA,SA,NR,27-Jan-15,01-Apr-15,01-Jan-15,20-Apr-15,27-Nov-14,06-Mar-15,29-Dec-14,23-Nov-15,01-Jan-15,,27-Nov-14,27-Nov-14,5,7,3,8,1,6,2,9,4,,32.20%,33.50%,39.30%,39.90%,60.20%,61.10%,65.50%,71.10%,71.40%,,71.40%,27-Jan-15,,-68,,197,,74,-90,220,109,173,83,192,48,147,80,409,83,,147,48,147,48,,532,596,506,615,471,570,503,832,506,,570,570,471,539,342,403,467,377,486,342,441,374,703,377,,441,129,293,294,130,,,,61,,41628
Jinarc (ADPKD),tolvaptan,Otsuka Pharmaceutical ,N,N,N,N,N,Y,N,Y,N,,25-Feb-15,,CADTH & INESSS,29-May-15,post-NOC,Initial,Autosomal dominant polycystic kidney disease (ADPKD),Completed,24-Feb-16,Do not list,Negative,04-Aug-15,post-NOC,New Drug,Autosomal dominant polycystic kidney disease (ADPKD),Completed,01-Feb-16,Avis de refus d'inscription aux listes de médicaments - Valeur thérapeutique,Negative,none,10-Jun-16,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,93,160,271,181,107,130,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,364,341,,,,,,,,42424
Jorveza,budesonide,AVIR Pharma ,N,N,N,N,N,N,N,N,N,01-May-19,06-Nov-19,189,CADTH & INESSS,08-Nov-19,post-NOC,Initial,"Eosinophilic esophagitis, adults",Completed,28-Oct-20,Reimburse with clinical criteria and/or conditions,Conditional,22-Nov-19,post-NOC,New Drug,Induction of remission of clinical pathology of adults with eosinophilc esophagitis,Completed,10-Jun-20,Inscription - Avec conditions,Conditional,1st,22-Oct-21,20-Jul-22,Negotiation,No agreement reached,NR,,NR,,,NR,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,2,16,355,201,359,499,271,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,357,217,630,770,,,,,,546
Jorveza,budesonide,AVIR Pharma Inc,N,N,N,N,N,N,N,N,N,01-May-20,16-Mar-21,319,CADTH & INESSS,05-Nov-20,pre-NOC,Initial,Maintenance of Eosinophilic esophagitis in adults,Completed,23-Aug-21,Reimburse with clinical criteria and/or conditions,Conditional,13-Nov-20,pre-NOC,New Indication,Maintenance of Eosinophilic esophagitis in adults,Completed,07-May-21,Inscription - Avec conditions,Conditional,1st,22-Oct-21,20-Jul-22,Negotiation,No agreement reached,NR,,NR,,,NR,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-131,-123,291,175,60,168,271,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,160,52,331,439,,,,,,479
Jublia,efinaconazole,Bausch Health (Valeant) ,N,N,N,Y,N,N,N,N,N,,02-Oct-13,,CADTH & INESSS,02-Aug-18,post-NOC,Initial,Onychomycosis,Completed,23-May-19,Do not reimburse,Negative,13-Aug-18,post-NOC,New Drug,Onychomycosis,Completed,13-Mar-19,Refus d’inscription,Negative,none,19-Jun-19,,Do Not Negotiate,n/a,,,NR,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,1765,1776,294,212,27,98,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2059,1988,,,,,,,,43608
Juluca,dolutegravir rilpivirine,ViiV Healthcare ,N,N,N,N,N,N,N,N,N,01-Jul-17,18-May-18,321,CADTH & INESSS,21-Dec-17,pre-NOC,Initial,HIV infection,Completed,20-Jun-18,Reimburse with clinical criteria and/or conditions,Conditional,01-Jan-18,pre-NOC,New Drug,HIV,Completed,05-Jul-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,03-Aug-18,13-Feb-19,Negotiation,Completed with Agreements,UR,UR,EDS,EDS,FB,SA,HIV,FB,SA,FB,,,01-Mar-20,22-Aug-19,30-Apr-19,07-Nov-19,01-Aug-19,27-May-19,29-Oct-19,11-Apr-19,30-Apr-19,11-Apr-19,,,8,5,2,7,4,3,6,1,28.60%,60.80%,61.20%,62.50%,68.00%,68.70%,69.60%,75.30%,,,75.30%,30-Apr-19,,-148,-137,181,185,44,29,194,,,382,190,76,267,169,103,258,57,206,76,188,57,,,,653,461,347,538,440,374,529,328,477,459,347,495,314,,,620,428,314,505,407,341,496,280,444,33,48,238,223,,,,19,,354
Juxtapid,lomitapide ,Aegerion Pharmaceuticals,N,N,N,Y,N,Y,N,Y,N,,04-Feb-14,,CADTH & INESSS,08-Jul-14,post-NOC,Initial,"Hypercholesterolemia, Homozygous Familial ",Completed,17-Apr-15,Do not list,Negative,22-Mar-14,post-NOC,New Drug,"Hypercholesterolemia, Homozygous Familial ",Completed,01-Oct-14,Avis de refus - Valeur thérapeutique,Negative,none,26-May-15,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,154,46,283,193,39,237,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,437,239,,,,,,,,42111
Kadcyla,trastuzumab emtansine,Hoffman-La Roche ,Y,Y,N,Y,Y,N,N,N,N,,11-Sep-13,,CADTH & INESSS,15-Mar-13,pre-NOC,New drug,Metastatic Breast Cancer,Completed,10-Jan-14,Cond'l on Cost,Conditional,24-Nov-13,post-NOC,New Drug,Metastatic Breast Cancer,Completed,02-Jun-14,Notice of Refusal to be Registered in Establishments - With Conditions,Conditional,1st,31-Jan-14,31-Mar-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-May-14,20-Jun-14,17-Apr-14,02-May-14,28-May-14,01-Oct-14,20-Nov-14,01-Aug-18,01-Apr-14,15-Jun-16,01-Apr-14,01-Apr-14,3,6,2,4,5,7,8,10,1,9,0.70%,6.40%,26.60%,32.20%,64.40%,68.90%,69.80%,71.10%,99.60%,100.00%,100.00%,28-May-14,15-Jun-16,-180,74,301,190,21,-122,59,31,81,17,32,58,184,234,1584,1,807,247,1,303,1,807,232,282,218,233,259,385,435,1785,202,1008,448,504,202,382,81,111,161,97,112,138,264,314,1664,81,744,327,121,264,80,-63,1008,806,806,57,749,41649
Kadcyla,trastuzumab emtansine,Hoffman-La Roche ,Y,Y,N,N,Y,N,N,N,Y,01-May-19,25-Nov-19,208,CADTH & INESSS,02-Jul-19,pre-NOC,New indication,"Early Breast Cancer (EBC): For the adjuvant treatment of patients with HER2-positive early breast cancer, who have residual disease, after pre-operative systemic treatment. ",Completed,22-Jan-20,Fund,Positive,19-Jul-19,pre-NOC,New Indication,Early Breast Cancer (EBC),Completed,05-Feb-20,Inscription - Avec conditions,Conditional,1st,21-May-20,05-Nov-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Under provincial consideration,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,01-May-21,31-Jan-23,01-Aug-21,,28-Feb-21,,,01-Apr-22,,16-Dec-20,28-Feb-21,16-Dec-20,3,6,4,,2,,,5,,1,28.60%,60.80%,81.10%,86.80%,87.10%,91.60%,,,,,91.60%,28-Feb-21,01-May-21,-146,-129,204,201,120,106,168,177,817,269,,115,,,512,,41,378,115,322,41,177,523,1163,615,,461,,,858,,387,724,668,461,607,403,465,1105,557,,403,,,800,,315,666,58,72,288,274,523,136,62,74,62,266
Kalydeco (CFTR G551D mutation),ivacaftor,Vertex Pharmaceuticals ,N,N,N,Y,N,Y,N,Y,N,,26-Nov-12,,CADTH & INESSS,27-Sep-12,pre-NOC,Initial,Cystic Fibrosis patients (G551D mutation),Completed,22-Mar-13,List with criteria/condition,Conditional,,,New Drug,CFTR G551D,Completed,03-Jun-13,Avis de refus,Negative,1st,31-Jan-14,16-Jun-14,Negotiation,Completed with Agreements,E,SA,EDS,EDS,EAP,SA,CF,SA,SA,EM,19-Mar-15,01-Jul-14,01-Sep-14,16-Oct-14,20-Jun-14,21-Nov-14,01-Oct-14,01-Aug-18,01-May-15,29-Sep-21,20-Jun-14,20-Jun-14,7,2,3,5,1,6,4,9,8,10,32.20%,36.70%,42.40%,43.70%,49.20%,50.10%,70.40%,71.10%,71.40%,100.00%,100.00%,21-Nov-14,29-Sep-21,-60,,176,,315,242,136,276,15,77,122,4,158,107,1507,319,2662,287,4,525,4,2662,843,582,644,689,571,725,674,2074,886,3229,854,1092,571,631,455,727,466,528,573,455,609,558,1958,770,3040,738,116,189,451,378,3229,2658,2658,154,2504,41355
Kalydeco (CFTR gating mutations),ivacaftor,Vertex Pharmaceuticals ,N,N,N,N,N,Y,N,Y,N,,06-Jun-14,,CADTH & INESSS,01-May-14,pre-NOC,Initial,Cystic Fibrosis (CFTR gating mutations),Completed,19-Dec-14,List with criteria/condition,Conditional,,,New Indication,CFTR non-G551D,Completed,01-Jun-15,Avis de refus - Valeur thérapeutique,Negative,1st,27-Jan-15,24-Oct-17,Negotiation,No agreement reached,E,NR,EDS,EDS,EAP,SA,CF,SA,SA,NR,13-Feb-20,,01-Jul-20,02-Mar-20,20-Dec-19,29-Jan-20,06-Feb-20,01-Nov-21,10-Sep-20,,20-Dec-19,20-Dec-19,4,,6,5,1,2,3,8,7,,32.20%,33.10%,34.40%,54.70%,60.20%,65.90%,66.60%,67.00%,,,67.00%,13-Feb-20,,-36,,232,,39,-125,1001,842,,981,860,787,827,835,1469,1052,,957,787,957,787,,2078,,2217,2096,2023,2063,2071,2705,2288,,2193,2193,2023,2059,1827,1882,,2021,1900,1827,1867,1875,2509,2092,,1997,196,360,1040,876,,,,55,,41992
Kalydeco (R117H CFTR gating mutation),ivacaftor,Vertex Pharmaceuticals ,N,N,N,N,N,Y,N,Y,N,,13-Mar-15,,CADTH,08-May-15,post-NOC,Initial,"Cystic Fibrosis, R117H CFTR gating mutation",Completed,19-Nov-15,List with criteria/condition,Conditional,,,,,,,,,1st,29-Mar-19,17-Jul-19,Negotiation,Completed with Agreements,E,SA,EDS,EDS,EAP,SA,CF,SA,SA,NR,13-Feb-20,01-Mar-20,01-Jul-20,02-Mar-20,20-Dec-19,29-Jan-20,06-Feb-20,01-Nov-21,10-Sep-20,,20-Dec-19,20-Dec-19,4,5,7,6,1,2,3,9,8,,32.20%,33.10%,34.40%,54.70%,59.10%,64.70%,70.40%,71.10%,71.40%,,71.40%,13-Feb-20,,56,,195,,1226,,110,211,228,350,229,156,196,204,838,421,,315,156,315,156,,1798,1815,1937,1816,1743,1783,1791,2425,2008,,1902,1902,1743,1687,1492,1547,1564,1686,1565,1492,1532,1540,2174,1757,,1651,251,,1336,,,,,55,,42327
Kanuma,sebelipase alfa,Alexion Pharmaceuticals,N,Y,N,Y,N,Y,Y,Y,N,01-Apr-17,15-Dec-17,258,CADTH & INESSS,02-Nov-17,pre-NOC,Initial,Lysosomal acid lipase deficiency,Completed,26-Sep-18,Reimburse with clinical criteria and/or conditions,Conditional,2019-06-07,post-NOC,New Drug,Lysosomal acid lipase deficiency,Completed,08-Jan-20,Refus d'inscription,Negative,1st,30-Nov-18,21-Oct-20,Negotiation,Completed with Agreements,UR,SA,UR,UR,UR,SA,EDS,UR,UR,NR,,01-Aug-21,,,,22-Apr-21,01-May-21,,,,22-Apr-21,22-Apr-21,,3,,,,1,2,,,,0.90%,2.20%,6.70%,,,,,,,,6.70%,,,-43,539,328,215,65,-404,691,,284,,,,183,192,,,,220,183,220,183,,,1325,,,,1224,1233,,,,1261,1261,1224,1267,939,,1040,,,,939,948,,,,976,285,754,756,287,,,,,,543
Kazano,alogliptin plus metformin,Takeda Canada Inc.,Y,N,N,N,N,N,N,N,N,,27-Nov-13,,CADTH & INESSS,30-Jan-14,post-NOC,Initial,Diabetes mellitus (Type 2),Completed,15-Jan-15,Do not list,Negative,22-Mar-14,post-NOC,New Drug,Type 2 diabetes,Completed,01-Oct-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,none,28-Jan-15,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,EM,,,,,,,,,,01-Oct-14,,01-Oct-14,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,64,115,350,193,13,119,,,,,,,,,,,,,,,,,,,,,,,,,,308,,308,,,,,,,,,,,,,0,,414,308,,,,,,,,42019
Kerendia,finerenone,Bayer Inc.,Y,N,N,Y,N,N,N,N,N,01-Dec-21,14-Oct-22,317,CADTH & INESSS,20-May-22,pre-NOC,Initial,Chronic kidney disease,Active,,Active,n/a,20-Jan-23,post-NOC,New Drug,Chronic kidney disease,under review,TBD,TBD,TBD,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-147,98,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44531
Kesimpta,ofatumumab,Novartis Pharmaceuticals Canada Inc.,Y,Y,N,N,N,N,N,N,Y,01-May-20,22-Jan-21,266,CADTH & INESSS,25-Aug-20,pre-NOC,Initial,"Multiple sclerosis, relapsing",Completed,25-Feb-21,Reimburse with clinical criteria and/or conditions,Conditional,25-Sep-20,pre-NOC,New Drug,Multple Sclerosis,Completed,03-Mar-21,Inscription - Avec conditions,Conditional,1st,27-Aug-21,02-Mar-22,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,,01-May-22,01-May-22,01-Jun-22,25-Mar-22,20-Jun-22,01-Sep-22,27-Mar-23,28-Nov-22,13-Apr-22,25-Mar-22,25-Mar-22,,3,4,5,1,6,7,9,8,2,32.20%,60.80%,65.30%,71.00%,76.50%,77.40%,78.70%,79.40%,79.70%,,79.70%,13-Apr-22,,-150,-119,184,159,183,177,187,,60,60,91,23,110,183,390,271,42,149,23,137,23,,,464,464,495,427,514,587,794,675,446,553,541,427,577,393,,430,430,461,393,480,553,760,641,406,519,34,40,370,364,,,,19,,300
Kevzara,sarilumab,Sanofi Genzyme,Y,Y,N,Y,N,N,N,N,N,01-Mar-16,12-Jan-17,317,CADTH & INESSS,12-Oct-16,pre-NOC,Initial,"Arthritis, Rheumatoid",Completed,18-Apr-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,rheumatoid arthritis,Completed,18-Oct-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,28-Jul-17,26-Oct-17,Negotiation,No agreement reached,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-92,71,188,208,101,-82,90,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,96,279,191,8,,,,,,413
Kevzara (2nd pCPA),sarilumab,Sanofi Genzyme,Y,Y,N,Y,N,N,N,N,N,01-Mar-16,12-Jan-17,317,CADTH & INESSS,12-Oct-16,pre-NOC,Initial,"Arthritis, Rheumatoid",Completed,18-Apr-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,rheumatoid arthritis,Completed,18-Oct-17,Avis de refus d'inscription aux listes des médicaments,Negative,2nd,14-Jun-18,26-Feb-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,30-Jun-20,01-Apr-19,01-Jun-19,22-Aug-19,09-Jul-19,26-Aug-19,12-Nov-20,22-Jul-19,04-Dec-19,11-Apr-19,01-Apr-19,01-Apr-19,9,1,3,6,4,7,10,5,8,2,4.50%,33.00%,38.80%,71.00%,71.40%,76.90%,77.80%,78.40%,98.70%,100.00%,100.00%,09-Jul-19,30-Jun-20,-92,71,188,208,422,239,257,490,34,95,177,133,181,625,146,281,44,240,34,221,34,490,1265,809,870,952,908,956,1400,921,1056,819,1015,996,809,901,713,1169,713,774,856,812,860,1304,825,960,540,919,96,279,679,496,1265,456,456,99,357,413
Keytruda,pembrolizumab,Merck ,Y,Y,N,Y,Y,Y,N,Y,N,,19-May-15,,CADTH & INESSS,16-Apr-15,pre-NOC,New drug,Metastatic melanoma,Completed,16-Nov-15,Cond'l on Cost,Conditional,22-Mar-15,pre-NOC,New Drug,Metastatic Melanom,Completed,19-Aug-16,Avis d'inscription à la Liste Établissements - Médicament d'exception - Avec conditions,Conditional,1st,08-Dec-15,10-Feb-16,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jun-16,15-Jul-16,20-May-16,30-May-16,02-Jun-16,02-Jun-16,02-Jun-16,01-Sep-16,02-Jun-16,16-Nov-15,20-May-16,16-Nov-15,4,9,2,3,5,6,7,10,8,1,28.60%,34.30%,39.80%,60.10%,92.30%,93.20%,94.50%,95.20%,99.60%,100.00%,100.00%,01-Jun-16,02-Jun-16,-33,-58,214,516,22,-255,64,112,156,100,110,113,113,113,204,113,-86,126,100,105,-86,113,379,423,367,377,380,380,380,471,380,181,393,372,367,400,186,198,242,186,196,199,199,199,290,199,-277,212,181,458,86,-191,380,199,13,198,1,42324
Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,N,,15-Apr-16,,CADTH & INESSS,21-Apr-16,post-NOC,New indication,"Lung, Non-Small Cell Lung Carcinoma (second Line or beyond)",Completed,03-Nov-16,Cond'l on Cost,Conditional,,,New Indication,"Lung, Non-Small Cell Lung Carcinoma (second Line or beyond)",Completed,16-Dec-16,Avis de refus d'ajout d'une indication reconnue à la Liste Établissements - Médicament d'exception,Negative,1st,30-Jan-17,01-Nov-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Feb-18,16-Feb-18,15-Dec-17,07-Dec-17,17-Jan-18,02-May-18,24-May-18,01-Aug-19,30-May-18,15-Nov-17,07-Dec-17,15-Nov-17,5,6,3,2,4,7,8,10,9,1,28.60%,34.10%,39.80%,72.10%,92.30%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,17-Jan-18,01-Feb-18,6,,196,,88,45,275,92,107,44,36,77,182,204,638,210,14,177,36,160,14,92,657,672,609,601,642,747,769,1203,775,579,742,725,601,595,399,455,470,407,399,440,545,567,1001,573,334,540,202,245,363,320,657,78,56,63,15,42677
Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,N,,12-Jul-17,,CADTH & INESSS,12-Dec-16,pre-NOC,New indication,Non-Small Cell Lung Carcinoma (First Line),Completed,23-Aug-17,Cond'l on Cost,Conditional,24-Mar-17,pre-NOC,New Indication,Non Small cell lung cancer (first line),Completed,18-Aug-17,Avis d'ajout d'une indication reconnue à la Liste Établissements - Médicament d'exception - Avec conditions,Conditional,1st,08-Sep-17,01-Nov-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Feb-18,16-Feb-18,07-Dec-17,15-Dec-17,17-Jan-18,02-May-18,24-May-18,01-Aug-19,30-May-18,15-Nov-17,07-Dec-17,15-Nov-17,5,6,2,3,4,7,8,10,9,1,28.60%,34.30%,39.80%,72.10%,92.30%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,17-Jan-18,01-Feb-18,-212,-110,254,147,16,21,54,92,107,36,44,77,182,204,638,210,14,177,36,160,14,92,204,219,148,156,189,294,316,750,322,126,289,272,148,360,106,162,177,106,114,147,252,274,708,280,89,247,42,37,70,75,204,78,56,63,15,42970
Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,Y,N,Y,N,01-Jan-17,08-Sep-17,250,CADTH & INESSS,07-Jul-17,pre-NOC,New indication,As monotherapy is indicated for the treatment of adult patients with refractory or relapsed classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) or who are not ASCT candidates and have failed BV,Completed,05-Jan-18,Cond'l on Cost,Conditional,,,New Indication,Recurrent or refractory classical Hodgkin lymphoma,Completed,01-Feb-18,Avis de refus d'ajout d'une indication reconnue à la Liste Établissements - Médicament d'exception,Negative,1st,10-Oct-18,15-Apr-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jun-20,15-Sep-20,01-May-20,01-May-20,04-Aug-20,16-Jul-20,01-May-20,,01-Jun-20,29-Apr-20,01-May-20,29-Apr-20,5,9,2,3,8,7,4,,6,1,28.60%,34.30%,39.80%,41.10%,61.40%,62.10%,63.00%,95.20%,99.60%,,99.60%,01-Jun-20,04-Aug-20,-63,,182,,278,251,553,47,153,16,16,111,92,16,,47,14,62,16,57,14,111,997,1103,966,966,1061,1042,966,,997,964,1012,1007,966,1029,847,878,984,847,847,942,923,847,,878,818,893,119,146,831,804,1061,97,95,33,64,369
Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,N,01-Mar-17,20-Sep-17,203,CADTH & INESSS,24-Jul-17,pre-NOC,New indication,Metastatic Urothelial Carcinoma,Completed,02-Mar-18,Cond'l on Cost,Conditional,,,New Indication,Metastatic Urothelial Carcinoma,Completed,11-Apr-18,Avis de refus d’ajout d’une indication reconnue à la Liste Établissements – Médicament d’exception,Negative,1st,27-Aug-18,15-Apr-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jun-20,01-Sep-20,01-May-20,22-Apr-20,24-Apr-20,16-Jul-20,01-May-20,,01-Jun-20,29-Apr-20,22-Apr-20,22-Apr-20,6,9,4,1,2,8,5,,7,3,5.50%,37.80%,66.30%,72.10%,73.40%,93.60%,94.30%,95.20%,99.60%,,99.60%,29-Apr-20,01-Jun-20,-58,,221,,178,138,597,47,139,16,7,9,92,16,,47,14,47,7,43,7,47,985,1077,954,945,947,1030,954,,985,952,985,981,945,1003,782,822,914,791,782,784,867,791,,822,749,822,163,203,775,735,985,40,40,7,33,366
Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,N,01-May-18,13-Mar-19,316,CADTH & INESSS,14-Sep-18,pre-NOC,New indication,Non-Squamous NSCLC,Completed,31-May-19,Cond'l on Cost,Conditional,20-Sep-18,pre-NOC,New Indication,Non-Squamous NSCLC,Completed,08-May-19,Inscription - Avec conditions,Conditional,1st,13-Aug-19,15-Apr-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jun-20,15-Sep-20,01-May-20,01-May-20,24-Apr-20,16-Jul-20,01-May-20,,01-Jun-20,29-Apr-20,24-Apr-20,24-Apr-20,6,9,3,4,1,8,5,,7,2,32.20%,60.80%,66.50%,72.10%,73.40%,93.60%,94.30%,95.20%,99.60%,,99.60%,29-Apr-20,01-Jun-20,-180,-174,259,230,74,97,246,47,153,16,16,9,92,16,,47,14,50,9,46,9,47,446,552,415,415,408,491,415,,446,413,449,445,408,588,329,367,473,336,336,329,412,336,,367,357,370,79,56,320,343,446,38,38,5,33,395
Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,Y,N,Y,N,01-Jun-18,02-Apr-19,305,CADTH & INESSS,13-Dec-18,pre-NOC,New indication,Melanoma Adjuvant Treatment,Completed,01-Aug-19,Cond'l on Cost,Conditional,05-Dec-18,pre-NOC,New Indication,Melanoma Adjuvant Treatment,Completed,05-Jun-19,Inscription - Avec conditions,Conditional,1st,13-Sep-19,15-Apr-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jun-20,15-Sep-20,01-May-20,04-May-20,04-Aug-20,16-Jul-20,01-May-20,,01-Jun-20,29-Apr-20,01-May-20,29-Apr-20,5,9,2,4,8,7,3,,6,1,28.60%,34.30%,35.60%,41.10%,61.40%,62.10%,63.00%,95.20%,99.60%,,99.60%,01-Jun-20,04-Aug-20,-110,-118,231,182,43,100,215,47,153,16,19,111,92,16,,47,14,63,16,57,14,111,426,532,395,398,490,471,395,,426,393,442,436,395,505,274,305,411,274,277,369,350,274,,305,329,321,121,64,258,315,490,97,95,33,64,426
Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,N,01-Oct-18,04-Jul-19,276,CADTH & INESSS,08-Feb-19,pre-NOC,New indication,Squamous NSCLC,Completed,03-Jan-20,Cond'l on Cost,Conditional,22-Feb-19,pre-NOC,New Indication,Squamous NSCLC,Completed,11-Sep-19,Inscription - Avec conditions,Conditional,1st,22-Jan-20,15-Apr-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jun-20,15-Sep-20,01-May-20,30-Apr-20,10-Jun-20,16-Jul-20,29-Apr-22,,01-Jun-20,29-Apr-20,30-Apr-20,29-Apr-20,4,8,3,2,6,7,9,,5,1,28.60%,34.10%,39.80%,60.10%,60.80%,93.00%,93.90%,98.30%,99.60%,,99.60%,01-Jun-20,10-Jun-20,-146,-132,329,201,19,133,84,47,153,16,15,56,92,744,,47,14,146,15,132,14,56,333,439,302,301,342,378,1030,,333,300,432,418,301,447,118,150,256,119,118,159,195,847,,150,231,249,183,69,103,217,342,42,41,33,9,459
Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,N,01-Sep-17,11-Apr-19,587,CADTH & INESSS,20-Feb-19,pre-NOC,New indication,Metastatic Urothelial Carcinoma (first line),Completed,03-Oct-19,Do not fund,Negative,01-Mar-19,pre-NOC,New Indication,Metastatic Urothelial Carcinoma (first line),Completed,07-Aug-19,Refus d'inscription,Negative,None,29-Nov-19,,Do Not Negotiate,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Not funded,Not funded,Not funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-50,-41,225,159,57,114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,175,118,,,,,,,,762
Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,N,01-Aug-18,16-Dec-19,502,CADTH & INESSS,02-Aug-19,pre-NOC,New indication,"For the treatment of patients with advanced renal cell carcinoma (RCC) in combination with axinitib, as first-line treatment.",Completed,02-Apr-20,Cond'l on Cost,Conditional,02-Jul-19,pre-NOC,New Indication,"For the treatment of patients with advanced renal cell carcinoma (RCC) in combination with axinitib, as first-line treatment.",Completed,04-Mar-20,Inscription - Avec conditions,Conditional,1st,11-May-20,01-Dec-20,Negotiation,Completed with Agreements,Funded,Funded,Under provincial consideration,Funded,Funded,Under provincial consideration,Funded,Funded,Under provincial consideration,EM,01-Mar-21,28-Feb-21,,21-Jan-21,31-Mar-21,,31-Mar-21,,,16-Dec-20,21-Jan-21,16-Dec-20,4,3,,2,5,,6,,,1,28.60%,34.10%,38.60%,58.80%,91.10%,92.40%,,,,,92.40%,01-Mar-21,31-Mar-21,-136,-167,244,246,39,68,204,90,89,,51,120,,120,,,15,94,51,81,15,120,441,440,,402,471,,471,,,366,445,432,402,538,294,333,332,,294,363,,363,,,287,337,108,79,243,272,471,105,69,75,30,610
Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,Y,01-Dec-19,09-Oct-20,313,CADTH & INESSS,01-May-20,pre-NOC,New indication,"First-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression [Combined Positive Score (CPS) ? 1] as determined by a validated test. First-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in combination with platinum and fluorouracil (FU) chemotherapy, in adult patients.",Completed,22-Dec-20,Cond'l on Cost,Conditional,29-May-20,pre-NOC,New Indication,Head and Neck Squamous Cell Carcinoma (HNSCC),Completed,02-Dec-20,Inscription - Avec conditions,Conditional,1st,10-Feb-21,10-Feb-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,01-Aug-21,31-Jul-21,01-Aug-21,28-Feb-23,30-Sep-21,,,,,03-Mar-21,31-Jul-21,03-Mar-21,3,2,4,6,5,,,,,1,28.60%,33.00%,53.30%,59.00%,91.20%,96.80%,,,,,96.80%,01-Aug-21,30-Sep-21,-161,-133,235,187,50,70,0,172,171,172,748,232,,,,,21,299,171,253,21,232,296,295,296,872,356,,,,,145,423,377,295,456,221,222,221,222,798,282,,,,,91,349,74,54,50,70,356,211,61,151,60,387
Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,Y,01-Jul-20,03-Mar-21,245,CADTH & INESSS,30-Nov-20,pre-NOC,Initial,For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC),Completed,27-Jul-21,Cond'l on Cost,Conditional,01-Jan-21,pre-NOC,New Indication,For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).,Completed,09-Jun-21,Inscription - Avec conditions,Conditional,1st,11-Aug-21,11-Aug-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,01-Feb-22,28-Feb-22,01-Dec-21,11-Jan-22,28-Feb-22,,,,,29-Sep-21,01-Dec-21,29-Sep-21,4,5,2,3,6,,,,,1,28.60%,34.30%,39.80%,60.10%,64.50%,96.80%,,,,,96.80%,01-Feb-22,28-Feb-22,-93,-61,239,159,15,63,0,174,201,112,153,201,,,,,49,168,112,148,49,201,335,362,273,314,362,,,,,210,329,309,273,366,127,189,216,127,168,216,,,,,112,183,146,98,15,63,362,152,89,125,27,391
Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,Y,N,Y,N,01-Jun-20,05-Feb-21,249,CADTH & INESSS,29-Jan-21,pre-NOC,Initial,"Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT",Completed,01-Nov-21,Cond'l on Cost,Conditional,23-Apr-21,post-NOC,New Indication,"Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT.",Completed,03-Nov-21,Inscription - Avec conditions,Conditional,1st,18-Nov-21,18-Nov-21,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,,,,01-Mar-23,31-Jan-23,,,,,15-Dec-21,31-Jan-23,15-Dec-21,,,,3,2,,,,,1,28.60%,60.80%,66.30%,,,,,,,,66.30%,31-Jan-23,,-7,77,276,194,17,15,0,,,,468,439,,,,,27,454,439,311,27,,,,,754,725,,,,,313,740,597,725,732,456,,,,485,456,,,,,42,471,269,271,17,15,,,,412,,518
Keytruda,pembrolizumab,Merck,Y,Y,N,N,Y,Y,N,Y,N,01-Dec-20,04-Jun-21,185,CADTH & INESSS,26-May-21,pre-NOC,Initial,"First-line treatment of locally advanced unresectable or metastatic, carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients.",Completed,20-Dec-21,Cond'l on Cost,Conditional,20-Aug-21,post-NOC,New Indication,"First-line treatment of locally advanced unresectable or metastatic, carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients.",Completed,02-Mar-22,Inscription - Avec conditions,Conditional,1st,11-Feb-22,11-Feb-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,01-Jul-22,31-May-22,01-Jun-22,28-Feb-23,31-Aug-22,,,,,13-Apr-22,31-May-22,13-Apr-22,4,2,3,6,5,,,,,1,28.60%,33.00%,38.80%,59.00%,91.20%,96.80%,,,,,96.80%,01-Jul-22,31-Aug-22,-9,77,208,194,53,-19,0,140,109,110,382,201,,,,,61,188,109,167,61,201,392,361,362,634,453,,,,,313,440,419,361,370,162,193,162,163,435,254,,,,,42,241,199,271,53,-19,453,140,92,79,61,384
Keytruda,pembrolizumab,Merck Canada,Y,Y,N,N,Y,N,N,N,N,01-Dec-21,18-Aug-22,260,CADTH & INESSS,03-Mar-22,pre-NOC,Initial,"Adjuvant treatment of adult patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.",Completed,29-Sep-22,Cond'l on Cost,Conditional,23-Sep-22,post-NOC,New Indication,"Adjuvant treatment of adult patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.",Completed,01-Mar-23,Refus d'inscription,Negative,1st,15-Dec-22,15-Dec-22,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,NR,,,,,31-Mar-23,,,,,,31-Mar-23,31-Mar-23,,,,,1,,,,,,32.20%,,,,,,,,,,32.20%,,,-168,36,210,159,77,-76,0,,,,,106,,,,,,106,106,106,106,,,,,,225,,,,,,225,225,225,393,183,,,,,183,,,,,,183,42,195,77,-76,,,,,,302
Keytruda,pembrolizumab,Merck Canada,Y,Y,N,N,Y,N,N,N,Y,01-Oct-21,12-Apr-22,193,CADTH & INESSS,17-Feb-22,pre-NOC,Initial,"Treatment of adult patients with early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery",Completed,31-Aug-22,Cond'l on Cost,Conditional,08-Jul-22,post-NOC,New Indication,"Treatment of adult patients with early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery",Completed,28-Dec-22,Avis de refus d’ajout d’une indication reconnue à la Liste Établissements – Médicament d’exception,Negative,1st,07-Oct-22,07-Oct-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,01-Feb-23,31-Jan-23,01-Mar-23,16-Mar-23,28-Feb-23,,,,,01-Mar-23,31-Jan-23,31-Jan-23,2,1,4,6,3,,,,,5,4.50%,24.70%,56.90%,62.70%,91.20%,96.80%,,,,,96.80%,28-Feb-23,01-Mar-23,-54,87,195,173,37,-82,0,117,116,145,160,144,,,,,145,136,116,138,116,145,295,294,323,338,322,,,,,323,314,316,294,348,153,154,153,182,197,181,,,,,63,173,141,260,37,-82,323,29,29,28,1,334
Keytruda,pembrolizumab,Merck Canada,Y,Y,N,N,Y,N,N,N,N,01-Jun-21,,,CADTH & INESSS,15-Dec-21,na,Initial,"Keytruda for adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy.",Completed,03-Feb-23,Cond'l on Cost,Conditional,01-Jan-21,,New Indication,"Keytruda for Adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy.",Completed,02-Nov-22,Inscription - Avec conditions,Conditional,1st,08-Mar-23,08-Mar-23,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,,,,,,,,,,01-Feb-23,,01-Feb-23,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,,,415,670,33,126,0,,,,,,,,,,-35,,,-35,-35,,,,,,,,,,,,,,,,,,,,,,,,,,91,,,,33,126,,,,,,612
Keytruda,pembrolizumab,Merck Canada,Y,Y,N,N,Y,Y,N,Y,N,01-Jan-22,05-Jul-22,185,CADTH & INESSS,26-Apr-22,pre-NOC,Initial,Pembrolizumab is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection.,Completed,04-Nov-22,Cond'l on Cost,Conditional,16-Dec-22,post-NOC,New Indication,Pembrolizumab is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection.,Under review,TBD,TBD,TBD,1st,08-Mar-23,08-Mar-23,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-70,164,192,,124,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,122,,124,,,,,,,307
Keytruda,pembrolizumab,Merck Canada Inc.,Y,Y,N,N,Y,N,N,N,N,01-Nov-21,07-Apr-22,157,CADTH & INESSS,20-May-22,post-NOC,Initial,"Pembrolizumab in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS=1) as determined by a validated test.",Completed,01-Dec-22,Cond'l on Cost,Conditional,16-Dec-22,post-NOC,New Indication,"Pembrolizumab in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS=1) as determined by a validated test.",Under review,TBD,TBD,TBD,1st,08-Mar-23,08-Mar-23,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,43,253,195,,97,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,238,,97,,,,,,,395
Keytruda,pembrolizumab,Merck Canada Inc.,Y,Y,N,N,Y,N,N,N,Y,01-Dec-20,17-Nov-21,351,CADTH & INESSS,20-Jun-22,post-NOC,Initial,"Pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumors express PD-L1 (Combined Positive Score [CPS] É¥ 10) as determined by a validated test",Completed,06-Jan-23,TBD,n/a,16-Dec-22,post-NOC,New Indication,"Pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumors express PD-L1 (Combined Positive Score [CPS] É¥ 10) as determined by a validated test",Under review,TBD,TBD,TBD,1st,08-Mar-23,08-Mar-23,Negotiation,Completed with Agreements,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,215,394,200,,61,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,415,,61,,,,,,,766
Keytruda and Lenvima,pembrolizumab and lenvatinib,Merck Canada,Y,Y,N,N,Y,N,N,N,N,01-Jun-21,,,CADTH & INESSS,15-Dec-21,na,Initial,"Keytruda for Adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy. Keytruda, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma who have disease progression following prior platinum-based systemic therapy in any setting and are not candidates for curative surgery or radiation.",Withdrawn,07-Mar-22,n/a,n/a,22-Apr-22,,New Indication,"Keytruda, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma who have disease progression following prior platinum-based systemic therapy in any setting and are not candidates for curative surgery or radiation.",Completed,02-Nov-22,Inscription - Avec conditions,Conditional,None,,,,,,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,82,194,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,279
Keytruda and Lenvima,pembrolizumab and lenvatinib,Merck Canada,Y,Y,N,N,Y,Y,N,Y,N,01-Jul-19,20-Sep-19,81,CADTH & INESSS,07-Mar-22,post-NOC,Initial,"Keytruda in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.",Completed,09-Sep-22,Cond'l on Cost,Conditional,22-Apr-22,post-NOC,New Indication,"Keytruda in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.",Completed,02-Nov-22,Inscription - Avec conditions,Conditional,1st,21-Oct-22,,Active,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,899,945,186,194,42,-12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1085,1139,,,,,,,,1166
Kimmtrak,tebentafusp,Medison Canada,N,N,N,Y,Y,Y,Y,Y,N,01-Dec-21,07-Jun-22,188,CADTH & INESSS,21-Apr-22,pre-NOC,Initial,For the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.,Completed,04-Jan-23,Cond'l on Cost,Conditional,16-Dec-22,post-NOC,New Drug,For the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.,Under review,TBD,TBD,TBD,None,,,Under consideration for negotiation,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-47,192,258,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,211,,,,,,,,,399
Kineret,anakinra,Swedish Orphan Biovitrum AB,N,Y,N,N/A,N,Y,N,Y,N,01-May-20,,,CADTH,21-Dec-20,na,Initial,"Still’s disease with active systemic features, in adults and pediatric patients aged 8 months and older with a body weight of 10 kg or above",Withdrawn,27-Oct-21,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,310,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,544
Kisqali,ribociclib,Novartis,Y,N,N,Y,Y,N,N,N,N,01-May-17,02-Mar-18,305,CADTH & INESSS,17-Oct-17,pre-NOC,New drug,"For the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as an initial endocrine-based therapy",Completed,18-Apr-18,Cond'l on Cost,Conditional,,,New Drug,Advanced or Metastatic Breast Cancer,Completed,06-Jun-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,17-Aug-18,26-Apr-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Oct-19,19-Nov-19,04-Nov-19,02-Mar-20,14-Aug-20,20-Jan-20,01-Nov-19,,,04-Jul-19,01-Oct-19,04-Jul-19,2,5,4,7,8,6,3,,,1,28.60%,48.80%,50.10%,55.90%,60.30%,61.20%,66.70%,99.00%,,,99.00%,01-Nov-19,14-Aug-20,-136,,183,,121,72,252,158,207,192,311,476,269,189,,,69,257,158,234,69,476,578,627,612,731,896,689,609,,,489,677,654,578,714,531,531,580,565,684,849,642,562,,,393,630,47,96,373,324,896,407,318,120,287,352
Kisqali,ribociclib,Novartis,Y,N,N,N,Y,N,N,N,N,01-Apr-19,07-Feb-20,312,CADTH & INESSS,26-Aug-19,pre-NOC,New indication,"In combination with an aromatase inhibitor (AI) and a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of pre/peri- menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy",Completed,04-Jun-20,Cond'l on Cost,Conditional,27-Sep-19,pre-NOC,New Indication,"In combination with an aromatase inhibitor (AI) and a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of pre/peri- menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy",Completed,14-May-20,Inscription- Avec conditions,Conditional,1st,22-Jun-20,14-Jul-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,Funded,EM,01-Feb-21,31-Jul-20,01-Aug-20,22-Oct-20,30-Apr-21,17-Sep-20,,12-Dec-22,31-Mar-23,19-Aug-20,31-Jul-20,31-Jul-20,6,1,2,5,7,4,,8,9,3,4.50%,10.20%,38.80%,39.70%,45.20%,65.40%,97.70%,98.00%,98.70%,,98.70%,01-Feb-21,30-Apr-21,-165,-133,283,230,18,39,22,202,17,18,100,290,65,,881,990,36,320,17,289,17,290,360,175,176,258,448,223,,1039,1148,194,478,447,175,340,57,242,57,58,140,330,105,,921,1030,97,360,118,97,40,61,448,273,273,185,88,430
Kisqali,ribociclib with fulvestrant,Novartis,Y,N,N,N,Y,N,N,N,N,01-Apr-19,07-Feb-20,312,CADTH & INESSS,26-Aug-19,pre-NOC,New indication,"+Fulvestrant for HR+, HER2- advanced or metastatic breast cancer",Completed,22-Apr-20,Cond'l on Cost,Conditional,11-Oct-19,pre-NOC,New Indication,"+Fulvestrant for HR+, HER2- advanced or metastatic breast cancer",Completed,14-May-20,Inscription - Avec conditions,Conditional,1st,11-May-20,14-Jul-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,Funded,EM,01-Feb-21,30-Apr-21,01-Aug-20,22-Oct-20,30-Apr-21,17-Sep-20,,12-Dec-22,31-Mar-23,19-Aug-20,01-Aug-20,01-Aug-20,5,6,1,4,7,3,,8,9,2,5.70%,34.30%,35.20%,40.70%,61.00%,65.40%,97.70%,98.00%,98.70%,,98.70%,01-Feb-21,30-Apr-21,-165,-119,240,216,19,-3,64,202,290,18,100,290,65,,881,990,36,355,18,319,18,290,360,448,176,258,448,223,,1039,1148,194,513,477,176,341,101,285,373,101,183,373,148,,964,1073,97,438,75,97,83,61,448,272,272,184,88,387
Komboglyze,saxagliptin + metformin ,Bristol-Myers Squibb & AstraZeneca ,Y,N,N,N,N,N,N,N,N,,02-Aug-13,,CADTH & INESSS,23-Aug-13,post-NOC,Initial,"Diabetes Mellitus, Type 2 ",Completed,20-Jun-14,List with criteria/condition,Conditional,04-Aug-13,post-NOC,New Drug,"Diabetes Mellitus, Type 2 ",Completed,01-Oct-13,Ajout aux listes de médicaments - Médicament d'exception,Conditional,none,30-Sep-14,,Negotiation by Province,n/a,SA,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,05-Aug-14,01-Apr-17,01-Jan-15,19-Jan-15,27-Nov-14,23-Jul-15,01-Apr-15,27-Jul-15,01-Jul-15,01-Oct-13,05-Aug-14,01-Oct-13,2,10,4,5,3,8,6,9,7,1,28.60%,48.80%,81.10%,86.80%,92.30%,93.60%,94.30%,95.20%,95.50%,100.00%,100.00%,27-Nov-14,27-Nov-14,21,2,301,58,102,364,,,,,,,,,,,,,,,,,368,1338,517,535,482,720,607,724,698,60,665,605,368,347,46,46,1016,195,213,160,398,285,402,376,0,343,322,60,,,482,422,114,422,0,41810
Komboglyze (Withdrawn),saxagliptin + metformin ,Bristol-Myers Squibb & AstraZeneca ,Y,N,N,N,N,N,N,N,N,,09-Jul-12,,CADTH,06-Jun-13,post-NOC,Initial,"Diabetes Mellitus, Type 2 ",Withdrawn,26-Jul-13,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,332,,50,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,382,,,,,,,,,41481
Korsuva,difelikefalin,Otsuka Canada Pharmaceutical Inc.,N,N,N,Y,N,N,N,N,N,01-Oct-21,16-Aug-22,319,CADTH,22-Sep-22,post-NOC,Initial,Chronic kidney disease,Active,,Active,n/a,,,,,,,,,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,37,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44470
Kymriah,tisagenlecleucel,Novartis,Y,N,N,N,Y,Y,Y,Y,N,01-May-22,19-Dec-22,232,CADTH,01-Feb-23,post-NOC,Initial,Treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of therapy.,Active,,TBD,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44682
Kynmobi,apomorphine hydrochloride,Sunovion Pharmaceuticals Canada Inc.,N,N,N,N,N,N,N,N,N,01-Aug-18,12-Jun-20,681,CADTH & INESSS,25-Jun-20,post-NOC,Initial,Parkinson's disease,Completed,24-Feb-21,Reimburse with clinical criteria and/or conditions,Conditional,26-Apr-19,pre-NOC,New drug,Parkinson’s disease,Completed,30-Dec-20,Inscription - Avec conditions,Conditional,1st,03-Sep-21,04-Apr-22,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,,SA,EM,27-Jun-22,01-Oct-22,01-Aug-22,20-Sep-22,15-Aug-22,20-Jun-22,01-Nov-22,,19-Aug-22,26-May-21,20-Jun-22,26-May-21,3,8,4,7,5,2,9,,6,1,28.60%,29.50%,49.70%,55.40%,87.70%,88.30%,93.90%,98.30%,99.60%,,99.60%,01-Aug-22,15-Aug-22,13,-413,244,614,191,247,213,84,180,119,169,133,77,211,,137,-313,139,77,89,-313,133,745,841,780,830,794,738,872,,798,348,800,750,738,725,481,488,584,523,573,537,481,615,,541,147,543,257,201,404,460,794,446,56,432,14,938
Kynmobi (Withdrawn),apomorphine hydrochloride,Sunovion Pharmaceuticals ,N,N,N,N,N,N,N,N,N,01-Aug-18,12-Jun-20,681,CADTH,25-Feb-19,pre-NOC,Initial,Parkinson's disease,Withdrawn,19-Jun-19,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-473,,114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-359,,,,,,,,,322
Kyprolis,carfilzomib,Amgen ,Y,N,N,N,Y,Y,Y,Y,N,,22-Nov-16,,CADTH & INESSS,09-Sep-16,pre-NOC,New indication,Multiple myeloma (relapsed),Completed,30-Mar-17,Cond'l on Cost,Conditional,24-Nov-16,post-NOC,New Drug,Multiple Myeloma ((with lenalidomide),Completed,01-Jun-17,Avis de refus d'inscription à la Liste Établissements,Negative,1st,02-Jun-17,08-Dec-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Apr-18,30-Oct-18,15-Aug-18,09-Mar-18,01-May-18,27-Sep-18,15-Oct-18,,03-Jul-18,05-Jul-18,09-Mar-18,09-Mar-18,2,9,6,1,3,7,8,,4,5,5.50%,25.80%,58.00%,58.70%,87.30%,93.00%,93.90%,95.20%,99.60%,,99.60%,01-May-18,05-Jul-18,-74,2,202,189,64,1,189,114,326,250,91,144,293,311,,207,209,217,91,216,91,209,495,707,631,472,525,674,692,,588,590,598,597,472,546,344,367,579,503,344,397,546,564,,460,399,470,128,191,253,190,590,118,118,53,65,42824
Kyprolis (with lenalidomide),carfilzomib (with lenalidomide),Amgen ,Y,N,N,Y,Y,Y,Y,Y,N,01-Jul-15,15-Jan-16,198,CADTH & INESSS,11-Dec-15,pre-NOC,New drug,Multiple Myeloma,Completed,11-Nov-16,Cond'l on Cost,Conditional,22-Mar-16,post-NOC,New Drug,Multiple Myeloma,Completed,03-Oct-16,Avis de refus d'inscription à la Liste Établissements,Negative,1st,14-Oct-16,08-Dec-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Apr-18,30-Oct-18,15-Aug-18,09-Mar-18,01-May-18,27-Sep-18,15-Oct-18,,03-Jul-18,05-Jul-18,09-Mar-18,09-Mar-18,2,9,6,1,3,7,8,,4,5,5.50%,25.80%,58.00%,58.70%,87.30%,93.00%,93.90%,95.20%,99.60%,,99.60%,01-May-18,05-Jul-18,-35,67,336,195,-28,11,420,114,326,250,91,144,293,311,,207,209,217,91,216,91,209,807,1019,943,784,837,986,1004,,900,902,910,909,784,819,483,506,718,642,483,536,685,703,,599,640,609,301,262,392,431,902,118,118,53,65,499
Lancora,ivabradine,Servier,N,N,N,Y,N,N,N,N,N,,23-Dec-16,,CADTH & INESSS,08-Nov-16,pre-NOC,Initial,"Heart failure, NYHA class II or III",Completed,24-May-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,treatment of heart failure,Completed,18-Oct-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,08-Dec-17,22-Aug-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,30-Oct-18,01-Dec-18,01-Oct-18,24-Jan-19,31-Oct-18,17-Dec-18,01-Jan-19,01-Aug-19,18-Dec-18,27-Sep-18,01-Oct-18,27-Sep-18,3,5,2,9,4,6,8,10,7,1,28.60%,34.30%,54.60%,86.80%,91.20%,92.10%,92.80%,94.10%,99.60%,100.00%,100.00%,30-Oct-18,31-Oct-18,-45,91,197,208,198,51,257,69,101,40,155,70,117,132,344,118,36,127,40,118,36,70,676,708,647,762,677,724,739,951,725,643,734,725,647,692,495,524,556,495,610,525,572,587,799,573,344,582,152,299,455,308,677,34,30,33,1,42879
Lapelga,pegfilgrastim,Apobiologix,N,Y,Y,N,N,N,N,N,N,01-Jun-17,05-Apr-18,308,CADTH & INESSS,23-Feb-18,pre-NOC,Initial,Febrile neutropenia,Completed,30-Apr-18,Not Applicable: Biosimilar,n/a,01-Feb-18,pre-NOC,New Drug,Neutropenia,Completed,08-Aug-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,10-Oct-18,28-Feb-19,Negotiation,Completed with Agreements,NR,SA,UR,UR,FB,SA,EDS,SA,SA,EM,,01-Jun-19,,,30-Aug-19,04-Jul-19,22-Apr-20,20-Dec-21,09-Sep-20,29-Apr-20,01-Jun-19,01-Jun-19,,1,,,3,2,4,7,6,5,4.50%,5.30%,37.60%,38.90%,67.50%,68.10%,68.50%,,,,68.50%,29-Apr-20,,-41,-63,66,188,163,63,141,,93,,,183,126,419,1026,559,426,401,93,405,93,,,422,,,512,455,748,1355,888,755,730,734,422,463,397,,397,,,487,430,723,1330,863,630,705,25,125,304,204,,,,333,,333
Lartruvo,olaratumab,Eli Lilly ,N,Y,N,N,Y,Y,Y,Y,N,01-Apr-17,23-Nov-17,236,CADTH & INESSS,26-Oct-17,pre-NOC,New indication,Advanced Soft Tissue Sarcoma (STS),Completed,18-Apr-18,Cond'l on Cost,Conditional,05-Dec-17,post-NOC,New Indication,Advanced Soft Tissue Sarcoma (STS),Completed,06-Jun-18,Avis de refus d'inscription à la Liste Établissements - Valeur thérapeutique,Negative,1st,26-Jul-18,31-Jan-19,Negotiation,No Agreement Reached,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-28,12,174,183,99,50,189,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,146,195,288,239,,,,,,382
Latuda,lurasidone,Sunovion Pharmaceuticals ,N,N,N,Y,N,N,N,N,N,,13-Jun-12,,CADTH & INESSS,03-Jul-12,post-NOC,Initial,schizophrenia,Completed,23-Jan-13,Do not list,Negative,,,New Drug,schizophrenia,Completed,01-Feb-13,Avis de refus - Valeur thérapeutique,Negative,none,31-Jan-14,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,20,,204,,373,364,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,224,233,,,,,,,,41297
Latuda (Resub),lurasidone,Sunovion Pharmaceuticals ,N,N,N,Y,N,N,N,N,N,,13-Jun-12,,CADTH & INESSS,09-May-13,post-NOC,Resubmission,Schizophrenia ,Completed,20-Dec-13,List with criteria/condition,Conditional,,,New Drug,schizophrenia,Completed,01-Oct-13,Avis de refus - Valeur thérapeutique,Negative,none,01-Apr-14,,Negotiation by Province,n/a,NR,FB,EDS,FB,FB,FB,EDS,SA,FB,EM,,01-Oct-14,01-Jul-15,16-Oct-14,29-May-14,25-Jun-14,20-May-14,27-Apr-15,28-Nov-14,01-Oct-14,20-May-14,20-May-14,,4,9,6,2,3,1,8,7,5,1.30%,33.50%,34.40%,38.90%,67.50%,73.00%,73.70%,74.00%,79.70%,,79.70%,01-Oct-14,,330,,225,,102,182,,,,,,,,,,,,,,,,,,840,1113,855,715,742,706,1048,898,840,865,862,706,376,151,,285,558,300,160,187,151,493,343,365,310,555,475,,,,,,134,,41628
Ledaga,chlormethine hydrochloride,Recordati Rare Diseases Canada Inc.,N,N,N,Y,Y,N,Y,Y,N,01-Aug-20,08-Jun-21,311,CADTH & INESSS,21-Dec-20,pre-NOC,Initial,Topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients,Completed,24-Nov-21,Do Not Fund,Negative,23-Apr-21,pre-NOC,New Drug,Topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients,Completed,08-Oct-21,Inscription - Avec conditions,Conditional,1st,21-Oct-22,27-Jan-23,Negotiation,No Agreement Reached,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Not funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,01-May-22,,,,,,,,,,01-May-22,01-May-22,1,,,,,,,,,,20.30%,,,,,,,,,,20.30%,,,-169,-46,338,168,331,378,98,-271,,,,,,,,,,-271,-271,-271,-271,,327,,,,,,,,,,327,327,327,496,158,158,,,,,,,,,,158,169,122,429,476,,,,,,480
Lemtrada,alemtuzumab ,Sanofi Genzyme,Y,Y,N,N,N,N,N,N,N,,12-Dec-13,,CADTH & INESSS,27-Nov-14,post-NOC,Initial,relapsing remitting multiple sclerosis,Completed,18-Jun-15,List with criteria/condition,Conditional,22-Mar-14,post-NOC,New Drug,relapsing remitting multiple sclerosis,Completed,01-Oct-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,28-Jul-15,11-May-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,NR,EM,06-Feb-18,01-Sep-16,01-Jul-16,21-Jul-16,06-Jul-16,24-Aug-16,01-Dec-16,07-Aug-17,,01-Oct-14,01-Jul-16,01-Oct-14,9,6,2,4,3,5,7,8,,1,28.60%,34.30%,66.50%,72.10%,73.00%,77.40%,78.70%,79.10%,99.30%,,99.30%,06-Jul-16,06-Feb-18,350,100,203,193,40,300,288,636,113,51,71,56,105,204,453,,-588,211,51,122,-588,636,1517,994,932,952,937,986,1085,1334,,293,1092,1003,932,582,379,964,441,379,399,384,433,532,781,,0,539,553,293,328,588,1517,1224,585,644,580,42173
Lemtrada (Withdrawn),alemtuzumab,Sanofi Genzyme,Y,Y,N,N,N,N,N,N,N,,12-Dec-13,,CADTH,01-Oct-13,pre-NOC,Initial,"Multiple Sclerosis, relapsing",Withdrawn,13-Aug-14,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-72,,316,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,244,,,,,,,,,41864
Lenvima,lenvatinib,Eisai Ltd.,N,N,N,Y,Y,Y,Y,Y,N,,22-Dec-15,,CADTH & INESSS,18-Apr-16,post-NOC,New drug,Differentiated Thyroid Cancer,Completed,20-Sep-16,Cond'l on Cost,Conditional,22-Mar-16,post-NOC,New Drug,Differentiated Thyroid Cancer,Completed,03-Oct-16,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions: 10mg & 14mg----Avis de refus d'inscription aux listes des médicaments: 20mg & 24 mg,Conditional,1st,04-Apr-17,16-Jun-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Oct-17,28-Nov-17,02-Aug-17,19-Oct-17,12-Sep-17,15-Dec-17,09-Apr-18,20-Feb-23,10-May-18,18-Aug-17,02-Aug-17,02-Aug-17,4,6,1,5,3,7,8,10,9,2,5.70%,34.30%,66.50%,86.80%,92.30%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,12-Sep-17,01-Oct-17,118,91,155,195,196,183,73,107,165,47,125,88,182,297,2075,328,63,379,47,348,47,107,649,707,589,667,630,724,839,2617,870,605,921,890,589,471,316,376,434,316,394,357,451,566,2344,597,319,648,273,286,269,256,649,60,60,41,19,42633
Lenvima,lenvatinib,Eisai Ltd.,N,N,N,N,Y,N,N,N,N,01-Nov-16,13-Sep-17,316,CADTH & INESSS,08-Jun-18,post-NOC,New indication,Renal Cell Carcinoma (RCC),Completed,04-Jan-19,Do Not Fund,Negative,01-Aug-18,post-NOC,New Indication,Renal Cell Carcinoma (RCC),Completed,09-Jan-19,Refus d’inscription,Negative,None,31-Jan-19,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,268,322,210,161,27,22,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,478,483,,,,,,,,794
Lenvima,lenvatinib,Eisai Ltd.,N,N,N,N,Y,Y,Y,Y,N,01-Feb-18,19-Dec-18,321,CADTH & INESSS,08-Feb-19,post-NOC,New indication,Hepatocellular Carcinoma,Completed,24-Jul-19,Cond'l on Cost,Conditional,15-Mar-19,post-NOC,New Indication,Hepatocellular Carcinoma,Completed,11-Sep-19,Inscription - Avec conditions,Conditional,1st,27-Sep-19,08-Nov-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jul-20,10-Apr-20,01-Mar-20,02-Apr-20,05-Mar-20,16-Jul-20,29-Apr-22,12-Jul-21,02-Sep-20,18-Dec-19,01-Mar-20,18-Dec-19,6,5,2,4,3,7,10,9,8,1,28.60%,34.30%,66.50%,72.10%,76.50%,96.80%,97.70%,98.30%,98.70%,100.00%,100.00%,05-Mar-20,01-Jul-20,51,86,166,180,65,16,42,236,154,114,146,118,251,903,612,299,40,315,114,287,40,236,560,478,438,470,442,575,1227,936,623,364,639,611,438,387,221,343,261,221,253,225,358,1010,719,406,98,422,217,266,107,58,560,196,122,78,118,538
Lenvima and Keytruda,lenvatinib and pembrolizumab,Eisai ,N,N,N,N,Y,N,N,N,Y,01-Jun-21,04-May-22,337,CADTH & INESSS,15-Nov-21,pre-NOC,Initial,"Lenvatinib, in combination with pembrolizumab, for the treatment of adult patients with advanced or metastatic RCC with no prior systemic therapy for metastatic RCC.",Completed,23-Jun-22,Cond'l on Cost,Conditional,03-Dec-21,pre-NOC,New Indication,"Lenvatinib, in combination with pembrolizumab, for the treatment of adult patients with advanced or metastatic RCC with no prior systemic therapy for metastatic RCC.",Completed,27-Jul-22,Inscription - Avec conditions,Conditional,1st,21-Oct-22,,Active,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-170,-152,220,236,120,86,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50,84,,,,,,,,387
Leqvio,inclisiran,Novartis Pharmaceuticals Canada Inc.,Y,N,N,Y,N,N,N,N,N,01-Sep-20,26-Jul-21,328,CADTH & INESSS,17-Mar-21,pre-NOC,Initial,Primary hypercholesterolemia,Completed,07-Feb-22,Do not reimburse,Negative,06-Aug-21,post-NOC,New Drug,"ndicated in adults with primary hypercholesterolemia (heterozygous familial and non-familial), as an adjunct to diet: • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach low density lipoprotein cholesterol (LDL-C) goals with the tolerated dose of a statin or, • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.",Completed,29-Dec-21,Inscription - Avec conditions (hypercholestérolémie familiale hétérozygote),Conditional,none,,,,,NR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-131,11,327,145,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,196,156,,,,,,,,524
Libtayo,cemiplimab,Sanofi Genzyme,Y,Y,N,Y,Y,N,N,N,N,01-Aug-18,10-Apr-19,252,CADTH & INESSS,09-Jul-19,post-NOC,New drug,Cutaneous Squamous Cell Carcinoma,Completed,22-Jan-20,Cond'l on Cost,Conditional,09-Aug-19,post-NOC,New Drug,Cutaneous Squamous Cell Carcinoma,Completed,04-Mar-20,Inscription - Avec conditions,Conditional,1st,08-Jun-20,04-Nov-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,,Under provincial consideration,EM,01-Feb-21,30-Apr-21,01-Jan-21,24-Nov-21,28-Feb-21,,,,,16-Dec-20,01-Jan-21,16-Dec-20,3,5,2,6,4,,,,,1,28.60%,34.30%,54.60%,86.80%,91.20%,96.80%,,,,,96.80%,01-Feb-21,28-Feb-21,90,121,197,208,138,96,149,89,177,58,385,116,,,,,42,165,58,145,42,116,663,751,632,959,690,,,,,616,739,719,632,542,345,376,464,345,672,403,,,,,287,452,287,329,287,245,690,74,58,47,27,539
Libtayo,cemiplimab,Sanofi Genzyme,Y,Y,N,N,Y,N,N,N,N,01-Dec-20,26-Oct-21,329,CADTH & INESSS,19-Aug-21,pre-NOC,Initial,For the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI).,Completed,04-Mar-22,Cond'l on Cost,Conditional,31-Dec-21,post-NOC,New Indication,For the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI).,Completed,01-Jun-22,Refus d’inscription,Negative,1st,03-Oct-22,,Active,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-68,66,197,152,213,124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,129,218,,,,,,,,458
Libtayo,cemiplimab,Sanofi Genzyme,Y,Y,N,N,Y,N,N,N,N,01-Dec-20,26-Oct-21,329,CADTH & INESSS,13-Oct-21,pre-NOC,Initial,"For the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ? 50% of tumour cells (Tumour Proportion Score [TPS] ? 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.",Completed,02-Jun-22,Cond'l on Cost,Conditional,13-May-22,post-NOC,New Indication,"For the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ? 50% of tumour cells (Tumour Proportion Score [TPS] ? 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.",Completed,02-Nov-22,Inscription - Avec conditions,Conditional,1st,03-Oct-22,,Active,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-13,199,232,173,123,-30,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,219,372,,,,,,,,548
Livtencity,maribavir,Takeda,Y,N,N,Y,N,Y,Y,Y,N,01-Mar-22,15-Sep-22,198,CADTH & INESSS,31-Mar-22,pre-NOC,Initial,Post-transplant cytomegalovirus infection,Completed,04-Nov-22,Reimburse with clinical criteria and/or conditions,Conditional,25-Nov-22,post-NOC,New Drug,CMV infection,under review,TBD,TBD,TBD,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-168,71,218,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50,,,,,,,,,248
Lixiana NVAF,edoxaban,Daiichi Sankyo,N,N,N,Y,N,N,N,N,N,01-Dec-15,04-Nov-16,339,CADTH & INESSS,09-Sep-16,pre-NOC,Initial,"Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism",Completed,21-Mar-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,Prevention of stroke and the systemic embolic event in people with atrial fibrilation,Completed,18-Oct-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,20-Jul-18,05-Feb-19,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,LU,FB,EDS,SA,SA,EM,,01-Mar-19,01-Apr-19,31-May-19,30-Apr-19,04-Jul-19,01-Jun-19,22-Jul-19,01-May-19,07-Mar-19,01-Mar-19,01-Mar-19,,1,3,6,4,8,7,9,5,2,4.50%,33.00%,38.80%,71.00%,71.70%,77.20%,78.50%,79.40%,79.70%,,79.70%,30-Apr-19,,-56,140,193,208,486,275,200,,24,55,115,84,149,116,167,85,30,99,24,92,24,,,847,878,938,907,972,939,990,908,853,922,915,847,903,710,,710,741,801,770,835,802,853,771,505,785,137,348,686,475,,,,60,,476
Lixiana VTE,edoxaban,Daiichi Sankyo,N,N,N,Y,N,N,N,N,N,01-Dec-15,04-Nov-16,339,CADTH & INESSS,09-Sep-16,pre-NOC,Initial,"Venous thromboembolism, treatment and recurrence prevention",Completed,25-May-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,Treatment of venous thromboembolism,Completed,18-Oct-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,20-Jul-18,05-Feb-19,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,LU,FB,EDS,SA,SA,EM,,01-Mar-19,01-Apr-19,31-May-19,30-Apr-19,04-Jul-19,01-Jun-19,22-Jul-19,01-May-19,07-Mar-19,01-Mar-19,01-Mar-19,,1,3,6,4,8,7,9,5,2,4.50%,33.00%,38.80%,71.00%,71.70%,77.20%,78.50%,79.40%,79.70%,,79.70%,30-Apr-19,,-56,140,258,208,421,275,200,,24,55,115,84,149,116,167,85,30,99,24,92,24,,,847,878,938,907,972,939,990,908,853,922,915,847,903,645,,645,676,736,705,770,737,788,706,505,720,202,348,621,475,,,,60,,541
Lokelma,sodium zirconium cyclosilicate,AstraZeneca,Y,N,N,Y,N,N,N,N,Y,01-Sep-18,25-Jul-19,327,CADTH & INESSS,16-May-19,pre-NOC,Initial,"Hyperkalemia, adults",Completed,25-Mar-20,Do not reimburse,Negative,07-Jun-19,pre-NOC,New Drug,Hyperkalemia,Completed,08-Jan-20,Refus d'inscription,Negative,none,16-Apr-20,,Do Not Negotiate,n/a,NR,,NR,,,NR,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-70,-48,314,215,22,99,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,244,167,,,,,,,,571
Lonsurf,trifluridine and tipiracil,Taiho Pharma,N,N,N,Y,Y,N,N,N,N,01-Jul-17,25-Jan-18,208,CADTH & INESSS,06-Nov-17,pre-NOC,New drug,Metastatic Colorectal Cancer,Completed,06-Jul-18,Do Not Fund,Negative,,,New Drug,CRC,Completed,06-Jun-18,Avis de refus d'inscription aux listes des médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,30-May-19,08-Aug-19,Negotiation,Completed with Agreements,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,EM,,,,,,,,,,15-Aug-19,,15-Aug-19,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,-80,,242,,328,358,70,,,,,,,,,,7,,,7,7,,,,,,,,,,,567,,567,,,,,,,,,,,,,435,,162,132,398,428,,,,,,370
Lonsurf,trifluridine and tipiracil,Taiho Pharma,N,N,N,N,Y,Y,N,Y,N,01-May-19,19-Nov-19,202,CADTH & INESSS,03-Sep-19,pre-NOC,New indication,Gastric Cancer,Completed,24-Mar-20,Cond'l on Cost,Conditional,11-Oct-19,pre-NOC,New Indication,Gastric Cancer,Completed,14-May-20,Inscription - Avec conditions,Conditional,1st,07-Jul-20,11-Jan-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,EM,01-Mar-21,28-Feb-21,01-Feb-21,01-Apr-21,30-Sep-21,24-Feb-21,30-May-21,23-Jan-23,,03-Mar-21,01-Feb-21,01-Feb-21,4,3,1,6,8,2,7,9,,5,5.70%,6.60%,11.10%,31.30%,59.90%,65.40%,66.70%,99.00%,99.30%,,99.30%,03-Mar-21,30-Sep-21,-77,-39,203,216,105,54,188,49,48,21,80,262,44,139,742,,51,173,21,160,21,262,468,467,440,499,681,463,558,1161,,470,592,579,440,517,314,342,341,314,373,555,337,432,1035,,293,466,126,177,293,242,681,241,241,30,211,328
Lonsurf (resubmission),trifluridine and tipiracil,Taiho Pharma,N,N,N,Y,Y,N,N,N,N,01-Jul-17,25-Jan-18,208,CADTH & INESSS,21-Jan-19,post-NOC,Resubmission,Metastatic Colorectal Cancer,Completed,29-Aug-19,Do Not Fund,Negative,,,New Drug,CRC,Completed,06-Jun-18,Avis de refus d'inscription aux listes des médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,None,18-Oct-19,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,EM,,,,,,,,,,15-Aug-19,,15-Aug-19,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,361,,220,,50,499,,,,,,,,,,,,,,,,,,,,,,,,,,567,,567,,,,,,,,,,,,,435,,581,132,,,,,,,,789
Lorbrena,lorlatinib,Pfizer,Y,N,N,Y,Y,Y,N,Y,N,01-Jun-18,22-Feb-19,266,CADTH & INESSS,11-Jun-19,post-NOC,New drug,"For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on: crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or alectinib.",Completed,30-Jan-20,Do Not Fund,Negative,14-Jun-19,post-NOC,New Drug,Non-Small Cell Lung Cancer (NSCLC),Completed,08-Jan-20,Refus d'inscription,Negative,None,21-Apr-20,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not Funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,109,112,233,208,82,104,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,342,320,,,,,,,,608
Lorbrena,lorlatinib,Pfizer,Y,N,N,Y,Y,Y,N,Y,Y,01-Jan-21,07-Jun-21,157,CADTH & INESSS,18-Jun-21,post-NOC,Initial,Monotherapy for use in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,Completed,17-Mar-22,Cond'l on Cost,Conditional,24-Sep-21,post-NOC,New Indication,Monotherapy for use in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,Completed,30-Mar-22,Inscription - Avec conditions,Conditional,1st,08-Jun-22,26-Aug-22,Negotiation,No Agreement Reached,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,11,109,272,187,83,70,79,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,283,296,162,149,,,,,,440
Lorbrena,lorlatinib,Pfizer,Y,N,N,Y,Y,Y,N,Y,Y,01-Jan-21,07-Jun-21,157,CADTH & INESSS,18-Jun-21,post-NOC,Initial,Monotherapy for use in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,Completed,17-Mar-22,Cond'l on Cost,Conditional,24-Sep-21,post-NOC,New Indication,Monotherapy for use in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,Completed,30-Mar-22,Inscription - Avec conditions,Conditional,2nd ,20-Mar-23,,Active,n/a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,11,109,272,187,368,355,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,283,296,,,,,,,,440
Lucentis (myopic CNV),ranibizumab,Novartis ,Y,Y,N,N,N,N,N,N,N,,28-Jan-14,,CADTH & INESSS,28-Feb-14,post-NOC,Initial,"Choroidal neovascularisation, myopic",Completed,19-Feb-15,List with criteria/condition,Conditional,22-Mar-14,post-NOC,New Indication,"Choroidal neovascularisation, myopic",Completed,01-Oct-14,Ajout d'une indication reconnue - Médicament d'exception,Conditional,none,31-May-15,,Negotiation by Province,n/a,BCRDT,NR,EDS,,LU,NR,,SA,NR,EM,,,01-Jul-15,,29-Jul-15,,,01-Aug-18,,01-Oct-14,01-Jul-15,01-Oct-14,,,2,,3,,,4,,1,28.60%,34.30%,66.50%,66.90%,,,,,,,66.90%,29-Jul-15,,31,53,356,193,101,242,,,,,,,,,,,,,,,,,,,519,,547,,,1646,,246,904,740,519,488,132,,,132,,160,,,1259,,0,517,387,246,,,,,,301,,42054
Lumakras,sotorasib,Amgen Canada,Y,N,N,Y,Y,Y,N,Y,N,01-Feb-21,10-Sep-21,221,CADTH & INESSS,19-Aug-22,post-NOC,Initial,Treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy,Suspended,,TBD,n/a,24-Mar-23,post-NOC,New Drug,Treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy,Suspended,TBD,TBD,TBD,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,343,560,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44228
Lutathera,lutetium (177LU) oxodotreotide,Advanced Accelerator Applications,N,N,N,Y,Y,Y,Y,Y,N,01-Jul-18,09-Jan-19,192,CADTH,30-Jul-18,pre-NOC,New drug,Gastroenteropancreatic neuroendocrine tumours (GEP-NETs),Completed,01-Aug-19,Cond'l on Cost,Conditional,,,,,,,,,1st,26-Sep-19,30-Dec-19,Negotiation,No Agreement Reached,Funded,Under provincial consideration,Funded,Funded,Funded,Not funded,Funded,Under provincial consideration,Under provincial consideration,EM,01-Mar-21,,01-Jun-21,01-Feb-22,08-Oct-20,,01-Aug-20,,,30-Sep-20,01-Aug-20,01-Aug-20,4,,5,6,3,,1,,,2,1.30%,29.90%,62.10%,82.40%,88.10%,93.60%,,,,,93.60%,08-Oct-20,01-Mar-21,-163,,367,,56,,95,427,,519,764,283,,215,,,275,442,215,414,215,427,782,,874,1119,638,,570,,,630,797,769,570,733,366,578,,670,915,434,,366,,,,593,204,,151,,782,212,212,68,144,396
Lutathera,lutetium (177LU) oxodotreotide,Advanced Accelerator Applications,N,N,N,Y,Y,Y,Y,Y,N,01-Jul-18,09-Jan-19,192,CADTH,30-Jul-18,pre-NOC,New drug,Gastroenteropancreatic neuroendocrine tumours (GEP-NETs),Completed,01-Aug-19,Cond'l on Cost,Conditional,,,,,,,,,2nd,26-Feb-20,29-Jul-20,Negotiation,Completed with Agreements,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-163,,367,,209,,154,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,204,,363,,,,,,,396
Lutathera,lutetium (177LU) oxodotreotide,Advanced Accelerator Applications (AAA),N,N,N,N,Y,Y,Y,Y,Y,01-Jul-18,09-Jan-19,192,CADTH & INESSS,23-Mar-22,post-NOC,Initial,"For the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults with progressive disease.",Completed,28-Sep-22,Cond'l on Cost,Conditional,,,New Indication,"For the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults with progressive disease.",Completed,13-Feb-19,Inscription - Avec conditions,Conditional,None,,,Under consideration for negotiation,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,,,,,,,,,,30-Sep-20,,30-Sep-20,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,1169,,189,,,,,,,,,,,,,,,,,,,,,,,,,,,,,630,,630,,,,,,,,,,,,,595,,1358,35,,,,,,,,1550
Luxturna ,voretigene neparvovec,Novartis Pharmaceuticals Canada Inc.,Y,Y,N,Y,N,Y,Y,Y,Y,01-Dec-19,13-Oct-20,317,CADTH & INESSS,23-Apr-20,pre-NOC,Initial,"Vision loss, inherited retinal dystrophy",Completed,12-Nov-20,Reimburse with clinical criteria and/or conditions,Conditional,08-May-20,pre-NOC,New Drug,Hereditary Retinal Dystrophy,Completed,02-Dec-20,Inscription - Avec conditions,Conditional,1st,25-Nov-21,16-Sep-22,Negotiation,Completed with Agreements,UR,,,,,,NR,,,EM,,,,,,,,,,28-Sep-22,,28-Sep-22,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,-173,-158,203,208,378,358,295,,,,,,,,,,12,,,12,12,,,,,,,,,,,715,,715,,,,,,,,,,,,,665,,30,50,673,653,,,,,,347
Lynparza,olaparib,AstraZeneca ,Y,N,N,Y,Y,Y,Y,Y,N,01-Jun-15,29-Apr-16,333,CADTH & INESSS,01-Apr-16,pre-NOC,New drug,"Ovarian Cancer:As monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy",Completed,29-Sep-16,Do Not Fund,Negative,,,New Drug,"As monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy",Completed,05-Sep-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,None,30-Nov-16,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,EM,,,,,,,,,,27-Sep-18,,27-Sep-18,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,-28,,181,,62,-644,,,,,,,,,,,,,,,,,,,,,,,,,,881,,881,,,,,,,,,,,,,22,,153,859,,,,,,,,486
Lynparza,olaparib,AstraZeneca ,Y,N,N,N,Y,Y,Y,Y,Y,01-Nov-18,06-May-19,186,CADTH & INESSS,18-Apr-19,pre-NOC,New indication,"Newly Diagnosed Ovarian Cancer: As monotherapy for the maintenance treatment of adult patients with newly diagnosed advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Completed,05-Dec-19,Cond'l on Cost,Conditional,10-May-19,post-NOC,New Indication,"Newly Diagnosed Ovarian Cancer: As monotherapy for the maintenance treatment of adult patients with newly diagnosed advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Completed,06-Nov-19,Inscription - Avec conditions,Conditional,1st,18-Jun-20,21-Oct-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Nov-20,28-Feb-21,01-Jan-21,21-Jan-21,31-Oct-22,22-Apr-21,31-Jan-21,12-Dec-22,01-Mar-23,16-Dec-20,01-Nov-20,01-Nov-20,1,6,3,4,8,7,5,9,10,2,20.30%,48.80%,54.60%,60.10%,61.40%,65.90%,66.70%,99.00%,99.30%,100.00%,100.00%,01-Jan-21,31-Oct-22,-18,4,231,180,196,225,125,11,130,72,92,740,183,102,782,861,56,330,11,303,11,740,545,664,606,626,1274,717,636,1316,1395,590,864,837,545,563,332,332,451,393,413,1061,504,423,1103,1182,406,651,213,184,321,350,1274,729,729,61,668,399
Lynparza,olaparib,AstraZeneca Canada ,Y,N,N,N,Y,N,N,N,Y,01-Jan-22,27-Jul-22,207,CADTH & INESSS,03-Aug-22,post-NOC,Initial,"Lynparza (olaparib) is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must have confirmation of a germline BRCA mutation before Lynparza treatment is initiated",Completed,01-Mar-23,Cond'l on Cost,Conditional,30-Sep-22,post-NOC,New Indication,"Lynparza (olaparib) is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must have confirmation of a germline BRCA mutation before Lynparza treatment is initiated",Under review,TBD,TBD,TBD,None,,,Under consideration for negotiation,n/a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,7,65,210,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,217,,,,,,,,,424
Lynparza ,olaparib,AstraZeneca ,Y,N,N,N,Y,N,N,N,N,01-Feb-20,21-Aug-20,202,CADTH & INESSS,22-Sep-20,post-NOC,New indication,As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene mutations (germline and/or somatic) who have progressed following prior treatment with a new hormonal agent (NHA),Completed,21-Apr-21,Cond'l on Cost,Conditional,16-Oct-20,post-NOC,New Indication,Metastatic Castration-Resistant Prostate Cancer (mCRPC),Completed,07-May-21,Inscription - Avec conditions et Refus d'inscription,Conditional,1st,07-Jul-21,17-Jan-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-May-22,28-Feb-22,01-May-22,01-Jun-22,30-Oct-21,01-Jul-22,01-Sep-22,12-Dec-22,28-Feb-23,13-Apr-22,30-Oct-21,30-Oct-21,4,2,5,6,1,7,8,9,10,3,32.20%,36.70%,65.30%,85.50%,91.20%,96.80%,97.70%,99.00%,99.30%,100.00%,100.00%,13-Apr-22,01-May-22,32,56,211,203,77,61,194,104,42,104,135,-79,165,227,329,407,86,159,-79,152,-79,104,618,556,618,649,435,679,741,843,921,600,673,666,435,403,192,375,313,375,406,192,436,498,600,678,341,430,243,259,271,255,618,183,183,165,18,445
Lynparza (resubmission),olaparib,AstraZeneca ,Y,N,N,Y,Y,Y,Y,Y,N,01-Jun-15,29-Apr-16,333,CADTH & INESSS,17-Mar-17,post-NOC,Resubmission,"Ovarian Cancer:As monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy",Completed,20-Sep-17,Cond'l on Cost,Conditional,19-Aug-17,post-NOC,New Drug,Ovarian (monotherapy maintenance treatment of patients with platinum-sensitive relapsed BRCA-mutated cancer),Completed,15-Dec-17,Add to Exception drug,Conditional,1st,10-Oct-17,15-May-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Sep-18,04-Sep-18,15-Nov-18,18-Oct-18,20-Aug-18,17-Dec-18,01-Apr-19,12-Dec-22,01-Aug-19,05-Jul-18,20-Aug-18,05-Jul-18,3,4,6,5,2,7,8,10,9,1,28.60%,60.80%,81.10%,85.50%,91.10%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,20-Aug-18,01-Sep-18,322,477,187,118,20,-66,217,109,112,184,156,97,216,321,1672,443,51,368,97,336,51,109,855,858,930,902,843,962,1067,2418,1189,797,1114,1082,843,521,334,346,349,421,393,334,453,558,1909,680,202,605,509,595,237,151,855,58,12,46,12,842
MAR-Trientine,Trientine Hydrochloride,Marcan Pharmaceuticals Inc.,N,N,N,N,N,Y,N,Y,N,01-Nov-19,14-Sep-20,318,CADTH & INESSS,19-Apr-21,post-NOC,Initial,Wilson's Disease,Completed,11-Nov-21,Reimburse with clinical criteria and/or conditions,Conditional,06-Aug-21,post-NOC,New drug,Wilson's Disease,Completed,29-Dec-21,Inscription - Avec conditions,Conditional,1st,07-Dec-21,25-Mar-22,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,,,EM,17-May-22,01-May-22,01-May-22,20-Sep-22,25-Mar-22,25-Jul-22,01-Sep-22,,,26-May-21,25-Mar-22,26-May-21,5,3,4,8,2,6,7,,,1,28.60%,60.80%,65.30%,71.00%,91.20%,92.10%,93.40%,99.00%,,,99.00%,25-Mar-22,17-May-22,217,326,206,145,26,-22,108,53,37,37,179,0,122,160,,,-303,84,0,36,-303,53,610,594,594,736,557,679,717,,,254,641,593,557,340,134,187,171,171,313,134,256,294,,,-217,218,423,471,134,86,610,356,53,303,53,741
Mavenclad,cladribine ,EMD Serono ,N,N,N,N,N,N,N,N,N,01-Feb-17,30-Nov-17,302,CADTH & INESSS,01-Dec-17,post-NOC,Initial,"Multiple Sclerosis, relapsing",Completed,24-Oct-18,Reimburse with clinical criteria and/or conditions,Conditional,01-Jan-18,post-NOC,New Drug,Multiple Sclerosis,Completed,05-Jul-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,14-Feb-19,22-Nov-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,NR,25-Jan-22,01-Jun-20,01-Jul-20,22-Oct-20,28-Apr-20,23-Apr-20,31-Jul-20,20-Feb-23,22-Dec-20,,23-Apr-20,23-Apr-20,8,3,4,6,2,1,5,9,7,,0.90%,33.10%,37.60%,43.30%,44.60%,50.10%,50.80%,71.10%,71.40%,,71.40%,22-Oct-20,,1,32,327,185,113,224,281,795,192,222,335,158,153,252,1186,396,,410,153,410,153,,1517,914,944,1057,880,875,974,1908,1118,,1132,1132,875,874,547,1189,586,616,729,552,547,646,1580,790,,804,328,217,394,505,,,,182,,630
Maviret,glecaprevir pibrentasvir,AbbVie ,Y,N,N,Y,N,N,N,N,N,01-Feb-17,16-Aug-17,196,CADTH & INESSS,09-Jun-17,pre-NOC,Initial,"Hepatitis C, chronic",Completed,23-Jan-18,Reimburse with clinical criteria and/or conditions,Conditional,17-Aug-17,post-NOC,New Drug,Hepatitis C,Completed,01-Mar-18,Avis d’inscription aux listes des médicaments – Médicament d’exception (Patients naïfs ou expérimentés à un traitement à base d’interféron ou de sofosbuvir) Avis d’inscription aux listes des médicaments – Médicament d’exception – Avec conditions (Patients expérimentés à un inhibiteur de la protéine NS5A ou un inhibiteur de la protéase NS3/4A),Conditional,1st,29-Jun-18,19-Dec-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,NR,SA,EM,29-Jan-19,01-Apr-19,01-Apr-19,31-May-19,28-Feb-19,16-May-19,01-May-19,,18-Dec-19,01-Feb-19,29-Jan-19,29-Jan-19,1,4,5,8,3,7,6,,9,2,20.30%,48.80%,81.10%,85.50%,91.20%,92.60%,93.40%,99.00%,99.60%,,99.60%,28-Feb-19,28-Feb-19,-68,1,228,196,157,120,173,41,103,103,163,71,148,133,,364,44,141,41,130,41,71,531,593,593,653,561,638,623,,854,534,631,620,531,599,371,371,433,433,493,401,478,463,,694,337,471,160,197,330,293,561,30,30,30,0,356
Mayzent,siponimod,Novartis ,Y,N,N,Y,N,N,N,N,Y,01-Feb-19,20-Feb-20,384,CADTH & INESSS,26-Sep-19,pre-NOC,Initial,Secondary progressive multiple sclerosis,Completed,21-Jul-20,Reimburse with clinical criteria and/or conditions,Conditional,25-Oct-19,pre-NOC,New Drug,Progressive secondary multiple sclerosis,Completed,14-May-20,Inscription - Avec conditions,Conditional,1st,27-Apr-21,22-Oct-21,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,25-Jan-22,01-Dec-21,01-Mar-22,24-Feb-22,25-Mar-22,24-Mar-22,27-Jun-22,27-Mar-23,05-Apr-22,15-Dec-21,01-Dec-21,01-Dec-21,3,1,5,4,7,6,9,10,8,2,4.50%,33.00%,53.30%,58.80%,64.50%,65.40%,97.70%,98.30%,99.60%,100.00%,100.00%,25-Jan-22,25-Mar-22,-147,-118,299,202,280,348,178,95,40,130,125,154,153,248,521,165,54,181,40,169,40,154,705,650,740,735,764,763,858,1131,775,664,791,779,650,797,498,553,498,588,583,612,611,706,979,623,580,639,152,84,458,526,764,114,114,55,59,536
MDK-nitisinone,nitisinone,MendeliKABS Inc,N,N,N,Y,N,N,N,N,N,01-Mar-16,20-Sep-16,203,CADTH & INESSS,29-Sep-17,post-NOC,Initial,Hereditary tyrosinemia type 1,Completed,25-Apr-18,Reimburse with clinical criteria and/or conditions,Conditional,04-Sep-17,post-NOC,New Drug,hereditary Type 1 tyrosinemia,Completed,01-Feb-18,Avis d'inscription à la Liste Établissements - Médicament d'exception - Avec conditions,Conditional,1st,20-Aug-18,28-Nov-18,Negotiation,Completed with Agreements,E,SA,NR,EDS,NR,SA,NR,NR,UR,EM,26-Feb-19,01-Feb-19,,31-May-19,,19-Dec-19,,,,01-Feb-18,01-Feb-19,01-Feb-18,3,2,,4,,5,,,,1,28.60%,33.00%,53.30%,58.80%,59.70%,,,,,,59.70%,26-Feb-19,,374,349,208,150,117,200,100,90,65,,184,,386,,,,-300,181,65,85,-300,,889,864,,983,,1185,,,,499,980,884,864,490,282,307,282,,401,,603,,,,0,398,582,499,217,300,,,,390,,785
Mekinist,trametinib,GlaxoSmithKline,Y,N,N,Y,Y,Y,N,Y,N,,18-Jul-13,,CADTH & INESSS,06-May-13,pre-NOC,New drug,Metastatic Melanoma,Completed,22-Oct-13,Cond'l on Cost,Conditional,01-Nov-13,post-NOC,New Drug,BRAF+ metastatic melanoma,Completed,03-Feb-14,Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable,Conditional,1st,18-Nov-13,25-Jun-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Dec-16,18-Oct-16,15-Sep-14,16-Oct-14,19-Aug-14,03-Oct-14,01-Sep-16,29-Oct-18,01-Aug-14,03-Feb-14,01-Aug-14,03-Feb-14,9,8,4,6,3,5,7,10,2,1,28.60%,29.30%,61.50%,67.20%,68.10%,73.60%,74.90%,79.40%,99.60%,100.00%,100.00%,19-Aug-14,01-Dec-16,-73,106,169,94,27,-77,219,890,846,82,113,55,100,799,1587,37,-142,501,37,437,-142,890,1232,1188,424,455,397,442,1141,1929,379,200,843,779,379,452,283,1136,1092,328,359,301,346,1045,1833,283,0,747,96,200,246,142,1232,1032,853,197,835,41569
Mictoryl,propiverine hydrochloride,Duchesnay ,N,N,N,Y,N,N,N,N,N,01-Mar-16,05-Jan-17,310,CADTH & INESSS,14-Oct-16,pre-NOC,Initial,Overactive bladder (OAB),Completed,19-Apr-17,Reimburse with clinical criteria and/or conditions,Conditional,19-Aug-17,post-NOC,New Drug,Overactive bladder (OAB),Completed,01-Feb-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,30-Aug-17,12-Feb-18,Negotiation,No agreement reached,NR,NR,NR,NR,NR,NR,NR,,NR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-83,226,187,166,133,-155,166,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,104,392,299,11,,,,,,414
Mictoryl (ped),propiverine hydrochloride,Duchesnay,N,N,N,Y,N,N,N,N,N,01-Mar-16,05-Jan-17,310,CADTH & INESSS,14-Oct-16,pre-NOC,Initial,"Overactive bladder (OAB), pediatric",Completed,19-Apr-17,Reimburse with clinical criteria and/or conditions,Conditional,19-Aug-17,post-NOC,New Drug,"Overactive bladder (OAB), pediatric",Completed,01-Feb-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,30-Aug-17,12-Feb-18,Negotiation,Completed with Agreements,NR,RB,EDS,EDS,LU,SA,EDS,SA,SA,EM,,01-Jun-18,01-Jul-18,19-Jul-18,31-May-18,11-Jun-18,31-Jul-20,25-Oct-21,12-Sep-18,24-May-18,31-May-18,24-May-18,,3,5,6,2,4,8,9,7,1,28.60%,60.80%,65.30%,66.20%,71.90%,77.40%,78.10%,79.40%,79.70%,,79.70%,31-May-18,,-83,226,187,166,133,-155,166,,109,139,157,108,119,900,1351,212,101,387,108,355,101,,,512,542,560,511,522,1303,1754,615,504,790,758,511,594,407,,408,438,456,407,418,1199,1650,511,112,686,104,392,299,11,,,,7,,414
Mifegymiso,mifepristone and misoprostol,Celopharma ,N,N,N,Y,N,N,N,N,N,,29-Jul-15,,CADTH,07-Oct-16,post-NOC,Initial,Medical termination of pregnancy,Completed,18-Apr-17,Reimburse,Positive,,,,,,,,,1st,21-Apr-17,05-Jul-17,Negotiation,Completed with Agreements,FB,FB,FB,FB,FB,FB,EDS,FB,FB,FB,25-Jul-17,24-Jul-17,05-Sep-17,20-Jul-17,10-Aug-17,07-Jul-17,01-Nov-17,08-Nov-17,01-Sep-18,15-Dec-17,07-Jul-17,07-Jul-17,4,3,6,2,5,1,7,8,10,9,0.90%,6.40%,10.90%,31.10%,63.40%,69.10%,70.40%,70.70%,99.30%,100.00%,100.00%,10-Aug-17,15-Dec-17,436,,193,,3,,75,20,19,62,15,36,2,119,126,423,163,91,2,99,2,163,727,726,769,722,743,709,826,833,1130,870,798,806,709,273,80,98,97,140,93,114,80,197,204,501,,169,629,,78,,870,161,161,34,127,42843
Mifegymiso (Withdrawn),mifepristone and misoprostol,Celopharma ,N,N,N,Y,N,N,N,N,N,,29-Jul-15,,CADTH,12-Feb-16,post-NOC,Initial,Medical termination of pregnancy (gestational age up to 49 days),Withdrawn,26-Jul-16,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,198,,165,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,363,,,,,,,,,42577
Minjuvi,tafasitamab,Incyte,N,Y,N,Y,Y,Y,Y,Y,N,01-Dec-20,19-Aug-21,261,CADTH & INESSS,19-Nov-21,post-NOC,Initial,"Tafasitamab is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT).",Completed,29-Sep-22,Do not Fund,Negative,01-Jul-22,post-NOC,New Drug,"Tafasitamab is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT).",Completed,30-Nov-22,Inscription - Avec conditions,Conditional,None,02-Nov-22,,Do Not Negotiate,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,92,316,314,152,34,-28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,406,468,,,,,,,,667
Monoferric,Iron (III) Isomaltoside 1000,Pharmacosmos A/S,N,N,N,Y,N,N,N,N,N,01-Jul-16,22-Jun-18,721,CADTH & INESSS,26-Jun-19,post-NOC,Initial,Iron deficiency anemia,Completed,25-Mar-20,Reimburse with clinical criteria and/or conditions,Conditional,20-Apr-18,pre-NOC,New Drug,Iron deficiency anemia,Completed,17-Oct-18,Inscription,Positive,1st,21-Jul-20,02-Feb-21,Negotiation,Completed with Agreements,SA,SA,,EDS,LU,SA,EDS,,SA,FB,06-Oct-21,01-May-21,,01-Jun-22,26-Feb-21,22-Apr-21,21-Mar-22,,29-Dec-21,15-Nov-18,26-Feb-21,15-Nov-18,5,4,,8,2,3,7,,6,1,28.60%,60.80%,61.70%,66.20%,86.40%,87.10%,88.40%,93.90%,,,93.90%,26-Feb-21,06-Oct-21,369,-63,273,180,118,643,196,246,88,,484,24,79,412,,330,-810,238,24,107,-810,246,1202,1044,,1440,980,1035,1368,,1286,146,1194,1063,980,611,338,560,402,,798,338,393,726,,644,29,552,642,117,314,839,1202,1056,222,834,222,1363
Monoprost ,latanoprost ,Laboratoires Théa,N,N,N,N,N,N,N,N,N,,07-Jul-16,,CADTH & INESSS,25-Oct-17,post-NOC,Initial,Glaucoma and ocular hypertension,Completed,24-Apr-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,Glaucoma or ocular hypertension,Completed,09-May-18,Avis de refus d'inscription aux listes des médicaments,Negative,1st,28-Sep-18,28-Aug-19,Negotiation,No agreement reached,NR,UR,NR,UR,UR,UR,UR,UR,UR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,475,,181,,157,142,334,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,656,671,491,476,,,,,,43214
Mounjaro,tirzepatide,Eli Lilly Canada Inc.,Y,N,N,Y,N,N,N,N,N,01-Feb-22,24-Nov-22,296,CADTH,12-Aug-22,pre-NOC,Initial,"Diabetes mellitus, type 2",Received,,Received,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-104,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44593
Movapo,apomorphine hydrochloride,Paladin Labs ,N,N,N,N,N,N,N,N,N,,22-Nov-16,,CADTH & INESSS,06-Jul-17,post-NOC,Initial,Parkinson's disease,Completed,23-Jan-18,Reimburse with clinical criteria and/or conditions,Conditional,19-Aug-17,post-NOC,New Drug,Parkinson,Completed,01-Feb-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,29-Jun-18,27-Mar-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,UR,SA,EM,26-Nov-19,01-Jun-19,01-May-19,22-Aug-19,22-Aug-19,26-Aug-19,01-May-19,,20-Jan-21,23-May-19,01-May-19,01-May-19,8,4,1,5,6,7,2,,9,3,5.70%,7.00%,35.60%,40.10%,45.60%,77.80%,78.70%,99.00%,99.60%,,99.60%,22-Aug-19,26-Nov-19,226,270,201,166,157,148,271,244,66,35,148,148,152,35,,665,57,187,35,172,35,244,1099,921,890,1003,1003,1007,890,,1520,912,1042,1027,890,664,463,672,494,463,576,576,580,463,,1093,476,615,427,436,428,419,1099,209,209,113,96,43123
Mvasi,bevacizumab,Amgen ,Y,Y,Y,Y,Y,N,N,N,N,01-Feb-17,30-Apr-18,453,CADTH & INESSS,03-Oct-18,post-NOC,New drug,Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar,Completed,14-Jan-19,n/a,n/a,,,New Drug,Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar,Completed,13-Feb-19,Inscription - Avec conditions,Conditional,1st,28-Feb-19,08-Jul-19,Negotiation,Completed with Agreements,Funded,Under provincial consideration,Funded,Under provincial consideration,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,01-Nov-19,,27-Jan-20,,19-Aug-19,,,01-Oct-19,,14-Nov-19,19-Aug-19,19-Aug-19,3,,5,,1,,,2,,4,32.20%,32.60%,52.80%,81.40%,87.10%,,,,,,87.10%,01-Nov-19,14-Nov-19,156,,103,,45,15,130,116,,203,,42,,,85,,129,112,42,115,42,129,550,,637,,476,,,519,,563,546,549,476,320,217,291,,378,,217,,,260,,274,287,259,289,175,145,563,87,87,74,13,712
Myinfla,colchicine,"Pendopharm, a division of Pharmascience Inc.",N,N,N,N,N,N,N,N,Y,01-Feb-21,23-Aug-21,203,CADTH & INESSS,28-May-21,pre-NOC,Initial,"	Atherothrombotic events in coronary artery disease",Completed,08-Mar-22,Do not reimburse,Negative,20-Aug-21,pre-NOC,New Drug,Reduce atherosclerotic events,Completed,04-Feb-22,Refus d'inscription,Negative,none,03-May-22,,Do Not Negotiate,n/a,NR,,NR,,,NR,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-87,-3,284,168,56,88,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,197,165,,,,,,,,400
Mylotarg,gemtuzumab ozogamicin,Pfizer,Y,Y,N,Y,Y,Y,Y,Y,Y,01-Feb-19,28-Nov-19,300,CADTH & INESSS,09-Aug-19,pre-NOC,New drug,"Acute Myeloid Leukemia:In combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of adult patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia",Completed,02-Apr-20,Fund,Positive,27-Sep-19,pre-NOC,New Drug,"Acute Myeloid Leukemia:In combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of adult patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia",Completed,08-Apr-20,Inscription - Avec conditions,Conditional,1st,17-Jun-20,12-Aug-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,01-Feb-21,31-Oct-22,01-Jan-21,13-Sep-22,30-Nov-21,,,,,30-Sep-20,01-Jan-21,30-Sep-20,3,6,2,5,4,,,,,1,28.60%,34.30%,54.60%,86.80%,92.30%,96.80%,,,,,96.80%,01-Feb-21,30-Nov-21,-111,-62,237,194,76,70,56,173,810,142,762,475,,,,,49,472,142,402,49,475,431,1068,400,1020,733,,,,,307,730,660,400,511,274,305,942,274,894,607,,,,,175,604,126,132,132,126,733,426,333,124,302,426
Myrbetriq,mirabegron,Astellas Pharma,N,N,N,Y,N,N,N,N,N,,06-Mar-13,,CADTH & INESSS,27-Nov-13,post-NOC,Initial,"Bladder, overactive",Completed,12-Nov-14,List with criteria/condition,Conditional,,,New Drug,"Bladder, Overactive ",Completed,03-Feb-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,14-Jan-15,08-Apr-15,Negotiation,Completed with Agreements,NR,SA,EDS,FB,LU,SA,EDS,SA,SA,EM,,01-Sep-15,01-Jul-15,22-Jul-15,28-May-15,14-Oct-15,29-Jun-15,26-Mar-18,01-Oct-15,03-Feb-14,28-May-15,03-Feb-14,,6,4,5,2,8,3,9,7,1,28.60%,60.80%,62.10%,67.80%,73.40%,77.80%,78.50%,79.40%,79.70%,,79.70%,28-May-15,,266,,350,,63,345,84,,146,84,105,50,189,82,1083,176,-429,239,50,165,-429,,,909,847,868,813,952,845,1846,939,334,1002,928,813,547,197,,293,231,252,197,336,229,1230,323,0,386,616,334,147,429,,,,479,,41955
Myrbetriq (Withdrawn),mirabegron ,Astellas Pharma,N,N,N,Y,N,N,N,N,N,,06-Mar-13,,CADTH & INESSS,08-Mar-13,post-NOC,Initial,"Bladder, Overactive ",Withdrawn,12-Nov-13,Cancelled or withdrawn,n/a,,,New Drug,"Bladder, Overactive ",Completed,01-Oct-13,Avis de refus - Valeur thérapeutique,Negative,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,2,,249,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,251,209,,,,,,,,41590
n/a,abiraterone acetate and prednisolone,N/A,N,N,N,N,Y,N,N,N,N,,,,CADTH,23-Mar-22,na,Non-sponsored Submission,For the treatment of high-risk non-metastatic prostate cancer.,Active,,TBD,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0
n/a,abiraterone acetate and prednisone/dexamethasone with docetaxel,N/A,N/A,N,N,N,Y,N,N,N,N,,,,CADTH,13-Jun-22,na,Non-sponsored Submission,For the treatment of metastatic castration sensitive prostate cancer in combination with androgen deprivation therapy.,Active,,TBD,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0
N/A,bevacizumab and lomustine,N/A,N/A,Y,N,N,Y,Y,N,Y,N,,,,CADTH,17-Feb-23,na,Non-sponsored Submission,"For the treatment of patients with glioblastoma after relapse or disease progression, following prior therapy.",Active,,TBD,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0
Naglazyme,galsulfase (Drug Plan Submission),BioMarin Pharmaceutical ,N,Y,N,Y,N,Y,N,Y,N,,16-Sep-13,,CADTH & INESSS,20-Aug-15,post-NOC,Initial,Mucopolysaccharidosis VI,Completed,19-Feb-16,List with clinical criteria and/or conditions,Conditional,19-Aug-17,post-NOC,New Drug,Mucopolysaccharidosis VI,Completed,01-Feb-18,Avis de refus d'inscription aux listes des médicaments,Negative,none,31-Jan-17,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,DRD,NR,NR,NR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,703,1433,183,166,347,-366,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,886,1599,,,,,,,,42419
Nerlynx,neratinib,Knight Therapeutics ,N,N,N,Y,Y,N,N,N,N,01-Sep-18,16-Jul-19,318,CADTH & INESSS,18-Apr-19,pre-NOC,New drug,Hormone Receptor-Positive Breast Cancer,Completed,05-Dec-19,Do Not Fund,Negative,24-May-19,pre-NOC,New Drug,Hormone Receptor-Positive Breast Cancer,Completed,11-Dec-19,Refus d'inscription,Negative,None,04-Feb-20,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-89,-53,231,201,61,55,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,142,148,,,,,,,,460
Nesina,alogliptin,Takeda Canada Inc.,Y,N,N,Y,N,N,N,N,N,,27-Nov-13,,CADTH & INESSS,30-Jan-14,post-NOC,Initial,Diabetes mellitus (Type 2),Completed,15-Jan-15,Do not list,Negative,22-Mar-14,post-NOC,New Drug,Type 2 diabetes,Completed,01-Oct-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,none,28-Jan-15,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,EM,,,,,,,,,,01-Oct-14,,01-Oct-14,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,64,115,350,193,13,119,,,,,,,,,,,,,,,,,,,,,,,,,,308,,308,,,,,,,,,,,,,0,,414,308,,,,,,,,42019
Neupro,rotigotine,UCB ,N,N,N,Y,N,N,N,N,N,,21-Mar-13,,CADTH & INESSS,31-Jul-13,post-NOC,Initial,Parkinson’s Disease,Completed,28-May-14,Do not list,Negative,01-Oct-13,post-NOC,New drug,Parkinsons Disease,Completed,03-Feb-14,Avis de refus - Valeur thérapeutique,Negative,none,31-Jul-14,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,132,194,301,125,64,178,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,433,319,,,,,,,,41787
Neupro (Resub),rotigotine,UCB ,N,N,N,Y,N,N,N,N,N,,21-Mar-13,,CADTH & INESSS,21-May-15,post-NOC,Resubmission,Parkinson’s Disease,Completed,19-Nov-15,List with clinical criteria and/or conditions,Conditional,01-Feb-15,post-NOC,Resubmission,Parkinsons Disease,Completed,01-Jun-15,Avis de refus - Valeur thérapeutique,Negative,1st,09-Feb-16,23-Jun-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,13-Nov-18,01-Oct-17,01-Oct-17,19-Oct-17,28-Sep-17,24-Oct-17,01-Nov-17,27-Nov-17,01-Dec-17,18-Oct-17,28-Sep-17,28-Sep-17,10,2,3,5,1,6,7,8,9,4,32.20%,36.70%,42.40%,71.00%,76.50%,77.40%,78.70%,79.10%,79.70%,100.00%,100.00%,18-Oct-17,13-Nov-18,791,682,182,120,82,253,500,508,100,100,118,97,123,131,157,161,117,166,97,161,97,508,2063,1655,1655,1673,1652,1678,1686,1712,1716,1672,1721,1716,1652,861,679,1090,682,682,700,679,705,713,739,743,870,748,973,802,582,753,2063,411,411,20,391,42327
Nexavar,sorafenib,Bayer ,Y,N,N,N,Y,Y,Y,Y,N,,27-Jun-14,,CADTH,19-Dec-14,post-NOC,New indication,Metastatic Progressive Differentiated Thyroid Carcinoma (DTC),Completed,16-Jul-15,Do Not Fund,Negative,,,,,,,,,None,29-Jul-15,,Do Not Negotiate,n/a,Not funded,Under provincial consideration,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,175,,209,,13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,384,,,,,,,,,42201
Nexplanon,etonogestrel,Merck,Y,N,N,N,N,N,N,N,N,01-May-19,25-May-20,390,CADTH,26-Sep-19,pre-NOC,Initial,Prevention of pregnancy,Withdrawn,19-Feb-20,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-242,,146,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-96,,,,,,,,,294
Nexplanon,etonogestrel,Merck Canada Inc.,Y,N,N,N,N,N,N,N,N,01-May-19,25-May-20,390,CADTH & INESSS,03-Jun-20,post-NOC,Initial,Prevention of pregnany,Completed,20-Oct-20,Reimburse with clinical criteria and/or conditions,Conditional,01-Nov-19,pre-NOC,New drug,Prevention of pregnancy,Completed,05-Nov-20,Inscription,Positive,1st,24-Feb-21,20-Sep-21,Negotiation,Completed with Agreements,FB,FB,FB,FB,FB,FB,FB,FB,FB,FB,07-Dec-21,01-Nov-21,01-Nov-21,24-Feb-22,17-Dec-21,18-Nov-21,11-Dec-21,22-Nov-21,01-Dec-21,10-Nov-21,01-Nov-21,01-Nov-21,7,1,2,10,9,4,8,5,6,3,4.50%,10.20%,38.80%,39.70%,40.00%,40.70%,60.90%,62.20%,94.50%,100.00%,100.00%,07-Dec-21,17-Dec-21,9,-206,139,370,127,111,208,78,42,42,157,88,59,82,63,72,51,76,42,73,42,88,561,525,525,640,571,542,565,546,555,534,559,556,525,516,377,413,377,377,492,423,394,417,398,407,370,411,148,164,335,319,571,46,46,36,10,538
Nexviazyme,avalglucosidase alfa,"Sanofi Genzyme, a division of sanofi-aventis Canada Inc.",N,Y,N,Y,N,Y,N,Y,N,01-Nov-20,12-Nov-21,376,CADTH & INESSS,30-Sep-21,pre-NOC,Initial,Pompe disease,Completed,05-Jul-22,Reimburse with clinical criteria and/or conditions,Conditional,31-Dec-21,post-NOC,New Drug,Pompe disease,Completed,29-Jun-22,Refus d'inscription,Negative,none,,,,,UR,,,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-43,49,278,180,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,235,229,,,,,,,,611
Ngenla,somatrogon,Pfizer Canada ULC,Y,N,N,N,N,N,Y,Y,N,01-Dec-20,26-Oct-21,329,CADTH & INESSS,03-Jun-21,pre-NOC,Initial,Growth hormone deficiency,Completed,08-Mar-22,Reimburse with clinical criteria and/or conditions,Conditional,22-Apr-22,post-NOC,New Drug,Growth hormone deficiency,Completed,31-Aug-22,Refus d'inscription,Negative,1st,17-Aug-22,28-Nov-22,Negotiation,Completed with Agreements,,,EDS,,,,,,,NR,,,01-Mar-23,,,,,,,,01-Mar-23,01-Mar-23,,,1,,,,,,,,5.70%,,,,,,,,,,5.70%,,,-145,178,278,131,162,-14,103,,,93,,,,,,,,93,93,93,93,,,,491,,,,,,,,491,491,491,636,358,,,358,,,,,,,,358,133,309,265,89,,,,,,462
Ninlaro,ixazomib,Takeda ,Y,N,N,Y,Y,Y,Y,Y,N,01-Feb-16,04-Aug-16,185,CADTH & INESSS,16-Dec-16,post-NOC,New drug,Lymphoma and Multiple Myeloma,Completed,29-Jun-17,Do not Fund,Negative,24-Nov-16,post-NOC,New Drug,Multiple myeloma,Completed,01-Jun-17,Avis de refus d'inscription à la Liste Établissements,Negative,None,18-Aug-17,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,134,112,195,189,50,78,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,329,301,,,,,,,,514
Ninlaro,ixazomib,Takeda ,Y,N,N,N,Y,Y,Y,Y,N,01-Feb-16,04-Aug-16,185,CADTH & INESSS,30-Nov-18,post-NOC,Resubmission,Multiple Myeloma (2nd-beyond),Completed,05-Jul-19,Do not Fund,Negative,24-Nov-16,post-NOC,New Drug,Multiple myeloma,Completed,01-Jun-17,Avis de refus d'inscription à la Liste Établissements,Negative,None,02-Aug-19,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,848,112,217,189,28,792,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1065,301,,,,,,,,1250
Nitisinone,nitisinone,Cycle Pharmaceuticals Ltd,N,N,N,Y,N,N,N,N,N,01-May-16,04-Nov-16,187,CADTH & INESSS,25-Jan-18,post-NOC,Initial,Hereditary tyrosinemia type 1,Completed,23-Aug-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,hereditary Type 1 tyrosinemia,Completed,01-Jun-17,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,21-Aug-18,28-Nov-18,Negotiation,Completed with Agreements,E,SA,NR,NR,NR,NR,EDS,NR,UR,EM,26-Feb-19,01-Feb-19,,,,,01-Aug-19,,,01-Feb-18,01-Feb-19,01-Feb-18,3,2,,,,,4,,,1,28.60%,33.00%,53.30%,54.60%,,,,,,,54.60%,26-Feb-19,,447,,210,,-2,446,99,90,65,,,,,246,,,-300,134,65,25,-300,,844,819,,,,,1000,,,454,888,779,819,372,162,187,162,,,,,343,,,245,231,657,209,97,545,,,,390,,844
Nivestym,filgrastim,Pfizer ,Y,Y,Y,N,N,N,N,N,N,01-Apr-18,16-Apr-20,746,CADTH & INESSS,01-Nov-18,pre-NOC,Initial,Prevention or treatment of neutropenia in various indications,Withdrawn,31-May-19,Cancelled or withdrawn,n/a,05-Jun-20,post-NOC,New Drug,Neutropenia,Completed,09-Sep-20,Inscription - Avec conditions,Conditional,1st,27-Apr-20,17-Jun-20,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,FB,SA,UR,SA,SA,EM,22-Mar-22,01-Dec-20,01-Sep-20,22-Oct-20,31-Jul-20,26-Nov-20,,25-Oct-21,09-Jun-21,30-Sep-20,31-Jul-20,31-Jul-20,9,6,2,4,1,5,,8,7,3,32.20%,38.00%,66.50%,72.10%,73.00%,77.40%,78.10%,78.40%,98.70%,,98.70%,30-Sep-20,22-Mar-22,-532,50,211,96,332,-135,51,643,167,76,127,44,162,,495,357,105,259,44,242,44,643,705,229,138,189,106,224,,557,419,167,321,304,106,638,427,1026,550,459,510,427,545,,878,740,21,642,-321,146,383,-84,705,599,599,61,538,425
Nubeqa,darolutamide,Bayer,Y,N,N,Y,Y,N,N,N,N,01-Apr-19,20-Feb-20,325,CADTH & INESSS,27-Aug-19,pre-NOC,New drug,Non-metastatic castration-resistant prostate cancer,Completed,22-Apr-20,Cond'l on Cost,Conditional,06-Sep-19,pre-NOC,New Drug,Non-metastatic castration-resistant prostate cancer,Completed,08-Apr-20,Inscription - Avec conditions,Conditional,1st,23-Oct-20,18-Feb-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Aug-21,31-May-21,01-Aug-21,05-Aug-21,08-Jun-21,19-Aug-21,30-May-21,23-Jan-23,11-Aug-21,14-Apr-21,30-May-21,14-Apr-21,5,3,6,7,4,9,2,10,8,1,28.60%,29.90%,34.30%,66.60%,86.80%,92.60%,98.10%,98.80%,99.60%,100.00%,100.00%,08-Jun-21,01-Aug-21,-177,-167,239,215,184,198,118,164,102,164,168,110,182,101,704,174,55,208,101,192,55,164,528,466,528,532,474,546,465,1068,538,419,572,556,465,642,403,466,404,466,470,412,484,403,1006,476,371,510,62,48,302,316,528,109,63,55,54,387
Nubeqa,darolutamide,Bayer Inc.,Y,N,N,N,Y,N,N,N,Y,01-Apr-22,29-Sep-22,181,CADTH & INESSS,16-Jun-22,pre-NOC,Initial,For the treatment of patients with metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel,Completed,05-Jan-23,Cond'l on Cost,Conditional,16-Dec-22,post-NOC,New Indication,For the treatment of patients with metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel,Under review,TBD,TBD,TBD,None,,,Under consideration for negotiation,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-105,78,203,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,98,,,,,,,,,279
Nucala,mepolizumab,GlaxoSmithKline,Y,Y,N,Y,N,N,N,N,N,,03-Dec-15,,CADTH & INESSS,18-Dec-15,post-NOC,Initial,"Asthma, severe eosinophilic",Completed,16-Jun-16,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Drug,"Asthma, severe eosinophilic",Completed,03-Oct-16,Avis de refus d’inscription aux listes des médicaments – Médicament d’exception – À moins que certaines conditions soient respectées,Conditional,1st,21-Oct-16,24-Nov-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,13-Nov-18,01-May-18,01-Jul-18,19-Apr-18,15-Mar-18,12-Feb-18,01-Feb-19,15-Mar-21,01-Oct-18,01-Feb-18,12-Feb-18,01-Feb-18,8,5,6,4,3,2,9,10,7,1,28.60%,29.50%,61.70%,67.20%,71.70%,77.40%,78.10%,98.30%,99.60%,100.00%,100.00%,15-Mar-18,13-Nov-18,15,110,181,195,127,18,399,354,158,219,146,111,80,434,1207,311,69,336,80,309,69,354,1076,880,941,868,833,802,1156,1929,1033,791,1058,1031,802,787,606,880,684,745,672,637,606,960,1733,837,486,862,196,305,526,417,1076,285,274,42,243,42537
Nucala,mepolizumab,GlaxoSmithKline Inc.,Y,Y,N,N,N,N,N,N,N,01-Jan-21,05-Nov-21,308,CADTH & INESSS,11-May-22,post-NOC,Initial,Severe chronic rhinosinusitis with nasal polyps,Completed,16-Nov-22,Reimburse with clinical criteria and/or conditions,Conditional,29-Apr-22,post-NOC,New Indication,Severe chronic rhinosinusitis with nasal polyps,under review,TBD,TBD,TBD,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,187,175,189,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,376,,,,,,,,,684
Nucala (Advice),mepolizumab,GlaxoSmithKline,Y,Y,N,Y,N,N,N,N,N,,03-Dec-15,,CADTH & INESSS,24-Oct-18,post-NOC,Request for Advice,"Asthma, severe eosinophilic",Completed,27-Mar-19,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,"Asthma, severe eosinophilic",Completed,05-Sep-18,Avis de modification d'une indication reconnue aux listes des médicaments - Médicament d'exception- Avec conditions,Conditional,none,,,,,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,29-Oct-19,01-Aug-19,01-Oct-19,02-Mar-20,23-Jul-19,04-Jul-19,01-Sep-19,15-Mar-21,21-Dec-20,04-Jul-19,04-Jul-19,04-Jul-19,7,4,6,8,3,1,5,10,9,2,0.90%,29.50%,61.70%,66.20%,67.50%,73.20%,93.40%,99.00%,99.60%,100.00%,100.00%,23-Jul-19,29-Oct-19,1056,,154,,,,,,,,,,,,,,,,,,,43767,1426,1337,1398,1551,1328,1309,1368,1929,1845,1309,1499,1480,1309,253,99,216,127,188,341,118,99,158,719,635,302,289,1210,1007,,,1426,117,117,19,98,43551
Nucynta,tapentadol hydrochloride,Paladin Labs ,N,N,N,N,N,N,N,N,N,,31-Oct-13,,CADTH & INESSS,17-Apr-18,post-NOC,Initial,"pain, severe",Completed,23-Oct-18,Do not reimburse,Negative,01-Aug-18,post-NOC,New Form,Pain,Completed,12-Dec-18,Refus d’inscription,Negative,none,29-Nov-18,,Do Not Negotiate,n/a,NR,UR,NR,NR,NR,NR,UR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,1629,1735,189,133,37,-13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1818,1868,,,,,,,,43396
Ocaliva,obeticholic acid,Intercept Pharmaceuticals ,N,N,N,Y,N,N,N,N,N,01-Oct-16,24-May-17,235,CADTH & INESSS,22-Dec-16,pre-NOC,Initial,Primary biliary cholangitis,Completed,25-Jul-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,pre-NOC,New Drug,Primary biliary cholangitis,Completed,18-Aug-17,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,08-Dec-17,27-Jun-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,30-Oct-18,01-Jan-19,01-Oct-18,18-Oct-18,13-Sep-18,17-Dec-18,01-Feb-19,20-Dec-21,16-Aug-19,16-Aug-18,13-Sep-18,16-Aug-18,5,7,3,4,2,6,8,10,9,1,28.60%,60.80%,66.50%,72.10%,92.30%,93.20%,97.70%,99.00%,99.60%,100.00%,100.00%,13-Sep-18,30-Oct-18,-153,-61,215,147,136,112,201,125,188,96,113,78,173,219,1272,415,50,298,78,273,50,125,524,587,495,512,477,572,618,1671,814,449,697,672,477,630,415,462,525,433,450,415,510,556,1609,752,363,635,62,86,337,313,524,75,47,28,47,297
Ocrevus,ocrelizumab,Hoffmann-La Roche Ltd.,Y,Y,N,Y,N,N,N,N,N,01-Oct-16,14-Aug-17,317,CADTH & INESSS,16-May-17,pre-NOC,Initial,"Multiple sclerosis, relapsing",Completed,21-Nov-17,Reimburse with clinical criteria and/or conditions,Conditional,15-Aug-17,post-NOC,New Drug,RRMS,Completed,01-Feb-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,19-Jul-18,13-Feb-19,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,,01-Apr-19,01-May-19,22-Aug-19,12-Sep-19,07-Nov-19,22-Apr-20,28-Dec-22,10-Oct-19,11-Apr-19,01-Apr-19,01-Apr-19,,1,3,4,5,7,8,9,6,2,4.50%,33.00%,38.80%,44.30%,76.50%,77.20%,78.10%,79.40%,79.70%,,79.70%,12-Sep-19,,-90,1,189,170,240,168,209,,47,77,190,211,267,434,1414,239,57,360,47,326,47,,,595,625,738,759,815,982,1962,787,605,908,874,595,685,496,,496,526,639,660,716,883,1863,688,434,809,99,171,449,377,,,,164,,416
Ocrevus (Primary),ocrelizumab,Hoffmann-La Roche Ltd.,Y,Y,N,N,N,N,N,N,N,01-Oct-16,14-Feb-18,501,CADTH & INESSS,26-Oct-17,pre-NOC,Initial,Primary progressive multiple sclerosis,Completed,26-Apr-18,Reimburse with clinical criteria and/or conditions,Conditional,23-Nov-17,pre-NOC,New Indication,PPMS,Completed,06-Jun-18,Avis de refus d'inscription aux listes des médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,19-Jul-18,13-Feb-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,20-Aug-20,01-Apr-19,01-May-19,22-Aug-19,12-Sep-19,07-Nov-19,22-Apr-20,28-Dec-22,10-Oct-19,11-Apr-19,01-Apr-19,01-Apr-19,9,1,3,4,5,7,8,10,6,2,4.50%,33.00%,38.80%,44.30%,76.50%,77.20%,78.10%,79.40%,99.60%,100.00%,100.00%,12-Sep-19,20-Aug-20,-111,-83,182,195,84,43,209,554,47,77,190,211,267,434,1414,239,57,381,47,349,47,554,918,411,441,554,575,631,798,1778,603,421,745,713,411,522,340,847,340,370,483,504,560,727,1707,532,309,674,71,112,293,252,918,507,507,164,343,572
Odefsey,emtricitabine/rilpivirine/ tenofovir alafenamide,Gilead Sciences ,Y,N,N,N,N,N,N,N,N,,10-Feb-17,,CADTH & INESSS,24-Nov-16,pre-NOC,Initial,HIV-1 infection,Completed,25-May-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,HIV,Completed,18-Oct-17,Avis d'inscription aux listes des médicaments,Positive,1st,04-Aug-17,06-Jun-18,Negotiation,Completed with Agreements,NR,NR,EDS,EDS,FB,SA,NR,HIV,SA,FB,,,01-Aug-18,18-Oct-18,30-Aug-18,30-Nov-18,,25-Nov-19,01-Dec-18,05-Jul-18,01-Aug-18,05-Jul-18,,,2,4,3,5,,7,6,1,28.60%,34.30%,66.50%,72.10%,73.00%,73.60%,74.00%,,,,74.00%,30-Aug-18,,-78,42,182,208,71,-75,306,,,56,134,85,177,,537,178,29,195,56,171,29,,,,537,615,566,658,,1018,659,510,676,652,537,615,433,,,433,511,462,554,,914,555,260,572,104,250,377,231,,,,56,,42880
Odomzo,sonidegib,Sun Pharma ,N,N,N,Y,Y,N,N,N,Y,01-Aug-19,12-Jun-20,316,CADTH & INESSS,19-Jun-20,post-NOC,New drug,Basal Cell Carcinoma (BCC),Completed,29-Apr-21,Do not Fund,Negative,14-Aug-20,post-NOC,New Drug,Basal Cell Carcinoma (BCC),Completed,30-Dec-20,Refus d'inscription,Negative,None,04-Jun-21,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,7,63,314,138,36,156,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,321,201,,,,,,,,637
Ofev,nintedanib,Boehringer Ingelheim (Canada) Ltd.,N,N,N,N,N,Y,N,Y,N,01-Nov-19,20-May-20,201,CADTH & INESSS,24-Jul-20,post-NOC,Initial,chronic fibrosing interstitial lung diseases,Completed,24-Feb-21,Reimburse with clinical criteria and/or conditions,Conditional,21-Aug-20,post-NOC,New Indication,Pulmonary interstitial disease,Completed,03-Mar-21,Inscription - Avec conditions,Conditional,1st,16-Jul-21,05-Feb-22,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,07-Jun-22,01-Apr-22,01-Jun-22,01-Jun-22,29-Apr-22,29-Apr-22,16-May-22,01-Jul-22,22-Apr-22,13-Apr-22,01-Apr-22,01-Apr-22,9,1,7,8,4,5,6,10,3,2,4.50%,33.00%,33.70%,65.90%,66.80%,68.10%,73.90%,79.40%,99.60%,100.00%,100.00%,29-Apr-22,07-Jun-22,65,93,215,194,142,135,204,122,55,116,116,83,83,100,146,76,67,100,55,96,55,122,748,681,742,742,709,709,726,772,702,693,726,722,681,616,401,468,401,462,462,429,429,446,492,422,406,446,280,287,346,339,748,67,67,28,39,481
Ofev,nintedanib,Boehringer Ingelheim ,N,N,N,Y,N,Y,N,Y,N,,25-Jun-15,,CADTH & INESSS,23-Apr-15,pre-NOC,Initial,Idiopathic pulmonary fibrosis (IPF),Completed,15-Oct-15,List with clinical criteria and/or conditions,Conditional,01-Dec-15,post-NOC,New Drug,Idiopathic pulmonary fibrosis (IPF),Completed,26-Apr-16,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,27-Oct-15,29-Aug-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,06-Feb-18,01-Nov-16,01-Oct-16,25-Jan-17,16-Sep-16,30-Nov-16,01-Dec-16,24-Apr-17,01-Feb-17,15-Mar-17,16-Sep-16,16-Sep-16,10,3,2,6,1,4,5,9,7,8,32.20%,38.00%,42.40%,43.30%,44.60%,50.10%,50.80%,79.40%,79.70%,100.00%,100.00%,25-Jan-17,06-Feb-18,-63,159,175,147,12,-182,307,526,64,33,149,18,93,94,238,156,198,152,18,157,18,526,957,495,464,580,449,524,525,669,587,629,583,588,449,512,337,845,383,352,468,337,412,413,557,475,323,471,112,306,319,125,957,508,508,131,377,42292
Ogivri,trastuzumab,BGP Pharma ULC,N,Y,Y,Y,Y,N,N,N,N,01-Jun-17,05-May-19,703,CADTH & INESSS,18-Dec-18,pre-NOC,New drug,Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar,Withdrawn,31-May-19,n/a,n/a,,,New Drug,Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar,Completed,10-Jul-19,Inscription - Avec conditions,Conditional,1st,30-May-19,03-Oct-19,Negotiation,Completed with Agreements,,,,,,,,,,EM,,,,,,,,,,11-Nov-20,,11-Nov-20,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,-138,,164,,-1,-41,126,,,,,,,,,,405,,,405,405,,,,,,,,,,,556,,556,,,,,,,,,,,,,490,,26,66,125,85,,,,,,729
Olumiant,baricitinib,Eli Lilly ,N,N,N,Y,N,N,N,N,N,01-May-16,17-Aug-18,838,CADTH & INESSS,20-Dec-18,post-NOC,Initial,"Arthritis, Rheumatoid",Completed,02-Aug-19,Reimburse with clinical criteria and/or conditions,Conditional,26-Nov-18,post-NOC,New Drug,Rheumatoid arthritis,Completed,05-Jun-19,Inscription - Avec conditions,Conditional,1st,20-Sep-19,10-May-21,Negotiation,Completed with Agreements,NR,SA,EDS,RB,LU,SA,,SA,,FB,,01-Jul-21,01-Jul-21,05-Aug-21,31-Aug-21,19-Aug-21,,28-Feb-22,,18-Aug-21,01-Jul-21,01-Jul-21,,1,2,3,6,5,,7,,4,4.50%,10.20%,15.70%,44.30%,45.20%,77.40%,77.80%,,,,77.80%,31-Aug-21,,125,101,225,191,49,107,598,,52,52,87,113,101,,294,,100,117,52,114,52,,,1049,1049,1084,1110,1098,,1291,,1097,1114,1111,1049,924,699,,699,699,734,760,748,,941,,805,764,350,292,647,705,,,,61,,1188
Onglyza (MET+SU),saxagliptin,Bristol-Myers Squibb & AstraZeneca ,Y,N,N,N,N,N,N,N,N,,13-May-13,,CADTH,09-May-13,pre-NOC,Initial,Diabetes Mellitus (Type 2) (MET + SU),Completed,15-Nov-13,List with criteria/condition,Conditional,,,,,,,,,1st,28-Feb-14,09-Jan-15,Negotiation,Completed with Agreements,SA,,,,,SA,EDS,SA,SA,,05-Aug-14,,,,,23-Jul-15,01-Apr-15,27-Apr-15,01-Jul-15,,05-Aug-14,05-Aug-14,1,,,,,5,2,3,4,,20.30%,21.60%,21.90%,22.60%,23.50%,,,,,,23.50%,,,-4,,190,,105,,315,-157,,,,,195,82,108,173,,80,-157,80,-157,,449,,,,,801,688,714,779,,686,686,449,453,263,263,,,,,615,502,528,593,,500,186,,420,,,,,,,41593
Onivyde,nanoliposomal irinotecan,Baxalta,N,N,N,N,Y,N,Y,Y,N,,09-Aug-17,,CADTH,n/a,na,New drug,Metastatic Pancreatic Cancer,File-Closed Not Submitted,,n/a,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0
Onivyde,irinotecan liposome,Shire ,Y,N,N,Y,Y,N,Y,Y,N,,09-Aug-17,,CADTH & INESSS,27-Apr-17,pre-NOC,New drug,Metastatic Pancreatic Cancer,Completed,05-Jan-18,Cond'l on Cost,Conditional,,,New Drug,Metastatic Pancreatic Cancer,Completed,01-Feb-18,Avis de refus d'inscription à la Liste Établissements - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,25-Jan-19,07-Jun-19,Negotiation,No Agreement Reached,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-104,,253,,385,358,133,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,149,176,518,491,,,,,,43105
Onpattro,patisiran,Alnylam Pharmaceuticals,N,N,N,Y,N,Y,Y,Y,Y,01-Dec-18,07-Jun-19,188,CADTH & INESSS,25-Jan-19,pre-NOC,Initial,Polyneuropathy in hereditary transthyretin-mediated amyloidosis,Completed,25-Jul-19,Reimburse with clinical criteria and/or conditions,Conditional,01-Mar-19,pre-NOC,New Drug,Polyneuropathy ATTRh,Completed,11-Sep-19,Inscription - Avec conditions,Conditional,1st,15-Nov-19,30-Nov-20,Negotiation,Completed with Agreements,EDRD,SA,EDS,EDS,EAP,SA,EDS,UR,SA,EM,01-Jan-22,01-Mar-21,01-Mar-21,01-Apr-21,08-Apr-21,24-Feb-21,01-May-21,,27-Oct-21,03-Feb-21,24-Feb-21,03-Feb-21,9,3,4,5,6,2,7,,8,1,28.60%,29.50%,33.90%,39.70%,45.20%,77.40%,78.70%,79.40%,99.60%,,99.60%,08-Apr-21,01-Jan-22,-133,-98,181,194,113,65,381,397,91,91,122,129,86,152,,331,65,175,86,163,65,397,939,633,633,664,671,628,694,,873,607,717,705,628,761,580,891,585,585,616,623,580,646,,825,511,669,48,96,494,446,939,332,311,64,268,236
Onstryv,safinamide,Valeo Pharma,N,N,N,Y,N,N,N,N,N,01-Mar-18,10-Jan-19,315,CADTH & INESSS,29-May-19,post-NOC,Initial,Parkinson's disease,Completed,25-Mar-20,Do not reimburse,Negative,12-Jul-19,post-NOC,New Drug,Parkinson,Completed,05-Feb-20,Inscription - Avec conditions,Conditional,1st,24-Oct-22,16-Jan-23,Negotiation,Completed with Agreements,,,,,,,,,,FB,,,,,,,,,,01-Feb-23,,01-Feb-23,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,139,183,301,208,943,992,84,,,,,,,,,,16,,,16,16,,,,,,,,,,,1483,,1483,,,,,,,,,,,,,1092,,440,391,1027,1076,,,,,,755
Onureg,azacitidine,Bristol-Myers Squibb ,Y,N,N,Y,Y,Y,N,Y,N,01-Jul-20,05-Jan-21,188,CADTH & INESSS,01-Mar-21,post-NOC,Initial,"Maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT).",Completed,20-Oct-21,Cond'l on Cost,Conditional,19-Apr-21,post-NOC,New Drug,"Maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT).",Completed,30-Nov-21,Inscription - Avec conditions,Conditional,1st,27-Jan-22,07-Jun-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,EM,01-Oct-22,30-Jun-22,01-Sep-22,20-Sep-22,31-Dec-22,19-Dec-22,01-Feb-23,,08-Feb-23,06-Jul-22,30-Jun-22,30-Jun-22,5,1,3,4,7,6,8,,9,2,4.50%,33.00%,38.80%,44.30%,64.50%,65.40%,97.70%,99.00%,99.60%,,99.60%,01-Oct-22,31-Dec-22,55,104,233,225,99,58,131,116,23,86,105,207,195,239,,246,29,152,23,138,23,207,634,541,604,623,725,713,757,,764,547,670,656,541,486,253,346,253,316,335,437,425,469,,476,218,382,288,329,230,189,725,184,184,93,91,476
Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,Y,Y,Y,N,Y,N,,25-Sep-15,,CADTH & INESSS,13-Aug-15,pre-NOC,New drug,Metastatic Melanoma,Completed,01-Apr-16,Cond'l on Cost,Conditional,24-Nov-15,post-NOC,New Drug,Metastatic Melanoma,Completed,19-Aug-16,Avis d'inscritpion à la Liste Établissements-Médicaments d'exception-Avec condition,Conditional,1st,04-May-16,20-Jan-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Mar-17,03-Apr-17,23-Mar-17,13-Mar-17,21-Mar-17,02-May-17,01-Apr-17,01-Aug-18,03-Aug-17,15-Mar-17,01-Mar-17,01-Mar-17,1,7,5,2,4,8,6,10,9,3,20.30%,25.80%,54.40%,86.60%,92.30%,93.60%,98.10%,99.00%,99.60%,100.00%,100.00%,15-Mar-17,21-Mar-17,-43,60,232,269,33,-107,261,40,73,62,52,60,102,71,558,195,54,135,40,127,40,60,523,556,545,535,543,585,554,1041,678,537,618,610,523,566,334,334,367,356,346,354,396,365,852,489,208,429,189,329,294,154,543,20,20,14,6,42461
Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,N,N,N,N,,26-Feb-16,,CADTH & INESSS,29-Oct-15,pre-NOC,New indication,Non-Small Cell Lung Cancer,Completed,03-Jun-16,Cond'l on Cost,Conditional,01-Mar-16,post-NOC,New Indication,Non-Small Cell Lung Cancer,Completed,19-Aug-16,Avis de refus d'inscription à la Liste Établissements,Negative,1st,04-Jul-16,20-Jan-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Mar-17,03-Apr-17,23-Mar-17,13-Mar-17,21-Mar-17,02-May-17,01-Apr-17,01-Aug-18,03-Aug-17,15-Mar-17,01-Mar-17,01-Mar-17,1,7,5,2,4,8,6,10,9,3,20.30%,25.80%,54.40%,86.60%,92.30%,93.60%,98.10%,99.00%,99.60%,100.00%,100.00%,15-Mar-17,21-Mar-17,-120,4,218,171,31,-46,200,40,73,62,52,60,102,71,558,195,54,135,40,127,40,60,369,402,391,381,389,431,400,887,524,383,464,456,369,489,271,271,304,293,283,291,333,302,789,426,208,366,98,175,231,154,389,20,20,14,6,42524
Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,N,N,N,N,,25-Apr-16,,CADTH & INESSS,24-Feb-16,pre-NOC,New indication,Metastatic Renal Cell Carcinoma,Completed,01-Sep-16,Cond'l on Cost,Conditional,01-Apr-16,pre-NOC,New Indication,Kidney Cancer,Completed,19-Aug-16,Avis de refus d'inscription à la Liste Établissements,Negative,1st,18-Nov-16,20-Jan-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Mar-17,03-Apr-17,23-Mar-17,13-Mar-17,21-Mar-17,02-May-17,01-Apr-17,01-Aug-18,03-Aug-17,15-Mar-17,01-Mar-17,01-Mar-17,1,7,5,2,4,8,6,10,9,3,20.30%,25.80%,54.40%,86.60%,92.30%,93.60%,98.10%,99.00%,99.60%,100.00%,100.00%,15-Mar-17,21-Mar-17,-61,-24,190,140,78,91,63,40,73,62,52,60,102,71,558,195,54,135,40,127,40,60,310,343,332,322,330,372,341,828,465,324,405,397,310,371,181,181,214,203,193,201,243,212,699,336,208,276,129,116,141,154,330,20,20,14,6,42614
Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,N,N,N,N,01-Nov-16,12-May-17,192,CADTH & INESSS,31-Jan-17,pre-NOC,New indication,Squamous Cell Carcinoma of the Head and Neck (SCCHN),Completed,31-Aug-17,Cond'l on Cost,Conditional,24-Mar-17,pre-NOC,New Indication,Head and Neck Cancer,Completed,18-Aug-17,Avis de refus d’ajout d’une indication reconnue à la Liste Établissements – Médicament d’exception – À moins que certaines conditions soient respectées,Conditional,1st,29-Sep-17,20-Nov-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Mar-18,08-May-18,07-Dec-17,05-Dec-17,17-Jan-18,18-Dec-17,18-Apr-18,,30-May-18,01-Feb-18,05-Dec-17,05-Dec-17,6,8,2,1,4,3,7,,9,5,5.50%,11.20%,12.10%,44.40%,73.00%,93.20%,94.50%,99.00%,99.60%,,99.60%,01-Feb-18,01-Mar-18,-101,-49,212,147,29,42,52,101,169,17,15,58,28,149,,191,73,91,15,89,15,101,293,361,209,207,250,220,341,,383,265,283,281,207,308,96,182,250,98,96,139,109,230,,272,167,172,111,98,81,94,293,86,86,58,28,303
Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,01-Mar-17,10-Nov-17,254,CADTH & INESSS,29-Sep-17,pre-NOC,New indication,Classical Hodgkin Lymphoma after failure of ASCT,Completed,03-May-18,Cond'l on Cost,Conditional,30-Oct-17,pre-NOC,New Indication,Classical Hodgkin Lymphoma after failure of ASCT,Completed,09-May-18,Avis de refus d'ajout d'une indication reconnue à la Liste Établissements - Médicament d'exception,Negative,1st,09-Oct-18,04-Oct-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,EM,01-Dec-19,10-Apr-20,01-Mar-20,03-Feb-20,29-Jan-20,06-Apr-20,01-Apr-20,,,18-Dec-19,01-Dec-19,01-Dec-19,1,8,5,4,3,7,6,,,2,20.30%,48.80%,81.10%,86.60%,92.30%,93.60%,94.50%,99.00%,,,99.00%,29-Jan-20,29-Jan-20,-42,-11,216,191,159,153,360,58,189,149,122,117,185,180,,,75,143,58,134,58,117,751,882,842,815,810,878,873,,,768,836,827,751,793,577,577,708,668,641,636,704,699,,,588,662,174,180,519,513,810,59,59,59,0,428
Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,01-Jul-17,23-Mar-18,265,CADTH & INESSS,08-May-18,post-NOC,New indication,Hepatocellular Carcinoma (HCC),Completed,29-Nov-18,Do Not Fund,Negative,26-Jun-18,post-NOC,New Indication,Hepatocellular Carcinoma (HCC),Completed,12-Dec-18,Refus d’inscription,Negative,None,29-Jan-19,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,46,95,205,169,61,48,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,251,264,,,,,,,,516
Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,01-Jan-18,15-Nov-18,318,CADTH & INESSS,27-Aug-18,pre-NOC,New indication,Melanoma Adjuvant Therapy,Completed,07-Mar-19,Cond'l on Cost,Conditional,01-Feb-19,post-NOC,New Indication,Adjuvant Melanoma,Completed,13-Mar-19,Inscription – Avec conditions,Conditional,1st,26-Jun-19,06-Sep-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,EM,01-Nov-19,10-Apr-20,01-Jan-20,15-Jan-20,20-Jan-20,06-Apr-20,01-Apr-20,,,02-Oct-19,01-Nov-19,02-Oct-19,2,8,3,4,5,7,6,,,1,28.60%,48.80%,54.60%,60.10%,92.30%,93.60%,94.50%,99.00%,,,99.00%,01-Jan-20,20-Jan-20,-80,78,192,40,111,105,72,56,217,117,131,136,213,208,,,26,154,56,138,26,136,351,512,412,426,431,508,503,,,321,449,433,351,431,239,239,400,300,314,319,396,391,,,203,337,112,118,183,177,431,110,80,91,19,430
Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,01-Jan-21,02-Jul-21,182,CADTH & INESSS,07-Jul-21,post-NOC,Initial,For the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).,Completed,26-Jan-22,Cond'l on Cost,Conditional,09-Aug-21,post-NOC,New Indication,Opdivo (nivolumab) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).,Completed,30-Mar-22,Inscription - Avec conditions,Conditional,1st,28-Jun-22,25-Aug-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,01-Nov-22,30-Sep-22,01-Dec-22,28-Oct-22,31-Mar-23,,,03-Apr-23,,28-Sep-22,30-Sep-22,28-Sep-22,4,2,5,3,6,,,7,,1,28.60%,33.00%,38.60%,58.80%,64.50%,96.80%,97.10%,,,,97.10%,01-Nov-22,31-Mar-23,5,38,203,233,153,90,58,68,36,98,64,218,,,221,,34,118,36,106,34,218,487,455,517,483,637,,,640,,453,537,525,455,450,247,279,247,309,275,429,,,432,,182,329,208,271,211,148,637,184,182,34,150,390
Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,01-Jan-21,28-Oct-21,300,CADTH & INESSS,18-Aug-21,pre-NOC,Initial,"In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.",Completed,04-Mar-22,Cond'l on Cost,Conditional,24-Sep-21,pre-NOC,New Indication,"In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.",Completed,30-Mar-22,Inscription - Avec conditions,Conditional,1st,28-Jun-22,25-Aug-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,01-Nov-22,31-Jan-23,01-Dec-22,20-Oct-22,30-Nov-22,,,03-Apr-23,,28-Sep-22,20-Oct-22,28-Sep-22,3,6,5,2,4,,,7,,1,28.60%,34.10%,54.40%,86.60%,92.30%,96.80%,97.10%,,,,97.10%,01-Nov-22,30-Nov-22,-71,-34,198,187,116,90,58,68,159,98,56,97,,,221,,34,117,56,105,34,97,369,460,399,357,398,,,522,,335,418,406,357,428,230,242,333,272,230,271,,,395,,182,291,127,153,174,148,398,63,41,34,29,427
Opdivo,nivolumab,Bristol Myers Squibb,Y,Y,N,N,Y,N,N,N,N,01-Jul-21,27-Jun-22,361,CADTH & INESSS,22-Feb-22,pre-NOC,Initial,Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of patients with muscle invasive urothelial carcinoma (MIUC) who are at high risk of recurrence after undergoing radical resection of MIUC.,Completed,28-Sep-22,Cond'l on Cost,Conditional,25-Nov-22,post-NOC,New Indication,Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of patients with muscle invasive urothelial carcinoma (MIUC) who are at high risk of recurrence after undergoing radical resection of MIUC.,Under review,TBD,TBD,TBD,1st,09-Dec-22,23-Dec-22,Negotiation,Completed with Agreements,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,01-Apr-23,,,,,,,,,,01-Apr-23,01-Apr-23,1,,,,,,,,,,20.30%,,,,,,,,,,20.30%,,,-125,151,218,,72,,14,99,,,,,,,,,,99,99,99,99,,278,,,,,,,,,,278,278,278,403,185,185,,,,,,,,,,185,93,,86,,,,,,,454
Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,N,N,N,N,01-Mar-22,18-Aug-22,170,CADTH,13-Sep-22,post-NOC,Initial,Neoadjuvant treatment of adult patients with resectable NSCLC (tumours 4cm or node positive) when used in combination with platinum-doublet chemotherapy.,Active,,TBD,n/a,,,New Indication,Neoadjuvant treatment of adult patients with resectable NSCLC (tumours 4cm or node positive) when used in combination with platinum-doublet chemotherapy.,Pending,TBD,TBD,TBD,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44621
Opdivo & Yervoy in combo,nivolumab & ipilimumab in combo,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,,26-Oct-16,,CADTH & INESSS,30-Nov-16,post-NOC,New indication,Metastatic Melanoma,Completed,30-Nov-17,Cond'l on Cost,Conditional,24-Mar-17,post-NOC,New Indication,Metastatic Melanoma,Completed,18-Oct-17,Avis de refus d'ajout d'une indication reconnue à la Liste Établissements - Médicament d'exception,Negative,1st,13-Jun-18,20-Mar-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Apr-19,16-Jul-19,15-Apr-19,15-Apr-19,04-Apr-19,28-Jun-19,01-Jul-19,,16-Jul-19,23-May-19,01-Apr-19,01-Apr-19,1,8,3,4,2,6,7,,9,5,20.30%,52.50%,58.20%,63.70%,92.30%,93.20%,94.50%,99.00%,99.60%,,99.60%,04-Apr-19,23-May-19,35,149,365,208,195,238,280,12,118,26,26,15,100,103,,118,64,65,12,65,12,64,887,993,901,901,890,975,978,,993,939,940,940,887,852,487,487,593,501,501,490,575,578,,593,582,540,400,357,475,518,939,52,52,3,49,43069
Opdivo in combination with Yervoy,nivolumab in combination with Ipilimumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,N,N,N,N,01-Jan-18,06-Jul-18,186,CADTH & INESSS,26-Apr-18,pre-NOC,New indication,Renal Cell Carinoma,Completed,01-Nov-18,Cond'l on Cost,Conditional,25-May-18,pre-NOC,New Indication,RCC,Completed,08-Nov-18,Inscription – Avec conditions,Conditional,1st,28-Dec-18,20-Mar-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-May-19,16-Jul-19,01-Jun-19,05-Jun-19,15-May-19,28-Jun-19,01-Jul-19,,16-Jul-19,23-May-19,01-May-19,01-May-19,1,8,4,5,2,6,7,,9,3,20.30%,52.50%,81.10%,86.80%,92.30%,93.20%,94.50%,99.00%,99.60%,,99.60%,15-May-19,23-May-19,-71,-42,189,167,57,50,82,42,118,73,77,56,100,103,,118,64,86,42,83,42,64,299,375,330,334,313,357,360,,375,321,343,340,299,370,181,181,257,212,216,195,239,242,,257,196,225,118,125,139,132,321,22,22,14,8,304
Opdivo in combination with Yervoy,nivolumab in combination with Ipilimumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,N,N,N,N,01-Mar-20,06-Aug-20,158,CADTH & INESSS,23-Jun-20,pre-NOC,New indication,"Non-Small Cell Lung Cancer (NSCLC):Nivolumab, in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations",Completed,04-Mar-21,Cond'l on Cost,Conditional,,,New Indication,"Non-Small Cell Lung Cancer (NSCLC):Nivolumab, in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations",Completed,03-Mar-21,Refus d'inscription,Negative,1st,01-Nov-21,18-Jan-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,NR,01-May-22,31-Mar-22,01-May-22,29-Mar-22,30-Jun-22,,,,,,29-Mar-22,29-Mar-22,3,2,4,1,5,,,,,,5.50%,10.00%,30.20%,36.00%,68.20%,,,,,,68.20%,30-Jun-22,,-44,,254,,242,243,78,103,72,103,70,163,,,,,,102,70,102,70,,633,602,633,600,693,,,,,,632,632,600,644,390,423,392,423,390,483,,,,,,422,210,209,320,321,,,,93,,368
Opdivo-Yervoy,nivolumab-ipilimumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,01-Sep-20,28-May-21,269,CADTH & INESSS,29-Oct-20,pre-NOC,Initial,"in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.",Completed,04-Aug-21,Cond'l on Cost,Conditional,22-Jan-21,pre-NOC,New Indication,"In combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.",Completed,28-Jul-21,Inscription - Avec conditions,Conditional,1st,29-Oct-21,18-Jan-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,01-May-22,31-Mar-22,01-May-22,01-Apr-22,30-Jun-22,,,,,02-Mar-22,31-Mar-22,02-Mar-22,4,2,5,3,6,,,,,1,28.60%,33.00%,38.60%,58.80%,64.50%,96.80%,,,,,96.80%,01-May-22,30-Jun-22,-211,-126,279,187,86,93,81,103,72,103,73,163,,,,,43,103,72,93,43,163,338,307,338,308,398,,,,,278,338,328,307,518,239,270,239,270,240,330,,,,,217,270,68,61,167,174,398,120,91,60,60,337
Opsumit,macitentan,Actelion,Y,N,N,Y,N,Y,Y,Y,N,,06-Nov-13,,CADTH & INESSS,18-Dec-13,post-NOC,Initial,Pulmonary arterial hypertension,Completed,28-Jan-15,List with clinical criteria and/or conditions,Conditional,,,New Drug,Pulmonary arterial hypertension,Completed,02-Jun-14,Avis de refus,Negative,1st,25-Mar-15,18-Dec-15,Negotiation,No agreement reached,NR,NR,NR,NR,NR,NR,NR,NR,NR,EM,,,,,,,,,,01-Oct-14,,01-Oct-14,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,42,,406,,56,296,268,,,,,,,,,,-443,,,-443,-443,,,,,,,,,,,329,,329,,,,,,,,,,,,,121,,448,208,324,564,,,,,,42032
Opsumit pCPA 2nd,macitentan,Actelion,Y,N,N,Y,N,Y,Y,Y,N,,06-Nov-13,,CADTH & INESSS,18-Dec-13,post-NOC,Initial,Pulmonary arterial hypertension,Completed,28-Jan-15,List with clinical criteria and/or conditions,Conditional,,,New Drug,Pulmonary arterial hypertension,Completed,02-Jun-14,Avis de refus,Negative,2nd,31-Jul-19,23-Dec-20,Negotiation,Completed with Agreements,,,EDS,EDS,EAP,SA,EDS,SA,SA,,,,01-Mar-21,01-Apr-21,20-Apr-21,15-Jul-21,21-Mar-22,23-Jan-23,07-Jul-22,,01-Mar-21,01-Mar-21,,,1,2,3,4,5,7,6,,5.70%,11.20%,43.50%,44.40%,45.70%,46.30%,46.70%,,,,46.70%,,,42,,406,,1645,1885,511,,,68,99,118,204,453,761,561,,323,68,323,68,,,,2672,2703,2722,2808,3057,3365,3165,,2927,2927,2672,2630,2224,,,2224,2255,2274,2360,2609,2917,2717,,2479,448,208,2156,2396,,,,,,42032
Opsynvi,macitentan and tadalafil,Janssen Inc.,Y,N,N,N,N,Y,N,Y,N,01-Dec-20,14-Oct-21,317,CADTH & INESSS,20-May-21,pre-NOC,Initial,Pulmonary arterial hypertension,Completed,14-Dec-21,Reimburse with clinical criteria and/or conditions,Conditional,04-Mar-22,post-NOC,New Drug,Pulmonary arterial hypertension,Completed,01-Jun-22,Inscription - Avec conditions,Conditional,1st,16-Feb-22,09-May-22,Negotiation,No Agreement reached,NR,,NR,,,NR,,,NR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-147,141,208,89,64,-105,82,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,61,230,146,-23,,,,,,378
Oralair,grass pollen allergen extract ,Paladin Labs ,N,Y,N,N,N,N,N,N,N,,15-Mar-12,,CADTH & INESSS,21-Sep-12,post-NOC,Initial,Allergic rhinitis (grass pollen) ,Completed,20-Mar-13,List with criteria/condition,Conditional,02-Aug-12,post-NOC,New Drug,Allergic rhinitis (grass pollen) ,Completed,01-Feb-13,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,31-Jan-14,17-Feb-14,Negotiation,Completed with Agreements,NR,NR,NR,EDS,LU,SA,EDS,NR,NR,EM,,,,16-Apr-14,27-Mar-14,23-Jul-15,04-May-15,,,01-Feb-13,27-Mar-14,01-Feb-13,,,,3,2,5,4,,,1,28.60%,60.80%,66.30%,67.70%,68.50%,,,,,,68.50%,27-Mar-14,,190,140,180,183,317,364,17,,,,58,38,521,441,,,-381,265,38,135,-381,,,,,762,742,1225,1145,,,323,969,839,742,552,372,,,,392,372,855,775,,,0,599,370,323,334,381,,,,419,,41353
Orencia (SC),abatacept ,Bristol-Myers Squibb ,Y,Y,N,N,N,N,N,N,N,,21-Feb-13,,CADTH & INESSS,29-Nov-12,pre-NOC,Initial,"Arthritis, Rheumatoid ",Completed,18-Jul-13,List with clinical criteria and/or conditions,Conditional,04-Aug-13,post-NOC,New Form,Rheumatoid arthritis,Completed,01-Oct-13,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,31-Jan-14,10-Sep-14,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,25-Feb-14,01-Nov-13,01-Apr-15,17-Oct-13,12-Jun-13,21-Nov-14,01-Dec-16,02-Mar-15,24-Nov-16,01-Oct-13,12-Jun-13,12-Jun-13,5,4,8,3,1,6,10,7,9,2,32.20%,60.80%,66.30%,70.80%,91.10%,91.90%,92.30%,98.00%,98.70%,100.00%,100.00%,01-Oct-13,25-Feb-14,-84,164,231,58,197,122,222,-197,-313,203,-328,-455,72,813,173,806,-344,86,-455,43,-455,-197,369,253,769,238,111,638,1379,739,1372,222,652,609,111,195,-36,222,106,622,91,-36,491,1232,592,1225,0,505,147,222,419,344,369,258,258,111,147,41473
Orfadin,nitisinone,Sobi Canada,N,N,N,Y,N,Y,N,Y,N,01-Jul-16,13-Dec-16,165,CADTH & INESSS,29-Aug-17,post-NOC,Initial,Hereditary tyrosinemia type 1,Completed,21-Feb-18,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,hereditary Type 1 tyrosinemia,Completed,18-Aug-17,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,20-Aug-18,28-Nov-18,Negotiation,Completed with Agreements,SA,SA,UR,EDS,UR,SA,EDS,UR,UR,EM,01-Jan-21,01-Feb-19,,22-Aug-19,,26-Aug-19,01-Aug-19,,,01-Feb-18,01-Feb-19,01-Feb-18,6,2,,4,,5,3,,,1,28.60%,33.00%,34.30%,39.90%,40.80%,61.00%,,,,,61.00%,01-Jan-21,,259,101,176,147,180,367,100,765,65,,267,,271,246,,,-300,323,65,219,-300,,1480,780,,982,,986,961,,,415,1038,934,780,521,345,1045,345,,547,,551,526,,,167,603,435,248,280,467,,,,1065,,600
Orkambi,lumacaftor/ivacaftor,Vertex Pharmaceuticals ,N,N,N,Y,N,Y,N,Y,N,,26-Jan-16,,CADTH & INESSS,28-Jan-16,post-NOC,Initial,"Cystic Fibrosis, F508del CFTR mutation",Completed,26-Oct-16,Do not reimburse,Negative,22-Mar-16,post-NOC,New Drug,"Cystic Fibrosis, F508del CFTR mutation",Completed,03-Oct-16,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,none,22-Nov-16,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,2,56,272,195,27,50,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,274,251,,,,,,,,42669
Orkambi,lumacaftor/ivacaftor,Vertex Pharmaceuticals ,N,N,N,N,N,Y,N,Y,N,01-Nov-16,18-Apr-17,168,CADTH & INESSS,22-Feb-18,post-NOC,Initial,"Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older",Completed,26-Sep-18,Do not reimburse,Negative,,,New Indication,Cystic Fibrosis,Completed,17-Oct-18,Refus d’inscription,Negative,none,19-Feb-19,,Do Not Negotiate,n/a,UR,SA,EDS,EDS,EAP,UR,CF,SA,UR,NR,,01-Aug-21,01-Jul-21,22-Oct-21,25-Jun-21,,18-Nov-21,01-Nov-21,,,25-Jun-21,25-Jun-21,,3,2,4,1,,6,5,,,32.20%,38.00%,42.40%,47.90%,48.30%,49.60%,,,,,49.60%,,,310,,216,,146,125,,,,,,,,,,,,,,,,,,1566,1535,1648,1529,,1675,1658,,,1602,1602,1529,1219,1003,,1040,1009,1122,1003,,1149,1132,,,1076,526,547,,,,,,,,694
Orladeyo,berotralstat,BioCryst Pharmaceuticals Inc.,N,N,N,Y,N,Y,Y,Y,Y,01-Aug-21,02-Jun-22,305,CADTH & INESSS,22-Feb-22,pre-NOC,Initial,hereditary angioedema (HAE),Completed,17-Feb-23,Reimburse with clinical criteria and/or conditions,Conditional,20-Jan-23,post-NOC,New Drug,hereditary angioedema (HAE),under review,TBD,TBD,TBD,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-100,232,360,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,260,,,,,,,,,565
Osphena,ospemifene,Duschesnay Inc,N,N,N,Y,N,N,N,N,N,01-Mar-19,16-Jul-21,868,CADTH & INESSS,26-Oct-21,post-NOC,n/a,"Dyspareunia, vaginal dryness",Completed,13-May-22,Reimburse with clinical criteria and/or conditions,Conditional,13-May-22,post-NOC,New Drug,Moderate to severe dyspareunia,Completed,07-Oct-22,Inscription - Avec conditions,Conditional,1st,15-Dec-22,,Active,n/a,,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,102,301,199,147,216,69,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,301,448,,,,,,,,1169
Otezla (PsA),apremilast,Celgene,N,N,N,N,N,N,N,N,N,,10-Jun-15,,CADTH & INESSS,08-Jun-15,pre-NOC,Initial,"Arthritis, psoriatic",Completed,17-Dec-15,List with criteria/condition,Conditional,04-Aug-15,post-NOC,New Indication,Psoriatic arthritis,Completed,01-Feb-16,Avis de refus d'ajout d'une indication reconnue aux listes de médicaments - Médicament d'exception - Valeur thérapeutique,Negative,1st,26-Jun-17,08-Sep-17,Negotiation,No agreement reached,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-2,55,192,181,557,511,74,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,190,236,631,585,,,,,,42355
Otezla (PsO),apremilast ,Celgene ,N,N,N,Y,N,N,N,N,N,,12-Nov-14,,CADTH & INESSS,08-Oct-14,pre-NOC,Initial,"Psoriasis, moderate to severe plaque ",Completed,22-Jul-15,Do not list,Negative,22-Mar-15,post-NOC,New Drug,"Psoriasis, moderate to severe plaque ",Completed,01-Oct-15,Avis d'inscription aux listes de médicaments - Médicament d'exception,Conditional,none,30-Sep-15,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,EM,,,,,,,,,,01-Oct-15,,01-Oct-15,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,-35,130,287,193,70,-1,,,,,,,,,,,,,,,,,,,,,,,,,,323,,323,,,,,,,,,,,,,0,,252,323,,,,,,,,42207
Otezla (Resub),apremilast ,Celgene,N,N,N,Y,N,N,N,N,N,,12-Nov-14,,CADTH,03-Mar-16,post-NOC,Resubmission,"Psoriasis, moderate to severe plaque",Completed,26-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,26-Jun-17,08-Sep-17,Negotiation,No agreement reached,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,477,,237,,243,,74,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,714,,317,,,,,,,42669
Oxervate,cenegermin,Dompé Farmaceutici S.p.A,N,N,N,Y,N,Y,Y,Y,N,01-Aug-18,08-Feb-19,191,CADTH,29-Oct-21,post-NOC,Initial,Neurotrophic keratitis,Completed,23-Jun-22,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,994,,237,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1231,,,,,,,,,1422
Oxlumo,lumasiran,Alnylam Netherlands B.V.,N,N,N,Y,N,Y,Y,Y,N,01-Aug-21,07-Mar-22,218,CADTH & INESSS,10-May-22,post-NOC,Initial,Primary hyperoxaluria type 1,Completed,08-Feb-23,Reimburse with clinical criteria and/or conditions,Conditional,16-Dec-22,post-NOC,New Drug,Primary hyperoxaluria type 1,under review,TBD,TBD,TBD,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,64,284,274,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,338,,,,,,,,,556
Ozanex,ozenoxacin,Cipher Pharmaceuticals ,N,N,N,Y,N,N,N,N,N,01-Jul-16,01-May-17,304,CADTH & INESSS,25-Jan-18,post-NOC,Initial,Impetigo ,Completed,24-Oct-18,Do not reimburse,Negative,,,New Drug,Impetigo,Completed,08-Aug-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,none,30-Nov-18,,Do Not Negotiate,n/a,NR,UR,NR,NR,NR,NR,UR,UR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,269,,272,,37,114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,541,464,,,,,,,,845
Ozempic,semaglutide,Novo Nordisk ,Y,Y,N,Y,N,N,N,N,N,01-Mar-17,04-Jan-18,309,CADTH & INESSS,23-Nov-18,post-NOC,Initial,"Diabetes mellitus, type 2",Completed,15-May-19,Reimburse with clinical criteria and/or conditions,Conditional,01-Jan-18,pre-NOC,New Drug,Type 2 diabetes,Completed,05-Sep-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,31-Jan-19,26-Jul-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,15-Dec-20,01-Sep-19,01-Oct-20,21-Jan-21,30-Sep-19,19-Dec-19,07-Oct-20,23-Sep-19,27-Nov-19,14-Nov-19,01-Sep-19,01-Sep-19,9,1,7,10,3,6,8,2,5,4,4.50%,4.80%,37.00%,65.60%,66.30%,67.20%,72.90%,74.20%,94.50%,100.00%,100.00%,14-Nov-19,15-Dec-20,323,-3,173,247,-104,148,176,508,37,433,545,66,146,439,59,124,111,262,37,247,37,508,1076,605,1001,1113,634,714,1007,627,692,679,830,815,605,282,109,580,109,505,617,138,218,511,131,196,435,334,496,244,72,324,1076,471,471,74,397,805
Ozurdex,dexamethasone ,Allergan ,N,N,N,N,N,N,N,N,N,,16-Apr-15,,CADTH & INESSS,26-Sep-17,post-NOC,Initial,Diabetic macular edema ,Completed,24-Oct-18,Do not reimburse,Negative,,,New Indication,Diabetic macular edema,Completed,01-Feb-16,Avis d'ajout d'une indication reconnue aux listes de médicaments - Médicament d'exception - Avec conditions,Conditional,none,29-Nov-18,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,EM,,,,,,,,,,01-Jul-16,,01-Jul-16,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,894,,393,,36,1032,,,,,,,,,,,,,,,,,,,,,,,,,,442,,442,,,,,,,,,,,,,151,,1287,291,,,,,,,,43397
Ozurdex,dexamethasone intravitreal implant,"Allergan, an AbbVie Company",Y,N,N,N,N,N,N,N,N,,16-Apr-15,,CADTH,08-Jun-22,post-NOC,Resubmission,Diabetic macular edema,Completed,13-Dec-22,Do not reimburse,Negative,,,,,,,,,none,09-Mar-23,,Do Not Negotiate,n/a,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,2610,,188,,86,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2798,,,,,,,,,44908
Padcev,enfortumab vedotin,SeaGen,N,Y,N,N,Y,N,N,N,Y,01-May-21,29-Oct-21,181,CADTH & INESSS,23-Jun-21,pre-NOC,Initial,"For the treatment of patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and who: have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting or are not eligible for cisplatin-containing chemotherapy",Completed,06-Jan-22,Cond'l on Cost,Conditional,24-Sep-21,pre-NOC,New Indication,"For the treatment of patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and who: have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting or are not eligible for cisplatin-containing chemotherapy",Completed,30-Mar-22,Inscription - Avec conditions,Conditional,1st,28-Jun-22,28-Nov-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,01-Mar-23,31-Jan-23,01-Mar-23,,,,,,,14-Dec-22,31-Jan-23,14-Dec-22,3,2,4,,,,,,,1,28.60%,33.00%,53.30%,59.00%,,,,,,,59.00%,01-Mar-23,,-128,-35,197,187,173,90,153,93,64,93,,,,,,,16,83,64,67,16,,488,459,488,,,,,,,411,478,462,459,587,390,419,390,419,,,,,,,259,409,69,152,326,243,,,,77,,250
Palynziq,pegvaliase,BioMarin Pharmaceutical ,N,N,N,Y,N,N,N,N,N,01-Jun-21,30-Mar-22,302,CADTH & INESSS,22-Dec-21,pre-NOC,Initial,Phenylketonuria,Completed,09-Nov-22,Reimburse with clinical criteria and/or conditions,Conditional,23-Sep-22,post-NOC,New Drug,Treatment of phenylketonuria in patients aged 16 years and older,Completed,29-Mar-23,Refus d'inscription,Negative,none,,,,,UR,,,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-98,177,322,187,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,224,364,,,,,,,,526
pdp-levETIRAcetam,Levetiracetam,"Pendopharm, a division of Pharmascience Inc.",N,N,N,N,N,N,N,N,N,01-Sep-18,11-Jul-19,313,CADTH & INESSS,23-Jul-20,post-NOC,Initial,Epilepsy,Completed,03-Feb-21,Reimburse with clinical criteria and/or conditions,Conditional,11-Sep-20,post-NOC,New Drug,Epilepsy,Completed,30-Dec-20,Inscription - Avec conditions,Conditional,1st,23-Nov-21,05-Aug-22,Negotiation,Completed with Agreements,SA,FB,FB,FB,LU,SA,EDS,SA,SA,EM,22-Nov-22,01-Oct-22,01-Sep-22,24-Jan-23,21-Dec-22,24-Oct-22,01-Nov-22,27-Mar-23,01-Feb-23,28-Sep-22,01-Sep-22,01-Sep-22,6,3,1,8,7,4,5,10,9,2,5.70%,34.30%,38.80%,39.70%,41.00%,61.20%,93.40%,99.00%,99.60%,100.00%,100.00%,22-Nov-22,21-Dec-22,378,428,195,110,293,328,255,109,57,27,172,138,80,88,234,180,54,121,27,114,27,138,1230,1178,1148,1293,1259,1201,1209,1355,1301,1175,1242,1235,1148,770,575,657,605,575,720,686,628,636,782,728,637,669,573,538,548,583,1259,111,111,82,29,886
Pemazyre,pemigatinib,Incyte Biosciences Canada,N,N,N,Y,Y,Y,Y,Y,Y,01-Oct-20,17-Sep-21,351,CADTH & INESSS,23-Jun-21,pre-NOC,Initial,"For the treatment of adults with previously treated, unresectable locally advanced or metastatic CCA with a FGFR2 fusion or other rearrangement.",Completed,23-Mar-22,Do not fund,Negative,09-Aug-21,pre-NOC,New Drug,"For the treatment of adults with previously treated, unresectable locally advanced or metastatic CCA with a FGFR2 fusion or other rearrangement.",Completed,04-May-22,Refus d’inscription,Negative,None,29-Jul-22,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-86,-39,273,268,128,86,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,187,229,,,,,,,,538
Perjeta,pertuzumab,Hoffman-La Roche,Y,Y,N,Y,Y,N,N,N,N,01-Sep-19,25-Feb-21,543,CADTH & INESSS,14-Apr-21,post-NOC,Initial,"in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either 2 cm in diameter or node positive).",Completed,25-Jan-22,Cond'l on Cost,Conditional,06-Aug-21,post-NOC,New Drug,"In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either 2 cm in diameter or node positive).",Completed,29-Dec-21,Inscription - Avec conditions,Conditional,None,,,Under consideration for negotiation,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,48,162,286,145,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,334,307,,,,,,,,877
Perjeta Herceptin Combo Pack,pertuzumab,Hoffman-La Roche ,Y,Y,N,Y,Y,N,N,N,N,,12-Apr-13,,CADTH & INESSS,02-Nov-12,pre-NOC,New drug,In combination with trastuzumab and a taxane for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease,Completed,01-Aug-13,Cond'l on Cost,Conditional,,,New Drug,In combination with trastuzumab and a taxane for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease,Completed,03-Feb-14,Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable,Conditional,1st,02-Aug-13,18-Oct-13,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Nov-13,19-Dec-13,25-Nov-13,14-Mar-14,25-Nov-13,01-Apr-14,23-Jun-14,27-Apr-15,01-Apr-14,24-Mar-16,01-Nov-13,01-Nov-13,1,4,2,5,3,6,8,9,7,10,20.30%,26.00%,58.20%,62.70%,68.20%,69.10%,69.80%,71.10%,71.40%,100.00%,100.00%,25-Nov-13,24-Mar-16,-161,,272,,1,-185,77,14,62,38,147,38,165,248,556,165,888,159,14,232,14,888,203,251,227,336,227,354,437,745,354,1077,348,421,203,364,92,92,140,116,225,116,243,326,634,243,780,237,111,297,78,-108,1077,874,874,24,850,41487
Perjeta or Perjeta-Herceptin Combo Pack,pertuzumab,Hoffman-La Roche ,Y,Y,N,N,Y,N,N,N,N,,12-Apr-13,,CADTH,19-Dec-14,post-NOC,New indication,"Neoadjuvant Breast Cancer: in combination with trastuzumab and chemotherapy prior to surgery for the treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (>2 cm in diameter or node positive) as part of a complete treatment regimen for early stage breast cancer",Completed,16-Jul-15,Do Not Fund,Negative,,,,,,,,,None,29-Jul-15,,Do Not Negotiate,n/a,Not funded,Under provincial consideration,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,616,,209,,13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,825,,,,,,,,,42201
Perjeta-Herceptin Combo Pack for Early Breast Cancer,pertuzumab-trastuzumab Combo Pack,Hoffman-La Roche ,Y,Y,N,N,Y,N,N,N,N,01-Nov-17,30-Aug-18,302,CADTH & INESSS,09-Apr-18,pre-NOC,New indication,Early Breast Cancer,Completed,29-Nov-18,Do Not Fund,Negative,,,New Indication,Early Breast Cancer,Completed,08-Nov-18,Refus d’inscription,Negative,None,28-Dec-18,,Do Not Negotiate,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-143,,234,,29,50,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,91,70,,,,,,,,393
Perseris,risperidone,HLS Therapeutics Inc.,N,N,N,Y,N,N,N,N,N,01-Jan-20,19-Nov-20,323,CADTH & INESSS,29-Jan-21,post-NOC,Initial,?Treatment of schizophrenia in adults,Completed,08-Sep-21,Reimburse with clinical criteria and/or conditions,Conditional,05-Nov-21,post-NOC,New Drug,Schizophrenia,Completed,04-May-22,Inscription - Avec conditions,Conditional,1st,28-Feb-22,01-Jun-22,Negotiation,No Agreement reached,NR,,NR,,,NR,,,NR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,71,351,222,180,173,-65,93,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,293,531,266,28,,,,,,616
Pheburane,sodium phenylbutyrate,Médunik Canada,N,N,N,Y,N,Y,N,Y,N,,26-Jan-15,,CADTH & INESSS,20-Oct-15,post-NOC,Initial,Urea cycle disorders,Completed,15-Apr-16,List,Positive,04-Aug-15,post-NOC,New Drug,Urea cycle disorders,Completed,01-Feb-16,Avis de refus d'inscription aux listes de médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,21-Apr-17,20-Nov-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,NR,SA,EDS,NR,SA,NR,23-Jan-18,01-May-18,01-Apr-18,19-Apr-18,,08-May-18,01-Apr-19,,01-Mar-18,,23-Jan-18,23-Jan-18,1,5,3,4,,6,7,,2,,20.30%,20.90%,26.60%,32.20%,36.60%,37.50%,38.80%,,,,38.80%,,,267,190,178,181,371,445,213,64,162,132,150,,169,497,,101,,182,64,182,64,,1093,1191,1161,1179,,1198,1526,,1130,,1211,1211,1093,826,648,648,746,716,734,,753,1081,,685,,766,445,371,584,658,,,,,,42475
Picato,ingenol mebutate,LEO Pharma,N,N,N,Y,N,N,N,N,N,,30-Jan-13,,CADTH & INESSS,09-May-13,post-NOC,Initial,"Keratosis, actinic ",Completed,22-Jan-14,Do not list,Negative,,,New Drug,Actinic Keratosis,Completed,01-Oct-13,Avis de refus - Valeur thérapeutique,Negative,none,,,,,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,99,,258,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,357,244,,,,,,,,41661
Picato (Advice),ingenol mebutate,LEO Pharma ,N,N,N,Y,N,N,N,N,N,,30-Jan-13,,CADTH & INESSS,26-May-14,post-NOC,Request for Advice,Actinic keratosis ,Completed,22-Oct-14,Not Applicable: Request for Advice (Do not list),Negative,,,New Drug,Actinic Keratosis,Completed,03-Feb-14,Avis de refus - Valeur thérapeutique,Negative,none,02-Dec-14,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,481,,149,,41,302,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,630,369,,,,,,,,41934
Pifeltro,doravirine,Merck,Y,N,N,Y,N,N,N,N,N,01-Dec-17,12-Oct-18,315,CADTH & INESSS,16-Nov-18,post-NOC,Initial,HIV-1,Completed,14-May-19,Reimburse with clinical criteria and/or conditions,Conditional,16-Nov-18,post-NOC,New Drug,HIV,Completed,08-May-19,Inscription,Positive,1st,14-Jun-19,15-Oct-19,Negotiation,Completed with Agreements,HIV,UR,UR,EDS,FB,SA,HIV,HIV,SA,FB,,,,02-Mar-20,31-Oct-19,21-May-20,01-Mar-21,31-May-21,11-Sep-20,14-Nov-19,31-Oct-19,31-Oct-19,,,,3,1,4,6,7,5,2,32.20%,60.80%,66.30%,67.20%,67.90%,69.20%,69.60%,,,,69.60%,14-Nov-19,,35,35,179,173,31,37,123,,,,139,16,219,503,594,332,30,301,16,262,16,,,,,507,384,587,871,962,700,398,669,630,384,349,170,,,,293,170,373,657,748,486,190,455,214,208,154,160,,,,14,,529
Piqray,alpelisib,Novartis,Y,N,N,Y,Y,N,N,N,N,01-May-19,11-Mar-20,315,CADTH & INESSS,21-Apr-21,post-NOC,Initial,"in combination with fulvestrant, is indicated for the treatment of postmenopausal women and men, with hormone receptor-positive, HER2-negative, PIK3CA mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.",Completed,26-Jan-22,Do not fund,Negative,20-Aug-21,post-NOC,New Drug,"in combination with fulvestrant, is indicated for the treatment of postmenopausal women and men, with hormone receptor-positive, HER2-negative, PIK3CA mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.",Completed,04-Feb-22,Inscription - Avec conditions,Conditional,1st,16-Dec-22,14-Mar-23,Negotiation,No Agreement Reached,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,406,527,280,168,324,315,88,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,686,695,412,403,,,,,,1001
Plegridy,peginterferon beta-1a,Biogen,N,Y,N,Y,N,N,N,N,N,,10-Aug-15,,CADTH & INESSS,26-Jun-15,pre-NOC,Initial,"Multiple Sclerosis, relapsing",Completed,17-Dec-15,List with criteria/condition,Conditional,24-Nov-15,post-NOC,New Drug,"Multiple Sclerosis, relapsing",Completed,01-Jun-16,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,17-Jun-16,14-Feb-17,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,SA,EDS,SA,SA,NR,,01-Jul-17,01-Apr-17,19-Jul-17,17-Mar-17,15-Aug-17,24-Oct-17,24-Apr-17,26-May-17,,17-Mar-17,17-Mar-17,,5,2,6,1,7,8,3,4,,32.20%,38.00%,38.30%,39.00%,43.40%,49.00%,49.90%,51.20%,,,51.20%,24-Oct-17,,-45,106,174,190,183,16,242,,137,46,155,31,182,252,69,101,,122,31,122,31,,,691,600,709,585,736,806,623,655,,676,676,585,630,456,,562,471,580,456,607,677,494,526,,547,129,296,425,258,,,,221,,42355
Pluvicto,lutetium vipivotide tetraxetan,"Advanced Accelerator Applications USA, Inc.",N,N,N,Y,Y,N,N,N,Y,01-Feb-22,25-Aug-22,205,CADTH,21-Jul-22,pre-NOC,Initial,The treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes,Completed,03-Mar-23,Cond'l on Cost,Conditional,16-Dec-22,post-NOC,New drug,The treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes,Under review,TBD,TBD,TBD,None,,,Under consideration for negotiation,n/a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-35,113,225,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,190,,,,,,,,,395
Polivy,polatuzumab vedotin,Hoffman-La Roche ,Y,Y,N,Y,Y,Y,Y,Y,N,01-Nov-19,09-Jul-20,251,CADTH & INESSS,29-Sep-20,post-NOC,New drug,"Diffuse Large B-Cell Lymphoma (DLBCL): Polatuzumab vedotin, in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who are not eligible for autologous stem cell transplant and have received at least one prior therapy.",Completed,21-Apr-21,Cond'l on Cost,Conditional,06-Nov-20,post-NOC,New Drug,Diffuse Large B-Cell Lymphoma (DLBCL),Completed,02-Jun-21,Refus d'inscription,Negative,1st,21-Jul-21,01-Dec-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,NR,01-Apr-22,28-Feb-22,01-Jan-22,04-Jan-22,31-May-22,,,,,,01-Jan-22,01-Jan-22,4,3,1,2,5,,,,,,5.70%,11.20%,15.70%,36.00%,68.20%,,,,,,68.20%,31-May-22,,82,120,204,208,91,49,133,121,89,31,34,181,,,,,,91,31,91,31,,631,599,541,544,691,,,,,,601,601,541,459,255,345,313,255,258,405,,,,,,315,286,328,224,182,,,,150,,537
Polivy,polatuzumab vedotin,Hoffmann-La Roche,Y,Y,N,N,Y,Y,Y,Y,N,01-Jan-22,14-Nov-22,317,CADTH,01-Mar-23,post-NOC,Initial,"Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL.",Active,,TBD,n/a,,,New Indication,"Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL.",Pending,TBD,TBD,TBD,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,107,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44562
Pomalyst,pomalidomide,Celgene ,N,N,N,Y,Y,Y,Y,Y,N,,20-Jan-14,,CADTH & INESSS,13-Jan-14,pre-NOC,New drug,Multiple Myeloma:In combination with low-dose dexamethasone for patients with multiple myeloma for whom both bortezomib and lenalidomide have failed and who have received at least two prior treatment regimens and have demonstrated disease progression on the last regimen,Completed,31-Jul-14,Cond'l on Cost,Conditional,24-Nov-13,pre-NOC,New Drug,Multiple Myeloma:In combination with low-dose dexamethasone for patients with multiple myeloma for whom both bortezomib and lenalidomide have failed and who have received at least two prior treatment regimens and have demonstrated disease progression on the last regimen,Completed,16-Jul-14,Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable,Conditional,2nd,09-Mar-18,25-Jul-18,Negotiation,Completed with Agreements,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-7,-57,199,234,1317,1332,138,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,192,177,1455,1470,,,,,,41851
Pomalyst,pomalidomide,Celgene ,N,N,N,Y,Y,Y,Y,Y,N,,20-Jan-14,,CADTH & INESSS,13-Jan-14,pre-NOC,New drug,Multiple Myeloma:In combination with low-dose dexamethasone for patients with multiple myeloma for whom both bortezomib and lenalidomide have failed and who have received at least two prior treatment regimens and have demonstrated disease progression on the last regimen,Completed,31-Jul-14,Cond'l on Cost,Conditional,24-Nov-13,pre-NOC,New Drug,Multiple Myeloma,Completed,16-Jul-14,Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable,Conditional,1st,21-Aug-14,23-Jan-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Mar-15,28-Apr-15,01-May-15,20-Apr-15,06-Feb-15,23-Mar-15,04-May-15,23-Nov-15,01-May-15,24-Mar-16,06-Feb-15,06-Feb-15,2,5,6,4,1,3,8,9,7,10,32.20%,52.50%,53.40%,58.90%,63.40%,69.10%,69.80%,71.10%,71.40%,100.00%,100.00%,01-Mar-15,24-Mar-16,-7,-57,199,234,21,36,155,37,95,98,87,14,59,101,304,98,426,99,14,132,14,426,405,463,466,455,382,427,469,672,466,794,467,500,382,389,190,213,271,274,263,190,235,277,480,274,617,275,192,177,176,191,794,412,412,23,389,41851
Pomalyst,pomalidomide,Celgene ,N,N,N,N,Y,Y,Y,Y,N,01-Sep-18,02-Jul-19,304,CADTH & INESSS,15-Mar-19,pre-NOC,New indication,Multiple Myeloma (second-line or beyond):Pomalidomide in combination with dexamethasone and bortezomib for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide,Completed,18-Sep-19,Cond'l on Cost,Conditional,22-Mar-19,pre-NOC,New Indication,Multiple Myeloma (second-line or beyond):Pomalidomide in combination with dexamethasone and bortezomib for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide,Completed,16-Oct-19,Inscription - Avec conditions,Conditional,None,04-Jun-21,,Do Not Negotiate,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-109,-102,187,208,625,597,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78,106,,,,,,,,382
Poteligeo,mogamulizumab,Kyowa Kirin Canada,N,Y,N,Y,Y,Y,Y,Y,Y,01-May-21,02-Jun-22,397,CADTH & INESSS,13-Sep-21,pre-NOC,Initial,Cutaneous T-cell lymphoma: the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.,Completed,12-Aug-22,Cond'l on Cost,Conditional,04-Mar-22,pre-NOC,New Drug,The treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.,Completed,27-Jul-22,Inscription - Avec conditions,Conditional,1st,19-Dec-22,,Active,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-262,-90,333,145,129,145,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,71,55,,,,,,,,468
Praluent,alirocumab,Sanofi-Aventis ,Y,Y,N,Y,N,N,N,N,N,01-Jun-15,11-Apr-16,315,CADTH & INESSS,12-Jan-16,pre-NOC,Initial,"Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia",Completed,20-Jul-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Drug,"Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia",Completed,01-Feb-17,Avis de refus d’inscription aux listes des médicaments – Médicament d’exception – À moins que certaines conditions soient respectées,Conditional,1st,26-Aug-16,02-Aug-18,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,LU,SA,EDS,SA,SA,NR,,01-Feb-19,01-Oct-18,31-May-19,28-Mar-19,30-Nov-18,01-May-19,25-Jul-22,02-May-22,,01-Oct-18,01-Oct-18,,3,1,6,4,2,5,8,7,,5.70%,6.60%,11.10%,43.30%,44.60%,50.10%,50.80%,51.20%,,,51.20%,31-May-19,,-90,123,190,173,37,-159,706,,183,60,302,238,120,272,1453,1369,,500,60,500,60,,,1026,903,1145,1081,963,1115,2296,2212,,1343,1343,903,993,803,,926,803,1045,981,863,1015,2196,2112,,1243,100,296,743,547,,,,242,,415
Praxbind (Drug Plan Submission)(Withdrawn),idarucizumab,Boehringer Ingelheim ,N,Y,N,Y,N,N,N,N,N,01-May-15,29-Apr-16,364,CADTH & INESSS,30-May-16,post-NOC,Initial,Reversal of dabigatran anticoagulant effects,Withdrawn,28-Sep-16,Cancelled or withdrawn,n/a,15-Aug-16,post-NOC,New Drug,Reversal of dabigatran anticoagulant effects,Completed,16-Dec-16,Avis d'inscription à la Liste Établissements - Médicament d'exception - Avec conditions,Conditional,none,,,,,,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,31,108,121,123,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,152,231,,,,,,,,516
Prevymis,letermovir,Merck,Y,N,N,Y,N,Y,Y,Y,N,01-May-17,01-Nov-17,184,CADTH & INESSS,07-Dec-17,post-NOC,Initial,"Cytomegalovirus infection, prophylaxis",Completed,20-Jun-18,Reimburse with clinical criteria and/or conditions,Conditional,22-Dec-17,post-NOC,New Drug,CMV Prophylaxis,Completed,05-Jul-18,Avis de refus d'inscription aux listes des médicaments,Negative,1st,29-Nov-18,18-Dec-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,18-May-21,01-Apr-20,01-Jul-20,16-Jul-20,22-Jan-20,16-Jul-20,01-Aug-21,20-Dec-21,08-Jun-21,05-Feb-20,22-Jan-20,22-Jan-20,7,3,4,5,1,6,9,10,8,2,32.20%,60.80%,65.30%,71.00%,76.50%,77.40%,97.70%,98.30%,99.60%,100.00%,100.00%,05-Feb-20,18-May-21,36,51,195,195,162,147,384,517,105,196,211,35,211,592,733,538,49,349,35,319,35,517,1294,882,973,988,812,988,1369,1510,1315,826,1126,1096,812,776,581,1063,651,742,757,581,757,1138,1279,1084,580,895,231,246,546,531,1294,482,482,14,468,415
Prezcobix,darunavir/cobicistat,Janssen ,Y,N,N,N,N,N,N,N,N,,19-Jun-14,,CADTH,22-May-14,pre-NOC,Initial,HIV infection,Completed,18-Mar-15,List with criteria/condition,Conditional,,,,,,,,,1st,10-Jun-15,24-Mar-16,Negotiation,Completed with Agreements,HIV,HIV,EDS,EDS,FB,SA,HIV,FB,SA,NR,12-Aug-15,,01-May-16,21-Jul-16,29-Jun-16,29-Sep-16,01-Sep-16,28-Nov-16,01-Nov-16,,12-Aug-15,12-Aug-15,1,,2,4,3,6,5,8,7,,20.30%,26.00%,58.20%,63.70%,65.00%,65.90%,66.60%,67.00%,,,67.00%,29-Jun-16,,-28,,300,,84,,288,-225,,38,119,97,189,161,249,222,,106,-225,106,-225,,419,,682,763,741,833,805,893,866,,750,750,419,447,147,147,,410,491,469,561,533,621,594,,478,272,,372,,,,,322,,42081
Prezcobix (Withdrawn),darunavir / cobicistat,Janssen ,Y,N,N,N,N,N,N,N,N,,19-Jun-14,,CADTH,04-Apr-14,pre-NOC,Initial,HIV infection,Withdrawn,08-Apr-14,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-76,,4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-72,,,,,,,,,41737
Probuphine,buprenorphine hydrochloride,Knight Therapeutics ,N,N,N,N,N,N,N,N,N,01-Jun-17,18-Apr-18,321,CADTH & INESSS,21-Dec-17,pre-NOC,Initial,"Opioid drug dependence, treatment",Completed,22-Aug-18,Reimburse with clinical criteria and/or conditions,Conditional,17-Apr-18,pre-NOC,New Drug,Opioid Dependency,Completed,17-Oct-18,Inscription – Avec conditions,Conditional,1st,30-Nov-18,03-May-19,Negotiation,Completed with Agreements,NR,SA,EDS,RB,LU,SA,EDS,SA,SA,EM,,01-Jul-19,01-Aug-19,02-Mar-20,30-Apr-20,26-Aug-19,06-Feb-20,31-May-21,04-Dec-19,14-Nov-19,01-Jul-19,01-Jul-19,,1,2,7,8,3,6,9,5,4,4.50%,10.20%,11.10%,39.70%,40.30%,41.60%,47.20%,79.40%,79.70%,,79.70%,30-Apr-20,,-118,-1,244,183,100,44,154,,59,90,304,363,115,279,759,215,195,273,59,264,59,,,439,470,684,743,495,659,1139,595,575,653,644,439,557,313,,313,344,558,617,369,533,1013,469,393,527,126,182,254,198,,,,304,,447
Procysbi,cysteamine bitartrate,Horizon Pharma,N,N,N,Y,N,N,Y,Y,N,,13-Jun-17,,CADTH & INESSS,08-Aug-17,post-NOC,Initial,Nephropathic cystinosis,Completed,24-Jan-18,Reimburse with clinical criteria and/or conditions,Conditional,05-Mar-18,post-NOC,New Drug,Nephropathic cystinosis,Completed,05-Sep-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,09-Feb-18,20-Jul-18,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,NR,SA,EDS,NR,SA,EM,,01-Sep-18,01-Oct-18,18-Oct-18,,30-Nov-18,01-Feb-19,,20-Apr-21,27-Sep-18,01-Sep-18,01-Sep-18,,1,3,4,,5,6,,7,2,4.50%,33.00%,38.80%,44.30%,45.20%,46.50%,47.20%,,,,47.20%,,,56,265,169,184,16,-208,161,,43,73,90,,133,196,,1005,69,257,43,230,43,,,445,475,492,,535,598,,1407,471,659,632,445,389,220,,220,250,267,,310,373,,1182,22,434,225,449,177,-47,,,,,,43124
Proleukin,aldesleukin (IL-2),Novartis,Y,Y,N,N,Y,Y,N,Y,N,,16-Sep-14,,CADTH,30-Jan-15,post-NOC,New indication,In-transit Melanoma,Completed,22-Jun-15,Fund,Positive,,,,,,,,,None,,,,,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,,01-Jun-21,18-Dec-15,11-Sep-15,09-Sep-15,09-Sep-16,14-Dec-17,01-Dec-15,,,,09-Sep-15,09-Sep-15,7,4,2,1,5,6,3,,,,5.50%,11.20%,12.60%,17.00%,49.20%,50.10%,70.40%,,,,70.40%,14-Dec-17,,136,,143,,,,,,,,,,,,,,,,,,,,2450,458,360,358,724,1185,441,,,,854,854,358,222,79,2171,179,81,79,445,906,162,,,,575,279,,,,,,,827,,42177
Prolia (men Osteo) (Drug Plan Submission),denosumab ,Amgen ,Y,Y,N,N,N,N,N,N,N,,21-Nov-12,,CADTH & INESSS,10-Mar-15,post-NOC,Request for Advice,"Osteoporosis, men",Completed,21-Sep-15,List with clinical criteria and/or conditions,Conditional,31-Jan-18,post-NOC,New Indication,"Osteoporosis, men",Completed,08-Aug-18,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception,Negative,1st,09-Dec-15,17-Oct-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,14-Feb-17,01-Feb-16,01-Jan-18,,31-Jan-18,12-Feb-18,01-Jun-19,25-Nov-19,16-Mar-18,16-Aug-18,01-Feb-16,01-Feb-16,2,1,3,,4,5,8,9,6,7,4.50%,24.70%,30.40%,62.70%,63.60%,64.20%,92.80%,94.10%,94.50%,,94.50%,31-Jan-18,16-Aug-18,839,1897,195,189,79,-973,678,-245,-624,76,,106,118,592,769,150,303,118,-624,138,-624,303,1546,1167,1867,,1897,1909,2383,2560,1941,2094,1909,1929,1167,328,133,512,133,833,,863,875,1349,1526,907,8,875,1034,2086,757,-295,2094,927,927,730,197,42268
Qinlock,ripretinib,Medison Pharma Canada Inc.,N,N,N,Y,Y,Y,Y,Y,N,01-Mar-20,19-Jun-20,110,CADTH & INESSS,15-Oct-21,post-NOC,Initial,"For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.",Completed,28-Apr-22,Cond'l on Cost,Conditional,25-Mar-22,post-NOC,New Drug,"For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.",Completed,27-Jul-22,Inscription - Avec conditions,Conditional,1st,12-Jul-22,,Active,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,483,644,195,124,75,-15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,678,768,,,,,,,,788
Quinsair,levofloxacin,Raptor Pharmaceuticals Inc.,N,N,N,N,N,N,N,N,N,,09-Jun-15,,CADTH & INESSS,31-May-16,post-NOC,Initial,Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections,Completed,21-Nov-16,Reimburse with clinical criteria and/or conditions,Conditional,,,New drug,Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections,completed,01-Jun-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,29-May-17,11-Oct-18,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,FB,CF,UR,SA,EM,,01-Dec-18,01-Jan-19,02-Mar-20,04-Feb-19,27-Mar-19,01-Apr-19,,01-Mar-19,15-Nov-18,01-Dec-18,15-Nov-18,,2,3,8,4,6,7,,5,1,28.60%,33.00%,38.80%,71.00%,71.70%,72.60%,73.90%,79.40%,,,79.40%,04-Feb-19,,357,,174,,189,-3,500,,51,82,508,116,167,172,,141,35,177,51,159,35,,,1271,1302,1728,1336,1387,1392,,1361,1255,1397,1379,1271,914,740,,740,771,1197,805,856,861,,830,532,866,531,723,689,497,,,,81,,42695
Qulipta,atogepant,Allergan Inc. (an AbbVie company),Y,N,N,Y,N,N,N,N,N,01-Jul-21,22-Dec-22,539,CADTH,23-Feb-22,pre-NOC,Initial,"Migraine, prevention",Active,,Active,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-302,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44378
Radicava,edaravone,Mitsubishi Tanabe Pharma Corporation,N,N,N,Y,N,Y,Y,Y,Y,01-Apr-18,03-Oct-18,185,CADTH & INESSS,05-Jul-18,pre-NOC,Initial,amyotrophic lateral sclerosis,Completed,27-Mar-19,Reimburse with clinical criteria and/or conditions,Conditional,11-Jul-18,pre-NOC,New Drug,Amyotropic lateral sclerosis,Completed,13-Feb-19,Inscription – Avec conditions,Conditional,1st,24-Sep-19,15-Apr-20,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,19-Aug-20,01-Jun-20,01-Jul-20,16-Jul-20,11-May-20,18-Jun-20,06-Jul-20,22-Nov-21,01-Mar-21,29-Apr-20,11-May-20,29-Apr-20,8,3,5,7,2,4,6,10,9,1,28.60%,60.80%,65.30%,66.20%,71.90%,73.20%,78.70%,99.00%,99.60%,100.00%,100.00%,11-May-20,19-Aug-20,-90,-84,265,217,181,223,204,126,47,77,92,26,64,82,586,320,14,158,26,143,14,126,686,607,637,652,586,624,642,1146,880,574,718,703,586,676,411,511,432,462,477,411,449,467,971,705,441,543,175,133,385,427,686,112,100,12,100,360
Radicava,edaravone,Mitsubishi Tanabe Pharma Corporation,N,N,N,N,N,Y,Y,Y,N,01-Apr-18,03-Oct-18,185,CADTH,10-Mar-22,post-NOC,Initial,Amyotrophic lateral sclerosis,Completed,22-Dec-22,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,14-Mar-23,,Active,n/a,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,1254,,287,,82,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1541,,,,,,,,,1726
Ravicti,glycerol phenylbutyrate,Horizon Therapeutics Canada/Horizon Pharma Ireland Ltd.,N,N,N,Y,N,Y,Y,Y,N,,18-Mar-16,,CADTH & INESSS,30-Aug-16,post-NOC,Initial,Urea cycle disorders,Completed,21-Mar-17,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,Chronic management of adult and pediatric patients two years of age and older with Urea Cycle Disorders (UCDs),Completed,06-Jan-17,Avis de refus d'inscription aux listes des médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,21-Apr-17,12-Dec-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,UR,SA,EM,23-Jan-18,01-May-18,01-Apr-18,19-Apr-18,09-Apr-18,18-Jul-18,01-Feb-19,,04-Mar-19,23-May-19,23-Jan-18,23-Jan-18,1,5,2,4,3,6,7,,8,9,20.30%,26.00%,58.20%,63.70%,68.20%,69.10%,70.40%,71.10%,99.60%,,99.60%,09-Apr-18,23-May-19,165,,203,,31,105,235,42,140,110,128,118,218,416,,447,527,202,42,238,42,527,676,774,744,762,752,852,1050,,1081,1161,836,872,676,511,308,308,406,376,394,384,484,682,,713,867,468,368,294,266,340,1161,485,485,76,409,42815
Rebif,interferon beta-1a ,EMD Serono ,N,Y,N,N,N,N,N,N,N,,07-Jun-12,,CADTH & INESSS,08-Mar-13,post-NOC,Initial,Clinically Isolated Syndrome ,Completed,15-Aug-13,Do not list,Negative,,,New Indication,CIS,Completed,03-Jun-13,Modification d'une indication reconnue - Médicament d'exception,Conditional,1st,11-Oct-13,21-Apr-15,Negotiation,Completed with Agreements,NR,NR,NR,NR,EAP,SA,NR,NR,NR,EM,,,,,25-May-15,,,,,01-Oct-03,25-May-15,01-Oct-03,,,,,2,,,,,1,28.60%,60.80%,,,,,,,,,60.80%,25-May-15,,274,,160,,57,130,557,,,,,34,,,,,-4220,34,34,-2093,-4220,,,,,,1082,,,,,-3172,1082,-1045,1082,808,648,,,,,648,,,,,-3533,648,434,361,614,687,,,,4254,,41501
Reblozyl,luspatercept,Celgene Inc./Bristol-Myers Squibb Canada Co.,Y,Y,N,Y,N,Y,Y,Y,N,01-Mar-20,25-Sep-20,208,CADTH & INESSS,26-Nov-20,post-NOC,Initial,beta-thalassemia associated anemia,Completed,08-Jun-21,Reimburse with clinical criteria and/or conditions,Conditional,01-Jan-21,post-NOC,New Drug,Beta-thalassemia related anemia requiring blood transfusion,Completed,02-Jun-21,Inscription - Avec conditions,Conditional,1st,07-Mar-22,18-Oct-22,Negotiation,Completed with Agreements,,SA,,,EAP,,,,,EM,,01-Feb-23,,,27-Feb-23,,,,,09-Nov-22,01-Feb-23,09-Nov-22,,2,,,3,,,,,1,28.60%,33.00%,65.30%,,,,,,,,65.30%,27-Feb-23,,62,98,194,152,272,278,225,,106,,,132,,,,,22,119,106,87,22,,,859,,,885,,,,,775,872,840,859,797,603,,603,,,629,,,,,525,616,256,250,497,503,,,,110,,464
Reblozyl,luspatercept,"Celgene Inc., a Bristol Myers Squibb company",N,Y,N,Y,N,Y,Y,Y,N,01-Mar-20,11-Feb-21,347,CADTH & INESSS,28-Jan-21,pre-NOC,Initial,Myelodysplastic syndromes-associated anemia,Completed,07-Dec-21,Reimburse with clinical criteria and/or conditions,Conditional,23-Apr-21,post-NOC,New Indication,Myelodysplastic syndromes-associated anemia,Completed,08-Oct-21,Inscription - Avec conditions,Conditional,1st,07-Mar-22,18-Oct-22,Negotiation,Completed with Agreements,,,,,EAP,,,,,EM,,,,,27-Feb-23,,,,,09-Nov-22,27-Feb-23,09-Nov-22,,,,,2,,,,,1,28.60%,60.80%,,,,,,,,,60.80%,27-Feb-23,,-14,71,313,168,90,150,225,,,,,132,,,,,22,132,132,77,22,,,,,,746,,,,,636,746,691,746,760,447,,,,,447,,,,,397,447,299,239,315,375,,,,110,,646
Remsima,infliximab ,"Celltrion Healthcare Co., Ltd",N,Y,Y,N,N,N,N,N,N,,28-Jan-21,,CADTH & INESSS,24-Sep-20,pre-NOC,Initial,Rheumatoid arthritis,Completed,22-Apr-21,Reimburse with clinical criteria and/or conditions,Conditional,27-Apr-21,post-NOC,New Form,Rheumatoid arthritis,Completed,08-Sep-21,Inscription - Avec conditions,Conditional,1st,04-Jun-21,10-Mar-22,Negotiation,No agreement reached,NR,,NR,,,NR,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-126,89,210,134,43,-96,279,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,84,223,322,183,,,,,,44308
Remsima (SEB) (Withdrawn),infliximab ,Fresenius ,N,Y,Y,N,N,N,N,N,N,,15-Jan-14,,CADTH,30-May-14,post-NOC,Initial,"Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis ",Withdrawn,21-Oct-14,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,135,,144,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,279,,,,,,,,,41933
Renflexis,infliximab,Merck,Y,Y,Y,N,N,N,N,N,N,,01-Dec-17,,CADTH & INESSS,05-Sep-17,pre-NOC,Initial,"rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis ",Completed,20-Feb-18,Reimburse with clinical criteria and/or conditions,Conditional,01-Feb-18,post-NOC,New Drug,Multiple,Completed,14-Jun-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,13-Apr-18,27-Jul-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,21-Aug-18,01-Jan-19,01-Apr-19,18-Oct-18,27-Sep-18,07-Feb-19,01-Sep-19,26-Nov-18,01-Dec-18,27-Sep-18,21-Aug-18,21-Aug-18,1,7,9,4,2,8,10,5,6,3,20.30%,52.50%,81.10%,86.60%,87.00%,87.60%,92.10%,93.00%,98.70%,100.00%,100.00%,27-Sep-18,27-Sep-18,-87,62,168,133,52,-62,105,25,158,248,83,62,195,401,122,127,62,158,25,148,25,62,263,396,486,321,300,433,639,360,365,300,396,386,263,350,182,182,315,405,240,219,352,558,279,284,105,315,81,195,157,43,300,37,37,37,0,43151
Repatha (HeFH or ASCVD),evolocumab,Amgen ,Y,Y,N,N,N,N,N,N,N,01-Aug-17,05-Jun-18,308,CADTH & INESSS,17-Feb-17,pre-NOC,Initial,Primary hyperlipidemia and mixed dyslipidemia,Completed,22-Nov-17,Reimburse with clinical criteria and/or conditions,Conditional,28-Feb-20,post-NOC,New Indication,Prevention of secondary cardiovascular events,Completed,05-Aug-20,Inscription - Avec conditions,Conditional,1st,08-Aug-18,25-Jul-19,Negotiation,No agreement reached,UR,UR,NR,UR,UR,NR,UR,UR,UR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-473,633,278,159,259,-728,351,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-195,792,610,-377,,,,,,113
Repatha (HeFH),evolocumab,Amgen ,Y,Y,N,Y,N,N,N,N,N,,10-Sep-15,,CADTH & INESSS,30-Jun-15,pre-NOC,Initial,Primary hyperlipidemia and mixed dyslipidemia,Completed,19-Feb-16,List with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New Drug,Primary hyperlipidemia and mixed dyslipidemia (homo),Completed,01-Jun-16,Avis de refus d'inscription aux listes des médicaments-Médicament d'exception-À moins que certaines conditions soient respectées (hypercholestérolémie familiale hétérozygote),Conditional,1st,26-Aug-16,23-Oct-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,18-Dec-18,01-Jun-18,01-Jul-18,25-Jan-18,30-Apr-18,18-Jul-18,01-May-19,28-Feb-22,14-Feb-20,01-Feb-18,25-Jan-18,25-Jan-18,7,4,5,1,3,6,8,10,9,2,5.50%,34.10%,66.30%,70.80%,76.50%,77.40%,97.70%,99.00%,99.60%,100.00%,100.00%,30-Apr-18,18-Dec-18,-72,75,234,190,189,86,423,421,221,251,94,189,268,555,1589,844,101,492,94,453,94,421,1195,995,1025,868,963,1042,1329,2363,1618,875,1266,1227,868,940,706,1033,833,863,706,801,880,1167,2201,1456,610,1104,162,265,612,509,1195,327,327,95,232,42419
Retevmo,selpercatinib,Eli Lilly ,N,N,N,Y,Y,Y,N,Y,N,01-Oct-20,15-Jun-21,257,CADTH & INESSS,17-Aug-21,post-NOC,Initial,Indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.,Completed,28-Apr-22,Cond'l on Cost,Conditional,28-Oct-22,post-NOC,New drug,Indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.,Under review,TBD,TBD,TBD,1st,17-Nov-22,31-Mar-23,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,63,500,254,,203,,134,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,317,,337,,,,,,,574
Retevmo,selpercatinib,Eli Lilly,N,N,N,Y,Y,Y,N,Y,N,01-Oct-20,15-Jun-21,257,CADTH & INESSS,29-Oct-21,post-NOC,Initial,Retevmo is indicated as monotherapy for the treatment of: RET-mutant medullary thyroid cancer in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.,Completed,26-Sep-22,Cond'l on Cost,Conditional,28-Oct-22,post-NOC,New Indication,Retevmo is indicated as monotherapy for the treatment of: RET-mutant medullary thyroid cancer in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.,Completed,29-Mar-23,Refus d'inscription,Negative,1st,17-Nov-22,31-Mar-23,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,136,500,332,152,52,-132,134,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,468,652,186,2,,,,,,725
Retevmo,selpercatinib,Eli Lilly ,N,N,N,Y,Y,Y,N,Y,N,01-Oct-20,15-Jun-21,257,CADTH & INESSS,29-Oct-21,post-NOC,Initial,Retevmo is indicated as monotherapy for the treatment of: • RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib,Completed,29-Jun-22,Cond'l on Cost,Conditional,25-Nov-22,post-NOC,New drug,Retevmo is indicated as monotherapy for the treatment of: • RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib,Under review,TBD,TBD,TBD,1st,17-Nov-22,31-Mar-23,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,136,528,243,,141,,134,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,379,,275,,,,,,,636
Revestive,teduglutide,Shire,Y,Y,N,Y,N,Y,Y,Y,N,,04-Sep-15,,CADTH & INESSS,26-Nov-15,post-NOC,Initial,Short Bowel Syndrome (SBS),Completed,27-Jul-16,Reimburse with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New Drug,Short Bowel Syndrome (SBS),Completed,01-Jun-16,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,30-Jun-17,07-Aug-18,Negotiation,Completed with Agreements,NR,SA,NR,EDS,EAP,SA,EDS,NR,NR,NR,,01-Jan-19,,24-Jan-19,12-Dec-18,04-Jul-19,01-Aug-19,,,,12-Dec-18,12-Dec-18,,2,,3,1,4,5,,,,32.20%,36.70%,42.20%,43.10%,44.40%,,,,,,44.40%,,,83,81,244,190,338,394,403,,147,,170,127,331,359,,,,227,127,227,127,,,1215,,1238,1195,1399,1427,,,,1295,1295,1195,1112,868,,888,,911,868,1072,1100,,,,968,327,271,741,797,,,,,,42578
Revestive,teduglutide,Shire,Y,Y,N,N,N,Y,Y,Y,N,01-Feb-19,13-Aug-19,193,CADTH,29-May-19,pre-NOC,Initial,"Short Bowel Syndrome (SBS), pediatrics",Completed,19-Nov-19,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,2nd,21-Feb-20,28-Oct-20,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,SA,EDS,UR,SA,,,01-May-21,01-May-21,01-Apr-21,06-Apr-21,22-Apr-21,01-May-21,,27-Oct-21,,01-Apr-21,01-Apr-21,,4,5,1,2,3,6,,7,,5.50%,37.80%,38.70%,43.10%,48.80%,50.10%,50.80%,,,,50.80%,01-May-21,,-76,,174,,94,,250,,185,185,155,160,176,185,,364,,201,155,201,155,,,627,627,597,602,618,627,,806,,643,643,597,673,499,,529,529,499,504,520,529,,708,,545,98,,344,,,,,30,,291
Revlimid,lenalidomide,Celgene ,N,N,N,N,Y,Y,Y,Y,N,,,,CADTH,05-Apr-13,na,New indication,For the maintenance treatment of newly diagnosed multiple myeloma in patients after stem-cell transplantation,Completed,22-Oct-13,Cond'l on Cost,Conditional,,,,,,,,,1st,12-Nov-13,25-Jul-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,,01-Jan-15,30-Sep-14,15-Sep-14,16-Oct-14,09-Sep-14,12-Dec-14,29-Dec-14,23-Nov-15,01-Dec-14,,09-Sep-14,09-Sep-14,8,3,2,4,1,6,7,9,5,,32.20%,38.00%,42.40%,47.90%,48.60%,49.50%,50.80%,71.10%,71.40%,,71.40%,29-Dec-14,,,,200,,21,,255,160,67,52,83,46,140,157,486,129,,147,46,147,46,,,,,,,,,,,,,,,522,322,436,343,328,359,322,416,433,762,405,,423,,,276,,,,,111,,41569
Revlimid,lenalidomide,Celgene ,N,N,N,N,Y,Y,Y,Y,N,,14-Dec-16,,CADTH & INESSS,04-May-15,pre-NOC,New indication,"In combination with low-dose dexamethasone, for treatment of newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation",Completed,03-Dec-15,Cond'l on Cost,Conditional,24-Mar-17,post-NOC,New Indication,Multiple myeloma- combination with dexamethasone,Completed,18-Oct-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,10-Dec-15,14-Sep-16,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Apr-17,18-Oct-16,27-Oct-16,20-Apr-17,14-Mar-17,21-Dec-16,01-Dec-16,11-Jul-22,31-Dec-16,05-Jul-18,18-Oct-16,18-Oct-16,7,1,2,8,6,4,3,10,5,9,4.50%,10.20%,11.50%,12.40%,13.00%,45.30%,65.50%,71.10%,99.60%,100.00%,100.00%,01-Apr-17,05-Jul-18,-590,100,213,208,7,-678,279,199,34,43,218,181,98,78,2126,108,659,343,34,374,34,659,108,-57,-48,127,90,7,-13,2035,17,568,252,283,-57,533,320,485,320,329,504,467,384,364,2412,394,260,629,-377,308,286,-399,568,625,625,165,460,42341
Revlimid,lenalidomide,Celgene ,N,N,N,N,Y,Y,Y,Y,N,,,,CADTH,14-Jan-19,na,New indication,"The combination of lenalidomide, bortezomib, and low-dose dexamethasone, for the treatment of newly diagnosed multiple myeloma patients in whom stem cell transplantation is not intended",Completed,19-Jun-19,Cond'l on Cost,Conditional,,,,,,,,,1st,24-Sep-19,10-Jun-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,,01-Feb-21,31-Dec-20,01-Sep-20,22-Oct-20,30-Jun-22,13-May-21,31-May-21,,,,01-Sep-20,01-Sep-20,4,3,1,2,7,5,6,,,,5.70%,11.20%,15.70%,36.00%,36.90%,38.20%,70.40%,,,,70.40%,30-Jun-22,,,,156,,97,,260,236,204,83,134,750,337,355,,,,300,83,300,83,,,,,,,,,,,,,,,596,440,593,561,440,491,1107,694,712,,,,657,,,357,,,,,667,,43635
Revolade (TCP),eltrombopag,GlaxoSmithKline,Y,N,N,N,N,N,N,N,N,,27-Mar-14,,CADTH & INESSS,31-Mar-14,post-NOC,Initial,"Thrombocytopenia, chronic hepatitis C-associated",Completed,18-Mar-15,List with criteria/condition,Conditional,22-Mar-14,pre-NOC,New Indication,"Thrombocytopenia, chronic hepatitis C-associated",Completed,01-Oct-14,Ajout d'une indication reconnue - Médicament d'exception - Avis de refus,Conditional,none,28-May-15,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,4,-5,352,193,71,239,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,356,188,,,,,,,,42081
Rexulti,brexpiprazole,Otsuka-Lundbeck,N,N,N,Y,N,N,N,N,N,01-Apr-16,16-Feb-17,321,CADTH & INESSS,03-Feb-17,pre-NOC,Initial,Schizophrenia,Completed,22-Nov-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,Schizophrenia,Completed,18-Oct-17,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,04-Apr-18,14-Dec-18,Negotiation,Completed with Agreements,SA,FB,EDS,FB,FB,FB,FB,FB,FB,NR,17-Dec-19,01-Apr-19,01-Jun-19,31-May-19,30-Apr-19,16-May-19,18-Aug-22,25-Mar-19,01-May-19,,25-Mar-19,25-Mar-19,8,2,7,6,3,5,9,1,4,,0.40%,4.80%,37.00%,37.70%,38.60%,44.10%,49.90%,70.10%,71.40%,,71.40%,17-Dec-19,,-13,36,292,208,133,168,254,368,108,169,168,137,153,1343,101,138,,298,101,298,101,,1034,774,835,834,803,819,2009,767,804,,964,964,767,780,488,755,495,556,555,524,540,1730,488,525,,685,279,244,387,422,,,,267,,600
Rinvoq,upadacitinib,AbbVie,Y,N,N,Y,N,N,N,N,N,01-Mar-19,23-Dec-19,297,CADTH & INESSS,04-Jul-19,pre-NOC,Initial,"Arthritis, Rheumatoid",Completed,04-Feb-20,Reimburse with clinical criteria and/or conditions,Conditional,09-Aug-19,pre-NOC,New Drug,Rheumatoid arthritis,Completed,04-Mar-20,Inscription - Avec conditions,Conditional,1st,21-Jan-21,08-Aug-22,Negotiation,Completed with Agreements,NR,SA,EDS,,LU,SA,EDS,,SA,EM,,01-Oct-22,01-Oct-22,,31-Oct-22,21-Nov-22,01-Mar-23,,23-Jan-23,28-Sep-22,01-Oct-22,28-Sep-22,,2,3,,4,5,7,,6,1,28.60%,33.00%,38.80%,71.00%,71.90%,72.60%,73.90%,,,,73.90%,31-Oct-22,,-172,-136,215,208,352,323,564,,54,54,,84,105,205,,168,51,112,54,103,51,,,1013,1013,,1043,1064,1164,,1127,1010,1071,1062,1013,1185,970,,970,970,,1000,1021,1121,,1084,938,1028,43,72,916,887,,,,33,,340
Rinvoq,upadacitinib,AbbVie,Y,N,N,N,N,N,N,N,N,01-Aug-20,03-Jun-21,306,CADTH & INESSS,04-Jan-21,pre-NOC,Initial,"Active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more DMARDs. Rinvoq may be used as monotherapy or in combination with nonbiologic DMARDs",Completed,20-Aug-21,Reimburse with clinical criteria and/or conditions,Conditional,19-Mar-21,pre-NOC,New Indication,Psoriatic arthritis,Completed,01-Sep-21,Inscription - Avec conditions,Conditional,1st,28-Feb-22,08-Aug-22,Negotiation,Completed with Agreements,NR,SA,EDS,,EAP,SA,EDS,,SA,EM,,01-Oct-22,01-Oct-22,,16-Nov-22,21-Nov-22,01-Mar-23,,23-Jan-23,28-Sep-22,01-Oct-22,28-Sep-22,,2,3,,4,5,7,,6,1,28.60%,33.00%,38.80%,71.00%,71.90%,72.60%,73.90%,,,,73.90%,16-Nov-22,,-150,-76,228,166,192,180,161,,54,54,,100,105,205,,168,51,114,54,105,51,,,485,485,,531,536,636,,599,482,545,536,485,635,407,,407,407,,453,458,558,,521,392,467,78,90,353,341,,,,49,,384
Rinvoq,upadacitinib,AbbVie,Y,N,N,N,N,N,N,N,N,01-Dec-20,01-Oct-21,304,CADTH & INESSS,13-Apr-21,pre-NOC,Initial,atopic dermatitis,Completed,08-Jun-22,Reimburse with clinical criteria and/or conditions,Conditional,20-Aug-21,pre-NOC,New Indication,Atopic dermatitis 12+,Completed,30-Mar-22,Inscription - Avec conditions,Conditional,1st,14-Feb-23,,Active,n/a,NR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-171,-42,421,222,251,321,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,250,180,,,,,,,,554
Rinvoq,upadacitinib,AbbVie,Y,N,N,N,N,N,N,N,N,01-Aug-20,06-Mar-21,217,CADTH & INESSS,18-Apr-22,post-NOC,Initial,Ulcerative colitis,Suspended,,Active,n/a,23-Sep-22,post-NOC,New Indication,Ulcerative colitis,under review,TBD,TBD,TBD,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,408,566,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44044
Rinvoq,upadacitinib,AbbVie Corporation,Y,N,N,N,N,N,N,N,N,01-Feb-21,14-Jul-22,528,CADTH,17-Oct-22,post-NOC,Initial,ankylosing spondylitis,Active,,Active,n/a,,,,,,,,,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,95,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44228
Rituxan,rituximab,Hoffman-La Roche ,Y,Y,N,Y,Y,N,N,N,N,,,,CADTH,13-Feb-17,na,New drug,Acute Lymphoblastic Leukemia,Completed,31-Aug-17,Do Not Fund,Negative,,,,,,,,,None,08-Dec-17,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,199,,99,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,42978
Rosiver,ivermectin,Galderma ,N,N,N,Y,N,N,N,N,N,,22-Apr-15,,CADTH & INESSS,30-Apr-15,post-NOC,Initial,Rosacea,Completed,19-Nov-15,List with criteria/condition,Conditional,24-Nov-15,post-NOC,New Drug,Rosacea,Completed,01-Jun-16,Avis de refus d'inscription aux listes de médicaments,Negative,1st,15-Apr-16,26-Aug-16,Negotiation,No agreement reached,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,8,216,203,190,148,-47,133,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,211,406,281,86,,,,,,42327
Rosiver (2nd pCPA),ivermectin,Galderma ,N,N,N,Y,N,N,N,N,N,,22-Apr-15,,CADTH & INESSS,30-Apr-15,post-NOC,Initial,Rosacea,Completed,19-Nov-15,List with criteria/condition,Conditional,24-Nov-15,post-NOC,New Drug,Rosacea,Completed,01-Jun-16,Avis de refus d'inscription aux listes de médicaments,Negative,2nd,23-Feb-18,23-May-18,Negotiation,No agreement reached,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,8,216,203,190,827,632,89,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,211,406,916,721,,,,,,42327
Rozlytrek,entrectinib,Hoffman-La Roche,Y,N,N,Y,Y,Y,N,Y,N,01-Jun-19,10-Feb-20,254,CADTH,29-Jul-19,pre-NOC,New drug,Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion-Positive Solid Tumours,Withdrawn,12-Feb-20,n/a,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-196,,198,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,256
Rozlytrek,entrectinib,Hoffman-La Roche,Y,N,N,N,Y,Y,N,Y,N,01-Jul-19,05-May-20,309,CADTH & INESSS,08-Jan-20,pre-NOC,New indication,ROS1-positive Non-Small Cell Lung Cancer: For the first-line treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer,Completed,27-Jan-21,Cond'l on Cost,Conditional,03-Jan-20,pre-NOC,New Indication,ROS1-positive Non-Small Cell Lung Cancer,Completed,05-Nov-20,Inscription - Avec conditions,Conditional,1st,04-May-21,06-Jul-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Apr-22,30-Nov-21,01-Nov-21,25-Nov-21,31-Jan-22,14-Oct-21,30-Nov-21,12-Dec-22,24-May-22,18-Aug-21,14-Oct-21,18-Aug-21,8,5,3,4,7,2,6,10,9,1,28.60%,29.50%,35.20%,40.70%,45.20%,46.50%,78.70%,99.00%,99.60%,100.00%,100.00%,31-Jan-22,01-Apr-22,-118,-123,385,307,97,180,63,269,147,118,142,209,100,147,524,322,43,220,100,202,43,269,696,574,545,569,636,527,574,951,749,470,647,629,527,645,260,429,307,278,302,369,260,307,684,482,286,380,267,184,160,243,696,226,169,166,60,576
Rozlytrek,entrectinib,Hoffmann-La Roche,Y,N,N,Y,Y,Y,N,Y,N,01-Jun-19,10-Feb-20,254,CADTH & INESSS,25-Jan-22,post-NOC,Initial,"For the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.",Completed,03-Nov-22,Cond'l on Cost,Conditional,01-Jul-22,post-NOC,New Drug,"For the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.",Completed,30-Nov-22,Avis de refus d’ajout d’une indication reconnue à la Liste Établissements – Médicament d’exception,Negative,1st,08-Dec-22,16-Mar-23,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,715,872,282,152,35,8,98,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,997,1024,133,106,,,,,,1251
Rukobia,fostemsavir,ViiV Healthcare ULC,N,N,N,Y,N,N,N,N,N,01-Apr-21,01-Oct-21,183,CADTH,28-Oct-22,post-NOC,Initial,Human immunodeficiency virus type 1 (HIV-1),Active,,Active,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,392,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44287
Ruzurgi,amifampridine,Médunik Canada Inc.,N,N,N,Y,N,Y,Y,Y,N,01-Feb-20,24-Jun-21,509,CADTH & INESSS,05-Oct-20,pre-NOC,Initial,Symptomatic treatment of Lambert-Eaton myasthenic Syndrome (LEMS) in patients 6 years of age and older,Completed,20-Apr-21,Reimburse with clinical criteria and/or conditions,Conditional,23-Oct-20,pre-NOC,New Drug,Lambert Eaton myasthenia syndrome,Completed,07-May-21,Inscription - Avec conditions,Conditional,1st,18-Oct-21,01-Jun-22,Negotiation,No Agreement reached,,SA,,,,,,,,EM,,01-Mar-23,,,,,,,,01-Mar-23,01-Mar-23,01-Mar-23,,1,,,,,,,,2,4.50%,33.00%,,,,,,,,,33.00%,,,-262,-244,197,196,181,164,226,,273,,,,,,,,273,273,273,273,273,,,615,,,,,,,,615,615,615,615,877,680,,680,,,,,,,,663,680,-65,-48,407,390,,,,,,444
Rybelsus,semaglutide,Novo Nordisk Canada Inc.,Y,Y,N,N,N,N,N,N,N,01-Jun-19,30-Mar-20,303,CADTH & INESSS,26-Nov-20,post-NOC,Initial,As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in combination with other medicinal products for the treatment of diabetes,Completed,08-Jun-21,Reimburse with clinical criteria and/or conditions,Conditional,18-Nov-19,pre-NOC,New Drug,Type 2 Diabetes,Completed,08-Jul-20,Inscription - Avec conditions,Conditional,1st,04-Nov-21,20-Dec-22,Negotiation,No agreement reached,NR,,,,,NR,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,241,-133,194,233,149,484,411,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,435,100,560,895,,,,,,738
Rybrevant,amivantamab,Janssen Inc.,Y,Y,N,Y,Y,N,N,N,N,01-Jul-21,30-Mar-22,272,CADTH & INESSS,21-Apr-22,post-NOC,Initial,"For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy.",Completed,01-Mar-23,Cond'l on Cost,Conditional,25-Nov-22,post-NOC,New Drug,"For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy.",Under review,TBD,TBD,TBD,None,,,Under consideration for negotiation,n/a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,22,240,314,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,336,,,,,,,,,608
Rydapt,midostaurin,Novartis,Y,N,N,Y,Y,Y,Y,Y,N,01-Jul-17,21-Jul-17,20,CADTH & INESSS,12-Jun-17,pre-NOC,New drug,Acute Myeloid Leukemia,Completed,19-Dec-17,Fund,Positive,15-Dec-17,post-NOC,New Drug,Acute Myeloid Leukemia,Completed,11-Apr-18,Avis d’inscription à la liste Établissements – Médicament d’exception,Positive,1st,02-Feb-18,05-Jul-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Dec-18,29-Jan-19,01-Nov-18,18-Oct-18,11-Oct-18,24-Jun-19,03-Sep-19,01-Apr-20,19-Dec-19,16-Aug-18,11-Oct-18,16-Aug-18,5,6,4,3,2,7,8,10,9,1,28.60%,60.80%,66.30%,72.10%,92.30%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,11-Oct-18,01-Dec-18,-39,147,190,117,45,-68,153,149,208,119,105,98,354,425,636,532,42,292,98,267,42,149,498,557,468,454,447,703,774,985,881,391,641,616,447,486,296,347,406,317,303,296,552,623,834,730,127,490,151,264,198,85,498,107,51,56,51,171
Rydapt,midostaurin,Novartis,Y,N,N,N,Y,Y,Y,Y,N,01-Dec-17,03-Oct-18,306,CADTH,13-Aug-19,post-NOC,New indication,Systemic Mastocytosis,Completed,02-Apr-20,Do Not Fund,Negative,,,,,,,,,None,25-May-20,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,314,,233,,53,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,547,,,,,,,,,853
Rylaze,crisantaspase recombinant,Jazz Pharmaceuticals Canada,N,N,N,Y,Y,Y,N,Y,N,01-Nov-21,02-Sep-22,305,CADTH,18-Aug-22,pre-NOC,Initial,Rylaze (crisantaspase recombinant) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of: Acute lymphoblastic leukemia (ALL) in adults and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. Lymphoblastic lymphoma (LBL) in adults and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.,Active,,TBD,n/a,,,New Drug,Rylaze (crisantaspase recombinant) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of: Acute lymphoblastic leukemia (ALL) in adults and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. Lymphoblastic lymphoma (LBL) in adults and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.,Pending,TBD,TBD,TBD,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44501
Saphnelo,anifrolumab,AstraZeneca Canada Inc.,Y,Y,N,Y,N,N,N,N,N,01-Dec-20,30-Nov-21,364,CADTH & INESSS,28-Jan-22,post-NOC,Initial,Systemic lupus erythematosus,Completed,20-Jan-23,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-22,post-NOC,New Drug,Systemic Lupus Erythematosus,Completed,01-Mar-23,Inscription – Avec conditions,Conditional,none,,,,,UR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,59,255,357,201,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,416,456,,,,,,,,780
Sarclisa,isatuximab,Sanofi Genzyme,Y,N,N,Y,Y,Y,Y,Y,N,01-Jul-19,29-Apr-20,303,CADTH & INESSS,17-Aug-20,post-NOC,New Drug,"Isatuximab in combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.",Completed,01-Apr-21,Cond'l on Cost,Conditional,18-Sep-20,post-NOC,New Drug,"Isatuximab in combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.",Completed,03-Mar-21,Refus d’inscription,Negative,1st,13-May-22,07-Mar-23,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,110,142,227,166,407,436,298,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,337,308,705,734,,,,,,640
Sarclisa,isatuximab,Sanofi Genzyme,Y,N,N,N,Y,Y,Y,Y,N,01-Oct-20,13-Sep-21,347,CADTH & INESSS,15-Jul-21,pre-NOC,Initial,In combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy,Completed,28-Jan-22,Cond'l on Cost,Conditional,05-Nov-21,post-NOC,New Indication,In combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy,Completed,01-Jun-22,Refus d’inscription,Negative,1st,13-May-22,07-Mar-23,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-60,53,197,208,105,-19,298,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,137,261,403,279,,,,,,484
Saxenda,liraglutide,Novo Nordisk Canada Inc.,Y,Y,N,N,N,N,N,N,N,,26-Feb-15,,CADTH,23-Dec-20,post-NOC,Initial,"Adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.",Completed,01-Sep-21,Do not reimburse,Negative,,,,,,,,,none,22-Nov-21,,Do not negotiate,n/a,NR,,NR,,,NR,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,2127,,252,,82,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2379,,,,,,,,,44440
Scemblix,asciminib,Novartis,Y,N,N,Y,Y,Y,Y,Y,Y,01-Aug-21,22-Jun-22,325,CADTH & INESSS,20-Jan-22,pre-NOC,Initial,Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors,Completed,05-Aug-22,Cond'l on Cost,Conditional,22-Jul-22,post-NOC,New Drug,Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors,Completed,28-Dec-22,Inscription - Avec conditions,Conditional,1st,21-Oct-22,09-Mar-23,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-153,30,197,159,77,-68,139,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,44,189,216,71,,,,,,369
Seebri,glycopyrronium bromide ,Novartis ,Y,N,N,N,N,N,N,N,N,,16-Oct-12,,CADTH & INESSS,30-Nov-12,post-NOC,Initial,"Chronic Obstructive Pulmonary Disease (COPD), maintenance bronchodilator treatment ",Completed,15-May-13,List with criteria/condition,Conditional,24-Nov-12,post-NOC,New Drug,"Chronic Obstructive Pulmonary Disease (COPD), maintenance bronchodilator treatment ",Completed,03-Jun-13,Ajout aux listes de médicaments,Positive,1st,01-Jun-13,29-Jul-13,Negotiation,Completed with Agreements,SA,FB,EDS,FB,LU,SA,EDS,SA,SA,FB,19-Sep-13,01-Dec-13,01-Sep-13,23-Jan-14,29-Aug-13,19-Dec-13,30-Dec-13,20-Jan-14,01-Mar-14,03-Jun-13,29-Aug-13,03-Jun-13,4,5,3,9,2,6,7,8,10,1,28.60%,60.80%,66.50%,86.80%,91.20%,92.10%,93.40%,93.80%,99.30%,100.00%,100.00%,29-Aug-13,19-Sep-13,45,39,166,191,17,-2,58,52,125,34,178,31,143,154,175,215,-56,123,31,105,-56,52,338,411,320,464,317,429,440,461,501,230,409,391,317,272,106,127,200,109,253,106,218,229,250,290,0,198,211,230,75,56,338,108,21,87,21,41409
Segluromet,ertuglifozin and metformin hydrochloride,Merck,Y,N,N,N,N,N,N,N,N,01-Aug-17,30-May-18,302,CADTH & INESSS,30-Apr-18,pre-NOC,Initial,"Diabetes mellitus, Type 2",Completed,23-Jan-19,Do not reimburse,Negative,10-May-18,pre-NOC,New Drug,Type 2 Diabetes,Completed,08-Nov-18,Inscription – Avec conditions,Conditional,1st,20-Mar-19,31-Mar-20,Negotiation,No agreement reached,NR,UR,NR,UR,UR,NR,UR,UR,UR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-30,-20,268,182,56,132,377,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,238,162,433,509,,,,,,540
Semglee (withdrawn),insulin glargine,BGP PHARMA ULC,N,Y,Y,N/A,N,N,N,N,Y,01-Apr-17,,,CADTH,14-Nov-18,na,Initial,"Diabetes mellitus, Type 1 & 2",Withdrawn,05-Mar-19,Cancelled or withdrawn,n/a,,,,,,,,,1st,17-Aug-22,07-Nov-22,Negotiation,Completed with Agreements,,FB,FB,FB,FB,FB,FB,FB,FB,,,01-Dec-22,01-Feb-23,24-Jan-23,21-Dec-22,30-Jan-23,01-Feb-23,20-Feb-23,04-Jan-23,,01-Dec-22,01-Dec-22,,1,6,4,2,5,7,8,3,,4.50%,36.70%,37.40%,42.90%,43.80%,49.50%,50.80%,51.20%,,,51.20%,01-Feb-23,,,,111,,1261,,82,,24,86,78,44,84,86,105,58,,71,24,71,24,,,,,,,,,,,,,,,1478,1367,,1367,1429,1421,1387,1427,1429,1448,1401,,1414,,,1343,,,,,62,,703
Signifor,pasireotide diaspartate,Novartis ,Y,N,N,Y,N,Y,N,Y,N,,23-Sep-13,,CADTH,27-Feb-14,post-NOC,Initial,Cushing’s Disease,Completed,24-Feb-15,Do not list,Negative,,,,,,,,,none,30-Apr-15,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,157,,362,,65,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,519,,,,,,,,,42059
Siliq,brodalumab,Bausch Health (Valeant) ,N,Y,N,Y,N,N,N,N,N,01-Jul-16,06-Mar-18,613,CADTH & INESSS,14-Dec-17,pre-NOC,Initial,"Psoriasis, moderate to severe plaque",Completed,20-Jun-18,Reimburse with clinical criteria and/or conditions,Conditional,01-Jan-18,pre-NOC,New Drug,Plaque psoriasis,Completed,05-Jul-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,05-Oct-18,14-Dec-18,Negotiation,Completed with Agreements,NR,NR,EDS,EDS,LU,SA,EDS,SA,SA,EM,,,01-Jun-19,31-May-19,30-Apr-19,24-Jun-19,01-May-19,25-Mar-19,01-May-19,01-Feb-19,25-Mar-19,01-Feb-19,,,7,6,3,8,4,2,5,1,28.60%,28.90%,61.20%,62.50%,63.10%,68.70%,74.40%,75.30%,,,75.30%,30-Apr-19,,-82,-64,188,185,107,92,70,,,169,168,137,192,138,101,138,49,149,101,137,49,,,,452,451,420,475,421,384,421,332,432,420,384,466,278,,,346,345,314,369,315,278,315,211,326,106,121,177,162,,,,88,,719
Simbrinza,brinzolamide / brimonidine,Alcon ,N,N,N,N,N,N,N,N,N,,11-Dec-14,,CADTH & INESSS,03-Nov-14,pre-NOC,Initial,Glaucoma and ocular hypertension,Completed,17-Jun-15,List,Positive,22-Mar-15,post-NOC,New Drug,Glaucoma and ocular hypertension,Completed,01-Oct-15,Avis d'inscription aux listes de médicaments,Positive,1st,06-Aug-15,27-Aug-15,Negotiation,Completed with Agreements,FB,FB,FB,FB,LU,FB,FB,FB,FB,FB,27-Oct-15,01-Dec-15,01-Oct-15,22-Oct-15,29-Oct-15,24-Nov-15,01-Feb-16,23-Nov-15,01-Oct-15,01-Oct-15,01-Oct-15,01-Oct-15,5,9,1,4,6,8,10,7,2,3,5.70%,6.40%,35.00%,40.50%,60.80%,93.00%,93.30%,94.20%,98.70%,100.00%,100.00%,27-Oct-15,29-Oct-15,-38,101,226,193,50,-56,21,61,96,35,56,63,89,158,88,35,35,76,35,72,35,63,320,355,294,315,322,348,417,347,294,294,335,331,294,332,106,132,167,106,127,134,160,229,159,106,0,147,188,294,71,-35,322,28,28,26,2,42172
Simponi (IV) (RA),golimumab,Janssen ,Y,Y,N,N,N,N,N,N,N,,28-Nov-13,,CADTH & INESSS,12-Sep-13,pre-NOC,Initial,"Arthritis, rheumatoid",Completed,17-Jul-14,List with criteria/condition,Conditional,24-Nov-13,pre-NOC,New Form,Rheumatoid arthritis,Completed,02-Jun-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,06-Oct-14,19-Apr-16,Negotiation,No agreement reached,NR,NR,EDS,EDS,NR,NR,NR,NR,NR,EM,,,01-Sep-16,16-Oct-14,,,,,,02-Jun-14,16-Oct-14,02-Jun-14,,,3,2,,,,,,1,28.60%,34.10%,39.80%,,,,,,,,39.80%,,,-77,-4,308,190,81,126,561,,,135,-551,,,,,,-687,-208,-551,-368,-687,,,,1008,322,,,,,,186,665,505,322,399,91,,,777,91,,,,,,0,434,231,186,642,687,,,,,,41837
Simponi (UC),golimumab,Janssen ,Y,Y,N,N,N,N,N,N,N,,19-Sep-13,,CADTH & INESSS,12-Jul-13,pre-NOC,Initial,Ulcerative colitis,Completed,19-Mar-14,Do not list at the submitted price,Negative,,,New Indication,ulcerative collitis,Completed,02-Jun-14,Ajout d'une indication reconnue - Médicament d'exception - Avis de refus - Valeur thérapeutique,Conditional,1st,23-May-14,12-Aug-16,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,SA,EDS,NR,SA,NR,,01-May-17,01-Sep-16,20-Apr-17,16-Sep-16,29-May-17,01-Feb-17,,12-Apr-17,,01-Sep-16,01-Sep-16,,6,1,5,2,7,3,,4,,5.70%,38.00%,39.30%,39.90%,45.50%,49.90%,50.80%,,,,50.80%,29-May-17,,-69,,250,,65,-10,812,,262,20,251,35,290,173,,243,,182,20,182,20,,,1320,1078,1309,1093,1348,1231,,1301,,1240,1240,1078,1147,897,,1139,897,1128,912,1167,1050,,1120,,1059,181,256,877,802,,,,270,,41717
Sivextro (Withdrawn),tedizolid phosphate,Cubist Pharmaceuticals ,N,N,N,Y,N,N,N,N,N,,17-Mar-15,,CADTH,16-Jan-15,pre-NOC,Initial,Acute bacterial skin and skin structure infections,Withdrawn,01-May-15,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-60,,105,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,45,,,,,,,,,42125
Skyrizi,risankizumab,AbbVie ,Y,Y,N,Y,N,N,N,N,N,01-Jun-18,17-Apr-19,320,CADTH & INESSS,22-Oct-18,pre-NOC,Initial,"Psoriasis, moderate to severe plaque",Completed,28-May-19,Reimburse with clinical criteria and/or conditions,Conditional,08-Oct-18,pre-NOC,New Drug,Plaque psoriasis,Completed,05-Jun-19,Inscription - Avec conditions,Conditional,1st,27-Jun-19,28-Nov-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,05-May-20,01-Feb-20,01-Feb-20,02-Mar-20,31-Jan-20,19-Mar-20,06-Feb-20,22-Feb-21,16-Sep-20,05-Feb-20,31-Jan-20,31-Jan-20,8,2,3,6,1,7,5,10,9,4,32.20%,36.70%,42.40%,71.00%,72.30%,77.80%,78.70%,99.00%,99.60%,100.00%,100.00%,05-Feb-20,05-May-20,-177,-191,218,240,30,22,154,159,65,65,95,64,112,70,452,293,69,153,64,144,64,159,384,290,290,320,289,337,295,677,518,294,378,369,289,466,248,343,249,249,279,248,296,254,636,477,245,337,41,49,184,176,384,95,95,5,90,361
Skyrizi,risankizumab,AbbVie,Y,Y,N,N,N,N,N,N,N,01-Dec-21,19-Oct-22,322,CADTH,28-Oct-22,post-NOC,Initial,Crohn's disease,Active,,Active,n/a,,,,,,,,,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44531
Sohonos,palovarotene,"Ipsen Biopharmaceuticals Canada, Inc",N,N,N,Y,N,Y,Y,Y,N,01-Jul-21,21-Jan-22,204,CADTH,21-Oct-22,post-NOC,Initial,Fibrodysplasia Ossificans Progressiva,Active,,Active,n/a,,,,,,,,,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,273,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44378
Soliqua,lixisenatide + insulin glargine,Sanofi-Aventis ,Y,N,N,N,N,N,N,N,N,01-Sep-17,06-Jul-18,308,CADTH & INESSS,18-May-18,pre-NOC,Initial,"Diabetes mellitus, Type 2",Completed,24-Dec-18,Reimburse with clinical criteria and/or conditions,Conditional,03-Jul-20,post-NOC,New Drug,Type 2 Diabetes,Completed,02-Dec-20,Refus d'inscription,Negative,1st,16-Apr-19,21-Nov-19,Negotiation,Completed with Agreements,NR,UR,EDS,EDS,FB,UR,UR,UR,SA,NR,,,01-Jan-21,05-Aug-21,20-Dec-19,,,,03-May-22,,20-Dec-19,20-Dec-19,,,2,3,1,,,,4,,32.20%,38.00%,43.50%,44.20%,,,,,,,44.20%,,,-49,728,220,152,113,-596,219,,,407,623,29,,,,894,,488,29,488,29,,,,910,1126,532,,,,1397,,991,991,532,581,361,,,739,955,361,,,,1226,,820,171,880,332,-377,,,,,,479
Soliris,eculizumab,Alexion Pharmaceuticals,N,Y,N,N,N,Y,Y,Y,N,01-Feb-18,20-Aug-18,200,CADTH & INESSS,01-Apr-20,post-NOC,Initial,"Myasthenia Gravis (gMG), adults",Completed,19-Oct-20,Reimburse with clinical criteria and/or conditions,Conditional,24-Sep-21,post-NOC,New Indication,"Myasthenia Gravis (gMG), adults",Completed,30-Mar-22,Refus d'inscription,Negative,1st,01-Apr-21,12-Dec-21,Negotiation,No agreement reached,,,,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,590,1131,201,187,164,-363,255,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,791,1318,419,-108,,,,,,991
Soliris,eculizumab,Alexion Pharmaceuticals,N,Y,N,N,N,Y,Y,Y,N,01-Apr-19,24-Sep-19,176,CADTH & INESSS,25-Feb-20,post-NOC,Initial,Neuromyelitis optica spectrum disorder,Completed,19-Aug-20,Reimburse with clinical criteria and/or conditions,Conditional,13-Mar-20,post-NOC,New Indication,NOSD,Completed,09-Sep-20,Inscription - Avec conditions,Conditional,1st,02-Mar-21,12-Dec-21,Negotiation,No agreement reached,NR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,154,171,176,180,195,174,285,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,330,351,480,459,,,,,,506
Soliris (Advice),eculizumab,Alexion Pharmaceuticals,N,Y,N,N,N,Y,Y,Y,N,,01-Mar-13,,CADTH,09-Feb-15,post-NOC,Request for Advice,"Hemolytic Uremic Syndrome, Atypical",Completed,20-May-15,Not Applicable: Request for Advice (Completed),n/a,,,,,,,,,1st,06-Aug-15,16-Feb-16,Negotiation,No agreement reached,E,NR,NR,NR,EAP,NR,NR,NR,NR,NR,20-Nov-17,,,,01-Feb-15,,,,,,01-Feb-15,01-Feb-15,2,,,,1,,,,,,32.20%,52.50%,,,,,,,,,52.50%,20-Nov-17,,710,,100,,78,,194,643,,,,-380,,,,,,132,-380,132,-380,,1725,,,,702,,,,,,1214,1214,702,-8,-108,915,,,,-108,,,,,,404,810,,272,,,,,1023,,42144
Soliris (HUS),eculizumab,Alexion Pharmaceuticals,N,Y,N,N,N,Y,Y,Y,N,,01-Mar-13,,CADTH,07-Jan-13,pre-NOC,Initial,"Hemolytic Uremic Syndrome (HUS), Atypical ",Completed,18-Jul-13,Do not list,Negative,,,,,,,,,none,31-Jan-14,,Do Not Negotiate,n/a,NR,NR,NR,NR,EAP,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-53,,192,,197,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,139,,,,,,,,,41473
Sotyktu,deucravacitinib,Bristol-Myers Squibb Company,Y,Y,N,Y,N,N,N,N,N,01-Jan-22,24-Nov-22,327,CADTH,27-Sep-22,pre-NOC,Initial,"Psoriasis, moderate to severe plaque",Active,,Active,n/a,,,,,,,,,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-58,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44562
Sovaldi,sofosbuvir,Gilead Sciences ,Y,N,N,Y,N,N,N,N,N,,13-Dec-13,,CADTH & INESSS,01-Oct-13,pre-NOC,Initial,"Hepatitis C, chronic",Completed,18-Aug-14,List with criteria/condition,Conditional,,,New Drug,Hepatitis C,Completed,02-Jun-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,02-Sep-14,05-Feb-15,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,NR,SA,EM,24-Mar-15,01-Apr-15,01-Apr-15,20-Apr-15,23-Feb-15,06-Mar-15,01-Apr-15,,01-Jun-15,02-Jun-14,23-Feb-15,02-Jun-14,4,5,6,8,2,3,7,,9,1,28.60%,60.80%,61.70%,82.00%,86.40%,92.10%,93.40%,99.00%,99.60%,,99.60%,23-Feb-15,24-Mar-15,-73,,321,,15,92,156,47,55,55,74,18,29,55,,116,-248,56,18,22,-248,47,466,474,474,493,437,448,474,,535,171,475,441,437,510,189,218,226,226,245,189,200,226,,287,0,227,248,171,171,248,466,295,29,266,29,41869
Sovaldi (Drug Plan Submission),sofosbuvir,Gilead Sciences ,Y,N,N,Y,N,N,N,N,N,,13-Dec-13,,CADTH & INESSS,06-Jan-16,post-NOC,Request for Advice,"Hepatitis C, chronic",Completed,18-May-16,Reimburse with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New drug,Hepatitis C,Completed,19-Aug-16,Avis d'ajout d'une indication reconnue aux listes des médicaments-Médicament d'exception,Conditional,2nd,,17-Feb-17,Negotiation,Completed with Agreements,,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,754,711,133,269,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,887,980,275,182,,,,,,42508
Spinraza,nusinersen,Biogen,N,N,N,Y,N,Y,Y,Y,N,01-Dec-16,29-Jun-17,210,CADTH & INESSS,28-Jun-17,pre-NOC,Initial,Spinal Muscular Atrophy,Completed,22-Dec-17,Reimburse with clinical criteria and/or conditions,Conditional,23-Jul-17,post-NOC,New Drug,spinal muscular atrophy,Completed,15-Dec-17,Avis de refus d'inscription à la Liste Établissements,Negative,1st,29-Jan-18,26-Sep-18,Negotiation,Completed with Agreements,UR,SA,EDS,EDS,EAP,SA,EDS,NR,NR,EM,,01-Dec-18,01-May-19,24-Jan-19,20-Nov-18,07-Feb-19,01-Sep-19,,,18-Dec-18,20-Nov-18,20-Nov-18,,2,6,4,1,5,7,,,3,32.20%,36.70%,65.30%,70.80%,71.70%,77.40%,78.70%,,,,78.70%,18-Dec-18,,-1,24,177,145,38,45,240,,66,217,120,55,134,340,,,83,155,55,145,55,,,520,671,574,509,588,794,,,537,609,599,509,510,333,,344,495,398,333,412,618,,,368,433,176,169,278,285,,,,28,,386
Spinraza,nusinersen,Biogen,N,N,N,Y,N,Y,Y,Y,N,01-Dec-16,29-Jun-17,210,CADTH & INESSS,24-Jul-18,post-NOC,Initial,Spinal Muscular Atrophy,Completed,27-Feb-19,Reimburse with clinical criteria and/or conditions,Conditional,,,New Indication,spinal muscular atrophy,Completed,14-Jan-19,Inscription – Avec conditions,Conditional,1st,25-Apr-19,26-Jun-19,Negotiation,Completed with Agreements,EDRD,UR,UR,UR,EAP,SA,EDS,SA,SA,EM,01-Jul-19,,,,12-Jun-19,26-Aug-19,01-Nov-22,28-Mar-22,14-Feb-20,18-Dec-18,12-Jun-19,18-Dec-18,3,,,,2,4,7,6,5,1,28.60%,60.80%,81.10%,82.00%,82.60%,83.00%,84.30%,,,,84.30%,12-Jun-19,01-Jul-19,390,,218,,57,101,62,5,,,,-14,61,1224,1006,233,-190,419,-14,332,-190,5,732,,,,713,788,1951,1733,960,537,1146,1059,713,323,105,124,,,,105,180,1343,1125,352,-27,538,608,564,119,163,732,195,19,176,19,818
Spinraza,nusinersen,"Biogen Canada, Inc.",N,N,N,Y,N,Y,Y,Y,N,01-Dec-16,29-Jun-17,210,CADTH,02-Dec-21,post-NOC,Reassessment,Spinal Muscular Atrophy (indication expansion),Completed,11-Aug-22,Do not reimburse,Negative,,,,,,,,,none,14-Nov-22,,Do not negotiate,n/a,NR,,,,,NR,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,1617,,252,,95,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1869,,,,,,,,,2079
Spiriva Respimat,tiotropium bromide,Boehringer Ingelheim ,N,N,N,N,N,N,N,N,N,,17-Dec-14,,CADTH & INESSS,23-Dec-14,post-NOC,Initial,Chronic Obstructive Pulmonary Disease (COPD),Completed,16-Jul-15,List with clinical criteria and/or conditions,Conditional,04-Aug-15,post-NOC,New Drug,Chronic Obstructive Pulmonary Disease (COPD),Completed,01-Feb-16,Avis d'inscription aux listes de médicaments,Positive,1st,21-Aug-15,02-Mar-16,Negotiation,Completed with Agreements,FB,FB,FB,FB,FB,SA,EDS,SA,SA,FB,07-Jul-20,01-May-16,01-May-16,21-Jul-16,30-Mar-16,12-Apr-16,01-May-16,25-Apr-16,01-Jul-16,04-May-16,30-Mar-16,30-Mar-16,10,4,5,9,1,2,6,3,8,7,32.20%,33.10%,33.50%,37.90%,43.70%,45.00%,73.50%,74.20%,79.70%,100.00%,100.00%,04-May-16,07-Jul-20,6,230,205,181,36,-164,194,1588,60,60,141,28,41,60,54,121,63,239,28,222,28,1588,2029,501,501,582,469,482,501,495,562,504,680,663,469,463,258,1818,290,290,371,258,271,290,284,351,93,469,211,411,230,30,2029,1560,1560,35,1525,42201
Spravato,esketamine hydrochloride,Janssen,Y,N,N,N,N,N,N,N,Y,01-Jan-19,20-May-20,505,CADTH & INESSS,24-Jun-19,pre-NOC,Initial,"Major depressive disorder (MDD), adults",Completed,16-Dec-20,Do not reimburse,Negative,29-May-20,post-NOC,New drug,Major depressive disorder,Completed,05-Nov-20,Refus d'inscription,Negative,none,27-Jan-21,,Do Not Negotiate,n/a,NR,,NR,,,NR,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-331,9,541,160,42,83,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,210,169,,,,,,,,715
Steglatro,ertuglifozin,Merck,Y,N,N,Y,N,N,N,N,N,01-Jul-17,09-May-18,312,CADTH & INESSS,30-Apr-18,pre-NOC,Initial,"Diabetes mellitus, Type 2",Completed,23-Jan-19,Do not reimburse,Negative,10-May-18,post-NOC,New Drug,Type 2 Diabetes,Completed,08-Nov-18,Inscription – Avec conditions,Conditional,1st,20-Mar-19,31-Mar-20,Negotiation,No agreement reached,NR,UR,NR,UR,UR,NR,UR,UR,UR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-9,1,268,182,56,132,377,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,259,183,433,509,,,,,,571
Stelara,ustekinumab,Janssen ,Y,Y,N,N,N,N,N,N,N,,21-Jan-14,,CADTH & INESSS,30-Oct-13,pre-NOC,Initial,"Arthritis, Psoriatic",Completed,20-Oct-14,Do not list at the submitted price,Negative,22-Mar-14,post-NOC,New Indication,"Arthritis, Psoriatic",Completed,01-Oct-14,Ajout d'une indication reconnue - Médicament d'exception,Conditional,none,27-Nov-14,,Do Not Negotiate,n/a,NR,NR,EDS,NR,NR,SA,NR,NR,NR,EM,,,01-Oct-15,,,27-Mar-19,,,,01-Oct-14,01-Oct-15,01-Oct-14,,,2,,,3,,,,1,28.60%,34.30%,35.20%,,,,,,,,35.20%,,,-83,60,355,193,38,57,,,,,,,,,,,,,,,,,,,618,,,1891,,,,253,1255,921,618,701,346,,,346,,,1619,,,,0,983,272,253,,,,,,,,41932
Stelara (CD),ustekinumab,Janssen ,Y,Y,N,N,N,N,N,N,N,,12-Dec-16,,CADTH & INESSS,12-Sep-16,pre-NOC,Initial,Crohn’s disease,Completed,21-Mar-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Indication,Crohn's Disease,Completed,18-Oct-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,09-Feb-18,29-Mar-19,Negotiation,No agreement reached,NR,UR,EDS,NR,NR,NR,NR,NR,NR,UR,,,01-Aug-18,,,,,,,,01-Aug-18,01-Aug-18,,,1,,,,,,,,5.70%,,,,,,,,,,5.70%,,,-91,102,190,208,325,114,413,,,-240,,,,,,,,-240,-240,-240,-240,,,,597,,,,,,,,597,597,597,688,498,,,498,,,,,,,,498,99,310,738,527,,,,,,42815
Stelara (UC),ustekinumab,Janssen ,Y,Y,N,N,N,N,N,N,N,01-Mar-19,23-Jan-20,328,CADTH & INESSS,12-Aug-19,pre-NOC,Initial,Ulcerative Colitis,Completed,16-Jul-20,Reimburse with clinical criteria and/or conditions,Conditional,18-Oct-19,pre-NOC,New Indication,Ulcerative Colitis,Completed,14-May-20,Inscription - Avec conditions,Conditional,1st,27-Apr-21,28-Jul-21,Negotiation,No agreement reached,NR,,,,,NR,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-164,-97,339,209,285,348,92,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,175,112,377,440,,,,,,503
Stivarga,regorafenib,Bayer ,Y,N,N,N,Y,Y,N,Y,N,01-Apr-17,18-Sep-17,170,CADTH & INESSS,12-Oct-17,post-NOC,New indication,Unresectable Hepatocellular Carcinoma (HCC),Completed,18-Apr-18,Cond'l on Cost,Conditional,05-Mar-18,post-NOC,New Indication,Unresectable Hepatocellular Carcinoma (HCC),Completed,05-Sep-18,Avis d'ajout d'une indication reconnue aux listes - Médicament d'exception - Avec conditions,Conditional,1st,10-Sep-18,07-Mar-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jul-19,18-Nov-19,03-Sep-19,02-Mar-20,30-Sep-20,07-Nov-19,01-Nov-19,,,11-Apr-19,01-Jul-19,11-Apr-19,2,6,3,7,8,5,4,,,1,28.60%,48.80%,54.60%,55.90%,56.80%,61.20%,66.70%,99.00%,,,99.00%,03-Sep-19,30-Sep-20,24,168,188,184,145,5,178,116,256,180,361,573,245,239,,,35,281,116,251,35,573,651,791,715,896,1108,780,774,,,570,816,786,651,627,439,439,579,503,684,896,568,562,,,218,604,212,352,323,183,1108,538,457,145,393,382
Stivarga (CRC),regorafenib,Bayer ,Y,N,N,Y,Y,N,N,N,N,,11-Mar-13,,CADTH & INESSS,22-Mar-13,post-NOC,New drug,Metastatic Colorectal Cancer,Completed,15-Nov-13,Do Not Fund,Negative,,,New Drug,Metastatic Colorectal Cancer,Completed,01-Oct-13,Avis de refus,Negative,None,31-May-14,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,11,,238,,197,242,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,249,204,,,,,,,,41593
Stivarga (GIST),regorafenib,Bayer ,Y,N,N,N,Y,Y,N,Y,N,,04-Oct-13,,CADTH & INESSS,11-Oct-13,post-NOC,New indication,Gastrointestinal Stromal Tumours,Completed,02-May-14,Cond'l on Cost,Conditional,24-Nov-13,post-NOC,New Indication,Gastrointestinal Stromal Tumours,Completed,02-Jun-14,Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable,Conditional,1st,31-May-14,11-Aug-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,NR,01-Feb-15,30-Mar-15,15-Sep-14,19-Jan-15,09-Sep-14,21-Nov-14,29-Dec-14,23-Jan-23,01-Oct-14,,09-Sep-14,09-Sep-14,7,8,2,6,1,4,5,9,3,,32.20%,38.00%,38.60%,39.50%,40.80%,46.30%,66.60%,71.10%,71.40%,,71.40%,01-Feb-15,,7,51,203,190,29,-2,72,174,231,35,161,29,102,140,3087,51,,446,29,446,29,,485,542,346,472,340,413,451,3398,362,,757,757,340,333,130,275,332,136,262,130,203,241,3188,152,,547,210,241,101,70,,,,145,,41761
Stivarga (GIST),regorafenib,Bayer ,Y,N,N,N,Y,Y,N,Y,N,,04-Oct-13,,CADTH & INESSS,11-Oct-13,post-NOC,New indication,Gastrointestinal Stromal Tumours,Completed,02-May-14,Cond'l on Cost,Conditional,24-Nov-13,post-NOC,New Indication,Gastrointestinal Stromal Tumours,Completed,02-Jun-14,Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable,Conditional,2nd,11-Aug-17,09-Nov-17,Negotiation,Completed with Agreements,,,,,,,,,,EM,,,,,,,,,,01-Feb-18,,01-Feb-18,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,7,51,203,190,1197,1166,90,,,,,,,,,,84,,,84,84,,,,,,,,,,,1581,,1581,,,,,,,,,,,,,1340,,210,241,1287,1256,,,,,,41761
Stivarga Resubmission (CRC),regorafenib,Bayer ,Y,N,N,Y,Y,N,N,N,N,,11-Mar-13,,CADTH,19-Dec-14,post-NOC,Resubmission,Metastatic Colorectal Cancer (Resub),Completed,16-Jul-15,Do Not Fund,Negative,,,,,,,,,None,31-Aug-15,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,648,,209,,46,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,857,,,,,,,,,42201
Strensiq,asfotase alfa,Alexion Pharmaceuticals,N,Y,N,Y,N,Y,Y,Y,Y,,14-Aug-15,,CADTH & INESSS,21-Aug-15,post-NOC,Initial,"Hypophosphatasia, pediatric-onset",Completed,23-Mar-16,List with criteria/condition,Conditional,24-Nov-15,post-NOC,New Drug,"Hypophosphatasia, pediatric-onset",Completed,01-Jun-16,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,30-Jun-16,09-Feb-17,Negotiation,No agreement reached,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,7,102,215,190,99,29,224,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,222,292,323,253,,,,,,42452
Strensiq (2nd pCPA),asfotase alfa,Alexion Pharmaceuticals,N,Y,N,Y,N,Y,Y,Y,Y,,14-Aug-15,,CADTH & INESSS,21-Aug-15,post-NOC,Initial,"Hypophosphatasia, pediatric-onset",Completed,23-Mar-16,List with criteria/condition,Conditional,22-Mar-16,post-NOC,Resubmission,"Hypophosphatasia, pediatric-onset",Completed,16-Dec-16,Avis de refus d'inscription aux listes des médicaments,Negative,2nd,07-Jun-17,09-Jan-18,Negotiation,Completed with Agreements,NR,SA,NR,NR,EAP,SA,EDS,NR,NR,UR,,01-Mar-18,,,06-Jun-18,29-Jan-20,10-Sep-20,,,,01-Mar-18,01-Mar-18,,1,,,2,3,4,,,,4.50%,36.70%,37.60%,38.90%,,,,,,,38.90%,,,7,221,215,269,441,173,216,,51,,,148,750,975,,,,481,51,481,51,,,930,,,1027,1629,1854,,,,1360,1360,930,923,708,,708,,,805,1407,1632,,,,1138,222,490,657,389,,,,,,42452
Stribild,elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate ,Gilead Sciences ,Y,N,N,Y,N,N,N,N,N,,26-Nov-12,,CADTH & INESSS,30-Nov-12,post-NOC,Initial,HIV-1 infection ,Completed,15-May-13,List with criteria/condition,Conditional,,,New Drug,HIV-1 infection ,Completed,03-Jun-13,Avis de refus,Negative,1st,10-Jun-13,11-Jul-13,Negotiation,Completed with Agreements,HIV,HIV,EDS,EDS,FB,SA,HIV,HIV,SA,FB,13-May-13,01-Nov-13,01-Nov-13,17-Oct-13,30-Jul-13,19-Dec-13,01-Dec-13,01-Jul-14,01-Jun-15,01-Oct-13,13-May-13,13-May-13,1,5,6,4,2,8,7,9,10,3,20.30%,52.50%,81.10%,86.60%,91.10%,96.80%,98.10%,99.00%,99.30%,100.00%,100.00%,30-Jul-13,01-Oct-13,4,,166,,26,7,31,-59,113,113,98,19,161,143,355,690,82,181,-59,172,-59,82,168,340,340,325,246,388,370,582,917,309,408,399,168,164,-2,-2,170,170,155,76,218,200,412,747,120,238,170,189,57,38,309,141,141,78,63,41409
Sublocade,buprenorphine,Indivior Canada Ltd.,N,N,N,N,N,N,N,N,N,01-May-18,21-Nov-18,204,CADTH & INESSS,20-Dec-18,post-NOC,Initial,"Opioid use disorder, treatment",Completed,19-Jun-19,Reimburse with clinical criteria and/or conditions,Conditional,01-Mar-19,post-NOC,New Drug,Opioid use disorder,Completed,11-Sep-19,Inscription - Avec conditions,Conditional,1st,09-Jul-19,08-Apr-20,Negotiation,Completed with Agreements,SA,SA,EDS,RB,LU,FB,FB,FB,SA,EM,30-Apr-20,01-Jun-20,01-Jul-20,16-Jul-20,30-Apr-21,21-May-20,03-Jun-20,26-Jul-21,15-Jun-20,29-Apr-20,30-Apr-20,29-Apr-20,2,4,7,8,9,3,5,10,6,1,28.60%,48.80%,49.70%,54.20%,55.50%,56.20%,61.90%,67.40%,99.60%,100.00%,100.00%,01-Jun-20,30-Apr-21,29,100,181,194,20,-64,274,22,54,84,99,387,43,56,474,68,21,143,22,131,21,387,526,558,588,603,891,547,560,978,572,525,647,635,526,497,316,316,348,378,393,681,337,350,768,362,231,437,210,294,294,210,891,366,365,33,333,414
Sunvepra,asunaprevir,Bristol-Myers Squibb ,Y,N,N,Y,N,N,N,N,N,,09-Mar-16,,CADTH & INESSS,13-Feb-15,pre-NOC,Initial,"Hepatitis C, chronic",Completed,20-Jul-16,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Drug,chronic hepatitis C (CHC),Completed,03-Oct-16,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,20-Jul-16,17-Feb-17,Negotiation,Completed with Agreements,DL,DL,DL,DL,DL,DL,DL,DL,DL,DL,21-Mar-17,01-Apr-17,01-Apr-17,,28-Feb-17,29-Mar-17,01-May-17,,01-Sep-17,01-Jun-08,28-Feb-17,01-Jun-08,3,5,6,,2,4,7,,8,1,28.60%,60.80%,81.10%,82.00%,86.40%,92.10%,93.40%,94.10%,,,94.10%,28-Feb-17,21-Mar-17,-390,13,523,195,0,-75,212,32,43,43,,11,40,73,,196,-3183,63,11,-343,-3183,32,377,388,388,,356,385,418,,541,-2838,408,2,356,746,223,244,255,255,,223,252,285,,408,-3046,275,133,208,212,137,377,3215,21,3194,21,42571
Sylvant,siltuximab,Janssen ,Y,Y,N,Y,Y,Y,Y,Y,N,,03-Dec-14,,CADTH,30-Jan-15,post-NOC,New drug,Lymphoma & myeloma: Multicentric Castleman's Disease (MCD),Completed,22-Jun-15,Cond'l on Cost,Conditional,,,,,,,,,1st,08-Aug-15,30-Sep-16,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Not funded,Funded,,01-Dec-16,01-Jan-18,02-Aug-17,05-Dec-16,22-Dec-16,10-Jul-17,01-Feb-20,,01-Feb-20,,01-Dec-16,01-Dec-16,1,6,5,2,3,4,7,,8,,20.30%,25.80%,58.00%,58.90%,64.60%,69.10%,70.40%,71.10%,,,71.10%,22-Dec-16,,58,,143,,47,,419,62,458,306,66,83,283,1219,,1219,,462,62,462,62,,729,1125,973,733,750,950,1886,,1886,,1129,1129,729,671,528,528,924,772,532,549,749,1685,,1685,,928,201,,466,,,,,21,,42177
Symtuza,darunavir/cobicistat/emtricitabine/tenofovir alafenamide,Janssen ,Y,N,N,N,N,N,N,N,N,01-May-17,08-Mar-18,311,CADTH,22-Dec-17,pre-NOC,Initial,HIV-1 infection,Completed,25-Jul-18,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,27-Feb-19,22-May-19,Negotiation,No agreement reached,UR,UR,NR,UR,UR,NR,UR,UR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-76,,215,,217,,84,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,139,,301,,,,,,,450
Synjardy,empagliflozin and metformin,Boehringer Ingelheim ,N,N,N,N,N,N,N,N,N,,29-Jul-16,,CADTH & INESSS,29-Apr-16,pre-NOC,Initial,Diabetes mellitus (Type 2),Completed,25-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Drug,Type 2 Diabetes,Completed,15-Mar-17,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,11-Sep-18,11-Sep-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,27-May-19,01-Jan-19,01-Jan-19,31-May-19,31-Oct-18,27-Feb-19,01-Jan-19,01-Aug-19,22-Oct-19,27-Sep-18,31-Oct-18,27-Sep-18,7,3,4,8,2,6,5,9,10,1,28.60%,60.80%,65.30%,71.00%,72.30%,73.20%,93.40%,99.00%,99.30%,100.00%,100.00%,31-Oct-18,27-May-19,-91,14,179,215,686,545,0,258,112,112,262,50,169,112,324,406,16,201,50,182,16,258,1032,886,886,1036,824,943,886,1098,1180,790,975,956,824,915,736,944,798,798,948,736,855,798,1010,1092,561,887,88,229,686,545,1032,242,208,34,208,42668
Tafinlar,dabrafenib,GlaxoSmithKline,Y,N,N,Y,Y,Y,N,Y,N,,16-Jul-13,,CADTH & INESSS,18-Mar-13,pre-NOC,New drug,Metastatic Melanoma,Completed,05-Dec-13,Cond'l on Cost,Conditional,02-Aug-13,post-NOC,New Drug,Metastatic Melanoma,Completed,03-Feb-14,Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable,Conditional,1st,31-Jan-14,25-Jun-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Dec-14,30-Mar-15,15-Sep-14,16-Oct-14,19-Aug-14,03-Oct-14,01-Sep-16,29-Oct-18,01-Aug-14,03-Feb-14,01-Aug-14,03-Feb-14,7,8,4,6,3,5,9,10,2,1,28.60%,29.30%,61.50%,67.20%,68.10%,73.60%,93.90%,98.30%,99.60%,100.00%,100.00%,19-Aug-14,01-Dec-14,-120,17,262,185,57,-3,145,159,278,82,113,55,100,799,1587,37,-142,357,37,307,-142,159,503,622,426,457,399,444,1143,1931,381,202,701,651,381,501,239,361,480,284,315,257,302,1001,1789,239,0,559,142,202,202,142,503,301,122,197,104,41613
Tafinlar & Mekinist in combo,dabrafenib & trametinib in combo,GlaxoSmithKline,Y,N,N,N,Y,Y,N,Y,N,,06-Mar-15,,CADTH & INESSS,13-Feb-15,pre-NOC,New indication,Metastatic Melanoma,Completed,21-Jul-15,Cond'l on Cost,Conditional,01-May-15,post-NOC,New Indication,Metastatic Melanoma,Completed,01-Oct-15,Avis de refus d’ajout d’une indication reconnue aux listes de médicaments – Médicament d’exception - À moins que certaines conditions soient respectées,Conditional,1st,18-Sep-15,25-May-16,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Aug-16,18-Oct-16,08-Aug-16,21-Jul-16,10-Aug-16,13-Mar-17,01-Sep-16,29-Oct-18,01-Feb-17,15-Jul-16,21-Jul-16,15-Jul-16,3,7,4,2,5,9,6,10,8,1,28.60%,34.10%,54.40%,60.10%,92.30%,93.60%,98.10%,98.80%,99.60%,100.00%,100.00%,01-Aug-16,10-Aug-16,-21,56,158,153,59,-301,250,68,146,75,57,77,292,99,887,252,51,217,57,200,51,77,514,592,521,503,523,738,545,1333,698,497,663,646,503,524,366,377,455,384,366,386,601,408,1196,561,0,526,137,497,309,-51,523,26,20,17,9,42206
Tafinlar & Mekinist in combo,dabrafenib & trametinib in combo,Novartis,Y,N,N,N,Y,Y,N,Y,N,01-Nov-16,16-May-17,196,CADTH & INESSS,31-Mar-17,pre-NOC,New indication,Non-Small Cell Lung Cancer,Completed,02-Nov-17,Do Not Fund,Negative,23-Jun-17,post-NOC,New Indication,In combination for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have been previously treated with chemotherapy,Completed,15-Dec-17,Avis de refus d’ajout d’une indication reconnue aux listes des médicaments – Médicament d’exception – Valeur thérapeutique,Negative,None,30-Nov-17,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-46,38,216,175,28,-15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,170,213,,,,,,,,366
Tafinlar & Mekinist in combo,dabrafenib & trametinib in combo,Novartis,Y,N,N,N,Y,Y,N,Y,N,01-Mar-18,21-Sep-18,204,CADTH & INESSS,21-Sep-18,pre-NOC,New indication,Melanoma Adjuvant Therapy,Completed,03-May-19,Cond'l on Cost,Conditional,17-Sep-18,pre-NOC,New Indication,Melanoma Adjuvant Therapy,Completed,13-Mar-19,Inscription – Avec conditions,Conditional,1st,11-Jun-19,30-Aug-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Nov-20,10-Apr-20,01-Jan-20,02-Mar-20,07-Jan-20,23-Apr-20,23-Apr-20,10-Jan-22,11-Aug-21,02-Oct-19,01-Jan-20,02-Oct-19,8,5,2,4,3,6,7,10,9,1,28.60%,34.30%,66.50%,72.10%,76.50%,77.40%,78.70%,99.00%,99.60%,100.00%,100.00%,07-Jan-20,01-Nov-20,0,-4,224,177,39,90,80,429,224,124,185,130,237,237,864,712,33,349,124,318,33,429,772,567,467,528,473,580,580,1207,1055,376,692,661,467,467,243,548,343,243,304,249,356,356,983,831,203,468,224,173,119,170,772,396,305,97,299,428
Tafinlar & Mekinist in combo,dabrafenib & trametinib in combo,Novartis,Y,N,N,N,Y,Y,N,Y,N,01-Nov-17,18-May-18,198,CADTH & INESSS,01-Oct-20,post-NOC,New indication,Non-Small Cell Lung Cancer (NSCLC) BRAF V600 mutation,Completed,28-May-21,Cond'l on Cost,Conditional,13-Nov-20,post-NOC,New Indication,For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have not received any prior anti-cancer therapy for metastatic disease.,Completed,07-May-21,Refus d'inscription,Negative,1st,10-Sep-21,30-Sep-22,Negotiation,No Agreement Reached,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,867,910,239,175,105,126,385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1106,1085,490,511,,,,,,1304
Tagrisso,osimertinib,AstraZeneca ,Y,N,N,Y,Y,Y,N,Y,N,01-Nov-15,05-Jul-16,247,CADTH & INESSS,01-Apr-16,pre-NOC,New drug,"Lung, NSCLC",Completed,04-May-17,Cond'l on Cost,Conditional,24-Nov-16,post-NOC,New Drug,Locally advanced or metastatic non-small cell lung cancer who have progressed on or after EGFR TKI therapy,Completed,01-Jun-17,Avis de refus d'inscription aux listes des médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,29-Sep-17,30-Jul-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Oct-18,20-Nov-18,01-Nov-18,18-Oct-18,03-Oct-18,27-Feb-19,01-Nov-19,01-Apr-20,20-Feb-20,15-Nov-18,01-Oct-18,01-Oct-18,1,6,4,3,2,7,8,10,9,5,20.30%,52.50%,58.00%,63.70%,92.30%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,03-Oct-18,15-Nov-18,-95,142,398,189,148,120,304,63,113,94,80,65,212,459,611,570,108,252,63,238,63,108,818,868,849,835,820,967,1214,1366,1325,863,1007,993,818,913,515,515,565,546,532,517,664,911,1063,1022,532,704,303,331,452,424,863,45,45,2,43,550
Tagrisso,osimertinib,AstraZeneca ,Y,N,N,N,Y,Y,N,Y,N,01-Jan-18,10-Jul-18,190,CADTH & INESSS,16-May-18,pre-NOC,New indication,Non-Small Cell Lung Cancer (first line),Completed,04-Jan-19,Cond'l on Cost,Conditional,,,New Indication,Non-Small Cell Lung Cancer (first line),Completed,12-Dec-18,Inscription – Avec conditions,Conditional,1st,14-Mar-19,19-Nov-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jan-20,10-Apr-20,01-Mar-20,02-Apr-20,10-Jan-20,19-Mar-20,01-May-20,14-Feb-22,20-Feb-20,18-Dec-19,01-Jan-20,18-Dec-19,2,8,5,7,3,6,9,10,4,1,28.60%,48.80%,81.10%,81.70%,87.50%,88.30%,93.90%,98.30%,99.60%,100.00%,100.00%,10-Jan-20,10-Jan-20,-55,,233,,69,92,250,43,143,103,135,52,121,164,818,93,29,186,43,170,29,52,540,640,600,632,549,618,661,1315,590,526,683,667,540,595,362,362,462,422,454,371,440,483,1137,412,371,505,178,155,319,342,549,23,9,23,0,368
Tagrisso,osimertinib,AstraZeneca ,Y,N,N,N,Y,Y,N,Y,N,01-Sep-20,18-Jan-21,139,CADTH & INESSS,24-Mar-21,post-NOC,Initial,Tagrisso (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. • A validated test is required to identify EGFR mutation-positive status (exon 19 deletions or exon 21 (L858R) substitution mutations) prior to treatment.,Completed,10-Jan-22,Cond'l on Cost,Conditional,18-Jun-21,post-NOC,New Indication,Tagrisso (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. • A validated test is required to identify EGFR mutation-positive status (exon 19 deletions or exon 21 (L858R) substitution mutations) prior to treatment.,Completed,30-Nov-21,Inscription - Avec conditions,Conditional,1st,16-May-22,07-Oct-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Under provincial consideration,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,EM,01-Feb-23,31-Jan-23,01-Feb-23,,31-Dec-22,27-Feb-23,01-Mar-23,,,09-Nov-22,31-Dec-22,09-Nov-22,4,3,5,,2,6,7,,,1,28.60%,60.80%,65.30%,85.50%,91.20%,92.10%,93.40%,,,,93.40%,31-Dec-22,01-Feb-23,65,151,292,165,126,167,144,117,116,117,,85,143,145,,,33,121,85,108,33,117,744,743,744,,712,770,772,,,660,748,735,712,647,355,387,386,387,,355,413,415,,,344,391,357,316,270,311,744,84,32,52,32,496
Takhzyro,lanadelumab,Shire,Y,Y,N,Y,N,Y,Y,Y,N,01-Mar-18,19-Sep-18,202,CADTH,29-May-19,post-NOC,Initial,"Hereditary angioedema, prevention",Completed,19-Nov-19,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,21-Feb-20,30-Oct-20,Negotiation,Completed with Agreements,EDRD,SA,EDS,EDS,EAP,SA,EDS,SA,SA,,04-Mar-21,01-May-21,01-May-21,01-Apr-21,12-Feb-21,27-Jan-21,01-Aug-21,20-Feb-23,17-Mar-21,,27-Jan-21,27-Jan-21,3,6,7,5,2,1,8,9,4,,0.90%,33.10%,53.40%,54.00%,59.60%,64.00%,69.80%,71.10%,71.40%,,71.40%,04-Mar-21,,252,,174,,94,,252,125,183,183,153,105,89,275,843,138,,233,89,233,89,,897,955,955,925,877,861,1047,1615,910,,1005,1005,861,609,435,471,529,529,499,451,435,621,1189,484,,579,426,,346,,,,,36,,628
Taltz,ixekizumab,Eli Lilly ,N,Y,N,Y,N,N,N,N,N,01-Jul-15,25-May-16,329,CADTH & INESSS,23-Mar-16,pre-NOC,Initial,"Psoriasis, moderate to severe plaque",Completed,25-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Drug,"Psoriasis, moderate to severe plaque",Completed,01-Feb-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,05-May-17,29-Dec-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,06-Mar-18,01-Jun-18,01-Apr-18,19-Apr-18,29-Mar-18,08-May-18,01-Feb-19,28-May-18,15-Mar-18,01-Mar-18,06-Mar-18,01-Mar-18,2,9,5,6,4,7,10,8,3,1,28.60%,48.80%,49.50%,81.70%,87.50%,93.00%,93.90%,94.20%,98.70%,100.00%,100.00%,29-Mar-18,29-Mar-18,-63,79,216,173,192,93,238,67,154,93,111,90,130,399,150,76,62,141,67,133,62,90,650,737,676,694,673,713,982,733,659,645,724,716,650,713,497,497,584,523,541,520,560,829,580,506,393,571,153,252,430,331,673,28,23,28,0,482
Taltz (AS),ixekizumab,Eli Lilly ,N,Y,N,N,N,N,N,N,Y,01-Apr-19,04-Feb-20,309,CADTH & INESSS,20-Sep-19,pre-NOC,Initial,Ankylosing spondylitis,Completed,24-Mar-20,Reimburse with clinical criteria and/or conditions,Conditional,18-Oct-19,pre-NOC,New Indication,Ankylosing spondylitis,Completed,10-Jun-20,Inscription - Avec conditions,Conditional,1st,13-Jan-21,19-Mar-21,Negotiation,No agreement reached,NR,,,,,NR,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-137,-109,186,236,295,217,65,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,49,127,360,282,,,,,,358
Taltz (PsA),ixekizumab,Eli Lilly ,N,Y,N,N,N,N,N,N,N,01-Jun-17,29-Mar-18,301,CADTH & INESSS,20-Feb-18,pre-NOC,Initial,"Arthritis, psoriatic",Completed,21-Aug-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New Indication,Psoriatic arthritis,Completed,05-Sep-18,Avis d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,03-Oct-18,08-Nov-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,27-May-19,01-Mar-19,01-Jan-19,31-May-19,04-Mar-19,27-Feb-19,01-Feb-19,25-Feb-19,16-Jan-19,13-Dec-18,01-Jan-19,13-Dec-18,9,7,2,10,8,6,4,5,3,1,28.60%,34.30%,35.00%,36.30%,36.60%,37.50%,42.00%,74.20%,94.50%,100.00%,100.00%,04-Mar-19,27-May-19,-37,,182,,43,28,36,200,113,54,204,116,111,85,109,69,35,118,54,110,35,200,424,337,278,428,340,335,309,333,293,259,342,334,278,315,133,279,192,133,283,195,190,164,188,148,99,197,145,160,79,64,424,165,146,81,84,446
Tavalisse,fostamatinib,Medison Pharma Canada Inc.,N,N,N,N,N,N,N,N,N,01-Jan-20,19-Nov-20,323,CADTH & INESSS,22-Jul-21,post-NOC,Initial,Chronic immune thrombocytopenia,Completed,05-Apr-22,Do not reimburse,Negative,05-Nov-21,post-NOC,New Drug,Chronic immune thrombocytopenia,Completed,04-May-22,Refus d'inscription,Negative,none,09-May-22,,Do Not Negotiate,n/a,NR,,NR,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,245,351,257,180,34,5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,502,531,,,,,,,,825
Tavneos,avacopan,Otsuka Canada Pharmaceutical Inc.,N,N,N,Y,N,Y,Y,Y,N,01-May-21,14-Apr-22,348,CADTH,14-Oct-22,post-NOC,Initial,Antineutrophil cytoplasmic antibody-associated vasculitis,Active,,Active,n/a,,,,,,,,,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,183,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44317
TBC,filgotinib,"Gilead Sciences Canada, Inc.",Y,N,N,N/A,N,N,N,N,N,01-Apr-20,,,CADTH,04-Aug-20,na,Initial,"Arthritis, Rheumatoid",Withdrawn,04-Feb-21,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,184,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,309
TBC,abaloparatide,Paladin Labs Inc.,N,N,N,Y,N,N,N,N,Y,01-Mar-22,,,CADTH,02-Aug-22,na,Initial,"Osteoporosis, postmenopausal women",Withdrawn,04-Nov-22,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,94,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,248
TBC,rivaroxaban,NA,N,N,N,N,N,N,N,N,N,01-Jan-20,12-Jan-21,377,CADTH,29-Jun-22,post-NOC,Non-sponsored Submission,Venous thromboembolic events (VTE),Active,,Active,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,533,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-43831
TBC,ferumoxytol,Covis Pharma Canada Ltd.,N,N,N,Y,N,N,N,N,N,01-Mar-22,,,CADTH,31-Aug-22,na,Initial,Iron deficiency anemia,Withdrawn,20-Mar-23,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,201,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,384
TBC,daprodustat,GlaxoSmithKline Inc.,Y,N,N,N,N,N,N,N,Y,01-May-22,,,CADTH,25-Oct-22,na,Initial,Anemia due to chronic kidney disease,Active,,Active,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44682
TBC,foslevodopa foscarbidopa,AbbVie Canada Inc.,Y,N,N,Y,N,N,N,N,N,01-Jul-22,,,CADTH,23-Nov-22,na,Initial,Parkinson’s disease,Active,,Active,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44743
TBC,setmelanotide,"Rhythm Pharmaceuticals, Inc.",N,N,N,Y,N,Y,Y,Y,Y,01-Nov-22,,,CADTH,07-Mar-23,na,Initial,Bardet-Biedl syndrome,Active,,Active,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44866
TBC,cenobamate,Paladin Labs Inc.,N,N,N,Y,N,N,N,N,Y,01-Jul-22,,,CADTH,07-Feb-23,na,Initial,"Epilepsy, partial-onset seizures",Active,,Active,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44743
TBC,andexanet alfa,Astrazeneca Canada Inc,Y,Y,N,Y,N,N,N,N,N,01-Oct-22,,,CADTH,02-Mar-23,na,Initial,Reversal of FXa inhibitor anticoagulant effects,Active,,Active,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44835
TBC,mirikizumab,Eli Lilly Canada,N,Y,N,Y,N,N,N,N,N,01-Sep-22,,,CADTH,07-Mar-23,na,Initial,Ulcerative colitis,Active,,Active,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44805
TBC,durvalumab and tremelimumab,AstraZeneca Canada ,Y,Y,N,Y,Y,Y,N,Y,N,01-May-22,,,CADTH,15-Dec-22,na,Initial,Tremelimumab for injection in combination with durvalumab is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma.,Suspended,,TBD,n/a,17-Mar-23,,New Drug,Tremelimumab for injection in combination with durvalumab is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma.,Suspended,TBD,TBD,TBD,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44682
Tecartus,brexucabtagene autoleucel,Gilead ,Y,N,N,Y,Y,Y,Y,Y,N,01-Dec-20,08-Jun-21,189,CADTH & INESSS,18-Dec-20,pre-NOC,Initial,Treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi),Completed,24-Aug-21,Cond'l on Cost,Conditional,22-Jan-21,pre-NOC,New Drug,Treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi),Completed,28-Jul-21,Inscription - Avec conditions,Conditional,1st,22-Nov-21,10-Nov-22,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,,,,,,,,,,14-Dec-22,,14-Dec-22,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,-172,-137,249,187,90,117,353,,,,,,,,,,34,,,34,34,,,,,,,,,,,554,,554,,,,,,,,,,,,,504,,77,50,443,470,,,,,,266
Tecartus,brexucabtagene autoleucel,Gilead ,Y,N,N,N,Y,Y,Y,Y,Y,01-Apr-22,16-Nov-22,229,CADTH & INESSS,16-Sep-22,pre-NOC,Initial,For the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL),Active,,TBD,n/a,20-Jan-23,post-NOC,New Indication,The indication filed for review with Health Canada is: -for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL),Under review,TBD,TBD,TBD,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-61,65,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44652
Tecentriq,atezolizumab,Hoffman-La Roche ,Y,Y,N,Y,Y,N,N,N,N,01-Jun-17,06-Apr-18,309,CADTH & INESSS,15-Dec-17,pre-NOC,New drug,Non-Small Cell Lung Cancer:For the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have progressed on or after systemic chemotherapy until loss of clinical benefit,Completed,20-Jun-18,Cond'l on Cost,Conditional,14-Feb-18,pre-NOC,New Indication,Non-Small Cell Lung Cancer in patients after chemo therapy,Completed,08-Aug-18,Avis de refus d'inscription à la Liste Établissements,Negative,1st,20-Jul-18,29-Nov-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,Under provincial consideration,EM,01-Nov-19,07-Oct-19,11-Feb-19,13-Feb-19,06-Dec-19,30-Oct-19,,,,01-Feb-19,11-Feb-19,01-Feb-19,6,4,2,3,7,5,,,,1,28.60%,34.30%,39.80%,44.30%,45.20%,65.40%,97.70%,,,,97.70%,01-Nov-19,06-Dec-19,-112,-51,187,175,30,-19,132,337,312,74,76,372,335,,,,64,251,74,224,64,372,574,549,311,313,609,572,,,,301,488,461,311,423,236,499,474,236,238,534,497,,,,177,413,75,124,162,113,609,308,298,273,35,384
Tecentriq,atezolizumab,Hoffman-La Roche ,Y,Y,N,N,Y,Y,N,Y,N,01-Feb-19,08-Aug-19,188,CADTH & INESSS,04-Mar-19,pre-NOC,New indication,For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity,Completed,30-Jan-20,Do Not Fund,Negative,22-Mar-19,pre-NOC,New Indication,For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. ,Completed,16-Oct-19,Refus d'inscription,Negative,1st,27-Sep-21,11-Feb-22,Negotiation,Completed with Agreements,,,,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-157,-139,332,208,606,712,137,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,175,69,743,849,,,,,,363
Tecentriq,atezolizumab,Hoffman-La Roche,Y,Y,N,N,Y,N,N,N,N,01-Feb-19,19-Sep-19,230,CADTH,02-Oct-19,post-NOC,New indication,Advanced of Metastatic Triple-Negative Breast Cancer (TNBC),Withdrawn,12-Feb-20,n/a,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,13,,133,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,146,,,,,,,,,376
Tecentriq,atezolizumab,Hoffmann-La Roche,Y,Y,N,N,Y,N,N,N,N,01-Jul-21,14-Jan-22,197,CADTH & INESSS,24-Feb-22,post-NOC,Initial,Adjuvant treatment following resection and platinum-based chemotherapy for patients with stage II-IIIA (according to AJCC/UICC 7th edition) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ? 1% of tumour cells (TCs) and do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.,Completed,01-Sep-22,Cond'l on Cost,Conditional,23-Sep-22,post-NOC,New Indication,Adjuvant treatment following resection and platinum-based chemotherapy for patients with stage II-IIIA (according to AJCC/UICC 7th edition) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ? 1% of tumour cells (TCs) and do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.,Completed,01-Mar-23,Inscription - Avec conditions,Conditional,1st,28-Nov-22,14-Mar-23,Active,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,41,252,189,159,88,-93,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,230,411,194,13,,,,,,427
Tecentriq,atezolizumab,Hoffmann-La Roche,Y,Y,N,N,Y,Y,N,Y,N,01-Feb-19,08-Aug-19,188,CADTH & INESSS,24-Jan-22,post-NOC,Initial,Tecentriq in combination with carboplatin and etoposide is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).,Completed,01-Sep-22,Cond'l on Cost,Conditional,22-Mar-19,pre-NOC,New Indication,Tecentriq in combination with carboplatin and etoposide is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).,Completed,16-Oct-19,Refus d'inscription,Negative,None,,,,,Under provincial consideration,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,,30-Sep-22,01-Mar-23,12-Jan-23,31-Mar-23,,,,,13-Apr-22,30-Sep-22,13-Apr-22,,2,4,3,5,,,,,1,28.60%,33.00%,38.60%,44.30%,76.50%,,,,,,76.50%,31-Mar-23,,900,-139,220,208,,,,,,,,,,,,,,,,,,,,1149,1301,1253,1331,,,,,979,1259,1203,1149,249,29,,29,181,133,211,,,,,910,139,1120,69,,,,,,352,,1308
Tecentriq & Avastin,atezolizumab & bevacizumab,Hoffman-La Roche,Y,Y,N,N,Y,N,N,N,N,01-Jul-18,24-May-19,327,CADTH,18-Nov-19,post-NOC,New indication,For the treatment of metastatic EGFR and/or ALK positive non-squamous non-small cell lung cancer in patients who have progressed on treatment with targeted therapies. Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity. Maintenance AVASTIN should be continued until disease progression or unacceptable toxicity.,Completed,03-Jul-20,Do Not Fund,Negative,,,,,,,,,None,01-Sep-20,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,178,,228,,60,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,406,,,,,,,,,733
Tecentriq & Avastin,atezolizumab & bevacizumab,Hoffman-La Roche,Y,Y,N,N,Y,Y,N,Y,N,01-Feb-20,07-Aug-20,188,CADTH & INESSS,21-May-20,pre-NOC,New indication,"Hepatocellular Carcinoma (HCC): TECENTRIQ (atezolizumab), in combination with AVASTIN (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.",Completed,17-Nov-20,Cond'l on Cost,Conditional,26-Jun-20,pre-NOC,New Indication,"Hepatocellular Carcinoma (HCC): TECENTRIQ (atezolizumab), in combination with AVASTIN (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.",Completed,30-Dec-20,Inscription - Avec conditions,Conditional,1st,26-Mar-21,14-Oct-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,01-Apr-22,31-Jan-22,01-Nov-21,24-Nov-21,31-Mar-22,,,,,15-Dec-21,01-Nov-21,01-Nov-21,6,4,1,2,5,,,,,3,5.70%,11.20%,39.80%,44.30%,76.50%,96.80%,,,,,96.80%,31-Mar-22,01-Apr-22,-78,-42,180,187,129,86,202,169,109,18,41,168,,,,,62,101,18,95,18,169,602,542,451,474,601,,,,,495,534,528,451,529,349,500,440,349,372,499,,,,,350,432,102,145,331,288,602,151,151,150,1,290
Tecfidera,dimethyl fumarate,Biogen,N,N,N,Y,N,N,N,N,N,,03-Apr-13,,CADTH & INESSS,04-Feb-13,pre-NOC,Initial,"Multiple Sclerosis, relapsing ",Completed,25-Sep-13,List with criteria/condition,Conditional,02-Aug-13,post-NOC,New Drug,"Multiple Sclerosis, relapsing ",Completed,03-Feb-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,31-Jan-14,10-Apr-14,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,24-Jun-14,01-Aug-14,01-May-14,17-Jul-14,01-May-14,03-Oct-14,23-Jul-14,25-May-15,22-May-14,03-Feb-14,01-May-14,03-Feb-14,5,8,2,6,3,9,7,10,4,1,28.60%,34.30%,66.50%,67.20%,87.50%,93.00%,94.30%,98.80%,99.60%,100.00%,100.00%,01-May-14,24-Jun-14,-58,121,233,185,128,-3,69,75,113,21,98,21,176,104,410,42,-66,118,21,99,-66,75,447,485,393,470,393,548,476,782,414,306,490,471,393,451,218,272,310,218,295,218,373,301,607,239,0,315,175,306,197,66,447,141,54,87,54,41542
Technivie,ombitasvir/ paritaprevir/ ritonavir,AbbVie ,Y,N,N,N,N,N,N,N,N,,20-Oct-15,,CADTH & INESSS,04-Sep-15,pre-NOC,Initial,"Hepatitis C, chronic (genotype 4)",Completed,18-Mar-16,List with clinical criteria and/or conditions,Conditional,04-Aug-15,pre-NOC,New Drug,"Hepatitis C, chronic (genotype 4)",Completed,26-Apr-16,Avis d’inscription aux listes des médicaments – Médicament d’exception,Conditional,1st,14-Apr-16,17-Feb-17,Negotiation,No agreement reached,NR,NR,NR,NR,NR,NR,NR,NR,NR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-46,-77,196,266,27,-12,309,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,150,189,336,297,,,,,,42447
Tegsedi,inotersen,Akcea Therapeutics ,N,N,N,Y,N,Y,Y,Y,Y,01-Apr-18,03-Oct-18,185,CADTH & INESSS,22-Feb-19,post-NOC,Initial,hereditary transthyretin amlyoidosis,Completed,18-Dec-19,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-19,post-NOC,New Drug,Polyneuropathy ATTRh,Completed,11-Sep-19,Inscription - Avec conditions,Conditional,1st,29-Nov-19,30-Apr-20,Negotiation,Completed with Agreements,EDRD,UR,EDS,EDS,EAP,SA,EDS,UR,UR,EM,01-Dec-21,,01-Oct-20,21-Jan-21,29-Jan-21,20-Aug-20,27-Jun-22,,,08-Jul-20,20-Aug-20,08-Jul-20,6,,3,4,5,2,7,,,1,28.60%,29.50%,35.20%,40.70%,73.00%,93.20%,94.50%,,,,94.50%,29-Jan-21,01-Dec-21,142,170,299,173,-19,79,153,580,,154,266,274,112,788,,,69,362,112,320,69,580,1155,,729,841,849,687,1363,,,644,937,895,687,545,246,714,,288,400,408,246,922,,,301,496,441,343,134,232,1155,511,468,205,306,626
Tepmetko,tepotinib,EMD Serono - Pfizer Alliance,N,N,N,Y,Y,Y,N,Y,N,01-Oct-20,27-May-21,238,CADTH & INESSS,30-Aug-21,post-NOC,Initial,For the treatment of adult patients with locally advanced unresectable metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.,Completed,24-Aug-22,Do Not Fund,Negative,22-Apr-22,post-NOC,New Drug,For the treatment of adult patients with locally advanced unresectable metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.,Completed,31-Aug-22,Inscription - Avec conditions,Conditional,1st,09-Mar-23,,Active,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,95,330,359,131,197,190,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,454,461,,,,,,,,692
Tezspire,tezepelumab,AstraZeneca Canada Inc,Y,Y,N,Y,N,N,N,N,Y,01-Oct-21,28-Jul-22,300,CADTH & INESSS,14-Apr-22,pre-NOC,Initial,Asthma,Completed,16-Nov-22,Reimburse with clinical criteria and/or conditions,Conditional,16-Dec-22,post-NOC,New Drug,Asthma,under review,TBD,TBD,TBD,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-105,141,216,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,111,,,,,,,,,411
Tivicay,dolutegravir,ViiV Healthcare ,N,N,N,Y,N,N,N,N,N,,31-Oct-13,,CADTH & INESSS,18-Oct-13,pre-NOC,Initial,HIV infection,Completed,18-Aug-14,List,Positive,24-Nov-13,post-NOC,New Drug,HIV infection,Completed,02-Jun-14,Ajout aux listes de médicaments,Positive,1st,28-Oct-14,08-Apr-15,Negotiation,Completed with Agreements,HIV,HIV,EDS,EDS,FB,FB,HIV,FB,SA,FB,10-Apr-14,01-Nov-15,01-Jul-15,22-Jul-15,30-Apr-15,29-Jun-15,06-Jun-15,23-Nov-15,01-Jul-15,02-Jun-14,10-Apr-14,10-Apr-14,1,9,6,8,3,5,4,10,7,2,20.30%,48.80%,81.10%,82.40%,83.30%,89.00%,89.70%,95.20%,99.60%,100.00%,100.00%,30-Apr-15,30-Apr-15,-13,24,304,190,71,148,162,-363,207,84,105,22,82,59,229,84,-310,57,-363,20,-363,22,161,731,608,629,546,606,583,753,608,214,581,544,161,174,-130,-130,440,317,338,255,315,292,462,317,0,290,291,214,233,310,546,385,385,385,0,41869
Toviaz,fesoterodine fumarate ,Pfizer ,Y,N,N,Y,N,N,N,N,N,,09-Feb-12,,CADTH & INESSS,27-Apr-12,post-NOC,Initial,"Bladder, overactive ",Completed,18-Oct-12,List in a similar manner,Conditional,02-Aug-12,post-NOC,New Drug,"Bladder, overactive ",Completed,01-Feb-13,Ajout aux listes de médicaments - Médicament d'exception,Conditional,none,,,,,NR,SA,EDS,FB,LU,SA,EDS,SA,SA,EM,,01-Feb-13,01-Jan-13,17-Jul-13,30-Apr-13,20-Jun-13,04-Mar-13,21-Jan-13,25-Apr-13,15-Mar-13,01-Jan-13,01-Jan-13,,3,1,9,7,8,4,2,6,5,5.70%,6.10%,10.50%,11.80%,40.40%,41.10%,73.30%,74.20%,79.70%,,79.70%,30-Apr-13,,78,175,174,183,,,,,,,,,,,,,,,,,,,,358,327,524,446,497,389,347,441,400,416,414,327,249,75,,106,75,272,194,245,137,95,189,42,164,252,358,,,,,,119,,41200
Trazimera,trastuzumab,Pfizer,Y,Y,Y,Y,Y,N,N,N,N,01-Feb-18,15-Aug-19,560,CADTH,n/a,na,New drug,Breast and Gastric Cancer Biosimilar,File-Closed Not Submitted,,n/a,n/a,,,,,,,,,1st,31-May-19,17-Oct-19,Negotiation,Completed with Agreements,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,139,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-43132
Treanda,bendamustine hydrochloride,Lundbeck,N,N,N,Y,Y,Y,N,Y,N,,24-Aug-12,,CADTH & INESSS,24-Apr-12,pre-NOC,New drug,Non-Hodgkin lymphoma (NHL),Completed,29-Nov-12,Fund,Positive,,,New Drug,Non-Hodgkin lymphoma (NHL),Completed,03-Jun-13,Avis de refus - Valeur thérapeutique,Negative,1st,19-Feb-13,25-Apr-13,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,NR,01-Jun-13,25-Mar-13,03-Apr-13,19-Mar-13,21-May-13,01-Feb-14,10-Jul-13,08-Apr-14,01-Jan-13,,01-Jan-13,01-Jan-13,6,3,4,2,5,8,7,9,1,,0.70%,6.20%,10.70%,16.40%,48.60%,68.90%,70.20%,71.10%,71.40%,,71.40%,01-Jun-13,,-122,,219,,82,-104,65,37,-31,-22,-37,26,282,76,348,-114,,63,-114,63,-114,,281,213,222,207,270,526,320,592,130,,307,307,130,252,33,184,116,125,110,173,429,223,495,33,,210,97,283,147,-39,,,,151,,41242
Treanda,bendamustine hydrochloride,Lundbeck,N,N,N,Y,Y,Y,N,Y,N,,24-Aug-12,,CADTH & INESSS,24-Apr-12,pre-NOC,New drug,Chronic lymphocytic leukemia (CLL) (1st Line),Completed,19-Feb-13,Cond'l on Cost,Conditional,24-Nov-12,post-NOC,New Drug,Chronic lymphocytic leukemia (CLL) (1st Line),Completed,03-Jun-13,Ajout à la Liste Établissements - Médicament d'exception,Positive,1st,,31-Jan-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jan-17,18-Jul-13,03-Apr-13,21-Jan-14,21-May-13,01-Feb-14,10-Jul-13,01-Aug-18,02-Jan-13,03-Jun-13,02-Jan-13,02-Jan-13,9,6,2,7,3,8,5,10,1,4,0.70%,6.40%,38.60%,67.20%,68.50%,73.00%,78.50%,79.40%,99.60%,100.00%,100.00%,03-Jun-13,01-Jan-17,-122,92,301,191,,,,1066,-197,-303,-10,-255,1,-205,1643,-394,-242,150,-394,110,-394,1066,1591,328,222,515,270,526,320,2168,131,283,675,635,131,253,-48,1412,149,43,336,91,347,141,1989,-48,0,496,179,283,346,242,1591,1460,1460,152,1308,41324
Treanda (in combination with rituximab),bendamustine hydrochloride,Lundbeck,N,N,N,N,Y,Y,N,Y,N,,,,CADTH,27-Jun-14,na,New indication,Chronic Lymphocytic Leukemia,Withdrawn,26-Sep-14,n/a,n/a,,,,,,,,,None,,,,,Funded,Funded,Funded,Funded,Not funded,Not funded,Funded,Not funded,Not funded,,01-Jan-17,01-Oct-15,01-Apr-15,01-Dec-15,,,01-Apr-17,,,,01-Apr-15,01-Apr-15,4,2,1,3,,,5,,,,5.70%,10.20%,15.70%,36.00%,37.30%,,,,,,37.30%,,,,,91,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,278,187,828,370,187,431,,,918,,,,547,,,,,,,,,,41908
Treanda (Relapsed),bendamustine hydrochloride,Lundbeck,N,N,N,Y,Y,Y,N,Y,N,,24-Aug-12,,CADTH,24-Apr-12,pre-NOC,New drug,Chronic Lymphocytic Leukemia (relapsed/refractory),Completed,29-Nov-12,Do Not Fund,Negative,,,,,,,,,1st,,31-Jan-14,Negotiation,Completed with Agreements,Funded,Funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,,01-Feb-13,01-Mar-13,,,,,,,,,01-Feb-13,01-Feb-13,1,2,,,,,,,,,20.30%,24.70%,,,,,,,,,24.70%,,,-122,,219,,,,,-364,-336,,,,,,,,,-350,-364,-350,-364,,161,189,,,,,,,,,175,175,161,283,64,64,92,,,,,,,,,78,97,,428,,,,,,,41242
Trelegy Ellipta,fluticasone furoate umeclidinium vilanterol,GlaxoSmithKline,Y,N,N,N,N,N,N,N,N,01-Jun-17,04-Apr-18,307,CADTH & INESSS,01-Mar-18,pre-NOC,Initial,Chronic Obstructive Pulmonary Disease (COPD),Completed,23-Aug-18,Reimburse with clinical criteria and/or conditions,Conditional,05-Mar-18,pre-NOC,New Drug,COPD,Completed,05-Sep-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,30-Nov-18,09-Sep-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,FB,SA,EM,07-Jul-20,01-Feb-20,01-Nov-19,02-Mar-20,30-Sep-19,01-Oct-19,01-Dec-19,25-Nov-19,03-Jan-20,14-Nov-19,30-Sep-19,30-Sep-19,10,8,3,9,1,2,6,5,7,4,32.20%,33.10%,38.80%,67.40%,67.80%,69.10%,69.80%,74.20%,79.70%,100.00%,100.00%,14-Nov-19,07-Jul-20,-34,-30,175,184,99,86,283,302,145,53,175,21,22,83,77,116,66,110,21,106,21,302,825,668,576,698,544,545,606,600,639,589,633,629,544,578,403,684,527,435,557,403,404,465,459,498,435,492,141,154,382,369,825,281,281,45,236,448
Tremfya,guselkumab,Janssen ,Y,Y,N,Y,N,N,N,N,N,01-Jan-17,10-Nov-17,313,CADTH & INESSS,25-Aug-17,pre-NOC,Initial,"Psoriasis, moderate to severe plaque",Completed,21-Feb-18,Reimburse with clinical criteria and/or conditions,Conditional,27-Aug-17,pre-NOC,New Drug,Psoriasis,Completed,01-Mar-18,Avis d’inscription aux listes des médicaments – Médicament d’exception – Avec conditions,Conditional,1st,30-Oct-18,21-Jun-19,Negotiation,No agreement reached,NR,UR,NR,UR,UR,NR,UR,UR,UR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-77,-75,180,186,251,243,234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,103,111,485,477,,,,,,416
Tremfya,guselkumab,Janssen Inc.,Y,Y,N,N,N,N,N,N,N,01-Nov-19,04-Sep-20,308,CADTH & INESSS,02-May-22,post-NOC,Initial,Psoriatic arthritis,Completed,17-Nov-22,Reimburse with clinical criteria and/or conditions,Conditional,16-Dec-22,post-NOC,New Indication,Psoriatic arthritis,under review,TBD,TBD,TBD,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,605,833,199,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,804,,,,,,,,,1112
Tresiba,insulin degludec,Novo Nordisk ,Y,Y,N,Y,N,N,N,N,N,01-Oct-16,25-Aug-17,328,CADTH & INESSS,31-May-17,pre-NOC,Initial,"Diabetes mellitus, Type 1 & 2",Completed,20-Nov-17,Reimburse with clinical criteria and/or conditions,Conditional,01-Aug-17,pre-NOC,New Drug,Diabetes,Completed,11-Apr-18,Avis d’inscription aux listes des médicaments – Médicament d’exception (diabète de type 1) Avis de refus d’inscription aux listes des médicaments (diabète de type 2),Conditional,1st,30-Apr-18,26-Jul-18,Negotiation,Completed with Agreements,NR,FB,FB,FB,FB,FB,FB,FB,FB,EM,,01-Dec-18,01-Oct-18,18-Oct-18,27-Sep-18,30-Nov-18,01-May-19,26-Nov-18,31-Jan-19,27-Sep-18,27-Sep-18,27-Sep-18,,7,3,4,1,6,9,5,8,2,32.20%,60.80%,66.50%,72.10%,72.40%,73.30%,77.80%,78.40%,79.70%,,79.70%,27-Sep-18,,-86,-24,173,253,161,19,87,,128,67,84,63,127,279,123,189,63,133,63,125,63,,,463,402,419,398,462,614,458,524,398,468,460,398,484,311,,376,315,332,311,375,527,371,437,169,381,87,229,248,106,,,,0,,415
Trikafta,elexacaftor/tezacaftor/ivacaftor and ivacaftor,Vertex Pharmaceuticals (Canada) Incorporated,N,N,N,Y,N,Y,Y,Y,Y,01-Dec-20,18-Jun-21,199,CADTH & INESSS,22-Jan-21,pre-NOC,Initial,Triple Combination Therapy (elexacaftor/tezacaftor/ivacaftor and ivacaftor) tablets for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene,Completed,16-Sep-21,Reimburse with clinical criteria and/or conditions,Conditional,05-Mar-21,pre-NOC,New Drug,Cystic fibrosis children over 12 with CFTR F508del mutation,Completed,01-Sep-21,Inscription - Avec conditions,Conditional,1st,17-Sep-21,17-Sep-21,Negotiation,Completed with Agreements,EDRD,SA,EDS,EDS,EAP,SA,CF,SA,SA,EM,05-Oct-21,24-Sep-21,01-Oct-21,22-Oct-21,22-Sep-21,14-Oct-21,18-Nov-21,01-Nov-21,19-Nov-21,29-Sep-21,22-Sep-21,22-Sep-21,5,2,4,7,1,6,9,8,10,3,32.20%,36.70%,65.30%,71.00%,91.20%,92.10%,97.70%,98.00%,99.30%,100.00%,100.00%,29-Sep-21,05-Oct-21,-147,-105,237,180,1,16,0,18,7,14,35,5,27,62,45,63,12,31,5,29,5,18,109,98,105,126,96,118,153,136,154,103,122,120,96,243,6,19,8,15,36,6,28,63,46,64,28,32,90,75,1,16,109,13,13,7,6,289
Trikafta,elexacaftor/tezacaftor/ivacaftor and ivacaftor,Vertex Pharmaceuticals (Canada) Incorporated,N,N,N,Y,N,Y,Y,Y,Y,01-Dec-20,20-Apr-22,505,CADTH & INESSS,05-Nov-21,pre-NOC,Initial,"Cystic fibrosis, F508del CFTR mutation, 6 years and olde",Completed,17-Jun-22,Reimburse with clinical criteria and/or conditions,Conditional,22-Apr-22,post-NOC,New Indication,Cystic fibrosis children over 6 with CFTR F508del mutation,Completed,04-Aug-22,Inscription - Avec conditions,Conditional,1st,07-Jul-22,07-Jul-22,Negotiation,Completed with Agreements,EDRD,SA,EDS,EDS,EAP,SA,CF,SA,SA,EM,13-Sep-22,01-Aug-22,01-Aug-22,17-Aug-22,08-Jul-22,25-Jul-22,18-Jul-22,08-Aug-22,08-Aug-22,04-Aug-22,08-Jul-22,08-Jul-22,10,4,5,9,1,3,2,7,8,6,32.20%,33.50%,34.40%,38.90%,44.60%,73.20%,73.50%,74.20%,79.70%,100.00%,100.00%,04-Aug-22,13-Sep-22,-166,2,224,104,20,-28,0,68,25,25,41,1,18,11,32,32,28,28,1,28,1,68,146,103,103,119,79,96,89,110,110,106,106,106,79,245,21,88,45,45,61,21,38,31,52,52,0,48,58,106,20,-28,146,67,67,27,40,563
Trintellix,vortioxetine,Lundbeck ,N,N,N,Y,N,N,N,N,N,,22-Oct-14,,CADTH & INESSS,01-May-19,post-NOC,Initial,"Major depressive disorder (MDD), adults",Completed,12-Feb-20,Reimburse with clinical criteria and/or conditions,Conditional,10-May-19,post-NOC,New Drug,Major depressive disorder,Completed,06-Nov-19,Refus d'inscription,Negative,1st,06-Jul-20,03-Dec-20,Negotiation,Completed with Agreements,SA,UR,FB,FB,FB,FB,FB,FB,FB,FB,06-Jul-21,,01-Feb-21,01-Apr-21,29-Jan-21,22-Apr-21,30-Nov-21,20-Dec-21,20-Apr-21,03-Feb-21,29-Jan-21,29-Jan-21,7,,2,4,1,6,8,9,5,3,32.20%,38.00%,66.50%,72.10%,72.70%,73.60%,93.90%,95.20%,95.50%,,95.50%,03-Feb-21,06-Jul-21,1652,1661,287,180,145,243,150,215,,60,119,57,140,362,382,138,62,184,57,171,57,215,2449,,2294,2353,2291,2374,2596,2616,2372,2296,2418,2405,2291,639,352,510,,355,414,352,435,657,677,433,455,479,1939,1841,295,393,2449,158,158,5,153,43873
Trintellix (Withdrawn),vortioxetine,Lundbeck ,N,N,N,Y,N,N,N,N,N,,22-Oct-14,,CADTH,31-Oct-14,post-NOC,Initial,"Depression, Major Depressive Disorder (MDD) ",Withdrawn,10-Jun-15,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,9,,222,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,231,,,,,,,,,42165
Trisenox,arsenic trioxide,Lundbeck,N,N,N,Y,Y,Y,Y,Y,N,,07-Jun-13,,CADTH,30-Aug-13,post-NOC,New drug,Acute Promyelocytic Leukemia,Completed,18-Feb-14,Fund,Positive,,,,,,,,,None,01-Apr-14,,Negotiation by Province,n/a,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,,01-May-14,01-May-14,02-Jul-14,17-Jun-14,02-Sep-14,15-Jul-15,22-Jul-14,08-Apr-14,01-May-14,,08-Apr-14,08-Apr-14,2,3,6,5,8,9,7,1,4,,0.40%,20.60%,25.10%,25.70%,31.30%,37.00%,38.30%,70.50%,71.40%,,71.40%,02-Sep-14,,84,,172,,42,,,,,,,,,,,,,,,,,,328,328,390,375,452,768,410,305,328,,409,409,305,221,49,72,72,134,119,196,512,154,49,72,,153,256,,,,,,,147,,41688
Triumeq,dolutegravir / abacavir / lamivudine ,ViiV Healthcare ,N,N,N,N,N,N,N,N,N,,09-Oct-14,,CADTH & INESSS,31-Jul-14,pre-NOC,Initial,HIV Infection,Completed,17-Apr-15,List with criteria/condition,Conditional,24-Nov-14,post-NOC,New Drug,HIV Infection,Completed,01-Jun-15,Ajout aux listes de médicaments,Positive,1st,,08-Apr-15,Negotiation,Completed with Agreements,HIV,HIV,EDS,EDS,FB,FB,HIV,FB,SA,FB,02-Aug-15,01-Nov-15,01-Oct-15,22-Oct-15,28-May-15,29-Jun-15,29-Jun-15,23-Nov-15,01-Jul-15,01-Jun-15,28-May-15,28-May-15,6,9,7,8,1,3,4,10,5,2,32.20%,60.80%,61.70%,63.00%,63.70%,83.90%,89.70%,95.20%,99.60%,100.00%,100.00%,01-Jun-15,02-Aug-15,-70,46,260,189,,,,116,207,176,197,50,82,82,229,84,54,136,50,128,50,116,297,388,357,378,231,263,263,410,265,235,317,309,231,301,41,107,198,167,188,41,73,73,220,75,0,127,190,235,-9,-54,297,66,66,4,62,42111
Trodelvy,sacituzumab govitecan,Gilead ,Y,Y,N,Y,Y,N,N,N,Y,01-Mar-21,24-Sep-21,207,CADTH & INESSS,30-Jun-21,pre-NOC,Initial,"For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior therapies, at least one of them for metastatic disease.",Completed,27-Jan-22,Cond'l on Cost,Conditional,05-Nov-21,post-NOC,New Drug,"For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior therapies, at least one of them for metastatic disease.",Completed,04-May-22,Inscription - Avec conditions,Conditional,1st,29-Jul-22,09-Mar-23,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-86,42,211,180,183,86,223,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,125,222,406,309,,,,,,332
Trulicity,dulaglutide,Eli Lilly ,N,Y,N,Y,N,N,N,N,N,,10-Nov-15,,CADTH & INESSS,22-Dec-15,post-NOC,Initial,"Diabetes mellitus, Type 2",Completed,16-Jun-16,Reimburse with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New Drug,"Diabetes mellitus, Type 2",Completed,01-Jun-16,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,07-Jul-17,27-Sep-19,Negotiation,No agreement reached,NR,UR,NR,UR,UR,NR,UR,UR,UR,EM,,,,,,,,,,01-Jun-16,,01-Jun-16,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,42,14,177,190,386,401,812,,,,,,,,,,-1213,,,-1213,-1213,,,,,,,,,,,204,,204,,,,,,,,,,,,,0,,219,204,1198,1213,,,,,,42537
Truvada (HIV pre-exposure prophylaxis),emtricitabine/tenofovir disoproxil fumarate,Gilead Sciences ,Y,N,N,N,N,N,N,N,N,,26-Feb-16,,CADTH,03-Mar-16,post-NOC,Initial,"HIV-1 infection, pre-exposure prophylaxis",Completed,24-Aug-16,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,none,08-Sep-17,,Do Not Negotiate,n/a,NR,NR,FB,FB,FB,FB,EDS,HIV,SA,FB,,,01-Jan-18,19-Apr-18,04-Sep-07,29-Jun-09,23-Jul-18,01-Mar-09,12-Sep-18,01-Oct-06,04-Sep-07,01-Oct-06,,,5,6,2,4,7,3,8,1,28.60%,60.80%,61.20%,62.10%,67.80%,73.30%,74.60%,75.30%,,,75.30%,04-Sep-07,,6,,174,,380,,,,,,,,,,,,,,,,,,,,675,783,-3097,-2433,878,-2553,929,-3435,-688,-1032,-3097,-3103,-3277,,,495,603,-3277,-2613,698,-2733,749,,-868,180,,,,,,,338,,42606
Truxima,rituximab,Teva Canada Innovation,N,Y,Y,Y,Y,Y,N,Y,N,01-Sep-17,04-Apr-19,580,CADTH,n/a,na,New drug,Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar,File-Closed Not Submitted,,n/a,n/a,,,,,,,,,1st,13-Sep-19,12-Feb-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,,,,EM,20-Aug-20,01-Jun-20,01-Jan-21,16-Jul-20,31-Mar-20,17-Sep-20,,,,16-Dec-20,31-Mar-20,31-Mar-20,4,2,7,3,1,5,,,,6,32.20%,36.70%,42.20%,62.50%,63.40%,91.90%,97.70%,,,,97.70%,20-Aug-20,16-Dec-20,,,,,,,152,190,110,324,155,48,218,,,,308,174,48,193,48,308,504,424,638,469,362,532,,,,622,488,507,362,,,,,,,,,,,,,,,,,,622,260,260,142,118,-42979
Tudorza Genuair,aclidinium bromide,Almirall ,N,N,N,Y,N,N,N,N,N,,29-Jul-13,,CADTH & INESSS,21-Aug-13,post-NOC,Initial,Chronic Obstructive Pulmonary Disease (COPD),Completed,21-Apr-14,List with criteria/condition,Conditional,,,New Drug,Chronic Obstructive Pulmonary Disease (COPD),Completed,03-Feb-14,Ajout aux listes de médicaments,Positive,1st,31-May-14,16-Jul-14,Negotiation,Completed with Agreements,SA,FB,EDS,FB,FB,SA,EDS,SA,SA,FB,30-Sep-14,01-Nov-14,01-Nov-14,16-Oct-14,28-Aug-14,11-Sep-14,31-Oct-14,01-Dec-14,14-Oct-14,03-Feb-14,28-Aug-14,03-Feb-14,4,8,9,6,2,3,7,10,5,1,28.60%,60.80%,61.70%,82.00%,82.60%,88.20%,89.50%,93.90%,99.60%,100.00%,100.00%,28-Aug-14,30-Sep-14,23,,243,,40,117,46,76,108,108,92,43,57,107,138,90,-163,91,43,66,-163,76,428,460,460,444,395,409,459,490,442,189,443,418,395,372,129,162,194,194,178,129,143,193,224,176,0,177,266,189,86,163,428,239,33,206,33,41750
Tukysa,tucatinib,Seagen,N,N,N,Y,Y,N,N,N,N,01-Feb-20,05-Jun-20,125,CADTH & INESSS,26-Mar-21,post-NOC,Initial,"Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination",Completed,17-Nov-21,Cond'l on Cost,Conditional,23-Apr-21,post-NOC,New Drug,"Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination",Completed,08-Sep-21,Inscription - Avec conditions,Conditional,1st,18-May-22,14-Sep-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,EM,01-Dec-22,30-Sep-22,01-Feb-23,24-Jan-23,28-Feb-23,27-Mar-23,01-Apr-23,,,09-Nov-22,30-Sep-22,30-Sep-22,3,1,5,4,6,7,8,,,2,4.50%,33.00%,53.30%,58.80%,64.50%,96.80%,97.70%,99.00%,,,99.00%,01-Dec-22,28-Feb-23,294,322,236,138,182,252,119,78,16,140,132,167,194,199,,,56,132,16,123,16,167,909,847,971,963,998,1025,1030,,,887,963,954,847,553,317,379,317,441,433,468,495,500,,,427,433,530,460,301,371,998,151,151,62,89,655
Ultibro Breezhaler,indacaterol / glycopyrronium,Novartis ,Y,N,N,N,N,N,N,N,N,,23-Dec-13,,CADTH & INESSS,03-Feb-14,post-NOC,Initial,COPD,Completed,19-Dec-14,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Drug,COPD,Completed,02-Feb-15,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,26-Jan-15,20-Apr-15,Negotiation,Completed with Agreements,SA,SA,EDS,FB,LU,SA,EDS,SA,SA,EM,02-Jun-15,01-Sep-15,01-Jul-15,22-Jul-15,28-May-15,02-Jun-15,29-Jun-15,27-Jul-15,01-Jul-15,02-Feb-15,28-May-15,02-Feb-15,3,10,6,8,2,4,5,9,7,1,28.60%,60.80%,81.10%,82.00%,83.30%,89.00%,89.70%,95.20%,95.50%,100.00%,100.00%,28-May-15,02-Jun-15,42,224,319,182,38,-7,84,43,134,72,93,38,43,70,98,72,-77,74,38,59,-77,43,526,617,555,576,521,526,553,581,555,406,557,542,521,479,160,165,256,194,215,160,165,192,220,194,0,196,361,406,122,77,526,120,5,115,5,41992
Ultomiris,ravulizumab,Alexion Pharmaceuticals,N,Y,N,Y,N,Y,Y,Y,N,01-Nov-18,28-Aug-19,300,CADTH,04-Jul-19,pre-NOC,Initial,Paroxysmal nocturnal hemoglobinuria,Withdrawn,19-Nov-20,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-55,,504,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,449,,,,,,,,,749
Ultomiris,ravulizumab,Alexion Pharma Canada Corp.,N,Y,N,Y,N,Y,Y,Y,N,01-Nov-18,28-Aug-19,300,CADTH & INESSS,22-Jul-21,post-NOC,Initial,Paroxysmal nocturnal hemoglobinuria,Completed,11-Feb-22,Reimburse with clinical criteria and/or conditions,Conditional,13-May-22,post-NOC,New Drug,Paroxysmal nocturnal hemoglobinuria,Completed,30-Nov-22,Inscription - Avec conditions,Conditional,none,,,,,UR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,694,989,204,201,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,898,1190,,,,,,,,1198
Ultomiris,ravulizumab,Alexion Pharma GmBH,N,Y,N,N,N,Y,N,Y,N,01-Jan-21,01-Nov-22,669,CADTH,08-Jun-22,pre-NOC,Initial,Atypical hemolytic uremic syndrome,Completed,27-Feb-23,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-146,,264,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,118,,,,,,,,,787
Ultomiris,ravulizumab,Alexion Pharma GmBH,N,Y,N,Y,N,Y,N,Y,N,01-Mar-22,06-Jan-23,311,CADTH,25-Oct-22,pre-NOC,Initial,AChR antibody-positive generalized Myasthenia Gravis,Active,,Active,n/a,,,,,,,,,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-73,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44621
Unituxin,dinutuximab,United Therapeutics Corp.,N,Y,N,Y,Y,Y,Y,Y,N,01-Feb-18,28-Nov-18,300,CADTH & INESSS,01-Oct-18,pre-NOC,New drug,Neuroblastoma,Completed,26-Mar-19,Cond'l on Cost,Conditional,26-Apr-19,post-NOC,New Drug,Neuroblastoma,Completed,16-Oct-19,Inscription - Avec conditions,Conditional,1st,08-May-19,30-Aug-19,Negotiation,Completed with Agreements,Funded,Under provincial consideration,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,01-Nov-19,,01-Mar-20,11-Feb-20,29-Jan-20,,,,,04-Mar-20,01-Nov-19,01-Nov-19,1,,4,3,2,,,,,5,20.30%,52.50%,58.00%,63.70%,92.30%,,,,,,92.30%,29-Jan-20,04-Mar-20,-58,149,176,173,43,-161,114,63,,184,165,152,,,,,187,141,63,150,63,187,338,,459,440,427,,,,,462,416,425,338,396,220,220,,341,322,309,,,,,140,298,118,322,157,-47,462,124,124,89,35,418
Unituxin,dinutuximab,United Therapeutics Corp.,N,Y,N,N,Y,Y,Y,Y,N,01-Feb-18,28-Nov-18,300,CADTH,23-Nov-20,post-NOC,Initial,"For the treatment of high-risk neuroblastoma patients in their first relapse ordetermination of refractory disease, in combination with irinotecan,temozolomide, and granulocyte macrophage colony-stimulating factor",Completed,23-Jul-21,Cond'l on Cost,Conditional,,,,,,,,,1st,16-Nov-21,24-Feb-22,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,726,,242,,116,,100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,968,,216,,,,,,,1268
Uptravi,selexipag,Actelion,Y,N,N,Y,N,Y,N,Y,N,,20-Jan-16,,CADTH & INESSS,31-Mar-16,post-NOC,Initial,Pulmonary arterial hypertension (WHO class II and III),Completed,28-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Drug,Pulmonary arterial hypertension (WHO class II and III),Completed,03-Oct-16,Avis de refus d’inscription aux listes des médicaments – Médicament d’exception – À moins que certaines conditions soient respectées,Conditional,1st,13-Apr-17,12-Dec-17,Negotiation,Completed with Agreements,SA,F,EDS,EDS,EAP,SA,EDS,SA,SA,EM,30-Oct-18,12-Jun-18,01-Apr-18,19-Apr-18,18-Apr-18,06-Sep-18,29-Oct-18,24-Dec-18,28-Mar-18,01-Mar-18,28-Mar-18,01-Mar-18,9,6,3,5,4,7,8,10,2,1,28.60%,29.30%,35.00%,67.20%,72.70%,77.20%,78.10%,79.40%,99.60%,100.00%,100.00%,18-Apr-18,30-Oct-18,71,62,211,195,167,192,243,322,182,110,128,127,268,321,377,106,79,216,106,202,79,322,1014,874,802,820,819,960,1013,1069,798,771,908,894,798,727,516,732,592,520,538,537,678,731,787,516,514,626,282,257,410,435,1014,243,216,48,195,42671
Vabysmo,faricimab,Roche,Y,Y,N,Y,N,N,N,N,N,01-Aug-21,27-May-22,299,CADTH & INESSS,31-Jan-22,pre-NOC,Initial,"Macular degeneration, age-related",Completed,12-Aug-22,Reimburse with clinical criteria and/or conditions,Conditional,13-May-22,pre-NOC,New Drug,Age-related macular degeneration,Completed,07-Oct-22,Inscription - Avec conditions,Conditional,1st,17-Feb-23,,Active,n/a,UR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-116,-14,193,147,189,133,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,77,133,,,,,,,,376
Vabysmo,faricimab,Roche,Y,Y,N,Y,N,N,N,N,N,01-Aug-21,27-May-22,299,CADTH & INESSS,24-Mar-22,pre-NOC,Initial,Diabetic Macular Edema,Completed,14-Oct-22,Reimburse with clinical criteria and/or conditions,Conditional,28-Oct-22,post-NOC,New Drug,Diabetic macula edema,Completed,01-Mar-23,Inscription - Avec conditions,Conditional,1st,17-Feb-23,,Active,n/a,UR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-64,154,204,124,126,-12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,140,278,,,,,,,,439
Vascepa,icosapent ethyl,HLS Therapeutics,N,N,N,Y,N,N,N,N,N,01-Jul-19,30-Dec-19,182,CADTH & INESSS,17-Jun-19,pre-NOC,Initial,Ischemic events in statin-treated patients,Completed,16-Jul-20,Reimburse with clinical criteria and/or conditions,Conditional,12-Jul-19,pre-NOC,New drug,Prevention of cardiovascular events,Completed,05-Feb-20,Refus d'inscription,Negative,1st,29-Jan-21,25-Apr-22,Negotiation,Completed with Agreements,,,EDS,EDS,EAP,SA,,,,EM,,,01-Aug-22,20-Sep-22,21-Jul-22,20-Jun-22,,,,26-May-21,20-Jun-22,26-May-21,,,4,5,3,2,,,,1,28.60%,29.50%,61.70%,67.40%,73.00%,,,,,,73.00%,21-Jul-22,,-196,-171,395,208,197,359,451,,,98,148,87,56,,,,-334,97,56,11,-334,,,,945,995,934,903,,,,513,944,858,903,1099,704,,,746,796,735,704,,,,476,745,199,37,648,810,,,,421,,381
Vectibix,panitumumab,Amgen ,Y,Y,N,N,Y,N,N,N,N,,31-Aug-15,,CADTH & INESSS,15-Apr-15,pre-NOC,New indication,Metastatic Colorectal Cancer,Completed,03-Dec-15,Cond'l on Cost,Conditional,24-Nov-15,post-NOC,New Indication,Metastatic Colorectal Cancer,Completed,01-Jun-16,Avis d’ajout d’une indication reconnue à la Liste Établissements – Médicament d’exception – Avec conditions (contre-indication ou intolérance au bevacizumab) Avis de refus d’ajout d’une indication reconnue à la Liste Établissements – Médicament d’exception – À moins que certaines conditions soient respectées (ensemble des patients),Conditional,1st,23-Dec-15,22-May-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Nov-17,30-Sep-22,02-Aug-17,01-Nov-17,01-Sep-17,20-Dec-17,01-Feb-18,01-Aug-18,03-Aug-17,19-Jul-17,02-Aug-17,19-Jul-17,5,10,2,6,4,7,8,9,3,1,28.60%,34.30%,35.00%,67.20%,87.50%,93.00%,93.90%,95.20%,95.50%,100.00%,100.00%,01-Sep-17,01-Nov-17,-138,85,232,190,20,-161,516,163,1957,72,163,102,212,255,436,73,58,381,72,349,58,163,793,2587,702,793,732,842,885,1066,703,688,1011,979,702,840,608,699,2493,608,699,638,748,791,972,609,413,917,94,275,536,355,793,105,91,44,61,42341
Vectibix,panitumumab,Amgen ,Y,Y,N,N,Y,N,N,N,N,,31-Aug-15,,CADTH & INESSS,08-Sep-17,post-NOC,New indication,Left Sided Metastatic Colorectal Cancer,Completed,29-Mar-18,Do Not Fund,Negative,24-Nov-16,post-NOC,New Indication,Left Sided Metastatic Colorectal Cancer,Completed,01-Jun-17,Avis d'inscription à la Liste Établissements - Médicament d'exception,Positive,None,10-May-18,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,739,451,202,189,42,343,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,941,640,,,,,,,,43188
Velcade,bortezomib,Janssen ,Y,N,N,N,Y,Y,N,Y,N,,24-Jun-13,,CADTH & INESSS,29-Oct-12,pre-NOC,New indication,For the treatment of patients with multiple myeloma pre-autologous stem cell transplantation in combination therapy and post-autologous stem cell transplantation as monotherapy,Completed,25-Mar-13,Fund,Positive,,,New Indication,For the treatment of patients with multiple myeloma pre-autologous stem cell transplantation in combination therapy and post-autologous stem cell transplantation as monotherapy,Completed,01-Dec-06,Ajout de nouveaux médicaments dans la Liste de médicaments – Établissements,Positive,None,,,,,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-May-10,18-Jul-13,01-Nov-10,21-Jun-11,28-Jun-13,01-Feb-14,01-Sep-12,01-Jun-11,01-Apr-13,01-Dec-06,01-May-10,01-Dec-06,2,9,3,5,8,10,6,4,7,1,28.60%,48.80%,54.60%,54.90%,60.40%,61.70%,62.40%,94.70%,99.10%,100.00%,100.00%,01-Nov-10,28-Jun-13,-238,,147,,,,,,,,,,,,,,,,,,,41453,-1150,24,-966,-734,4,222,-296,-754,-84,-2397,-415,-613,-1150,-912,-1059,-1059,115,-875,-643,95,313,-205,-663,7,0,-324,-91,-2397,,,4,2401,1154,1431,970,41358
Velphoro,sucroferric oxyhydride,Vifor Fresnius Medical Care Renal Pharma,N,N,N,Y,N,N,N,N,N,01-Feb-17,05-Jan-18,338,CADTH & INESSS,12-Jun-18,post-NOC,Initial,"Hyperphosphatemia, end-stage renal disease",Completed,02-Jan-19,Reimburse with clinical criteria and/or conditions,Conditional,11-Jul-18,post-NOC,New Drug,Hyperphosphatemia,Completed,09-Jan-19,Inscription – Avec conditions,Conditional,1st,12-Apr-19,17-Sep-19,Negotiation,Completed with Agreements,UR,UR,EDS,EDS,EAP,SA,EDS,UR,SA,EM,,,01-Nov-20,16-Jul-20,26-Feb-20,18-Jun-20,07-Oct-20,,14-Sep-20,02-Oct-19,26-Feb-20,02-Oct-19,,,7,4,2,3,6,,5,1,28.60%,60.80%,61.70%,67.20%,67.90%,69.20%,74.90%,,,,74.90%,26-Feb-20,,158,187,204,182,100,93,158,,,411,303,162,275,386,,363,15,317,162,274,15,,,,1031,923,782,895,1006,,983,635,937,894,782,624,420,,,669,561,420,533,644,,621,266,575,362,369,258,251,,,,147,,700
Veltassa,patiromer,Otsuka Canada Pharmaceuticals Inc.,N,N,N,Y,N,N,N,N,N,01-Dec-17,03-Oct-18,306,CADTH & INESSS,30-Oct-20,post-NOC,Initial,Hyperkalemia in adults with chronickidney disease (eGFR ?15mL/min/1.73m),Completed,08-Jun-21,Reimburse with clinical criteria and/or conditions,Conditional,19-Feb-21,post-NOC,New Drug,Hyperkalemia,Completed,28-Jul-21,Refus d'inscription,Negative,1st,18-Nov-21,18-Feb-22,Negotiation,No agreement reached,,,NR,,,NR,,,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,758,870,221,159,163,113,92,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,979,1029,255,205,,,,,,1285
Vemlidy,tenofovir alafenamide,Gilead Sciences ,Y,N,N,N,N,N,N,N,N,01-Jul-16,17-May-17,320,CADTH & INESSS,28-Sep-17,post-NOC,Initial,"Hepatitis B, chronic",Completed,26-Mar-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,Hepatitis B,Completed,11-Apr-18,Avis de refus d’inscription aux listes des médicaments,Negative,1st,25-Sep-18,31-Oct-18,Negotiation,No agreement reached,NR,UR,NR,NR,NR,NR,NR,NR,NR,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,134,,179,,183,167,36,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,313,329,219,203,,,,,,633
Venclexta,venetoclax,AbbVie ,Y,N,N,Y,Y,Y,Y,Y,N,01-Feb-16,30-Sep-16,242,CADTH,08-Jul-16,pre-NOC,New drug,Chronic Lymphocytic Leukemia (with 17p deletion),Withdrawn,10-Jan-17,n/a,n/a,,,,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-84,,186,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,102,,,,,,,,,344
Venclexta,venetoclax,AbbVie ,Y,N,N,Y,Y,Y,Y,Y,N,01-Feb-16,30-Sep-16,242,CADTH & INESSS,10-Jul-17,post-NOC,New indication,Chronic Lymphocytic Leukemia,Completed,02-Mar-18,Cond'l on Cost,Conditional,23-Jul-17,post-NOC,New Drug,chronic lymphocytic leukemia,Completed,01-Feb-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,21-Jun-18,06-Mar-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,NR,01-Sep-19,26-Jul-19,03-Sep-19,22-Aug-19,13-May-19,24-Oct-19,03-Oct-19,10-May-21,10-Sep-19,,13-May-19,13-May-19,4,2,5,3,1,8,7,9,6,,32.20%,36.70%,42.20%,62.50%,68.20%,68.90%,70.20%,71.10%,71.40%,,71.40%,01-Sep-19,,283,296,235,193,111,140,258,179,142,181,169,68,232,211,796,188,,241,68,241,68,,1066,1029,1068,1056,955,1119,1098,1683,1075,,1128,1128,955,672,437,548,511,550,538,437,601,580,1165,557,,610,518,489,369,398,,,,111,,760
Venclexta,venetoclax with obinutuzumab,AbbVie ,Y,N,N,N,Y,Y,Y,Y,N,01-Jul-19,28-Apr-20,302,CADTH & INESSS,17-Apr-20,pre-NOC,New indication,Chronic Lymphocytic Leukemia (CLL):Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible.,Completed,17-Nov-20,Cond'l on Cost,Conditional,22-May-20,post-NOC,New Indication,Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible,Completed,05-Nov-20,Inscription - Avec conditions,Conditional,1st,23-Feb-21,13-Oct-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Feb-22,31-Jan-22,01-Feb-22,24-Feb-22,31-May-22,29-Apr-22,10-Jun-22,12-Dec-22,31-Oct-22,10-Nov-21,31-Jan-22,10-Nov-21,3,2,4,5,7,6,8,10,9,1,28.60%,33.00%,53.30%,59.00%,64.50%,65.40%,97.70%,99.00%,99.60%,100.00%,100.00%,01-Feb-22,31-May-22,-11,24,214,167,98,110,232,111,110,111,134,230,198,240,425,383,28,216,110,197,28,230,644,643,644,667,763,731,773,958,916,561,749,730,643,654,440,441,440,441,464,560,528,570,755,713,370,546,203,191,330,342,763,202,120,83,119,505
Venclexta,venetoclax with azacitidine,AbbVie ,Y,N,N,N,Y,Y,Y,Y,Y,01-Jun-20,04-Dec-20,186,CADTH & INESSS,08-Jan-21,post-NOC,Initial,"In combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",Completed,20-Aug-21,Cond'l on Cost,Conditional,19-Feb-21,post-NOC,New Indication,"In combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",Completed,15-Aug-21,Inscription - Avec conditions,Conditional,1st,29-Sep-21,06-Dec-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-May-22,28-Feb-22,01-Feb-22,24-Feb-22,31-Aug-22,29-Apr-22,10-Jun-22,12-Dec-22,31-Oct-22,02-Feb-22,01-Feb-22,01-Feb-22,6,4,1,3,8,5,7,10,9,2,5.70%,34.30%,39.80%,44.30%,45.20%,65.40%,66.70%,99.00%,99.60%,100.00%,100.00%,01-May-22,31-Aug-22,35,77,224,177,40,45,68,146,84,57,80,268,144,186,371,329,58,185,57,172,57,268,513,451,424,447,635,511,553,738,696,425,552,539,424,389,165,254,192,165,188,376,252,294,479,437,171,293,259,254,108,113,635,211,211,89,122,445
Venclexta,venetoclax with cytarabine,AbbVie ,Y,N,N,N,Y,Y,Y,Y,Y,01-Jun-20,04-Dec-20,186,CADTH & INESSS,22-Jan-21,post-NOC,Initial,"In combination with low-dose cytarabine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",Completed,23-Aug-21,Do not Fund,Negative,19-Feb-21,post-NOC,New Indication,"In combination with low-dose cytarabine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",Completed,01-Sep-21,Refus d’inscription,Negative,None,28-Sep-21,,Do Not Negotiate,n/a,,,,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,49,77,213,194,36,27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,262,271,,,,,,,,448
Venclexta in combo Rituximab,venetoclax,AbbVie ,Y,N,N,N,Y,Y,Y,Y,N,01-Mar-18,21-Sep-18,204,CADTH & INESSS,24-Oct-18,post-NOC,New indication,Chronic Lymphocytic Leukemia (CLL) -2L+,Completed,31-May-19,Cond'l on Cost,Conditional,22-Oct-18,post-NOC,New Indication,In combination with rituximab (V+R) is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy,Completed,05-Jun-19,Inscription - Avec conditions,Conditional,1st,26-Jun-19,28-Oct-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jan-20,10-Apr-20,01-Mar-20,02-Apr-20,31-Mar-20,16-Jul-20,01-Jul-20,10-May-21,02-Sep-20,18-Dec-19,01-Jan-20,18-Dec-19,2,6,3,5,4,8,7,10,9,1,28.60%,48.80%,54.60%,86.80%,92.30%,96.80%,98.10%,99.00%,99.60%,100.00%,100.00%,01-Mar-20,31-Mar-20,33,31,219,226,26,21,124,65,165,125,157,155,262,247,560,310,51,227,65,210,51,155,467,567,527,559,557,664,649,962,712,453,629,612,467,434,215,215,315,275,307,305,412,397,710,460,196,377,252,257,150,145,557,104,90,74,30,456
Verkazia,cyclosporine,Santen,N,N,N,N,N,Y,Y,Y,N,01-Jul-18,24-Dec-18,176,CADTH & INESSS,22-May-19,post-NOC,Initial,"Severe vernal keratoconjunctivitis, pediatric (?4 years)",Completed,18-Nov-19,Reimburse with clinical criteria and/or conditions,Conditional,14-Jun-19,post-NOC,New Drug,Vernal keratoconjunctivitis,Completed,08-Jan-20,Inscription - Avec conditions,Conditional,1st,27-Feb-20,20-Nov-20,Negotiation,Completed with Agreements,NR,UR,EDS,UR,EAP,SA,EDS,SA,UR,EM,,,01-Nov-21,,03-Mar-21,17-Jun-21,27-Jun-22,23-Jan-23,,03-Mar-21,03-Mar-21,03-Mar-21,,,4,,1,3,5,6,,2,32.20%,60.80%,61.70%,67.40%,68.70%,69.10%,,,,,69.10%,03-Mar-21,,149,172,180,208,101,50,267,,,346,,103,209,584,794,,103,407,103,357,103,,,,1043,,800,906,1281,1491,,800,1104,1054,800,651,471,,,714,,471,577,952,1162,,420,775,329,380,368,317,,,,0,,505
Verquvo,vericiguat,Bayer Inc.,Y,N,N,Y,N,N,N,N,N,01-Jan-21,,,CADTH,14-Oct-22,na,Initial,Heart failure,Active,,Active,n/a,,,,,,,,,none,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44197
Verzenio,abemaciclib,Eli Lilly ,N,N,N,Y,Y,N,N,N,Y,01-Jun-18,05-Apr-19,308,CADTH & INESSS,03-Dec-18,pre-NOC,New drug,Advanced or metastatic breast cancer,Completed,05-Jul-19,Cond'l on Cost,Conditional,18-Jan-19,pre-NOC,New Drug,Advanced or metastatic breast cancer,Completed,10-Jul-19,Inscription - Avec conditions,Conditional,1st,30-Sep-19,09-Apr-20,Negotiation,No Agreement Reached,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-123,-77,214,173,87,82,192,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,91,96,279,274,,,,,,399
Verzenio,abemaciclib,Eli Lilly,N,N,N,N,Y,N,N,N,Y,01-Mar-21,12-Jan-22,317,CADTH & INESSS,23-Mar-22,post-NOC,Initial,"Verzenio is indicated in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features and a Ki-67 score ?20%.",Completed,29-Sep-22,Cond'l on Cost,Conditional,28-Oct-22,post-NOC,New Indication,"Verzenio is indicated in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features and a Ki-67 score ?20%.",Under review,TBD,TBD,TBD,1st,13-Mar-23,,Active,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,70,289,190,,165,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,260,,,,,,,,,577
VesiFlow (Withdrawn),solifenacin succinate / tamsulosin hydrochloride,Astellas Pharma,N,N,N,N/A,N,N,N,N,N,,,,CADTH,06-Apr-15,na,Initial,Benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms,Withdrawn,12-Jun-15,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,67,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,42167
Viacoram,perindopril arginine / amlodipine,Servier,N,N,N,N,N,N,N,N,N,,28-Jan-16,,CADTH & INESSS,02-May-16,post-NOC,Initial,"Hypertension, essential",Completed,26-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,01-Aug-16,post-NOC,New Drug,"Hypertension, essential",Completed,15-Mar-17,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,none,31-Jul-17,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,95,186,177,226,278,138,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,272,412,,,,,,,,42669
Viacoram (2nd pCPA),perindopril arginine / amlodipine,Servier,N,N,N,N,N,N,N,N,N,,28-Jan-16,,CADTH & INESSS,02-May-16,post-NOC,Initial,"Hypertension, essential",Completed,26-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,01-Aug-16,post-NOC,New Drug,"Hypertension, essential",Completed,15-Mar-17,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,19-Apr-18,22-May-19,Negotiation,No agreement reached,NR,UR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,95,186,177,226,540,400,398,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,272,412,938,798,,,,,,42669
Viberzi,eluxadoline,Allergan ,N,N,N,Y,N,N,N,N,N,01-Apr-16,26-Jan-17,300,CADTH & INESSS,23-Feb-18,post-NOC,Initial,Irritable bowel syndrome with diarrhea,Completed,24-Aug-18,Do not reimburse,Negative,19-Aug-17,post-NOC,New Drug,Irritable bowel syndrome with diarrhea,Completed,01-Feb-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,none,07-Nov-18,,Do Not Negotiate,n/a,NR,UR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,393,205,182,166,75,279,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,575,371,,,,,,,,875
Vimizim,elosulfase alfa ,BioMarin Pharmaceutical ,N,Y,N,Y,N,Y,Y,Y,N,,02-Jul-14,,CADTH & INESSS,05-Aug-14,post-NOC,Initial,Mucopolysaccharidosis IVA (Morquio A syndrome) ,Completed,25-Mar-15,Do not list,Negative,04-Aug-14,post-NOC,New Drug,Mucopolysaccharidosis IVA (Morquio A syndrome) ,Completed,02-Feb-15,Avis de refus - Valeur thérapeutique,Negative,none,30-Jun-15,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,34,33,232,182,97,148,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,266,215,,,,,,,,42088
Vimizim (resub),elosulfase alfa,BioMarin Pharmaceutical ,N,Y,N,Y,N,Y,Y,Y,N,,02-Jul-14,,CADTH & INESSS,10-Nov-15,post-NOC,Resubmission,Mucopolysaccharidosis IVA (Morquio A syndrome),Completed,20-May-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,Resubmission,Mucopolysaccharidosis IVA (Morquio A syndrome) ,Completed,01-Feb-17,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,28-Oct-16,29-Nov-18,Negotiation,Completed with Agreements,UR,UR,UR,UR,EAP,UR,UR,UR,UR,NR,,,,,13-May-19,,,,,,13-May-19,13-May-19,,,,,1,,,,,,32.20%,,,,,,,,,,32.20%,,,496,772,192,173,161,-96,762,,,,,165,,,,,,165,165,165,165,,,,,,1776,,,,,,1776,1776,1776,1280,1088,,,,,1088,,,,,,1088,688,945,923,666,,,,,,42510
Vitrakvi,larotrectinib,Bayer ,Y,N,N,Y,Y,Y,Y,Y,Y,01-Nov-18,10-Jul-19,251,CADTH & INESSS,25-Feb-19,pre-NOC,New drug,"For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.",Completed,31-Oct-19,Do Not Fund,Negative,15-Mar-19,pre-NOC,New Drug,"For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.",Completed,06-Nov-19,Refus d'inscription,Negative,None,30-Dec-19,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-135,-117,248,236,60,54,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,113,119,,,,,,,,364
Vitrakvi,larotrectinib,Bayer ,Y,N,N,Y,Y,Y,Y,Y,Y,01-Nov-18,10-Jul-19,251,CADTH & INESSS,16-Nov-20,post-NOC,Resubmission,"For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.",Completed,13-Sep-21,Cond'l on Cost,Conditional,01-Jan-21,post-NOC,Resubmission,"For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.",Completed,09-Jun-21,Inscription - Avec conditions,Conditional,1st,31-Mar-22,07-Nov-22,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,,,01-Dec-22,01-Apr-23,24-Feb-23,,,,,14-Dec-22,01-Dec-22,01-Dec-22,,,1,4,3,,,,,2,5.70%,34.30%,66.50%,72.10%,,,,,,,72.10%,24-Feb-23,,495,541,301,159,199,295,221,,,24,145,109,,,,,37,93,24,79,24,,,,1240,1361,1325,,,,,1253,1309,1295,1240,745,444,,,444,565,529,,,,,553,513,796,700,420,516,,,,85,,1047
Vizimpro,dacomitinib,Pfizer,Y,N,N,Y,Y,Y,N,Y,Y,01-May-18,26-Feb-19,301,CADTH & INESSS,19-Sep-18,pre-NOC,New drug,For the first-line treatment of patients with locally advanced or metastatic non?small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations,Completed,31-May-19,Cond'l on Cost,Conditional,,,New Drug,Non-Small Cell Lung Cancer,Completed,10-Apr-19,Refus d'inscription,Negative,1st,13-Aug-19,11-Feb-20,Negotiation,No Agreement Reached,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-160,,254,,74,125,182,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,94,43,256,307,,,,,,395
Vonvendi,von Willebrand Factor (recombinant),"Shire Pharma Canada ULC, now part of Takeda",Y,Y,N,Y,N,Y,N,Y,N,01-Jun-17,10-Jan-19,588,CADTH,29-Apr-20,post-NOC,Initial,"von Willebrand disease, adults, treatment and perioperative management ",Completed,17-Mar-21,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,475,,322,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,797,,,,,,,,,1385
Vosevi,sofosbuvir velpatasvir voxilaprevir,Gilead Sciences ,Y,N,N,Y,N,N,N,N,N,01-Feb-17,16-Aug-17,196,CADTH & INESSS,28-Jul-17,pre-NOC,Initial,"Hepatitis C, chronic",Completed,23-Jan-18,Reimburse with clinical criteria and/or conditions,Conditional,04-Aug-17,pre-NOC,New Drug,"Hepatitis C, chronic",Completed,01-Feb-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,14-Feb-18,14-Feb-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,UR,SA,EM,13-Mar-18,01-May-18,01-Apr-18,19-Jul-18,28-Feb-18,08-May-18,01-Oct-18,,20-Sep-18,01-Mar-18,28-Feb-18,28-Feb-18,3,5,4,7,1,6,9,,8,2,32.20%,60.80%,81.10%,86.80%,91.20%,92.10%,97.70%,98.30%,99.60%,,99.60%,01-Mar-18,13-Mar-18,-19,-12,179,181,22,13,0,27,76,46,155,14,83,229,,218,15,106,14,96,14,27,209,258,228,337,196,265,411,,400,197,288,278,196,215,36,49,98,68,177,36,105,251,,240,28,128,160,169,22,13,209,13,13,1,12,356
Votrient,pazopanib hydrochloride,GlaxoSmithKline,Y,N,N,N,Y,Y,N,Y,N,,12-Jul-12,,CADTH & INESSS,04-Jun-12,pre-NOC,New indication,Soft Tissue Sarcoma (STS),Completed,29-Nov-12,Do Not Fund,Negative,,,New Indication,Soft Tissue Sarcoma (STS),Completed,01-Feb-13,Avis de refus - Valeur thérapeutique,Negative,None,,,,,Not funded,Not funded,Not funded,Under provincial consideration,Not funded,Not funded,Not funded,Not funded,Not funded,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-38,,178,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,140,204,,,,,,,,41242
Vraylar,cariprazine,Allergan (an AbbVie Company),N,N,N,Y,N,N,N,N,N,01-Jun-21,22-Apr-22,325,CADTH & INESSS,29-Oct-21,pre-NOC,Initial,Schizophrenia,Completed,10-Aug-22,Do not reimburse,Negative,13-May-22,post-NOC,New Drug,Schizophrenia,Completed,07-Oct-22,Inscription - Avec conditions,Conditional,1st,25-Jan-23,28-Mar-23,Negotiation,Completed with Agreements,UR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-175,21,285,147,168,110,62,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,110,168,230,172,,,,,,435
Vraylar,cariprazine,Allergan (an AbbVie Company),N,N,N,Y,N,N,N,N,N,01-Jun-21,22-Apr-22,325,CADTH & INESSS,28-Jan-22,pre-NOC,Initial,Bipolar Disorder,Completed,09-Nov-22,Do not reimburse,Negative,13-May-22,post-NOC,New Drug,Bipolar Disorder,Completed,02-Nov-22,Refus d'inscription,Negative,none,16-Dec-22,,Do not negotiate,n/a,UR,,,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-84,21,285,173,37,44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,201,194,,,,,,,,526
Vyepti,eptinezumab,Lundbeck Canada Inc.,N,Y,N,Y,N,N,N,N,N,01-Mar-20,11-Jan-21,316,CADTH & INESSS,08-Jun-22,post-NOC,Initial,Migraine,Completed,15-Dec-22,Reimburse with clinical criteria and/or conditions,Conditional,16-Dec-22,post-NOC,New Drug,Migraine,under review,TBD,TBD,TBD,1st,16-Feb-23,,Active,n/a,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,513,704,190,,63,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,703,,,,,,,,,1019
Vyndaqel,tafamidis,Pfizer ,Y,N,N,Y,N,N,N,N,N,01-Jul-19,20-Jan-20,203,CADTH & INESSS,04-Jul-19,pre-NOC,Initial,Transthyretin-mediated amyloidosis,Completed,19-Feb-20,Reimburse with clinical criteria and/or conditions,Conditional,12-Jul-19,pre-NOC,New Drug,Cardiomyopathy ATTR,Completed,08-Apr-20,Refus d'inscription,Negative,1st,10-Jun-20,04-Feb-21,Negotiation,Completed with Agreements,,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,,01-May-21,01-Jun-21,05-Aug-21,12-May-21,13-May-21,01-Sep-22,22-Nov-21,20-Aug-21,03-Mar-21,01-May-21,03-Mar-21,,2,5,6,3,4,9,8,7,1,28.60%,33.00%,65.30%,66.20%,71.90%,77.40%,78.10%,78.40%,79.70%,,79.70%,12-May-21,,-200,-192,230,271,112,63,239,,86,117,182,97,98,574,291,197,27,205,86,185,27,,,467,498,563,478,479,955,672,578,408,586,566,467,667,437,,437,468,533,448,449,925,642,548,329,556,30,79,351,302,,,,70,,233
Vyndaqel,tafamidis,Pfizer ,Y,N,N,Y,N,N,N,N,N,01-Jul-19,20-Jan-20,203,CADTH,14-Dec-21,post-NOC,Request for Advice,Transthyretin-mediated amyloidosis,Completed,17-Jun-22,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,07-Sep-22,07-Sep-22,Negotiation,Completed with Agreements,,,EDS,EDS,EAP,,EDS,,SA,,,,01-Dec-22,24-Jan-23,15-Sep-22,,01-Nov-22,,05-Jan-23,,15-Sep-22,15-Sep-22,,,3,5,1,,2,,4,,32.20%,33.50%,39.30%,39.90%,45.50%,,,,,,45.50%,,,694,,185,,82,,0,,,85,139,8,,55,,120,,81,8,81,8,,,,1046,1100,969,,1016,,1081,,1042,1042,969,275,90,,,167,221,90,,137,,202,,163,879,,82,,,,,,,1082
Vyxeos,daunorubicin and cytarabine,Jazz Pharmaceuticals,N,N,N,Y,Y,Y,Y,Y,N,01-Nov-20,29-Apr-21,179,CADTH & INESSS,22-Jan-21,pre-NOC,Initial,For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). For the treatment of relapsed or refractory AML in pediatric and young adult patients aged 1 to 21 years old.,Completed,24-Aug-21,Cond'l on Cost,Conditional,19-Feb-21,pre-NOC,New Drug,For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). For the treatment of relapsed or refractory AML in pediatric and young adult patients aged 1 to 21 years old.,Completed,01-Sep-21,Inscription - Avec conditions,Conditional,1st,13-Jan-22,27-Apr-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,EM,01-Oct-22,30-Sep-22,01-Aug-22,14-Jul-22,31-Oct-22,,,,,26-May-22,14-Jul-22,26-May-22,5,4,3,2,6,,,,,1,28.60%,34.10%,39.80%,44.30%,64.50%,96.80%,,,,,96.80%,01-Oct-22,31-Oct-22,-97,-69,214,194,142,134,104,157,156,96,78,187,,,,,29,135,78,117,29,187,520,519,459,441,550,,,,,392,498,480,441,538,324,403,402,342,324,433,,,,,267,381,117,125,246,238,550,158,109,128,30,296
Vyzulta,latanoprostene bunod,Bausch & Lomb ,N,N,N,Y,N,N,N,N,Y,01-Mar-18,27-Dec-18,301,CADTH & INESSS,23-Nov-18,pre-NOC,Initial,Open-angle glaucoma or ocular hypertension,Completed,24-Jul-19,Reimburse with clinical criteria and/or conditions,Conditional,20-Dec-18,pre-NOC,New Drug,Glaucoma or ocular hypertension,Completed,07-Aug-19,Refus d'inscription,Negative,1st,30-Aug-19,20-Nov-19,Negotiation,Completed with Agreements,FB,FB,FB,FB,LU,FB,FB,FB,FB,NR,30-Oct-20,01-Mar-20,01-Feb-20,02-Mar-20,20-Dec-19,23-Apr-20,31-Jul-20,28-Dec-20,15-Jun-20,,20-Dec-19,20-Dec-19,8,3,2,4,1,5,7,9,6,,32.20%,38.00%,42.40%,47.90%,48.80%,49.50%,50.80%,71.10%,71.40%,,71.40%,31-Jul-20,,-34,-7,243,230,37,23,82,345,102,73,103,30,155,254,404,208,,186,30,186,30,,673,430,401,431,358,483,582,732,536,,514,514,358,392,149,464,221,192,222,149,274,373,523,327,,305,209,223,119,105,,,,224,,510
Wakix,pitolisant hydrochloride,Endo Ventures LTD,N,N,N,Y,N,Y,Y,Y,N,01-May-20,25-May-21,389,CADTH & INESSS,09-Dec-21,post-NOC,Initial,Narcolepsy,Completed,06-Dec-22,Do not reimburse,Negative,01-Jul-22,post-NOC,New Drug,Treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy,Completed,28-Dec-22,Inscription – Avec conditions,Conditional,1st,25-Jan-23,,Active,n/a,UR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,198,402,362,180,50,28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,560,582,,,,,,,,949
Waymade-Trientine,trientine hydrochloride,Waymade PLC,N,N,N,N,N,N,N,N,N,01-Jun-20,20-Apr-21,323,CADTH & INESSS,21-Jul-21,post-NOC,Initial,Wilson's Disease,Completed,08-Feb-22,Reimburse with clinical criteria and/or conditions,Conditional,10-Dec-21,post-NOC,New Drug,Wilson's Disease,Completed,29-Dec-21,Inscription - Avec conditions,Conditional,1st,13-Apr-22,11-Aug-22,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,,EDS,,,EM,25-Oct-22,01-Oct-22,01-Nov-22,24-Jan-23,11-Aug-22,,01-Nov-22,,,14-Dec-22,11-Aug-22,11-Aug-22,3,2,4,7,1,,5,,,6,32.20%,36.70%,56.90%,62.70%,64.00%,92.60%,98.10%,,,,98.10%,25-Oct-22,14-Dec-22,92,234,202,19,64,105,120,75,51,82,166,0,,82,,,125,76,0,83,0,125,553,529,560,644,478,,560,,,603,554,561,478,386,184,259,235,266,350,184,,266,,,350,260,294,253,184,225,603,125,125,75,50,617
Wegovy,semaglutide,Novo Nordisk Canada Inc.,Y,Y,N,N,N,N,N,N,N,01-Jan-21,23-Nov-21,326,CADTH,10-Mar-22,post-NOC,Initial,Weight management,Completed,16-Sep-22,Do not reimburse,Negative,,,,,,,,,none,25-Oct-22,,Do not negotiate,n/a,NR,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,107,,190,,39,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,297,,,,,,,,,623
Welireg,belzutifan,Merck,Y,N,N,Y,Y,Y,Y,Y,N,01-Sep-21,11-Jul-22,313,CADTH,23-Jan-23,post-NOC,Initial,"Patients with VHL disease-associated non-metastatic RCC, CNS hemangioblastomas or non-metastatic pNET, not requiring immediate surgery, consistent with the results of MK-6482-004 and in consideration of the high unmet need of these patients who have no options besides surgical resections",Active,,TBD,n/a,17-Mar-23,post-NOC,New Drug,"Patients with VHL disease-associated non-metastatic RCC, CNS hemangioblastomas or non-metastatic pNET, not requiring immediate surgery, consistent with the results of MK-6482-004 and in consideration of the high unmet need of these patients who have no options besides surgical resections",Under review,TBD,TBD,TBD,None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,196,249,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44440
Xalkori,crizotinib,Pfizer ,Y,N,N,Y,Y,Y,N,Y,N,,25-Apr-12,,CADTH & INESSS,26-Mar-12,pre-NOC,New drug,Patients with anaplastic lymphoma kinase-(ALK) positive advanced non-small cell lung cancer (NSCLC),Completed,04-Oct-12,Do Not Fund,Negative,02-Aug-13,post-NOC,New Drug,Patients with anaplastic lymphoma kinase-(ALK) positive advanced non-small cell lung cancer (NSCLC),Completed,03-Feb-14,Avis de refus - Valeur thérapeutique (1re intention) Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable (2e intention),Conditional,None,,,,,,,,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-30,464,192,185,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,162,649,,,,,,,,41186
Xalkori,crizotinib,Pfizer ,Y,N,N,Y,Y,Y,N,Y,N,,25-Apr-12,,CADTH & INESSS,17-Feb-15,post-NOC,Resubmission,First Line ALK Positive Advanced NSCLC,Completed,21-Jul-15,Cond'l on Cost,Conditional,04-Aug-15,post-NOC,New Indication,First Line ALK Positive Advanced NSCLC,Completed,01-Feb-16,Avis d’ajout d’une indication reconnue aux listes de médicaments – Médicament d’exception – Avec conditions,Conditional,1st,17-Jul-15,08-Oct-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Dec-15,18-Dec-15,28-Dec-15,18-Jan-16,04-Dec-15,12-Apr-16,02-May-16,01-Aug-18,01-Feb-16,16-Jul-14,01-Dec-15,16-Jul-14,2,4,5,6,3,8,9,10,7,1,28.60%,48.80%,81.10%,85.50%,91.20%,96.80%,97.40%,98.30%,99.60%,100.00%,100.00%,04-Dec-15,04-Dec-15,1028,1196,154,181,-4,-199,83,54,71,81,102,57,187,207,1028,116,-449,211,54,145,-449,57,1315,1332,1342,1363,1318,1448,1468,2289,1377,812,1472,1406,1315,287,133,133,150,160,181,136,266,286,1107,195,-565,290,1182,1377,79,-116,1318,506,3,506,0,42206
Xalkori,crizotinib,Pfizer ,Y,N,N,N,Y,Y,N,Y,N,01-Nov-16,28-Aug-17,300,CADTH & INESSS,30-Oct-18,post-NOC,Request for Advice,ROS1-positive advanced Non-Small Cell Lung Cancer,Completed,23-May-19,Cond'l on Cost,Conditional,26-Apr-19,post-NOC,New Indication,ROS1-positive advanced Non-Small Cell Lung Cancer,Completed,16-Oct-19,Inscription - Avec conditions,Conditional,1st,27-Aug-19,20-Mar-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Jul-20,30-Jul-20,01-Aug-20,21-Jan-21,31-Mar-21,16-Jul-20,31-Jan-21,23-Jan-23,01-May-20,29-Apr-20,01-May-20,29-Apr-20,3,5,6,7,9,4,8,10,2,1,28.60%,29.30%,49.50%,50.40%,54.90%,60.60%,66.10%,67.40%,99.60%,100.00%,100.00%,16-Jul-20,31-Mar-21,428,606,205,173,96,-50,206,103,132,134,307,376,118,317,1039,42,40,285,42,261,40,376,1038,1067,1069,1242,1311,1053,1252,1974,977,975,1220,1196,977,549,344,405,434,436,609,678,420,619,1341,344,196,587,633,779,302,156,1311,336,334,78,258,933
Xalkori (resub),crizotinib,Pfizer ,Y,N,N,Y,Y,Y,N,Y,N,,25-Apr-12,,CADTH & INESSS,23-Oct-12,post-NOC,Resubmission,As monotherapy for use in patients with anaplastic lymphoma kinase (ALK)-positive advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC),Completed,02-May-13,Cond'l on Cost,Conditional,,,New Drug,As monotherapy for use in patients with anaplastic lymphoma kinase (ALK)-positive advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC),Completed,03-Feb-14,Avis de refus - Valeur thérapeutique (1re intention) Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable (2e intention),Conditional,1st,28-May-13,08-Aug-13,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Mar-14,31-Oct-13,03-Oct-13,17-Oct-13,01-Oct-13,08-Nov-13,01-Dec-13,08-Apr-14,01-Apr-14,03-Feb-14,01-Oct-13,01-Oct-13,8,4,2,3,1,5,6,10,9,7,32.20%,38.00%,43.50%,47.90%,48.80%,50.10%,78.70%,99.00%,99.60%,100.00%,100.00%,01-Dec-13,01-Mar-14,181,,191,,26,-251,72,205,84,56,70,54,92,115,243,236,179,128,54,133,54,205,675,554,526,540,524,562,585,713,706,649,598,603,524,343,152,303,182,154,168,152,190,213,341,334,0,226,372,649,98,-179,675,151,151,61,90,41396
Xarelto (2.5mg),rivaroxaban,Bayer ,Y,N,N,N,N,N,N,N,N,01-Jan-18,14-Sep-18,256,CADTH & INESSS,24-May-18,pre-NOC,Initial,Prevention of stroke and cardiovascular events in coronary and peripheral artery disease,Completed,20-Nov-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New Indication,Prevention of cardiovascular events,Completed,09-Jan-19,Inscription – Avec conditions,Conditional,1st,29-Mar-19,15-Nov-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,FB,EDS,SA,SA,EM,01-Apr-20,01-Jun-20,01-Mar-20,02-Mar-20,20-Dec-19,18-Jun-20,14-Dec-20,22-Nov-21,01-Sep-20,18-Dec-19,20-Dec-19,18-Dec-19,5,6,3,4,2,7,9,10,8,1,28.60%,60.80%,66.50%,72.10%,92.30%,96.80%,97.70%,98.30%,99.60%,100.00%,100.00%,20-Dec-19,01-Apr-20,-113,,180,,129,79,231,138,199,107,108,35,216,395,738,291,33,247,35,226,33,138,565,626,534,535,462,643,822,1165,718,460,674,653,462,575,395,498,559,467,468,395,576,755,1098,651,343,607,67,117,360,310,565,105,103,2,103,323
Xarelto (DVT),rivaroxaban,Bayer ,Y,N,N,N,N,N,N,N,N,,15-Feb-12,,CADTH & INESSS,27-Feb-12,post-NOC,Initial,"Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism",Completed,16-Aug-12,List with clinical criteria and/or conditions,Conditional,,,New Indication,"Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism",Completed,01-Oct-12,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,,31-Jan-14,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,FB,EDS,SA,SA,EM,16-May-13,01-Sep-13,01-Jul-13,21-Jan-13,27-Jun-13,11-Sep-13,01-Dec-13,02-Mar-15,01-May-14,01-Oct-12,21-Jan-13,01-Oct-12,3,6,5,2,4,7,8,10,9,1,28.60%,34.10%,54.40%,86.60%,92.30%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,16-May-13,27-Jun-13,12,,171,,,,,-260,-152,-214,-375,-218,-142,-61,395,90,-487,-104,-375,-142,-487,-218,456,564,502,341,498,574,655,1111,806,229,612,574,341,329,158,273,381,319,158,315,391,472,928,623,0,429,183,229,533,487,498,269,157,227,42,41137
Xarelto (SPAF),rivaroxaban,Bayer ,Y,N,N,N,N,N,N,N,N,,16-Jan-12,,CADTH & INESSS,21-Oct-11,pre-NOC,Initial,Stroke Prevention in Patients with Atrial Fibrillation ,Completed,19-Apr-12,List with clinical criteria and/or conditions,Conditional,,,New Indication,Stroke Prevention in Patients with Atrial Fibrillation ,Completed,01-Oct-12,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,,19-Jun-12,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,FB,EDS,SA,SA,EM,02-Aug-12,01-Oct-12,01-Aug-12,24-Sep-12,27-Jul-12,25-Sep-12,01-Sep-12,18-Feb-13,01-May-13,01-Oct-12,27-Jul-12,27-Jul-12,3,7,2,5,1,6,4,9,10,8,32.20%,38.00%,58.20%,59.50%,65.00%,65.90%,70.40%,99.00%,99.30%,100.00%,100.00%,02-Aug-12,01-Oct-12,-87,,181,,,,,44,104,43,97,38,98,74,244,316,104,118,38,116,38,104,199,259,198,252,193,253,229,399,471,259,273,271,193,280,99,105,165,104,158,99,159,135,305,377,0,179,94,259,61,-104,259,66,66,6,60,41018
Xarelto (SPAF) (Advice),rivaroxaban ,Bayer ,Y,N,N,N,N,N,N,N,N,,16-Jan-12,,CADTH,18-Mar-13,post-NOC,Request for Advice,Stroke prevention in patients with atrial fibrillation,Completed,18-Jul-13,List with clinical criteria and/or conditions,Conditional,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,427,,122,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,549,,,,,,,,,41473
Xarelto (VTE),rivaroxaban ,Bayer ,Y,N,N,N,N,N,N,N,N,,18-Apr-13,,CADTH & INESSS,06-May-13,post-NOC,Initial,"Thromboembolic events (venous), pulmonary embolism ",Completed,26-Mar-14,List with criteria/condition,Conditional,,,New Indication,"Thromboembolic events (venous), pulmonary embolism ",Completed,03-Feb-14,Ajout d'une indication reconnue - Médicament d'exception,Conditional,1st,28-May-14,29-Jul-14,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,FB,EDS,SA,SA,EM,30-Sep-14,01-Mar-15,01-Apr-15,16-Oct-14,30-Sep-15,06-Mar-15,31-Oct-14,02-Mar-15,01-Oct-14,03-Feb-14,30-Sep-14,03-Feb-14,2,6,9,4,10,8,5,7,3,1,28.60%,48.80%,49.50%,55.00%,56.30%,60.80%,61.20%,62.00%,67.80%,100.00%,100.00%,16-Oct-14,30-Sep-15,18,,324,,63,114,62,63,215,246,79,428,220,94,216,64,-176,181,63,145,-176,428,530,682,713,546,895,687,561,683,531,291,648,612,530,512,188,188,340,371,204,553,345,219,341,189,0,306,342,291,125,176,895,604,365,255,349,41724
Xarelto DVT (Advice),rivaroxaban,Bayer ,Y,N,N,N,N,N,N,N,N,,16-Feb-12,,CADTH,10-Oct-12,post-NOC,Request for Advice,"Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism ",Completed,05-Apr-13,Not Applicable: Request for Advice (Completed),n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,237,,177,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,414,,,,,,,,,41369
Xeljanz,tofacitinib ,Pfizer ,Y,N,N,Y,N,N,N,N,N,,17-Apr-14,,CADTH & INESSS,05-May-14,post-NOC,Initial,"Arthritis, Rheumatoid",Completed,17-Apr-15,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Drug,"Arthritis, Rheumatoid",Completed,02-Feb-15,Avis de refus - Valeur thérapeutique,Negative,1st,21-Jul-15,26-Apr-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,31-Jan-17,01-Aug-16,01-May-16,21-Jul-16,22-Dec-16,24-Aug-16,01-Dec-16,24-Dec-18,01-Apr-17,01-Jun-15,01-May-16,01-Jun-15,8,4,2,3,7,5,6,10,9,1,28.60%,34.30%,39.80%,44.30%,45.20%,46.50%,78.70%,99.00%,99.60%,100.00%,100.00%,22-Dec-16,31-Jan-17,18,109,347,182,95,169,280,280,97,5,86,240,120,219,972,340,-330,262,5,203,-330,280,1020,837,745,826,980,860,959,1712,1080,410,1002,943,745,727,380,655,472,380,461,615,495,594,1347,715,119,637,365,291,375,449,1020,610,275,570,40,42111
Xeljanz,tofacitinib ,Pfizer ,Y,N,N,N,N,N,N,N,N,01-Nov-17,11-Sep-18,314,CADTH & INESSS,27-Jun-18,pre-NOC,Initial,Ulcerative Colitis,Completed,27-Feb-19,Reimburse with clinical criteria and/or conditions,Conditional,18-Jul-18,pre-NOC,New Indication,Ulcerative Colitis,Completed,09-Jan-19,Inscription – Avec conditions,Conditional,1st,05-Jul-19,24-Jul-20,Negotiation,Completed with Agreements,SA,UR,EDS,RB,LU,SA,EDS,SA,SA,EM,17-Nov-20,,01-Oct-20,22-Oct-20,30-Sep-20,22-Oct-20,01-Jan-21,28-Mar-22,29-Dec-21,30-Sep-20,30-Sep-20,30-Sep-20,6,,3,4,1,5,7,9,8,2,32.20%,60.80%,66.50%,72.10%,73.00%,93.20%,94.50%,95.20%,95.50%,,95.50%,30-Sep-20,17-Nov-20,-76,-55,245,175,128,177,385,116,,69,90,68,90,161,612,523,68,216,68,200,68,116,798,,751,772,750,772,843,1294,1205,750,898,882,750,826,581,629,,582,603,581,603,674,1125,1036,630,729,169,120,513,562,798,48,48,0,48,483
Xeljanz,tofacitinib ,Pfizer ,Y,N,N,N,N,N,N,N,N,01-Dec-17,04-Oct-18,307,CADTH,N/A,na,Initial,"Arthritis, Psoriatic",Cancelled,,Cancelled or withdrawn,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-43070
Xeomin,incobotulinumtoxin A,Merz Pharmaceuticals GMBH,N,Y,N,N,N,N,N,N,N,01-Jan-20,17-Nov-20,321,CADTH & INESSS,26-Feb-21,post-NOC,Initial,Chronic sialorrhea associated with neurological disorders,Completed,09-Sep-21,Reimburse with clinical criteria and/or conditions,Conditional,14-May-21,post-NOC,New Indication,For the treatment of chronic sialorrhea associated with neurological disorders in adults,Completed,03-Nov-21,Inscription - Avec conditions,Conditional,1st,28-Jan-22,23-Dec-22,Negotiation,No agreement reached,,,,,,NR,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,101,178,195,173,141,86,329,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,296,351,470,415,,,,,,617
Xermelo,telotristat,Ipsen Biopharmaceuticals ,N,N,N,Y,N,Y,Y,Y,Y,01-Dec-17,10-Oct-18,313,CADTH & INESSS,27-Sep-18,pre-NOC,Initial,carcinoid syndrome,Completed,26-Jun-19,Do not reimburse,Negative,03-Dec-18,post-NOC,New Drug,Carcinoid syndrome,Completed,05-Jun-19,Refus d'inscription,Negative,none,12-Jul-19,,Do Not Negotiate,n/a,,,,,,,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-13,54,272,184,16,37,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,259,238,,,,,,,,572
Xiaflex,collagenase clostridium histolyticum,Auxilium & Actelion ,N,Y,N,Y,N,N,N,N,N,,05-Jul-12,,CADTH & INESSS,30-Aug-12,post-NOC,Initial,Dupuytren’s contracture with a palpable cord,Completed,27-Mar-13,List with criteria/condition,Conditional,,,New Drug,Vitreomacular adhesion,Completed,03-Jun-13,Avis de refus - Valeur thérapeutique,Negative,none,18-Mar-14,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,56,,209,,356,288,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,265,333,,,,,,,,41360
XigDuo,dapagliflozin/metformin hydrochloride,AstraZeneca ,Y,N,N,N,N,N,N,N,N,,10-Dec-15,,CADTH & INESSS,07-Jan-16,post-NOC,Initial,"Diabetes Mellitus, Type 2",Completed,20-Jul-16,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Drug,Type 2 diabetes,Completed,16-Dec-16,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,13-Apr-17,13-Jun-17,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,,01-Oct-17,01-Jul-17,19-Oct-17,31-Jul-17,24-Oct-17,01-Aug-17,26-Mar-18,01-Sep-17,15-Nov-17,01-Jul-17,01-Jul-17,,5,1,6,2,7,3,9,4,8,5.70%,38.00%,39.30%,39.90%,44.40%,49.90%,50.80%,79.40%,79.70%,,79.70%,24-Oct-17,,28,103,195,269,267,118,61,,110,18,128,48,133,49,286,80,155,107,18,112,18,,,661,569,679,599,684,600,837,631,706,658,663,569,541,346,,438,346,456,376,461,377,614,408,334,435,223,372,328,179,,,,115,,42571
Xolair (CIU),omalizumab ,Novartis ,Y,Y,N,N,N,N,N,N,N,,26-Aug-14,,CADTH & INESSS,22-Sep-14,post-NOC,Initial,"Urticaria, chronic idiopathic ",Completed,07-May-15,List with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New Indication,"Urticaria, chronic idiopathic ",Completed,01-Jun-16,Avis de refus d’inscription aux listes des médicaments – Médicament d’exception – À moins que certaines conditions soient respectées,Conditional,1st,17-Jul-15,28-Nov-16,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,,01-Apr-18,01-Jan-17,20-Apr-17,27-Apr-17,28-Jun-17,01-Dec-16,15-Mar-21,19-Jul-17,01-Jun-17,01-Dec-16,01-Dec-16,,8,2,3,4,6,1,9,7,5,1.30%,7.00%,12.60%,44.80%,73.40%,74.30%,74.90%,79.40%,79.70%,,79.70%,01-Jun-17,,27,455,227,190,71,-320,500,,489,34,143,150,212,3,1568,233,185,354,3,335,3,,,1314,859,968,975,1037,828,2393,1058,1010,1179,1160,828,801,574,,1060,605,714,721,783,574,2139,804,365,925,254,645,571,180,,,,182,,42131
Xospata,gilteritinib,Astellas,N,N,N,N,Y,Y,Y,Y,Y,01-Jun-19,23-Dec-19,205,CADTH & INESSS,28-Oct-19,pre-NOC,New indication,Acute Myeloid Leukemia (AML):For the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by a validated test.,Completed,20-May-20,Cond'l on Cost,Conditional,22-Nov-19,pre-NOC,New Indication,Acute Myeloid Leukemia (AML):For the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by a validated test.,Completed,10-Jun-20,Inscription - Avec conditions,Conditional,1st,17-Aug-20,15-Mar-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Sep-21,31-May-21,01-Aug-21,05-Aug-21,31-Dec-21,16-Sep-21,31-Oct-21,12-Dec-22,01-Dec-21,27-May-21,31-May-21,27-May-21,5,2,3,4,9,6,7,10,8,1,28.60%,33.00%,38.80%,44.30%,64.50%,65.40%,66.70%,67.40%,99.60%,100.00%,100.00%,01-Sep-21,31-Dec-21,-56,-31,205,201,89,68,210,170,77,139,143,291,185,230,637,261,73,237,77,221,73,291,618,525,587,591,739,633,678,1085,709,521,685,669,525,581,376,469,376,438,442,590,484,529,936,560,351,536,149,170,299,278,739,218,214,97,121,354
Xpovio,selinexor,FORUS Therapeutics,N,N,N,Y,Y,Y,Y,Y,N,01-Aug-21,31-May-22,303,CADTH & INESSS,14-Jan-22,pre-NOC,Initial,In combination with bortezomib (V) and dexamethasone (d) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.,Completed,29-Jul-22,Cond'l on Cost,Conditional,12-Aug-22,post-NOC,New Drug,In combination with bortezomib (V) and dexamethasone (d) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.,Completed,01-Feb-23,Refus d'inscription,Negative,1st,20-Dec-22,,Active,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-137,73,196,173,144,-43,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,59,246,,,,,,,,362
Xtandi,enzalutamide,Astellas,N,N,N,Y,Y,N,N,N,N,,29-May-13,,CADTH & INESSS,04-Mar-13,pre-NOC,New drug,Metastatic Castration Resistant Prostate Cancer,Completed,23-Jul-13,Fund,Positive,02-Aug-13,post-NOC,New Drug,Metastatic Castration Resistant Prostate Cancer,Completed,03-Feb-14,Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable.,Conditional,1st,07-Aug-13,23-Sep-13,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Dec-13,19-Dec-13,25-Nov-13,16-Apr-14,10-Oct-13,19-Dec-13,20-May-14,27-Apr-15,04-Feb-14,03-Feb-14,10-Oct-13,10-Oct-13,3,4,2,8,1,5,9,10,7,6,32.20%,38.00%,58.20%,62.70%,63.60%,92.10%,92.80%,98.30%,99.60%,100.00%,100.00%,01-Dec-13,03-Feb-14,-86,65,141,185,15,-180,47,69,87,63,205,17,87,239,581,134,133,165,17,162,17,133,186,204,180,322,134,204,356,698,251,250,282,279,134,220,79,131,149,125,267,79,149,301,643,196,0,227,55,250,62,-133,250,116,116,52,64,41478
Xtandi,enzalutamide,Astellas,N,N,N,N,Y,N,N,N,N,,15-Apr-15,,CADTH & INESSS,02-Oct-14,pre-NOC,New indication,Genitourinary: First Line Metastatic Castration-Resistant Prostate Cancer,Completed,22-Jun-15,Cond'l on Cost,Conditional,04-Aug-15,post-NOC,Resubmission,First Line Metastatic Castration-Resistant Prostate Cancer,Completed,01-Feb-16,Notice of Approval to Add an Approved Indication to the List - Exception Drug - With Conditions,Conditional,1st,24-Jun-15,22-Jul-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Oct-15,18-Dec-15,29-Jul-15,18-Jan-16,31-Aug-15,14-Oct-15,02-Nov-15,22-Feb-16,01-Oct-15,24-Mar-16,29-Jul-15,29-Jul-15,3,7,1,8,2,5,6,9,4,10,5.70%,38.00%,58.20%,58.90%,59.80%,61.10%,65.50%,71.10%,71.40%,100.00%,100.00%,01-Oct-15,24-Mar-16,-195,111,263,181,2,-222,28,71,149,7,180,40,84,103,215,71,246,102,7,117,7,246,169,247,105,278,138,182,201,313,169,344,200,215,105,300,37,101,179,37,210,70,114,133,245,101,52,132,68,292,30,-194,344,239,239,64,175,42177
Xtandi,enzalutamide,Astellas,N,N,N,N,Y,N,N,N,N,01-Jun-18,20-Dec-18,202,CADTH & INESSS,24-Sep-18,pre-NOC,New indication,Non-metastatic castration-resistant prostate cancer,Completed,26-Mar-19,Cond'l on Cost,Conditional,,,New Indication,Non-metastatic castration-resistant prostate cancer,Completed,10-Apr-19,Inscription - Avec conditions,Conditional,1st,31-Jul-19,26-Feb-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Oct-20,30-Jul-20,01-Jun-20,16-Jul-20,01-Jun-20,26-Nov-20,01-Dec-20,12-Dec-22,01-Dec-21,29-Apr-20,01-Jun-20,29-Apr-20,6,5,2,4,3,7,8,10,9,1,28.60%,34.30%,66.50%,72.10%,76.50%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,01-Jun-20,01-Oct-20,-87,,183,,127,112,210,218,155,96,141,96,274,279,1020,644,63,325,96,299,63,218,651,588,529,574,529,707,712,1453,1077,496,758,732,529,616,433,555,492,433,478,433,611,616,1357,981,385,662,96,111,337,322,651,155,122,33,122,298
Xtandi,enzalutamide,Astellas,N,N,N,N,Y,N,N,N,N,01-Feb-19,02-Jun-20,487,CADTH & INESSS,24-Feb-20,pre-NOC,New indication,Metastatic Castration Sensitive Prostate Cancer (mCSPC),Completed,23-Sep-20,Cond'l on Cost,Conditional,13-Mar-20,pre-NOC,New Indication,Metastatic Castration Sensitive Prostate Cancer (mCSPC),Completed,09-Sep-20,Inscription - Avec conditions,Conditional,1st,30-Oct-20,30-Jul-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Dec-21,30-Nov-21,01-Nov-21,25-Nov-21,31-Dec-21,20-Jan-22,28-Feb-22,28-Dec-22,01-Dec-21,29-Sep-21,01-Nov-21,29-Sep-21,5,4,2,3,7,8,9,10,6,1,28.60%,34.30%,39.80%,44.30%,64.50%,65.20%,97.40%,98.30%,99.60%,100.00%,100.00%,01-Dec-21,31-Dec-21,-99,-81,212,180,37,51,273,124,123,94,118,154,174,213,516,124,61,182,94,170,61,154,547,546,517,541,577,597,636,939,547,484,605,593,517,616,404,434,433,404,428,464,484,523,826,434,385,492,113,99,310,324,577,93,60,63,30,600
Xultophy,insulin degludec + liraglutide,Novo Nordisk ,Y,Y,N,N,N,N,N,N,N,01-Jun-17,11-Apr-18,314,CADTH & INESSS,30-Jan-19,post-NOC,Initial,"Diabetes mellitus, Type 2",Completed,24-Oct-19,Reimburse with clinical criteria and/or conditions,Conditional,01-Mar-19,post-NOC,New Drug,Type 2 diabetes,Completed,11-Sep-19,Refus d'inscription,Negative,1st,31-Jan-20,26-Apr-21,Negotiation,No agreement reached,NR,,,,,NR,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,294,324,267,194,99,142,451,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,561,518,550,593,,,,,,875
Xydalba,dalbavancin,Paladin Labs Inc.,N,N,N,Y,N,N,N,N,N,01-Mar-18,04-Sep-18,187,CADTH & INESSS,11-Apr-22,post-NOC,Initial,Acute bacterial skin and skin structure infections,Completed,16-Nov-22,Reimburse with clinical criteria and/or conditions,Conditional,22-Apr-22,post-NOC,New Drug,Acute bacterial skin and skin structure infections,Completed,31-Aug-22,Inscription - Avec conditions,Conditional,none,,,,,UR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,1315,1326,219,131,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1534,1457,,,,,,,,1721
Yervoy,ipilimumab,Bristol-Myers Squibb ,Y,Y,N,Y,Y,Y,N,Y,N,,01-Feb-12,,CADTH & INESSS,01-Dec-11,pre-NOC,New drug,Advanced Melanoma ,Completed,18-Apr-12,Cond'l on Cost,Conditional,,,New Drug,Advanced Melanoma ,Completed,15-Nov-12,Ajout Liste Établissements - Méd. d'exc. - Conditionnel à une entente de partage de risque financier,Conditional,1st,01-Jun-12,28-Aug-12,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Nov-12,19-Oct-12,04-Sep-12,01-Jul-12,13-Sep-12,01-Feb-14,01-Jan-13,08-Apr-14,01-Jan-13,15-Nov-12,01-Jul-12,01-Jul-12,5,4,2,1,3,9,7,10,8,6,5.50%,11.20%,43.50%,47.90%,68.20%,96.80%,98.10%,98.80%,99.60%,100.00%,100.00%,01-Nov-12,15-Nov-12,-62,,139,,44,-167,88,65,52,7,-58,16,522,126,588,126,79,160,-58,152,-58,79,274,261,216,151,225,731,335,797,335,288,369,361,151,213,74,197,184,139,74,148,654,258,720,258,0,292,77,288,132,-79,288,137,137,123,14,41017
Yervoy,ipilimumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,,10-Sep-14,,CADTH & INESSS,15-Aug-14,pre-NOC,New indication,1st Line (unresectable or metastatic) Advanced Melanoma ,Completed,22-Dec-14,Cond'l on Cost,Conditional,24-Nov-14,post-NOC,New Indication,1st Line (unresectable or metastatic) Advanced Melanoma ,Completed,02-Feb-15,Ajout d’une indication reconnue à la Liste Établissements – Médicament d’exception – Avis de refus – À moins que le rapport entre le coût et l’efficacité soit modifié pour atteindre un niveau acceptable et qu’un suivi soit instauré,Conditional,1st,31-Jan-15,02-Mar-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,EM,01-Jul-15,30-Mar-15,01-May-15,05-Mar-15,01-Apr-15,15-Jul-15,01-Apr-15,30-Jun-16,,24-Mar-16,05-Mar-15,05-Mar-15,6,2,5,1,3,7,4,9,,8,5.50%,10.00%,42.20%,43.50%,49.20%,69.50%,70.40%,99.00%,99.30%,,99.30%,01-Jul-15,24-Mar-16,-26,75,129,70,40,-2,30,121,28,60,3,30,135,30,486,,388,112,3,142,3,388,294,201,233,176,203,308,203,659,,561,285,315,176,202,73,191,98,130,73,100,205,100,556,,416,182,103,145,70,28,561,385,385,118,267,41995
Yescarta,axicabtagene ciloleucel,Gilead Sciences Canada Inc.,N,N,N,Y,Y,Y,Y,Y,Y,18-Jan-22,13-Feb-19,-1070,CADTH & INESSS,09-Jun-22,post-NOC,Initial,The treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL),Completed,03-Feb-23,Cond'l on Cost,Conditional,20-Jan-23,post-NOC,New Drug,The treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL),Under review,TBD,TBD,TBD,None,,,Under consideration for negotiation,n/a,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,1212,1437,239,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1451,,,,,,,,,381
Zaltrap,aflibercept,Sanofi,Y,Y,N,Y,Y,N,N,N,N,,12-Feb-14,,CADTH,26-Nov-13,pre-NOC,New drug,Metastatic Colorectal Cancer,Completed,23-Sep-14,Do Not Fund,Negative,,,,,,,,,None,25-Sep-14,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-78,,301,,2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,223,,,,,,,,,41905
Zaxine,rifaximin ,Salix Pharmaceuticals Inc. ,N,N,N,Y,N,N,N,N,N,,13-Aug-13,,CADTH & INESSS,05-Aug-14,post-NOC,Initial,"Encephalopathy, Hepatic ",Completed,16-Apr-15,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Drug,"Encephalopathy, Hepatic ",Completed,02-Feb-15,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,30-Jun-15,02-Mar-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,06-Feb-18,01-Sep-16,01-May-16,21-Jul-16,29-Jun-16,07-Jul-16,01-Jun-16,01-Aug-18,01-Apr-16,02-Feb-15,01-Apr-16,02-Feb-15,9,8,3,7,5,6,4,10,2,1,28.60%,29.30%,35.00%,36.30%,68.50%,69.40%,74.90%,79.40%,99.60%,100.00%,100.00%,29-Jun-16,06-Feb-18,357,356,254,182,75,148,246,706,183,60,141,119,127,91,882,30,-394,260,30,195,-394,706,1638,1115,992,1073,1051,1059,1023,1814,962,538,1192,1127,962,605,351,1027,504,381,462,440,448,412,1203,351,0,581,611,538,321,394,1638,1100,676,513,587,42110
Zejula,niraparib,GlaxoSmithKline,N,N,N,Y,Y,Y,Y,Y,N,01-Sep-18,27-Jun-19,299,CADTH & INESSS,07-Feb-20,post-NOC,New drug,"Ovarian Cancer (recurrent): as monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",Completed,03-Sep-20,Cond'l on Cost,Conditional,13-Mar-20,post-NOC,New Drug,"Ovarian Cancer (recurrent): as monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",Completed,09-Sep-20,Inscription - Avec conditions,Conditional,1st,13-Nov-20,11-Aug-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Dec-21,30-Nov-21,01-Dec-21,25-Nov-21,28-Feb-22,17-Feb-22,29-Apr-22,12-Dec-22,14-Jan-22,29-Sep-21,25-Nov-21,29-Sep-21,4,3,5,2,8,7,9,10,6,1,28.60%,34.10%,38.60%,58.80%,64.50%,65.20%,66.10%,98.30%,99.60%,100.00%,100.00%,01-Dec-21,28-Feb-22,225,260,209,180,71,65,271,112,111,112,106,201,190,261,488,156,49,193,106,179,49,201,888,887,888,882,977,966,1037,1264,932,825,969,955,882,657,448,454,453,454,448,543,532,603,830,498,385,535,434,440,342,336,977,152,95,63,89,733
Zejula,niraparib,GlaxoSmithKline,N,N,N,N,Y,Y,Y,Y,Y,01-Apr-20,02-Oct-20,184,CADTH & INESSS,21-Sep-20,pre-NOC,New indication,First line Ovarian Cancer,Completed,29-Apr-21,Cond'l on Cost,Conditional,02-Oct-20,pre-NOC,New Indication,"Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy",Completed,31-Mar-21,Inscription - Avec conditions,Conditional,1st,01-Jun-21,11-Aug-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Dec-21,30-Nov-21,01-Dec-21,25-Nov-21,28-Feb-22,17-Feb-22,30-Apr-22,12-Dec-22,14-Jan-22,29-Sep-21,25-Nov-21,29-Sep-21,4,3,5,2,8,7,9,10,6,1,28.60%,34.10%,38.60%,58.80%,64.50%,65.20%,66.10%,98.30%,99.60%,100.00%,100.00%,01-Dec-21,28-Feb-22,-11,0,220,180,33,62,71,112,111,112,106,201,190,262,488,156,49,193,106,179,49,201,425,424,425,419,514,503,575,801,469,362,506,492,419,430,210,216,215,216,210,305,294,366,592,260,182,297,209,180,104,133,514,152,95,63,89,393
Zelboraf,vemurafenib,Hoffman-La Roche ,Y,N,N,Y,Y,N,N,N,N,,15-Feb-12,,CADTH & INESSS,06-Dec-11,pre-NOC,New drug,Advanced Melanoma ,Completed,01-Jun-12,Cond'l on Cost,Conditional,,,New Drug,Advanced Melanoma ,Completed,15-Nov-12,Ajout aux listes - Méd. d'exc. - Conditionnel à une entente de partage de risque financier,Conditional,None,,,,,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Oct-12,19-Oct-12,04-Sep-12,24-Sep-12,31-Aug-12,11-Sep-13,04-Mar-13,27-Apr-15,20-Dec-13,15-Nov-12,31-Aug-12,31-Aug-12,4,5,2,3,1,8,7,10,9,6,32.20%,38.00%,43.50%,63.70%,68.20%,96.80%,98.10%,99.00%,99.60%,100.00%,100.00%,01-Oct-12,15-Nov-12,-71,,178,,,,,,,,,,,,,,,,,,,41228,229,247,202,222,198,574,383,1167,674,274,433,417,198,269,91,122,140,95,115,91,467,276,1060,567,0,326,107,274,,,274,76,76,31,45,41061
Zemaira,Alpha1-proteinase inhibitor (Human),"CSL Behring Canada, Inc.",N,Y,N,N,N,N,N,N,N,,21-Sep-16,,CADTH & INESSS,01-Oct-21,post-NOC,Initial,Severe Alpha1-proteinase inhibitor deficiency,Completed,13-Apr-22,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,Severe Alpha1-proteinase inhibitor deficiency,Pending,TBD,TBD,TBD,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,1836,,194,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2030,,,,,,,,,44664
Zepatier,grazoprevir/elbasvir,Merck,Y,N,N,Y,N,N,N,N,N,01-Jul-15,19-Jan-16,202,CADTH & INESSS,27-Oct-15,pre-NOC,Initial,"Hepatitis C, chronic",Completed,19-May-16,Reimburse with clinical criteria and/or conditions,Conditional,24-Nov-15,pre-NOC,New Drug,"Hepatitis C, chronic",Completed,15-Jul-16,Avis d’inscription aux listes des médicaments – Médicament d’exception – Avec conditions (Hépatite C chronique de génotypes 1 et 4) Avis de refus d’inscription aux listes des médicaments – Valeur thérapeutique (Hépatite C chronique de génotype 3),Conditional,1st,14-Apr-16,17-Feb-17,Negotiation,Completed with Agreements,DL,SA,EDS,EDS,LU,SA,EDS,NR,SA,EM,21-Mar-17,01-Apr-17,01-Apr-17,20-Apr-17,28-Feb-17,13-Apr-17,01-May-17,,01-Aug-17,15-Mar-17,28-Feb-17,28-Feb-17,3,4,5,7,1,6,8,,9,2,32.20%,60.80%,81.10%,85.50%,91.20%,92.10%,97.70%,99.00%,99.60%,,99.60%,15-Mar-17,21-Mar-17,-84,-56,205,234,-35,-92,309,32,43,43,62,11,55,73,,165,26,61,11,57,11,32,427,438,438,457,406,450,468,,560,421,456,452,406,490,285,306,317,317,336,285,329,347,,439,243,335,121,178,274,217,427,21,21,15,6,323
Zeposia,ozanimod,Celgene Inc.,N,N,N,Y,N,N,N,N,Y,01-Dec-19,02-Oct-20,306,CADTH & INESSS,25-Aug-20,pre-NOC,Initial,"Multiple Sclerosis, relapsing - remitting",Completed,23-Jun-21,Do not reimburse,Negative,02-Oct-20,pre-NOC,New Drug,Multiple sclerosis,Completed,31-Mar-21,Refus d'inscription,Negative,none,29-Jul-21,,Do Not Negotiate,n/a,,,NR,,,NR,,,,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-38,0,302,180,36,120,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,264,180,,,,,,,,570
Zeposia,ozanimod,"Celgene Inc., a Bristol Myers Squibb Company",N,N,N,N,N,N,N,N,N,01-May-21,08-Apr-22,342,CADTH & INESSS,05-Jan-22,pre-NOC,Initial,Ulcerative colitis,Completed,17-Nov-22,Reimburse with clinical criteria and/or conditions,Conditional,23-Sep-22,post-NOC,New Indication,Ulcerative colitis,Completed,29-Mar-23,Inscription – Avec conditions,Conditional,none,,,,,NR,,,,,,,,,UR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-93,168,316,187,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,223,355,,,,,,,,565
Zepzelca,lurbinectedin,Jazz Pharmaceuticals ,N,N,N,Y,Y,Y,Y,Y,N,01-Jan-21,29-Sep-21,271,CADTH & INESSS,24-Feb-22,post-NOC,Initial,Treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy,Completed,19-Dec-22,Do not Fund,Negative,16-Dec-22,post-NOC,New Drug,Treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy,Under review,TBD,TBD,TBD,None,,,Under consideration for negotiation,n/a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,148,443,298,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,446,,,,,,,,,717
Zinbryta,daclizumab beta,Biogen,N,Y,N,Y,N,N,N,N,N,01-Feb-16,08-Dec-16,311,CADTH & INESSS,20-Dec-16,post-NOC,Initial,"Multiple Sclerosis, relapsing",Completed,20-Jun-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,Relapsing forms of Multiple Scleoriss,Completed,18-Oct-17,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,none,29-Mar-18,,Do Not Negotiate,n/a,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,12,106,182,208,282,162,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,194,314,,,,,,,,505
Zirabev,bevacizumab,Pfizer,Y,Y,Y,Y,Y,N,N,N,N,01-Aug-18,14-Jun-19,317,CADTH & INESSS,14-Mar-19,pre-NOC,New drug,Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,File-Closed Not Submitted,,n/a,n/a,,,New Drug,Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Completed,07-Aug-19,Inscription- Avec conditions,Conditional,1st,12-Mar-19,28-Aug-19,Negotiation,Completed with Agreements,,,,,,,,,,EM,,,,,,,,,,14-Nov-19,,14-Nov-19,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,-92,,,,,-148,169,,,,,,,,,,78,,,78,78,,,,,,,,,,,153,,153,,,,,,,,,,,,,99,,,54,,21,,,,,,-43313
Zolgensma,onasemnogene abeparvovec,Novartis Pharmaceuticals Canada Inc.,Y,Y,N,Y,N,Y,Y,Y,Y,01-Jun-20,15-Dec-20,197,CADTH & INESSS,26-May-20,pre-NOC,Initial,"Spinal muscular atrophy (SMA), pediatrics",Completed,24-Mar-21,Reimburse with clinical criteria and/or conditions,Conditional,14-Aug-20,pre-NOC,New Drug,spinal muscular atrophy,Completed,18-Jan-21,Inscription - Avec conditions,Conditional,1st,19-Feb-21,08-Oct-21,Negotiation,Completed with Agreements,EDRD,,,EDS,EAP,SA,EDF,,,EM,19-Nov-21,,,01-Jun-22,29-Oct-21,25-Jul-22,01-Oct-22,,,20-Oct-21,29-Oct-21,20-Oct-21,3,,,4,2,5,6,,,1,28.60%,60.80%,81.10%,86.60%,87.50%,88.80%,,,,,88.80%,29-Oct-21,19-Nov-21,-203,-123,302,157,-33,32,231,42,,,236,21,290,358,,,12,189,21,160,12,42,339,,,533,318,587,655,,,309,486,457,318,521,219,240,,,434,219,488,556,,,275,387,99,34,198,263,339,30,21,9,21,296
Zoryve,roflumilast,"Arcutis Biotherapeutics, Inc.",N,N,N,Y,N,N,N,N,N,01-Jul-22,,,CADTH,02-Feb-23,na,Initial,Plaque psoriasis,Active,,Active,n/a,,,,,,,,,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-44743
Zydelig,idelalisib,Gilead,Y,N,N,Y,Y,Y,N,Y,N,,27-Mar-15,,CADTH & INESSS,07-Apr-15,post-NOC,New drug,In combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL),Completed,18-Aug-15,Cond'l on Cost,Conditional,22-Mar-15,pre-NOC,New Drug,In combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL),Completed,19-Aug-16,Avis de refus d’inscription aux listes des médicaments – À moins que certaines conditions soient respectées,Conditional,1st,24-Sep-15,03-Jun-16,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Not funded,Funded,EM,01-Aug-17,18-Oct-16,08-Aug-16,20-Oct-16,19-Oct-16,21-Dec-16,01-May-17,,01-Jan-17,15-Nov-16,08-Aug-16,08-Aug-16,9,2,1,4,3,6,8,,7,5,5.70%,10.20%,42.40%,47.90%,76.50%,77.40%,78.10%,79.40%,99.60%,,99.60%,15-Nov-16,01-Aug-17,11,-5,133,516,37,-330,253,424,137,66,139,138,201,332,,212,165,206,66,202,66,424,858,571,500,573,572,635,766,,646,599,640,636,500,489,356,714,427,356,429,428,491,622,,502,88,496,144,511,290,-77,858,358,358,99,259,42234
Zydelig,idelalisib,Gilead,Y,N,N,N,Y,Y,N,Y,N,,27-Mar-15,,CADTH,12-Apr-16,post-NOC,New indication,Follicular lymphoma,Completed,29-Sep-16,Do Not Fund,Negative,,,,,,,,,None,13-Jan-17,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,382,,170,,106,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,552,,,,,,,,,42642
Zykadia,ceritinib,Novartis,Y,N,N,Y,Y,Y,N,Y,N,,27-Mar-15,,CADTH & INESSS,05-Jun-15,post-NOC,New drug,ALK+ non-small cell lung cancer: For treatment as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have progressed on or who were intolerant to crizotinib.,Completed,03-Dec-15,Do Not Fund,Negative,24-Nov-16,post-NOC,New Drug,Metastatic Non-Small Cell Lung Cancer,Completed,01-Jun-17,Avis de refus d'inscription aux listes des médicaments,Negative,None,05-Feb-16,,Do Not Negotiate,n/a,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,EM,,,,,,,,,,05-Jul-18,,05-Jul-18,,,,,,,,,,1,28.60%,,,,,,,,,,28.60%,,,70,608,181,189,64,-482,,,,,,,,,,,,,,,,,,,,,,,,,,1196,,1196,,,,,,,,,,,,,399,,251,797,,,,,,,,42341
Zykadia (resubmission),ceritinib,Novartis,Y,N,N,Y,Y,Y,N,Y,N,,27-Mar-15,,CADTH & INESSS,19-Oct-16,post-NOC,Resubmission,Non-small cell lung cancer: For treatment as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have progressed on or who were intolerant to crizotinib,Completed,21-Mar-17,Cond'l on Cost,Conditional,24-Nov-16,post-NOC,New Drug,Metastatic Non-Small Cell Lung Cancer,Completed,01-Jun-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,13-Jul-17,20-Mar-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Sep-18,30-Oct-18,15-Aug-18,19-Jul-18,11-Oct-18,30-Nov-18,03-Oct-19,26-Sep-22,,05-Jul-18,19-Jul-18,05-Jul-18,4,6,3,2,5,7,8,9,,1,28.60%,34.10%,39.80%,60.10%,92.30%,96.80%,97.70%,99.00%,99.30%,,99.30%,01-Sep-18,11-Oct-18,572,608,153,189,114,42,250,165,224,148,121,205,255,562,1651,,107,416,121,382,107,205,1254,1313,1237,1210,1294,1344,1651,2740,,1196,1505,1471,1210,638,485,529,588,512,485,569,619,926,2015,,399,780,725,797,364,292,1294,98,84,58,40,42815
Zytiga,abiraterone acetate,Janssen,Y,N,N,N,Y,N,N,N,N,,28-May-13,,CADTH & INESSS,28-Mar-13,pre-NOC,New indication,Metastatic Castration Resistant Prostate Cancer,Completed,22-Oct-13,Cond'l on Cost,Conditional,24-Nov-16,post-NOC,New Drug,Prostate Cancer,Completed,01-Jun-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Positive,2nd,31-Aug-16,31-Jan-17,Negotiation,Completed with Agreements,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,-61,1276,208,189,1044,-274,153,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,147,1465,1197,-121,,,,,,41569
Zytiga,abiraterone acetate,Janssen,Y,N,N,N,Y,N,N,N,N,,28-May-13,,CADTH & INESSS,28-Mar-13,pre-NOC,New indication,Metastatic Castration Resistant Prostate Cancer,Completed,22-Oct-13,Cond'l on Cost,Conditional,24-Nov-16,post-NOC,New Drug,Prostate Cancer,Completed,01-Jun-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Positive,1st,12-Nov-13,23-Jan-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,01-Dec-13,01-May-14,14-Feb-14,16-Apr-14,13-Feb-14,30-Apr-14,02-Nov-15,27-Apr-15,01-May-14,01-Feb-12,01-Dec-13,01-Feb-12,2,7,4,5,3,6,10,9,8,1,28.60%,48.80%,81.10%,86.80%,92.30%,93.20%,97.70%,98.30%,98.70%,100.00%,100.00%,13-Feb-14,13-Feb-14,-61,1276,208,189,21,-1297,72,-53,98,22,83,21,97,648,459,98,-722,164,-53,75,-722,21,187,338,262,323,261,337,888,699,338,-482,404,315,187,248,40,40,191,115,176,114,190,741,552,191,-1947,257,147,1465,93,-1225,261,743,74,743,0,41569
Zytiga,abiraterone,Janssen,Y,N,N,N,Y,N,N,N,N,01-Aug-17,13-Feb-18,196,CADTH,25-Feb-19,post-NOC,New indication,Newly diagnosed high-risk metastatic castration sensitive prostate cancer without small-cell histologic features.,Withdrawn,03-May-19,n/a,n/a,,,,,,,,,None,,,,,Funded,Funded,Funded,Under provincial consideration,Not funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,01-Sep-21,30-Nov-21,01-Nov-21,,,,,,,,01-Sep-21,01-Sep-21,1,3,2,,,,,,,,20.30%,26.00%,30.40%,,,,,,,,30.40%,,,377,,67,,,,,,,,,,,,,,,,,,,,1296,1386,1357,,,,,,,,1346,1346,1296,919,852,852,942,913,,,,,,,,902,444,,,,,,,,,640
Zytiga (Resubmission),abiraterone,Janssen,Y,N,N,N,Y,N,N,N,N,01-Aug-17,13-Feb-18,196,CADTH,29-Jul-19,post-NOC,Resubmission,Newly diagnosed high-risk metastatic castration sensitive prostate cancer without small-cell histologic features,Withdrawn,06-Apr-21,n/a,n/a,,,,,,,,,None,,,,,Funded,Funded,Under provincial consideration,Under provincial consideration,Not funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,01-Sep-21,30-Nov-21,,,,,,,,,01-Sep-21,01-Sep-21,1,2,,,,,,,,,20.30%,24.70%,,,,,,,,,24.70%,,,531,,617,,,,,,,,,,,,,,,,,,,,1296,1386,,,,,,,,,1341,1341,1296,765,148,148,238,,,,,,,,,193,1148,,,,,,,,,1344
